<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Pancreatobiliary Pathology Society Journal Watch</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 300;
src: url(data:application/font-sfnt;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 400;
src: url(data:application/font-sfnt;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 500;
src: url(data:application/font-sfnt;base64,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) format('truetype');
}
@font-face {
font-family: 'Roboto';
font-style: normal;
font-weight: 700;
src: url(data:application/font-sfnt;base64,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) format('truetype');
}
html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:bold}dfn{font-style:italic}h1{font-size:2em;margin:0.67em 0}mark{background:#ff0;color:#000}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sup{top:-0.5em}sub{bottom:-0.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;height:0}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace, monospace;font-size:1em}button,input,optgroup,select,textarea{color:inherit;font:inherit;margin:0}button{overflow:visible}button,select{text-transform:none}button,html input[type="button"],input[type="reset"],input[type="submit"]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{border:0;padding:0}input{line-height:normal}input[type="checkbox"],input[type="radio"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type="number"]::-webkit-inner-spin-button,input[type="number"]::-webkit-outer-spin-button{height:auto}input[type="search"]{-webkit-appearance:textfield;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}input[type="search"]::-webkit-search-cancel-button,input[type="search"]::-webkit-search-decoration{-webkit-appearance:none}fieldset{border:1px solid #c0c0c0;margin:0 2px;padding:0.35em 0.625em 0.75em}legend{border:0;padding:0}textarea{overflow:auto}optgroup{font-weight:bold}table{border-collapse:collapse;border-spacing:0}td,th{padding:0}@media print{*,*:before,*:after{background:transparent !important;color:#000 !important;-webkit-box-shadow:none !important;box-shadow:none !important;text-shadow:none !important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="#"]:after,a[href^="javascript:"]:after{content:""}pre,blockquote{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}tr,img{page-break-inside:avoid}img{max-width:100% !important}p,h2,h3{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000 !important}.label{border:1px solid #000}.table{border-collapse:collapse !important}.table td,.table th{background-color:#fff !important}.table-bordered th,.table-bordered td{border:1px solid #ddd !important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/font-sfnt;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:normal;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\002a"}.glyphicon-plus:before{content:"\002b"}.glyphicon-euro:before,.glyphicon-eur:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}*:before,*:after{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-size:13px;line-height:1.846;color:#666666;background-color:#ffffff}input,button,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#2196f3;text-decoration:none}a:hover,a:focus{color:#0a6ebd;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.img-responsive,.thumbnail>img,.thumbnail a>img,.carousel-inner>.item>img,.carousel-inner>.item>a>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:3px}.img-thumbnail{padding:4px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out;display:inline-block;max-width:100%;height:auto}.img-circle{border-radius:50%}hr{margin-top:23px;margin-bottom:23px;border:0;border-top:1px solid #eeeeee}.sr-only{position:absolute;width:1px;height:1px;margin:-1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role="button"]{cursor:pointer}h1,h2,h3,h4,h5,h6,.h1,.h2,.h3,.h4,.h5,.h6{font-family:inherit;font-weight:400;line-height:1.1;color:#444444}h1 small,h2 small,h3 small,h4 small,h5 small,h6 small,.h1 small,.h2 small,.h3 small,.h4 small,.h5 small,.h6 small,h1 .small,h2 .small,h3 .small,h4 .small,h5 .small,h6 .small,.h1 .small,.h2 .small,.h3 .small,.h4 .small,.h5 .small,.h6 .small{font-weight:normal;line-height:1;color:#bbbbbb}h1,.h1,h2,.h2,h3,.h3{margin-top:23px;margin-bottom:11.5px}h1 small,.h1 small,h2 small,.h2 small,h3 small,.h3 small,h1 .small,.h1 .small,h2 .small,.h2 .small,h3 .small,.h3 .small{font-size:65%}h4,.h4,h5,.h5,h6,.h6{margin-top:11.5px;margin-bottom:11.5px}h4 small,.h4 small,h5 small,.h5 small,h6 small,.h6 small,h4 .small,.h4 .small,h5 .small,.h5 .small,h6 .small,.h6 .small{font-size:75%}h1,.h1{font-size:56px}h2,.h2{font-size:45px}h3,.h3{font-size:34px}h4,.h4{font-size:24px}h5,.h5{font-size:20px}h6,.h6{font-size:14px}p{margin:0 0 11.5px}.lead{margin-bottom:23px;font-size:14px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:19.5px}}small,.small{font-size:92%}mark,.mark{background-color:#ffe0b2;padding:.2em}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#bbbbbb}.text-primary{color:#2196f3}a.text-primary:hover,a.text-primary:focus{color:#0c7cd5}.text-success{color:#4caf50}a.text-success:hover,a.text-success:focus{color:#3d8b40}.text-info{color:#9c27b0}a.text-info:hover,a.text-info:focus{color:#771e86}.text-warning{color:#ff9800}a.text-warning:hover,a.text-warning:focus{color:#cc7a00}.text-danger{color:#e51c23}a.text-danger:hover,a.text-danger:focus{color:#b9151b}.bg-primary{color:#fff;background-color:#2196f3}a.bg-primary:hover,a.bg-primary:focus{background-color:#0c7cd5}.bg-success{background-color:#dff0d8}a.bg-success:hover,a.bg-success:focus{background-color:#c1e2b3}.bg-info{background-color:#e1bee7}a.bg-info:hover,a.bg-info:focus{background-color:#d099d9}.bg-warning{background-color:#ffe0b2}a.bg-warning:hover,a.bg-warning:focus{background-color:#ffcb7f}.bg-danger{background-color:#f9bdbb}a.bg-danger:hover,a.bg-danger:focus{background-color:#f5908c}.page-header{padding-bottom:10.5px;margin:46px 0 23px;border-bottom:1px solid #eeeeee}ul,ol{margin-top:0;margin-bottom:11.5px}ul ul,ol ul,ul ol,ol ol{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;list-style:none;margin-left:-5px}.list-inline>li{display:inline-block;padding-left:5px;padding-right:5px}dl{margin-top:0;margin-bottom:23px}dt,dd{line-height:1.846}dt{font-weight:bold}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;clear:left;text-align:right;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[title],abbr[data-original-title]{cursor:help;border-bottom:1px dotted #bbbbbb}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:11.5px 23px;margin:0 0 23px;font-size:16.25px;border-left:5px solid #eeeeee}blockquote p:last-child,blockquote ul:last-child,blockquote ol:last-child{margin-bottom:0}blockquote footer,blockquote small,blockquote .small{display:block;font-size:80%;line-height:1.846;color:#bbbbbb}blockquote footer:before,blockquote small:before,blockquote .small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;border-right:5px solid #eeeeee;border-left:0;text-align:right}.blockquote-reverse footer:before,blockquote.pull-right footer:before,.blockquote-reverse small:before,blockquote.pull-right small:before,.blockquote-reverse .small:before,blockquote.pull-right .small:before{content:''}.blockquote-reverse footer:after,blockquote.pull-right footer:after,.blockquote-reverse small:after,blockquote.pull-right small:after,.blockquote-reverse .small:after,blockquote.pull-right .small:after{content:'\00A0 \2014'}address{margin-bottom:23px;font-style:normal;line-height:1.846}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:3px}kbd{padding:2px 4px;font-size:90%;color:#ffffff;background-color:#333333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.25)}kbd kbd{padding:0;font-size:100%;font-weight:bold;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:11px;margin:0 0 11.5px;font-size:12px;line-height:1.846;word-break:break-all;word-wrap:break-word;color:#212121;background-color:#f5f5f5;border:1px solid #cccccc;border-radius:3px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.col-xs-1,.col-sm-1,.col-md-1,.col-lg-1,.col-xs-2,.col-sm-2,.col-md-2,.col-lg-2,.col-xs-3,.col-sm-3,.col-md-3,.col-lg-3,.col-xs-4,.col-sm-4,.col-md-4,.col-lg-4,.col-xs-5,.col-sm-5,.col-md-5,.col-lg-5,.col-xs-6,.col-sm-6,.col-md-6,.col-lg-6,.col-xs-7,.col-sm-7,.col-md-7,.col-lg-7,.col-xs-8,.col-sm-8,.col-md-8,.col-lg-8,.col-xs-9,.col-sm-9,.col-md-9,.col-lg-9,.col-xs-10,.col-sm-10,.col-md-10,.col-lg-10,.col-xs-11,.col-sm-11,.col-md-11,.col-lg-11,.col-xs-12,.col-sm-12,.col-md-12,.col-lg-12{position:relative;min-height:1px;padding-left:15px;padding-right:15px}.col-xs-1,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9,.col-xs-10,.col-xs-11,.col-xs-12{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0%}@media (min-width:768px){.col-sm-1,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-sm-10,.col-sm-11,.col-sm-12{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0%}}@media (min-width:992px){.col-md-1,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-md-10,.col-md-11,.col-md-12{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0%}}@media (min-width:1200px){.col-lg-1,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-lg-10,.col-lg-11,.col-lg-12{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0%}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#bbbbbb;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:23px}.table>thead>tr>th,.table>tbody>tr>th,.table>tfoot>tr>th,.table>thead>tr>td,.table>tbody>tr>td,.table>tfoot>tr>td{padding:8px;line-height:1.846;vertical-align:top;border-top:1px solid #dddddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #dddddd}.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>th,.table>caption+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>td,.table>thead:first-child>tr:first-child>td{border-top:0}.table>tbody+tbody{border-top:2px solid #dddddd}.table .table{background-color:#ffffff}.table-condensed>thead>tr>th,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>tbody>tr>td,.table-condensed>tfoot>tr>td{padding:5px}.table-bordered{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>tbody>tr>td,.table-bordered>tfoot>tr>td{border:1px solid #dddddd}.table-bordered>thead>tr>th,.table-bordered>thead>tr>td{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*="col-"]{position:static;float:none;display:table-column}table td[class*="col-"],table th[class*="col-"]{position:static;float:none;display:table-cell}.table>thead>tr>td.active,.table>tbody>tr>td.active,.table>tfoot>tr>td.active,.table>thead>tr>th.active,.table>tbody>tr>th.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>tbody>tr.active>td,.table>tfoot>tr.active>td,.table>thead>tr.active>th,.table>tbody>tr.active>th,.table>tfoot>tr.active>th{background-color:#f5f5f5}.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover,.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr.active:hover>th{background-color:#e8e8e8}.table>thead>tr>td.success,.table>tbody>tr>td.success,.table>tfoot>tr>td.success,.table>thead>tr>th.success,.table>tbody>tr>th.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>tbody>tr.success>td,.table>tfoot>tr.success>td,.table>thead>tr.success>th,.table>tbody>tr.success>th,.table>tfoot>tr.success>th{background-color:#dff0d8}.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover,.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr.success:hover>th{background-color:#d0e9c6}.table>thead>tr>td.info,.table>tbody>tr>td.info,.table>tfoot>tr>td.info,.table>thead>tr>th.info,.table>tbody>tr>th.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>tbody>tr.info>td,.table>tfoot>tr.info>td,.table>thead>tr.info>th,.table>tbody>tr.info>th,.table>tfoot>tr.info>th{background-color:#e1bee7}.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover,.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr.info:hover>th{background-color:#d8abe0}.table>thead>tr>td.warning,.table>tbody>tr>td.warning,.table>tfoot>tr>td.warning,.table>thead>tr>th.warning,.table>tbody>tr>th.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>tbody>tr.warning>td,.table>tfoot>tr.warning>td,.table>thead>tr.warning>th,.table>tbody>tr.warning>th,.table>tfoot>tr.warning>th{background-color:#ffe0b2}.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover,.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr.warning:hover>th{background-color:#ffd699}.table>thead>tr>td.danger,.table>tbody>tr>td.danger,.table>tfoot>tr>td.danger,.table>thead>tr>th.danger,.table>tbody>tr>th.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>tbody>tr.danger>td,.table>tfoot>tr.danger>td,.table>thead>tr.danger>th,.table>tbody>tr.danger>th,.table>tfoot>tr.danger>th{background-color:#f9bdbb}.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover,.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr.danger:hover>th{background-color:#f7a6a4}.table-responsive{overflow-x:auto;min-height:0.01%}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:17.25px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #dddddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>thead>tr>th,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tfoot>tr>td{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>thead>tr>th:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.table-responsive>.table-bordered>thead>tr>th:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>th,.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>td{border-bottom:0}}fieldset{padding:0;margin:0;border:0;min-width:0}legend{display:block;width:100%;padding:0;margin-bottom:23px;font-size:19.5px;line-height:inherit;color:#212121;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:bold}input[type="search"]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type="radio"],input[type="checkbox"]{margin:4px 0 0;margin-top:1px \9;line-height:normal}input[type="file"]{display:block}input[type="range"]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type="file"]:focus,input[type="radio"]:focus,input[type="checkbox"]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:13px;line-height:1.846;color:#666666}.form-control{display:block;width:100%;height:37px;padding:6px 16px;font-size:13px;line-height:1.846;color:#666666;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 8px rgba(102,175,233,0.6)}.form-control::-moz-placeholder{color:#bbbbbb;opacity:1}.form-control:-ms-input-placeholder{color:#bbbbbb}.form-control::-webkit-input-placeholder{color:#bbbbbb}.form-control::-ms-expand{border:0;background-color:transparent}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:transparent;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type="search"]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type="date"].form-control,input[type="time"].form-control,input[type="datetime-local"].form-control,input[type="month"].form-control{line-height:37px}input[type="date"].input-sm,input[type="time"].input-sm,input[type="datetime-local"].input-sm,input[type="month"].input-sm,.input-group-sm input[type="date"],.input-group-sm input[type="time"],.input-group-sm input[type="datetime-local"],.input-group-sm input[type="month"]{line-height:30px}input[type="date"].input-lg,input[type="time"].input-lg,input[type="datetime-local"].input-lg,input[type="month"].input-lg,.input-group-lg input[type="date"],.input-group-lg input[type="time"],.input-group-lg input[type="datetime-local"],.input-group-lg input[type="month"]{line-height:45px}}.form-group{margin-bottom:15px}.radio,.checkbox{position:relative;display:block;margin-top:10px;margin-bottom:10px}.radio label,.checkbox label{min-height:23px;padding-left:20px;margin-bottom:0;font-weight:normal;cursor:pointer}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:absolute;margin-left:-20px;margin-top:4px \9}.radio+.radio,.checkbox+.checkbox{margin-top:-5px}.radio-inline,.checkbox-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;vertical-align:middle;font-weight:normal;cursor:pointer}.radio-inline+.radio-inline,.checkbox-inline+.checkbox-inline{margin-top:0;margin-left:10px}input[type="radio"][disabled],input[type="checkbox"][disabled],input[type="radio"].disabled,input[type="checkbox"].disabled,fieldset[disabled] input[type="radio"],fieldset[disabled] input[type="checkbox"]{cursor:not-allowed}.radio-inline.disabled,.checkbox-inline.disabled,fieldset[disabled] .radio-inline,fieldset[disabled] .checkbox-inline{cursor:not-allowed}.radio.disabled label,.checkbox.disabled label,fieldset[disabled] .radio label,fieldset[disabled] .checkbox label{cursor:not-allowed}.form-control-static{padding-top:7px;padding-bottom:7px;margin-bottom:0;min-height:36px}.form-control-static.input-lg,.form-control-static.input-sm{padding-left:0;padding-right:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}textarea.input-sm,select[multiple].input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm textarea.form-control,.form-group-sm select[multiple].form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:35px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-lg{height:45px;line-height:45px}textarea.input-lg,select[multiple].input-lg{height:auto}.form-group-lg .form-control{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.form-group-lg select.form-control{height:45px;line-height:45px}.form-group-lg textarea.form-control,.form-group-lg select[multiple].form-control{height:auto}.form-group-lg .form-control-static{height:45px;min-height:40px;padding:11px 16px;font-size:17px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:46.25px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:37px;height:37px;line-height:37px;text-align:center;pointer-events:none}.input-lg+.form-control-feedback,.input-group-lg+.form-control-feedback,.form-group-lg .form-control+.form-control-feedback{width:45px;height:45px;line-height:45px}.input-sm+.form-control-feedback,.input-group-sm+.form-control-feedback,.form-group-sm .form-control+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .help-block,.has-success .control-label,.has-success .radio,.has-success .checkbox,.has-success .radio-inline,.has-success .checkbox-inline,.has-success.radio label,.has-success.checkbox label,.has-success.radio-inline label,.has-success.checkbox-inline label{color:#4caf50}.has-success .form-control{border-color:#4caf50;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-success .form-control:focus{border-color:#3d8b40;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #92cf94}.has-success .input-group-addon{color:#4caf50;border-color:#4caf50;background-color:#dff0d8}.has-success .form-control-feedback{color:#4caf50}.has-warning .help-block,.has-warning .control-label,.has-warning .radio,.has-warning .checkbox,.has-warning .radio-inline,.has-warning .checkbox-inline,.has-warning.radio label,.has-warning.checkbox label,.has-warning.radio-inline label,.has-warning.checkbox-inline label{color:#ff9800}.has-warning .form-control{border-color:#ff9800;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-warning .form-control:focus{border-color:#cc7a00;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ffc166}.has-warning .input-group-addon{color:#ff9800;border-color:#ff9800;background-color:#ffe0b2}.has-warning .form-control-feedback{color:#ff9800}.has-error .help-block,.has-error .control-label,.has-error .radio,.has-error .checkbox,.has-error .radio-inline,.has-error .checkbox-inline,.has-error.radio label,.has-error.checkbox label,.has-error.radio-inline label,.has-error.checkbox-inline label{color:#e51c23}.has-error .form-control{border-color:#e51c23;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075);box-shadow:inset 0 1px 1px rgba(0,0,0,0.075)}.has-error .form-control:focus{border-color:#b9151b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c;box-shadow:inset 0 1px 1px rgba(0,0,0,0.075),0 0 6px #ef787c}.has-error .input-group-addon{color:#e51c23;border-color:#e51c23;background-color:#f9bdbb}.has-error .form-control-feedback{color:#e51c23}.has-feedback label~.form-control-feedback{top:28px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#a6a6a6}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn,.form-inline .input-group .form-control{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .radio,.form-inline .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .radio label,.form-inline .checkbox label{padding-left:0}.form-inline .radio input[type="radio"],.form-inline .checkbox input[type="checkbox"]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .radio,.form-horizontal .checkbox,.form-horizontal .radio-inline,.form-horizontal .checkbox-inline{margin-top:0;margin-bottom:0;padding-top:7px}.form-horizontal .radio,.form-horizontal .checkbox{min-height:30px}.form-horizontal .form-group{margin-left:-15px;margin-right:-15px}@media (min-width:768px){.form-horizontal .control-label{text-align:right;margin-bottom:0;padding-top:7px}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:11px;font-size:17px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;margin-bottom:0;font-weight:normal;text-align:center;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;background-image:none;border:1px solid transparent;white-space:nowrap;padding:6px 16px;font-size:13px;line-height:1.846;border-radius:3px;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}.btn:focus,.btn:active:focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn.active.focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn:hover,.btn:focus,.btn.focus{color:#444444;text-decoration:none}.btn:active,.btn.active{outline:0;background-image:none;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;opacity:0.65;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#444444;background-color:#ffffff;border-color:transparent}.btn-default:focus,.btn-default.focus{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:hover{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{color:#444444;background-color:#e6e6e6;border-color:rgba(0,0,0,0)}.btn-default:active:hover,.btn-default.active:hover,.open>.dropdown-toggle.btn-default:hover,.btn-default:active:focus,.btn-default.active:focus,.open>.dropdown-toggle.btn-default:focus,.btn-default:active.focus,.btn-default.active.focus,.open>.dropdown-toggle.btn-default.focus{color:#444444;background-color:#d4d4d4;border-color:rgba(0,0,0,0)}.btn-default:active,.btn-default.active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled:hover,.btn-default[disabled]:hover,fieldset[disabled] .btn-default:hover,.btn-default.disabled:focus,.btn-default[disabled]:focus,fieldset[disabled] .btn-default:focus,.btn-default.disabled.focus,.btn-default[disabled].focus,fieldset[disabled] .btn-default.focus{background-color:#ffffff;border-color:transparent}.btn-default .badge{color:#ffffff;background-color:#444444}.btn-primary{color:#ffffff;background-color:#2196f3;border-color:transparent}.btn-primary:focus,.btn-primary.focus{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:hover{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{color:#ffffff;background-color:#0c7cd5;border-color:rgba(0,0,0,0)}.btn-primary:active:hover,.btn-primary.active:hover,.open>.dropdown-toggle.btn-primary:hover,.btn-primary:active:focus,.btn-primary.active:focus,.open>.dropdown-toggle.btn-primary:focus,.btn-primary:active.focus,.btn-primary.active.focus,.open>.dropdown-toggle.btn-primary.focus{color:#ffffff;background-color:#0a68b4;border-color:rgba(0,0,0,0)}.btn-primary:active,.btn-primary.active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled:hover,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary:hover,.btn-primary.disabled:focus,.btn-primary[disabled]:focus,fieldset[disabled] .btn-primary:focus,.btn-primary.disabled.focus,.btn-primary[disabled].focus,fieldset[disabled] .btn-primary.focus{background-color:#2196f3;border-color:transparent}.btn-primary .badge{color:#2196f3;background-color:#ffffff}.btn-success{color:#ffffff;background-color:#4caf50;border-color:transparent}.btn-success:focus,.btn-success.focus{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:hover{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{color:#ffffff;background-color:#3d8b40;border-color:rgba(0,0,0,0)}.btn-success:active:hover,.btn-success.active:hover,.open>.dropdown-toggle.btn-success:hover,.btn-success:active:focus,.btn-success.active:focus,.open>.dropdown-toggle.btn-success:focus,.btn-success:active.focus,.btn-success.active.focus,.open>.dropdown-toggle.btn-success.focus{color:#ffffff;background-color:#327334;border-color:rgba(0,0,0,0)}.btn-success:active,.btn-success.active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled:hover,.btn-success[disabled]:hover,fieldset[disabled] .btn-success:hover,.btn-success.disabled:focus,.btn-success[disabled]:focus,fieldset[disabled] .btn-success:focus,.btn-success.disabled.focus,.btn-success[disabled].focus,fieldset[disabled] .btn-success.focus{background-color:#4caf50;border-color:transparent}.btn-success .badge{color:#4caf50;background-color:#ffffff}.btn-info{color:#ffffff;background-color:#9c27b0;border-color:transparent}.btn-info:focus,.btn-info.focus{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:hover{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{color:#ffffff;background-color:#771e86;border-color:rgba(0,0,0,0)}.btn-info:active:hover,.btn-info.active:hover,.open>.dropdown-toggle.btn-info:hover,.btn-info:active:focus,.btn-info.active:focus,.open>.dropdown-toggle.btn-info:focus,.btn-info:active.focus,.btn-info.active.focus,.open>.dropdown-toggle.btn-info.focus{color:#ffffff;background-color:#5d1769;border-color:rgba(0,0,0,0)}.btn-info:active,.btn-info.active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled:hover,.btn-info[disabled]:hover,fieldset[disabled] .btn-info:hover,.btn-info.disabled:focus,.btn-info[disabled]:focus,fieldset[disabled] .btn-info:focus,.btn-info.disabled.focus,.btn-info[disabled].focus,fieldset[disabled] .btn-info.focus{background-color:#9c27b0;border-color:transparent}.btn-info .badge{color:#9c27b0;background-color:#ffffff}.btn-warning{color:#ffffff;background-color:#ff9800;border-color:transparent}.btn-warning:focus,.btn-warning.focus{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:hover{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{color:#ffffff;background-color:#cc7a00;border-color:rgba(0,0,0,0)}.btn-warning:active:hover,.btn-warning.active:hover,.open>.dropdown-toggle.btn-warning:hover,.btn-warning:active:focus,.btn-warning.active:focus,.open>.dropdown-toggle.btn-warning:focus,.btn-warning:active.focus,.btn-warning.active.focus,.open>.dropdown-toggle.btn-warning.focus{color:#ffffff;background-color:#a86400;border-color:rgba(0,0,0,0)}.btn-warning:active,.btn-warning.active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled:hover,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning:hover,.btn-warning.disabled:focus,.btn-warning[disabled]:focus,fieldset[disabled] .btn-warning:focus,.btn-warning.disabled.focus,.btn-warning[disabled].focus,fieldset[disabled] .btn-warning.focus{background-color:#ff9800;border-color:transparent}.btn-warning .badge{color:#ff9800;background-color:#ffffff}.btn-danger{color:#ffffff;background-color:#e51c23;border-color:transparent}.btn-danger:focus,.btn-danger.focus{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:hover{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{color:#ffffff;background-color:#b9151b;border-color:rgba(0,0,0,0)}.btn-danger:active:hover,.btn-danger.active:hover,.open>.dropdown-toggle.btn-danger:hover,.btn-danger:active:focus,.btn-danger.active:focus,.open>.dropdown-toggle.btn-danger:focus,.btn-danger:active.focus,.btn-danger.active.focus,.open>.dropdown-toggle.btn-danger.focus{color:#ffffff;background-color:#991216;border-color:rgba(0,0,0,0)}.btn-danger:active,.btn-danger.active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled:hover,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger:hover,.btn-danger.disabled:focus,.btn-danger[disabled]:focus,fieldset[disabled] .btn-danger:focus,.btn-danger.disabled.focus,.btn-danger[disabled].focus,fieldset[disabled] .btn-danger.focus{background-color:#e51c23;border-color:transparent}.btn-danger .badge{color:#e51c23;background-color:#ffffff}.btn-link{color:#2196f3;font-weight:normal;border-radius:0}.btn-link,.btn-link:active,.btn-link.active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:hover,.btn-link:focus,.btn-link:active{border-color:transparent}.btn-link:hover,.btn-link:focus{color:#0a6ebd;text-decoration:underline;background-color:transparent}.btn-link[disabled]:hover,fieldset[disabled] .btn-link:hover,.btn-link[disabled]:focus,fieldset[disabled] .btn-link:focus{color:#bbbbbb;text-decoration:none}.btn-lg,.btn-group-lg>.btn{padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}.btn-sm,.btn-group-sm>.btn{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-xs,.btn-group-xs>.btn{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type="submit"].btn-block,input[type="reset"].btn-block,input[type="button"].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity 0.15s linear;-o-transition:opacity 0.15s linear;transition:opacity 0.15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-property:height, visibility;-o-transition-property:height, visibility;transition-property:height, visibility;-webkit-transition-duration:0.35s;-o-transition-duration:0.35s;transition-duration:0.35s;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid \9;border-right:4px solid transparent;border-left:4px solid transparent}.dropup,.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;list-style:none;font-size:13px;text-align:left;background-color:#ffffff;border:1px solid #cccccc;border:1px solid rgba(0,0,0,0.15);border-radius:3px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,0.175);box-shadow:0 6px 12px rgba(0,0,0,0.175);-webkit-background-clip:padding-box;background-clip:padding-box}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:normal;line-height:1.846;color:#666666;white-space:nowrap}.dropdown-menu>li>a:hover,.dropdown-menu>li>a:focus{text-decoration:none;color:#141414;background-color:#eeeeee}.dropdown-menu>.active>a,.dropdown-menu>.active>a:hover,.dropdown-menu>.active>a:focus{color:#ffffff;text-decoration:none;outline:0;background-color:#2196f3}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{color:#bbbbbb}.dropdown-menu>.disabled>a:hover,.dropdown-menu>.disabled>a:focus{text-decoration:none;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false);cursor:not-allowed}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{left:auto;right:0}.dropdown-menu-left{left:0;right:auto}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.846;color:#bbbbbb;white-space:nowrap}.dropdown-backdrop{position:fixed;left:0;right:0;bottom:0;top:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{border-top:0;border-bottom:4px dashed;border-bottom:4px solid \9;content:""}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{left:auto;right:0}.navbar-right .dropdown-menu-left{left:0;right:auto}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group>.btn,.btn-group-vertical>.btn{position:relative;float:left}.btn-group>.btn:hover,.btn-group-vertical>.btn:hover,.btn-group>.btn:focus,.btn-group-vertical>.btn:focus,.btn-group>.btn:active,.btn-group-vertical>.btn:active,.btn-group>.btn.active,.btn-group-vertical>.btn.active{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-bottom-left-radius:0;border-top-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-left:8px;padding-right:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-left:12px;padding-right:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,0.125);box-shadow:inset 0 3px 5px rgba(0,0,0,0.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-right-radius:0;border-top-left-radius:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-right-radius:0;border-top-left-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{float:none;display:table-cell;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle="buttons"]>.btn input[type="radio"],[data-toggle="buttons"]>.btn-group>.btn input[type="radio"],[data-toggle="buttons"]>.btn input[type="checkbox"],[data-toggle="buttons"]>.btn-group>.btn input[type="checkbox"]{position:absolute;clip:rect(0, 0, 0, 0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*="col-"]{float:none;padding-left:0;padding-right:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group .form-control:focus{z-index:3}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:45px;padding:10px 16px;font-size:17px;line-height:1.3333333;border-radius:3px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:45px;line-height:45px}textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn,select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn,select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn{height:auto}.input-group-addon,.input-group-btn,.input-group .form-control{display:table-cell}.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child),.input-group .form-control:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 16px;font-size:13px;font-weight:normal;line-height:1;color:#666666;text-align:center;background-color:transparent;border:1px solid transparent;border-radius:3px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:17px;border-radius:3px}.input-group-addon input[type="radio"],.input-group-addon input[type="checkbox"]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle),.input-group-btn:last-child>.btn-group:not(:last-child)>.btn{border-bottom-right-radius:0;border-top-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:first-child>.btn-group:not(:first-child)>.btn{border-bottom-left-radius:0;border-top-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:hover,.input-group-btn>.btn:focus,.input-group-btn>.btn:active{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:hover,.nav>li>a:focus{text-decoration:none;background-color:#eeeeee}.nav>li.disabled>a{color:#bbbbbb}.nav>li.disabled>a:hover,.nav>li.disabled>a:focus{color:#bbbbbb;text-decoration:none;background-color:transparent;cursor:not-allowed}.nav .open>a,.nav .open>a:hover,.nav .open>a:focus{background-color:#eeeeee;border-color:#2196f3}.nav .nav-divider{height:1px;margin:10.5px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid transparent}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.846;border:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs>li>a:hover{border-color:#eeeeee #eeeeee transparent}.nav-tabs>li.active>a,.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus{color:#666666;background-color:transparent;border:1px solid transparent;border-bottom-color:transparent;cursor:default}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border-bottom-color:#ffffff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:3px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:hover,.nav-pills>li.active>a:focus{color:#ffffff;background-color:#2196f3}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{text-align:center;margin-bottom:5px}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:3px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border:1px solid transparent}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid transparent;border-radius:3px 3px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:hover,.nav-tabs-justified>.active>a:focus{border-bottom-color:#ffffff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-right-radius:0;border-top-left-radius:0}.navbar{position:relative;min-height:64px;margin-bottom:23px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:3px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{overflow-x:visible;padding-right:15px;padding-left:15px;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1);-webkit-overflow-scrolling:touch}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block !important;height:auto !important;padding-bottom:0;overflow:visible !important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{padding-left:0;padding-right:0}}.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-top .navbar-collapse,.navbar-fixed-bottom .navbar-collapse{max-height:200px}}.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header,.container-fluid>.navbar-header,.container>.navbar-collapse,.container-fluid>.navbar-collapse{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-top,.navbar-fixed-bottom{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top,.navbar-fixed-bottom{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;padding:20.5px 15px;font-size:17px;line-height:23px;height:64px}.navbar-brand:hover,.navbar-brand:focus{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;margin-right:15px;padding:9px 10px;margin-top:15px;margin-bottom:15px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:3px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:10.25px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:23px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu>li>a,.navbar-nav .open .dropdown-menu .dropdown-header{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:23px}.navbar-nav .open .dropdown-menu>li>a:hover,.navbar-nav .open .dropdown-menu>li>a:focus{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:20.5px;padding-bottom:20.5px}}.navbar-form{margin-left:-15px;margin-right:-15px;padding:10px 15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);box-shadow:inset 0 1px 0 rgba(255,255,255,0.1),0 1px 0 rgba(255,255,255,0.1);margin-top:13.5px;margin-bottom:13.5px}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn,.navbar-form .input-group .form-control{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .radio,.navbar-form .checkbox{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .radio label,.navbar-form .checkbox label{padding-left:0}.navbar-form .radio input[type="radio"],.navbar-form .checkbox input[type="checkbox"]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;border:0;margin-left:0;margin-right:0;padding-top:0;padding-bottom:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-right-radius:0;border-top-left-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-right-radius:3px;border-top-left-radius:3px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:13.5px;margin-bottom:13.5px}.navbar-btn.btn-sm{margin-top:17px;margin-bottom:17px}.navbar-btn.btn-xs{margin-top:21px;margin-bottom:21px}.navbar-text{margin-top:20.5px;margin-bottom:20.5px}@media (min-width:768px){.navbar-text{float:left;margin-left:15px;margin-right:15px}}@media (min-width:768px){.navbar-left{float:left !important}.navbar-right{float:right !important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#ffffff;border-color:transparent}.navbar-default .navbar-brand{color:#666666}.navbar-default .navbar-brand:hover,.navbar-default .navbar-brand:focus{color:#212121;background-color:transparent}.navbar-default .navbar-text{color:#bbbbbb}.navbar-default .navbar-nav>li>a{color:#666666}.navbar-default .navbar-nav>li>a:hover,.navbar-default .navbar-nav>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:hover,.navbar-default .navbar-nav>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:hover,.navbar-default .navbar-nav>.disabled>a:focus{color:#cccccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:transparent}.navbar-default .navbar-toggle:hover,.navbar-default .navbar-toggle:focus{background-color:transparent}.navbar-default .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:transparent}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:hover,.navbar-default .navbar-nav>.open>a:focus{background-color:#eeeeee;color:#212121}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#666666}.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus{color:#212121;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus{color:#212121;background-color:#eeeeee}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#cccccc;background-color:transparent}}.navbar-default .navbar-link{color:#666666}.navbar-default .navbar-link:hover{color:#212121}.navbar-default .btn-link{color:#666666}.navbar-default .btn-link:hover,.navbar-default .btn-link:focus{color:#212121}.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:hover,.navbar-default .btn-link[disabled]:focus,fieldset[disabled] .navbar-default .btn-link:focus{color:#cccccc}.navbar-inverse{background-color:#2196f3;border-color:transparent}.navbar-inverse .navbar-brand{color:#b2dbfb}.navbar-inverse .navbar-brand:hover,.navbar-inverse .navbar-brand:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-text{color:#bbbbbb}.navbar-inverse .navbar-nav>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav>li>a:hover,.navbar-inverse .navbar-nav>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:hover,.navbar-inverse .navbar-nav>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:hover,.navbar-inverse .navbar-nav>.disabled>a:focus{color:#444444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:transparent}.navbar-inverse .navbar-toggle:hover,.navbar-inverse .navbar-toggle:focus{background-color:transparent}.navbar-inverse .navbar-toggle .icon-bar{background-color:rgba(0,0,0,0.5)}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#0c84e4}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:hover,.navbar-inverse .navbar-nav>.open>a:focus{background-color:#0c7cd5;color:#ffffff}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#b2dbfb}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus{color:#ffffff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus{color:#ffffff;background-color:#0c7cd5}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus{color:#444444;background-color:transparent}}.navbar-inverse .navbar-link{color:#b2dbfb}.navbar-inverse .navbar-link:hover{color:#ffffff}.navbar-inverse .btn-link{color:#b2dbfb}.navbar-inverse .btn-link:hover,.navbar-inverse .btn-link:focus{color:#ffffff}.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:hover,.navbar-inverse .btn-link[disabled]:focus,fieldset[disabled] .navbar-inverse .btn-link:focus{color:#444444}.breadcrumb{padding:8px 15px;margin-bottom:23px;list-style:none;background-color:#f5f5f5;border-radius:3px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{content:"/\00a0";padding:0 5px;color:#cccccc}.breadcrumb>.active{color:#bbbbbb}.pagination{display:inline-block;padding-left:0;margin:23px 0;border-radius:3px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 16px;line-height:1.846;text-decoration:none;color:#2196f3;background-color:#ffffff;border:1px solid #dddddd;margin-left:-1px}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination>li>a:hover,.pagination>li>span:hover,.pagination>li>a:focus,.pagination>li>span:focus{z-index:2;color:#0a6ebd;background-color:#eeeeee;border-color:#dddddd}.pagination>.active>a,.pagination>.active>span,.pagination>.active>a:hover,.pagination>.active>span:hover,.pagination>.active>a:focus,.pagination>.active>span:focus{z-index:3;color:#ffffff;background-color:#2196f3;border-color:#2196f3;cursor:default}.pagination>.disabled>span,.pagination>.disabled>span:hover,.pagination>.disabled>span:focus,.pagination>.disabled>a,.pagination>.disabled>a:hover,.pagination>.disabled>a:focus{color:#bbbbbb;background-color:#ffffff;border-color:#dddddd;cursor:not-allowed}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:17px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-bottom-left-radius:3px;border-top-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-bottom-right-radius:3px;border-top-right-radius:3px}.pager{padding-left:0;margin:23px 0;list-style:none;text-align:center}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#ffffff;border:1px solid #dddddd;border-radius:15px}.pager li>a:hover,.pager li>a:focus{text-decoration:none;background-color:#eeeeee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:hover,.pager .disabled>a:focus,.pager .disabled>span{color:#bbbbbb;background-color:#ffffff;cursor:not-allowed}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:bold;line-height:1;color:#ffffff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:hover,a.label:focus{color:#ffffff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#bbbbbb}.label-default[href]:hover,.label-default[href]:focus{background-color:#a2a2a2}.label-primary{background-color:#2196f3}.label-primary[href]:hover,.label-primary[href]:focus{background-color:#0c7cd5}.label-success{background-color:#4caf50}.label-success[href]:hover,.label-success[href]:focus{background-color:#3d8b40}.label-info{background-color:#9c27b0}.label-info[href]:hover,.label-info[href]:focus{background-color:#771e86}.label-warning{background-color:#ff9800}.label-warning[href]:hover,.label-warning[href]:focus{background-color:#cc7a00}.label-danger{background-color:#e51c23}.label-danger[href]:hover,.label-danger[href]:focus{background-color:#b9151b}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:normal;color:#ffffff;line-height:1;vertical-align:middle;white-space:nowrap;text-align:center;background-color:#bbbbbb;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-xs .badge,.btn-group-xs>.btn .badge{top:0;padding:1px 5px}a.badge:hover,a.badge:focus{color:#ffffff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#2196f3;background-color:#ffffff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#f9f9f9}.jumbotron h1,.jumbotron .h1{color:#444444}.jumbotron p{margin-bottom:15px;font-size:20px;font-weight:200}.jumbotron>hr{border-top-color:#e0e0e0}.container .jumbotron,.container-fluid .jumbotron{border-radius:3px;padding-left:15px;padding-right:15px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-left:60px;padding-right:60px}.jumbotron h1,.jumbotron .h1{font-size:59px}}.thumbnail{display:block;padding:4px;margin-bottom:23px;line-height:1.846;background-color:#ffffff;border:1px solid #dddddd;border-radius:3px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail>img,.thumbnail a>img{margin-left:auto;margin-right:auto}a.thumbnail:hover,a.thumbnail:focus,a.thumbnail.active{border-color:#2196f3}.thumbnail .caption{padding:9px;color:#666666}.alert{padding:15px;margin-bottom:23px;border:1px solid transparent;border-radius:3px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:bold}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{background-color:#dff0d8;border-color:#d6e9c6;color:#4caf50}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#3d8b40}.alert-info{background-color:#e1bee7;border-color:#cba4dd;color:#9c27b0}.alert-info hr{border-top-color:#c191d6}.alert-info .alert-link{color:#771e86}.alert-warning{background-color:#ffe0b2;border-color:#ffc599;color:#ff9800}.alert-warning hr{border-top-color:#ffb67f}.alert-warning .alert-link{color:#cc7a00}.alert-danger{background-color:#f9bdbb;border-color:#f7a4af;color:#e51c23}.alert-danger hr{border-top-color:#f58c9a}.alert-danger .alert-link{color:#b9151b}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{overflow:hidden;height:23px;margin-bottom:23px;background-color:#f5f5f5;border-radius:3px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,0.1);box-shadow:inset 0 1px 2px rgba(0,0,0,0.1)}.progress-bar{float:left;width:0%;height:100%;font-size:12px;line-height:23px;color:#ffffff;text-align:center;background-color:#2196f3;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,0.15);-webkit-transition:width 0.6s ease;-o-transition:width 0.6s ease;transition:width 0.6s ease}.progress-striped .progress-bar,.progress-bar-striped{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress.active .progress-bar,.progress-bar.active{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#4caf50}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-info{background-color:#9c27b0}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-warning{background-color:#ff9800}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.progress-bar-danger{background-color:#e51c23}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:-o-linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent);background-image:linear-gradient(45deg, rgba(255,255,255,0.15) 25%, transparent 25%, transparent 50%, rgba(255,255,255,0.15) 50%, rgba(255,255,255,0.15) 75%, transparent 75%, transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{zoom:1;overflow:hidden}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-left,.media-right,.media-body{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{margin-bottom:20px;padding-left:0}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#ffffff;border:1px solid #dddddd}.list-group-item:first-child{border-top-right-radius:3px;border-top-left-radius:3px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}a.list-group-item,button.list-group-item{color:#555555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333333}a.list-group-item:hover,button.list-group-item:hover,a.list-group-item:focus,button.list-group-item:focus{text-decoration:none;color:#555555;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:hover,.list-group-item.disabled:focus{background-color:#eeeeee;color:#bbbbbb;cursor:not-allowed}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text{color:#bbbbbb}.list-group-item.active,.list-group-item.active:hover,.list-group-item.active:focus{z-index:2;color:#ffffff;background-color:#2196f3;border-color:#2196f3}.list-group-item.active .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>.small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:hover .list-group-item-text,.list-group-item.active:focus .list-group-item-text{color:#e3f2fd}.list-group-item-success{color:#4caf50;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#4caf50}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:hover,button.list-group-item-success:hover,a.list-group-item-success:focus,button.list-group-item-success:focus{color:#4caf50;background-color:#d0e9c6}a.list-group-item-success.active,button.list-group-item-success.active,a.list-group-item-success.active:hover,button.list-group-item-success.active:hover,a.list-group-item-success.active:focus,button.list-group-item-success.active:focus{color:#fff;background-color:#4caf50;border-color:#4caf50}.list-group-item-info{color:#9c27b0;background-color:#e1bee7}a.list-group-item-info,button.list-group-item-info{color:#9c27b0}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:hover,button.list-group-item-info:hover,a.list-group-item-info:focus,button.list-group-item-info:focus{color:#9c27b0;background-color:#d8abe0}a.list-group-item-info.active,button.list-group-item-info.active,a.list-group-item-info.active:hover,button.list-group-item-info.active:hover,a.list-group-item-info.active:focus,button.list-group-item-info.active:focus{color:#fff;background-color:#9c27b0;border-color:#9c27b0}.list-group-item-warning{color:#ff9800;background-color:#ffe0b2}a.list-group-item-warning,button.list-group-item-warning{color:#ff9800}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:hover,button.list-group-item-warning:hover,a.list-group-item-warning:focus,button.list-group-item-warning:focus{color:#ff9800;background-color:#ffd699}a.list-group-item-warning.active,button.list-group-item-warning.active,a.list-group-item-warning.active:hover,button.list-group-item-warning.active:hover,a.list-group-item-warning.active:focus,button.list-group-item-warning.active:focus{color:#fff;background-color:#ff9800;border-color:#ff9800}.list-group-item-danger{color:#e51c23;background-color:#f9bdbb}a.list-group-item-danger,button.list-group-item-danger{color:#e51c23}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:hover,button.list-group-item-danger:hover,a.list-group-item-danger:focus,button.list-group-item-danger:focus{color:#e51c23;background-color:#f7a6a4}a.list-group-item-danger.active,button.list-group-item-danger.active,a.list-group-item-danger.active:hover,button.list-group-item-danger.active:hover,a.list-group-item-danger.active:focus,button.list-group-item-danger.active:focus{color:#fff;background-color:#e51c23;border-color:#e51c23}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:23px;background-color:#ffffff;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,0.05);box-shadow:0 1px 1px rgba(0,0,0,0.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-right-radius:2px;border-top-left-radius:2px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:15px;color:inherit}.panel-title>a,.panel-title>small,.panel-title>.small,.panel-title>small>a,.panel-title>.small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #dddddd;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-right-radius:2px;border-top-left-radius:2px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-right-radius:0;border-top-left-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.table,.panel>.table-responsive>.table,.panel>.panel-collapse>.table{margin-bottom:0}.panel>.table caption,.panel>.table-responsive>.table caption,.panel>.panel-collapse>.table caption{padding-left:15px;padding-right:15px}.panel>.table:first-child,.panel>.table-responsive:first-child>.table:first-child{border-top-right-radius:2px;border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child{border-top-left-radius:2px;border-top-right-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child{border-top-left-radius:2px}.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child{border-top-right-radius:2px}.panel>.table:last-child,.panel>.table-responsive:last-child>.table:last-child{border-bottom-right-radius:2px;border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-left-radius:2px;border-bottom-right-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:2px}.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:2px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #dddddd}.panel>.table>tbody:first-child>tr:first-child th,.panel>.table>tbody:first-child>tr:first-child td{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child{border-left:0}.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child{border-right:0}.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{border:0;margin-bottom:0}.panel-group{margin-bottom:23px}.panel-group .panel{margin-bottom:0;border-radius:3px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.panel-body,.panel-group .panel-heading+.panel-collapse>.list-group{border-top:1px solid #dddddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #dddddd}.panel-default{border-color:#dddddd}.panel-default>.panel-heading{color:#212121;background-color:#f5f5f5;border-color:#dddddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#dddddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#212121}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#dddddd}.panel-primary{border-color:#2196f3}.panel-primary>.panel-heading{color:#ffffff;background-color:#2196f3;border-color:#2196f3}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#2196f3}.panel-primary>.panel-heading .badge{color:#2196f3;background-color:#ffffff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#2196f3}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#ffffff;background-color:#4caf50;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#4caf50;background-color:#ffffff}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#cba4dd}.panel-info>.panel-heading{color:#ffffff;background-color:#9c27b0;border-color:#cba4dd}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#cba4dd}.panel-info>.panel-heading .badge{color:#9c27b0;background-color:#ffffff}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#cba4dd}.panel-warning{border-color:#ffc599}.panel-warning>.panel-heading{color:#ffffff;background-color:#ff9800;border-color:#ffc599}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ffc599}.panel-warning>.panel-heading .badge{color:#ff9800;background-color:#ffffff}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ffc599}.panel-danger{border-color:#f7a4af}.panel-danger>.panel-heading{color:#ffffff;background-color:#e51c23;border-color:#f7a4af}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#f7a4af}.panel-danger>.panel-heading .badge{color:#e51c23;background-color:#ffffff}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#f7a4af}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive iframe,.embed-responsive embed,.embed-responsive object,.embed-responsive video{position:absolute;top:0;left:0;bottom:0;height:100%;width:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f9f9f9;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,0.05);box-shadow:inset 0 1px 1px rgba(0,0,0,0.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,0.15)}.well-lg{padding:24px;border-radius:3px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:19.5px;font-weight:normal;line-height:1;color:#000000;text-shadow:none;opacity:0.2;filter:alpha(opacity=20)}.close:hover,.close:focus{color:#000000;text-decoration:none;cursor:pointer;opacity:0.5;filter:alpha(opacity=50)}button.close{padding:0;cursor:pointer;background:transparent;border:0;-webkit-appearance:none}.modal-open{overflow:hidden}.modal{display:none;overflow:hidden;position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transform:translate(0, -25%);-ms-transform:translate(0, -25%);-o-transform:translate(0, -25%);transform:translate(0, -25%);-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out}.modal.in .modal-dialog{-webkit-transform:translate(0, 0);-ms-transform:translate(0, 0);-o-transform:translate(0, 0);transform:translate(0, 0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#ffffff;border:1px solid #999999;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 3px 9px rgba(0,0,0,0.5);box-shadow:0 3px 9px rgba(0,0,0,0.5);-webkit-background-clip:padding-box;background-clip:padding-box;outline:0}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000000}.modal-backdrop.fade{opacity:0;filter:alpha(opacity=0)}.modal-backdrop.in{opacity:0.5;filter:alpha(opacity=50)}.modal-header{padding:15px;border-bottom:1px solid transparent}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.846}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid transparent}.modal-footer .btn+.btn{margin-left:5px;margin-bottom:0}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,0.5);box-shadow:0 5px 15px rgba(0,0,0,0.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:12px;opacity:0;filter:alpha(opacity=0)}.tooltip.in{opacity:0.9;filter:alpha(opacity=90)}.tooltip.top{margin-top:-3px;padding:5px 0}.tooltip.right{margin-left:3px;padding:0 5px}.tooltip.bottom{margin-top:3px;padding:5px 0}.tooltip.left{margin-left:-3px;padding:0 5px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#ffffff;text-align:center;background-color:#727272;border-radius:3px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-left .tooltip-arrow{bottom:0;right:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#727272}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#727272}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#727272}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#727272}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Roboto","Helvetica Neue",Helvetica,Arial,sans-serif;font-style:normal;font-weight:normal;letter-spacing:normal;line-break:auto;line-height:1.846;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;word-wrap:normal;font-size:13px;background-color:#ffffff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid transparent;border-radius:3px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,0.2);box-shadow:0 5px 10px rgba(0,0,0,0.2)}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{margin:0;padding:8px 14px;font-size:13px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:2px 2px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{border-width:10px;content:""}.popover.top>.arrow{left:50%;margin-left:-11px;border-bottom-width:0;border-top-color:rgba(0,0,0,0);border-top-color:rgba(0,0,0,0.075);bottom:-11px}.popover.top>.arrow:after{content:" ";bottom:1px;margin-left:-10px;border-bottom-width:0;border-top-color:#ffffff}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-left-width:0;border-right-color:rgba(0,0,0,0);border-right-color:rgba(0,0,0,0.075)}.popover.right>.arrow:after{content:" ";left:1px;bottom:-10px;border-left-width:0;border-right-color:#ffffff}.popover.bottom>.arrow{left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:rgba(0,0,0,0);border-bottom-color:rgba(0,0,0,0.075);top:-11px}.popover.bottom>.arrow:after{content:" ";top:1px;margin-left:-10px;border-top-width:0;border-bottom-color:#ffffff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:rgba(0,0,0,0);border-left-color:rgba(0,0,0,0.075)}.popover.left>.arrow:after{content:" ";right:1px;border-right-width:0;border-left-color:#ffffff;bottom:-10px}.carousel{position:relative}.carousel-inner{position:relative;overflow:hidden;width:100%}.carousel-inner>.item{display:none;position:relative;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>img,.carousel-inner>.item>a>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.next,.carousel-inner>.item.active.right{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0);left:0}.carousel-inner>.item.prev,.carousel-inner>.item.active.left{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0);left:0}.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right,.carousel-inner>.item.active{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0);left:0}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;left:0;bottom:0;width:15%;opacity:0.5;filter:alpha(opacity=50);font-size:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6);background-color:rgba(0,0,0,0)}.carousel-control.left{background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.5)), to(rgba(0,0,0,0.0001)));background-image:linear-gradient(to right, rgba(0,0,0,0.5) 0, rgba(0,0,0,0.0001) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1)}.carousel-control.right{left:auto;right:0;background-image:-webkit-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-o-linear-gradient(left, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-image:-webkit-gradient(linear, left top, right top, from(rgba(0,0,0,0.0001)), to(rgba(0,0,0,0.5)));background-image:linear-gradient(to right, rgba(0,0,0,0.0001) 0, rgba(0,0,0,0.5) 100%);background-repeat:repeat-x;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1)}.carousel-control:hover,.carousel-control:focus{outline:0;color:#ffffff;text-decoration:none;opacity:0.9;filter:alpha(opacity=90)}.carousel-control .icon-prev,.carousel-control .icon-next,.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right{position:absolute;top:50%;margin-top:-10px;z-index:5;display:inline-block}.carousel-control .icon-prev,.carousel-control .glyphicon-chevron-left{left:50%;margin-left:-10px}.carousel-control .icon-next,.carousel-control .glyphicon-chevron-right{right:50%;margin-right:-10px}.carousel-control .icon-prev,.carousel-control .icon-next{width:20px;height:20px;line-height:1;font-family:serif}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;margin-left:-30%;padding-left:0;list-style:none;text-align:center}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;border:1px solid #ffffff;border-radius:10px;cursor:pointer;background-color:#000 \9;background-color:rgba(0,0,0,0)}.carousel-indicators .active{margin:0;width:12px;height:12px;background-color:#ffffff}.carousel-caption{position:absolute;left:15%;right:15%;bottom:20px;z-index:10;padding-top:20px;padding-bottom:20px;color:#ffffff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,0.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-prev,.carousel-control .icon-next{width:30px;height:30px;margin-top:-10px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-10px}.carousel-caption{left:20%;right:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.clearfix:before,.clearfix:after,.dl-horizontal dd:before,.dl-horizontal dd:after,.container:before,.container:after,.container-fluid:before,.container-fluid:after,.row:before,.row:after,.form-horizontal .form-group:before,.form-horizontal .form-group:after,.btn-toolbar:before,.btn-toolbar:after,.btn-group-vertical>.btn-group:before,.btn-group-vertical>.btn-group:after,.nav:before,.nav:after,.navbar:before,.navbar:after,.navbar-header:before,.navbar-header:after,.navbar-collapse:before,.navbar-collapse:after,.pager:before,.pager:after,.panel-body:before,.panel-body:after,.modal-header:before,.modal-header:after,.modal-footer:before,.modal-footer:after{content:" ";display:table}.clearfix:after,.dl-horizontal dd:after,.container:after,.container-fluid:after,.row:after,.form-horizontal .form-group:after,.btn-toolbar:after,.btn-group-vertical>.btn-group:after,.nav:after,.navbar:after,.navbar-header:after,.navbar-collapse:after,.pager:after,.panel-body:after,.modal-header:after,.modal-footer:after{clear:both}.center-block{display:block;margin-left:auto;margin-right:auto}.pull-right{float:right !important}.pull-left{float:left !important}.hide{display:none !important}.show{display:block !important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none !important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-xs,.visible-sm,.visible-md,.visible-lg{display:none !important}.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block{display:none !important}@media (max-width:767px){.visible-xs{display:block !important}table.visible-xs{display:table !important}tr.visible-xs{display:table-row !important}th.visible-xs,td.visible-xs{display:table-cell !important}}@media (max-width:767px){.visible-xs-block{display:block !important}}@media (max-width:767px){.visible-xs-inline{display:inline !important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block !important}table.visible-sm{display:table !important}tr.visible-sm{display:table-row !important}th.visible-sm,td.visible-sm{display:table-cell !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline !important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block !important}table.visible-md{display:table !important}tr.visible-md{display:table-row !important}th.visible-md,td.visible-md{display:table-cell !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline !important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block !important}}@media (min-width:1200px){.visible-lg{display:block !important}table.visible-lg{display:table !important}tr.visible-lg{display:table-row !important}th.visible-lg,td.visible-lg{display:table-cell !important}}@media (min-width:1200px){.visible-lg-block{display:block !important}}@media (min-width:1200px){.visible-lg-inline{display:inline !important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block !important}}@media (max-width:767px){.hidden-xs{display:none !important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none !important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none !important}}@media (min-width:1200px){.hidden-lg{display:none !important}}.visible-print{display:none !important}@media print{.visible-print{display:block !important}table.visible-print{display:table !important}tr.visible-print{display:table-row !important}th.visible-print,td.visible-print{display:table-cell !important}}.visible-print-block{display:none !important}@media print{.visible-print-block{display:block !important}}.visible-print-inline{display:none !important}@media print{.visible-print-inline{display:inline !important}}.visible-print-inline-block{display:none !important}@media print{.visible-print-inline-block{display:inline-block !important}}@media print{.hidden-print{display:none !important}}.navbar{border:none;-webkit-box-shadow:0 1px 2px rgba(0,0,0,0.3);box-shadow:0 1px 2px rgba(0,0,0,0.3)}.navbar-brand{font-size:24px}.navbar-inverse .navbar-form input[type=text],.navbar-inverse .navbar-form input[type=password]{color:#fff;-webkit-box-shadow:inset 0 -1px 0 #b2dbfb;box-shadow:inset 0 -1px 0 #b2dbfb}.navbar-inverse .navbar-form input[type=text]::-moz-placeholder,.navbar-inverse .navbar-form input[type=password]::-moz-placeholder{color:#b2dbfb;opacity:1}.navbar-inverse .navbar-form input[type=text]:-ms-input-placeholder,.navbar-inverse .navbar-form input[type=password]:-ms-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]::-webkit-input-placeholder,.navbar-inverse .navbar-form input[type=password]::-webkit-input-placeholder{color:#b2dbfb}.navbar-inverse .navbar-form input[type=text]:focus,.navbar-inverse .navbar-form input[type=password]:focus{-webkit-box-shadow:inset 0 -2px 0 #fff;box-shadow:inset 0 -2px 0 #fff}.btn-default{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-default:focus{background-color:#ffffff}.btn-default:hover,.btn-default:active:hover{background-color:#f0f0f0}.btn-default:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-primary{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-primary:focus{background-color:#2196f3}.btn-primary:hover,.btn-primary:active:hover{background-color:#0d87e9}.btn-primary:active{background-color:#0b76cc;background-image:-webkit-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:-o-radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-image:radial-gradient(circle, #0b76cc 10%, #2196f3 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-success{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-success:focus{background-color:#4caf50}.btn-success:hover,.btn-success:active:hover{background-color:#439a46}.btn-success:active{background-color:#39843c;background-image:-webkit-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:-o-radial-gradient(circle, #39843c 10%, #4caf50 11%);background-image:radial-gradient(circle, #39843c 10%, #4caf50 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-info{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-info:focus{background-color:#9c27b0}.btn-info:hover,.btn-info:active:hover{background-color:#862197}.btn-info:active{background-color:#701c7e;background-image:-webkit-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:-o-radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-image:radial-gradient(circle, #701c7e 10%, #9c27b0 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-warning{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-warning:focus{background-color:#ff9800}.btn-warning:hover,.btn-warning:active:hover{background-color:#e08600}.btn-warning:active{background-color:#c27400;background-image:-webkit-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:-o-radial-gradient(circle, #c27400 10%, #ff9800 11%);background-image:radial-gradient(circle, #c27400 10%, #ff9800 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-danger{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-danger:focus{background-color:#e51c23}.btn-danger:hover,.btn-danger:active:hover{background-color:#cb171e}.btn-danger:active{background-color:#b0141a;background-image:-webkit-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:-o-radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-image:radial-gradient(circle, #b0141a 10%, #e51c23 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn-link{-webkit-background-size:200% 200%;background-size:200%;background-position:50%}.btn-link:focus{background-color:#ffffff}.btn-link:hover,.btn-link:active:hover{background-color:#f0f0f0}.btn-link:active{background-color:#e0e0e0;background-image:-webkit-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:-o-radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-image:radial-gradient(circle, #e0e0e0 10%, #fff 11%);background-repeat:no-repeat;-webkit-background-size:1000% 1000%;background-size:1000%;-webkit-box-shadow:2px 2px 4px rgba(0,0,0,0.4);box-shadow:2px 2px 4px rgba(0,0,0,0.4)}.btn{text-transform:uppercase;border:none;-webkit-box-shadow:1px 1px 4px rgba(0,0,0,0.4);box-shadow:1px 1px 4px rgba(0,0,0,0.4);-webkit-transition:all 0.4s;-o-transition:all 0.4s;transition:all 0.4s}.btn-link{border-radius:3px;-webkit-box-shadow:none;box-shadow:none;color:#444444}.btn-link:hover,.btn-link:focus{-webkit-box-shadow:none;box-shadow:none;color:#444444;text-decoration:none}.btn-default.disabled{background-color:rgba(0,0,0,0.1);color:rgba(0,0,0,0.4);opacity:1}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:0}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:0}body{-webkit-font-smoothing:antialiased;letter-spacing:.1px}p{margin:0 0 1em}input,button{-webkit-font-smoothing:antialiased;letter-spacing:.1px}a{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.table-hover>tbody>tr,.table-hover>tbody>tr>th,.table-hover>tbody>tr>td{-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}label{font-weight:normal}textarea,textarea.form-control,input.form-control,input[type=text],input[type=password],input[type=email],input[type=number],[type=text].form-control,[type=password].form-control,[type=email].form-control,[type=tel].form-control,[contenteditable].form-control{padding:0;border:none;border-radius:0;-webkit-appearance:none;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px}textarea:focus,textarea.form-control:focus,input.form-control:focus,input[type=text]:focus,input[type=password]:focus,input[type=email]:focus,input[type=number]:focus,[type=text].form-control:focus,[type=password].form-control:focus,[type=email].form-control:focus,[type=tel].form-control:focus,[contenteditable].form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3}textarea[disabled],textarea.form-control[disabled],input.form-control[disabled],input[type=text][disabled],input[type=password][disabled],input[type=email][disabled],input[type=number][disabled],[type=text].form-control[disabled],[type=password].form-control[disabled],[type=email].form-control[disabled],[type=tel].form-control[disabled],[contenteditable].form-control[disabled],textarea[readonly],textarea.form-control[readonly],input.form-control[readonly],input[type=text][readonly],input[type=password][readonly],input[type=email][readonly],input[type=number][readonly],[type=text].form-control[readonly],[type=password].form-control[readonly],[type=email].form-control[readonly],[type=tel].form-control[readonly],[contenteditable].form-control[readonly]{-webkit-box-shadow:none;box-shadow:none;border-bottom:1px dotted #ddd}textarea.input-sm,textarea.form-control.input-sm,input.form-control.input-sm,input[type=text].input-sm,input[type=password].input-sm,input[type=email].input-sm,input[type=number].input-sm,[type=text].form-control.input-sm,[type=password].form-control.input-sm,[type=email].form-control.input-sm,[type=tel].form-control.input-sm,[contenteditable].form-control.input-sm{font-size:12px}textarea.input-lg,textarea.form-control.input-lg,input.form-control.input-lg,input[type=text].input-lg,input[type=password].input-lg,input[type=email].input-lg,input[type=number].input-lg,[type=text].form-control.input-lg,[type=password].form-control.input-lg,[type=email].form-control.input-lg,[type=tel].form-control.input-lg,[contenteditable].form-control.input-lg{font-size:17px}select,select.form-control{border:0;border-radius:0;-webkit-appearance:none;-moz-appearance:none;appearance:none;padding-left:0;padding-right:0\9;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEVmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmZmaP/QSjAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=);-webkit-background-size:13px 13px;background-size:13px;background-repeat:no-repeat;background-position:right center;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;font-size:16px;line-height:1.5}select::-ms-expand,select.form-control::-ms-expand{display:none}select.input-sm,select.form-control.input-sm{font-size:12px}select.input-lg,select.form-control.input-lg{font-size:17px}select:focus,select.form-control:focus{-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAMAAACelLz8AAAAJ1BMVEUhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISEhISF8S9ewAAAADHRSTlMAAgMJC0uWpKa6wMxMdjkoAAAANUlEQVR4AeXJyQEAERAAsNl7Hf3X6xt0QL6JpZWq30pdvdadme+0PMdzvHm8YThHcT1H7K0BtOMDniZhWOgAAAAASUVORK5CYII=)}select[multiple],select.form-control[multiple]{background:none}.radio label,.radio-inline label,.checkbox label,.checkbox-inline label{padding-left:25px}.radio input[type="radio"],.radio-inline input[type="radio"],.checkbox input[type="radio"],.checkbox-inline input[type="radio"],.radio input[type="checkbox"],.radio-inline input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{margin-left:-25px}input[type="radio"],.radio input[type="radio"],.radio-inline input[type="radio"]{position:relative;margin-top:6px;margin-right:4px;vertical-align:top;border:none;background-color:transparent;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="radio"]:focus,.radio input[type="radio"]:focus,.radio-inline input[type="radio"]:focus{outline:none}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before,input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{content:"";display:block;width:18px;height:18px;border-radius:50%;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="radio"]:before,.radio input[type="radio"]:before,.radio-inline input[type="radio"]:before{position:absolute;left:0;top:-3px;background-color:#2196f3;-webkit-transform:scale(0);-ms-transform:scale(0);-o-transform:scale(0);transform:scale(0)}input[type="radio"]:after,.radio input[type="radio"]:after,.radio-inline input[type="radio"]:after{position:relative;top:-3px;border:2px solid #666666}input[type="radio"]:checked:before,.radio input[type="radio"]:checked:before,.radio-inline input[type="radio"]:checked:before{-webkit-transform:scale(.5);-ms-transform:scale(.5);-o-transform:scale(.5);transform:scale(.5)}input[type="radio"]:disabled:checked:before,.radio input[type="radio"]:disabled:checked:before,.radio-inline input[type="radio"]:disabled:checked:before{background-color:#bbbbbb}input[type="radio"]:checked:after,.radio input[type="radio"]:checked:after,.radio-inline input[type="radio"]:checked:after{border-color:#2196f3}input[type="radio"]:disabled:after,.radio input[type="radio"]:disabled:after,.radio-inline input[type="radio"]:disabled:after,input[type="radio"]:disabled:checked:after,.radio input[type="radio"]:disabled:checked:after,.radio-inline input[type="radio"]:disabled:checked:after{border-color:#bbbbbb}input[type="checkbox"],.checkbox input[type="checkbox"],.checkbox-inline input[type="checkbox"]{position:relative;border:none;margin-bottom:-4px;-webkit-appearance:none;appearance:none;cursor:pointer}input[type="checkbox"]:focus,.checkbox input[type="checkbox"]:focus,.checkbox-inline input[type="checkbox"]:focus{outline:none}input[type="checkbox"]:focus:after,.checkbox input[type="checkbox"]:focus:after,.checkbox-inline input[type="checkbox"]:focus:after{border-color:#2196f3}input[type="checkbox"]:after,.checkbox input[type="checkbox"]:after,.checkbox-inline input[type="checkbox"]:after{content:"";display:block;width:18px;height:18px;margin-top:-2px;margin-right:5px;border:2px solid #666666;border-radius:2px;-webkit-transition:240ms;-o-transition:240ms;transition:240ms}input[type="checkbox"]:checked:before,.checkbox input[type="checkbox"]:checked:before,.checkbox-inline input[type="checkbox"]:checked:before{content:"";position:absolute;top:0;left:6px;display:table;width:6px;height:12px;border:2px solid #fff;border-top-width:0;border-left-width:0;-webkit-transform:rotate(45deg);-ms-transform:rotate(45deg);-o-transform:rotate(45deg);transform:rotate(45deg)}input[type="checkbox"]:checked:after,.checkbox input[type="checkbox"]:checked:after,.checkbox-inline input[type="checkbox"]:checked:after{background-color:#2196f3;border-color:#2196f3}input[type="checkbox"]:disabled:after,.checkbox input[type="checkbox"]:disabled:after,.checkbox-inline input[type="checkbox"]:disabled:after{border-color:#bbbbbb}input[type="checkbox"]:disabled:checked:after,.checkbox input[type="checkbox"]:disabled:checked:after,.checkbox-inline input[type="checkbox"]:disabled:checked:after{background-color:#bbbbbb;border-color:transparent}.has-warning input:not([type=checkbox]),.has-warning .form-control,.has-warning input.form-control[readonly],.has-warning input[type=text][readonly],.has-warning [type=text].form-control[readonly],.has-warning input:not([type=checkbox]):focus,.has-warning .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #ff9800;box-shadow:inset 0 -2px 0 #ff9800}.has-error input:not([type=checkbox]),.has-error .form-control,.has-error input.form-control[readonly],.has-error input[type=text][readonly],.has-error [type=text].form-control[readonly],.has-error input:not([type=checkbox]):focus,.has-error .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #e51c23;box-shadow:inset 0 -2px 0 #e51c23}.has-success input:not([type=checkbox]),.has-success .form-control,.has-success input.form-control[readonly],.has-success input[type=text][readonly],.has-success [type=text].form-control[readonly],.has-success input:not([type=checkbox]):focus,.has-success .form-control:focus{border-bottom:none;-webkit-box-shadow:inset 0 -2px 0 #4caf50;box-shadow:inset 0 -2px 0 #4caf50}.has-warning .input-group-addon,.has-error .input-group-addon,.has-success .input-group-addon{color:#666666;border-color:transparent;background-color:transparent}.nav-tabs>li>a,.nav-tabs>li>a:focus{margin-right:0;background-color:transparent;border:none;color:#666666;-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.nav-tabs>li>a:hover,.nav-tabs>li>a:focus:hover{background-color:transparent;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus{border:none;-webkit-box-shadow:inset 0 -2px 0 #2196f3;box-shadow:inset 0 -2px 0 #2196f3;color:#2196f3}.nav-tabs>li.active>a:hover,.nav-tabs>li.active>a:focus:hover{border:none;color:#2196f3}.nav-tabs>li.disabled>a{-webkit-box-shadow:inset 0 -1px 0 #ddd;box-shadow:inset 0 -1px 0 #ddd}.nav-tabs.nav-justified>li>a,.nav-tabs.nav-justified>li>a:hover,.nav-tabs.nav-justified>li>a:focus,.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:hover,.nav-tabs.nav-justified>.active>a:focus{border:none}.nav-tabs .dropdown-menu{margin-top:0}.dropdown-menu{margin-top:0;border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.alert{border:none;color:#fff}.alert-success{background-color:#4caf50}.alert-info{background-color:#9c27b0}.alert-warning{background-color:#ff9800}.alert-danger{background-color:#e51c23}.alert a:not(.close),.alert .alert-link{color:#fff;font-weight:bold}.alert .close{color:#fff}.badge{padding:4px 6px 4px}.progress{position:relative;z-index:1;height:6px;border-radius:0;-webkit-box-shadow:none;box-shadow:none}.progress-bar{-webkit-box-shadow:none;box-shadow:none}.progress-bar:last-child{border-radius:0 3px 3px 0}.progress-bar:last-child:before{display:block;content:"";position:absolute;width:100%;height:100%;left:0;right:0;z-index:-1;background-color:#cae6fc}.progress-bar-success:last-child.progress-bar:before{background-color:#c7e7c8}.progress-bar-info:last-child.progress-bar:before{background-color:#edc9f3}.progress-bar-warning:last-child.progress-bar:before{background-color:#ffe0b3}.progress-bar-danger:last-child.progress-bar:before{background-color:#f28e92}.close{font-size:34px;font-weight:300;line-height:24px;opacity:0.6;-webkit-transition:all 0.2s;-o-transition:all 0.2s;transition:all 0.2s}.close:hover{opacity:1}.list-group-item{padding:15px}.list-group-item-text{color:#bbbbbb}.well{border-radius:0;-webkit-box-shadow:none;box-shadow:none}.panel{border:none;border-radius:2px;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.panel-heading{border-bottom:none}.panel-footer{border-top:none}.popover{border:none;-webkit-box-shadow:0 1px 4px rgba(0,0,0,0.3);box-shadow:0 1px 4px rgba(0,0,0,0.3)}.carousel-caption h1,.carousel-caption h2,.carousel-caption h3,.carousel-caption h4,.carousel-caption h5,.carousel-caption h6{color:inherit}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia, pre.foldable');
  rCodeBlocks.each(function() {

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    var showThis = (show || $(this).hasClass('fold-show')) && !$(this).hasClass('fold-hide');
    if (showThis) div.addClass('in');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (showThis ? 'Hide' : 'Code') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs code-folding-btn pull-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-target', '#' + id)
        .attr('aria-expanded', showThis)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // update state of button on show/hide
    div.on('hidden.bs.collapse', function () {
      showCodeText.text('Code');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
    });
  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>
<style type="text/css">
a.anchor-section {margin-left: 10px; visibility: hidden; color: inherit;}
a.anchor-section::before {content: '#';}
.hasAnchor:hover a.anchor-section {visibility: visible;}
ul > li > .anchor-section {display: none;}
</style>
<script>// Anchor sections v1.0 written by Atsushi Yasumoto on Oct 3rd, 2020.
document.addEventListener('DOMContentLoaded', function() {
  // Do nothing if AnchorJS is used
  if (typeof window.anchors === 'object' && anchors.hasOwnProperty('hasAnchorJSLink')) {
    return;
  }

  const h = document.querySelectorAll('h1, h2, h3, h4, h5, h6');

  // Do nothing if sections are already anchored
  if (Array.from(h).some(x => x.classList.contains('hasAnchor'))) {
    return null;
  }

  // Use section id when pandoc runs with --section-divs
  const section_id = function(x) {
    return ((x.classList.contains('section') || (x.tagName === 'SECTION'))
            ? x.id : '');
  };

  // Add anchors
  h.forEach(function(x) {
    const id = x.id || section_id(x.parentElement);
    if (id === '' || x.matches(':empty')) {
      return null;
    }
    let anchor = document.createElement('a');
    anchor.href = '#' + id;
    anchor.classList = ['anchor-section'];
    x.classList.add('hasAnchor');
    x.appendChild(anchor);
  });
});
</script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>




<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
#rmd-source-code {
  display: none;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">

<div class="btn-group pull-right">
<button type="button" class="btn btn-default btn-xs dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu" style="min-width: 50px;">
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Pancreatobiliary Pathology Society Journal Watch</h1>
<h3 class="subtitle">Recent Articles that will be Selected</h3>
<h4 class="date">Last Update on 2020-11-15</h4>

</div>


<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<style type="text/css">

h1{
  text-align: center;
}
h2{
  text-align: center;
}
h3{
  text-align: center;
}
h4{
  text-align: center;
}
h4.date{
  text-align: center;
}

</style>
<!-- Open all links in new tab-->
<p><base target="_blank"></base></p>
<hr />
<div id="pbpath_jw" class="section level1 tabset tabset-fade tabset-pills">
<h1 class="tabset tabset-fade tabset-pills">PBPath Journal Watch Articles</h1>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><strong>Welcome to the PBPath Journal Watch!</strong></p>
<p>This bi-monthly journal watch features exciting recently published pancreas and biliary pathology articles that will provide up to date medical knowledge in our field. These articles will be showcased in several convenient categories, including surgical pathology, cytopathology, molecular pathology, pancreas, gallbladder, bile ducts, and ampulla among others. The articles in each category are in no particular order. See the list of journals we search regularly <a href="http://pbpath.org/pbpath-journal-watch/">here</a>. Previous months’ issues may be found in our <em><a href="http://pbpath.org/journal-watch-archive/">archive</a></em> and you may see <a href="http://pbpath.org/journal-watch-upcoming-issue/">drafts of the upcoming issue here</a>.</p>
<p>We encourage members to actively participate by recommending new articles and providing feedback using the <a href="#feedback" target="_self">forms provided below.</a></p>
<p><strong>We hope that you will enjoy the new PBPath Journal Watch!</strong></p>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details>
<summary>
Click here to see these articles and graphical summaries in other databases
</summary>
<p>The <em>journal watch</em> articles are collected in <a href="https://doi.org/10.5281/zenodo.3635440">zenodo</a> and <a href="https://osf.io/3d67y/">OSF</a>.<br />
<a href="https://doi.org/10.5281/zenodo.3635440"><img src="data:image/svg+xml; charset=utf-8;base64,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" alt="DOI" /></a></p>
<p>To see these selected articles in <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33177357[uid] OR 33177340[uid] OR 33176750[uid] OR 33174146[uid] OR 33172395[uid] OR 33169301[uid] OR 33168600[uid] OR 33168404[uid] OR 33159698[uid] OR 33158979[uid] OR 33156465[uid] OR 33156066[uid] OR 33151547[uid] OR 33148667[uid] OR 33148667[uid] OR 33148628[uid] OR 33148205[uid] OR 33148196[uid] OR 33145705[uid] OR 33142117[uid] OR 33141373[uid] OR 33139271[uid] OR 33139201[uid] OR 33136337[uid] OR 33135147[uid] OR 33135146[uid] OR 33135144[uid] OR 33132046[uid] OR 33129823[uid] OR 33129375[uid] OR 33129276[uid] OR 33128119[uid] OR 33127392[uid] OR 33124049[uid] OR 33123857[uid] OR 33123857[uid] OR 33123857[uid] OR 33122531[uid] OR 33122530[uid] OR 33122528[uid] OR 33122527[uid] OR 33122526[uid] OR 33122525[uid] OR 33122524[uid] OR 33122523[uid] OR 33122522[uid] OR 33122521[uid] OR 33122518[uid] OR 33122516[uid] OR 33122513[uid] OR 33121946[uid] OR 33121847[uid] OR 33109735[uid] OR 33109470[uid] OR 33108683[uid] OR 33097588[uid] OR 33097431[uid] OR 33097430[uid] OR 33097020[uid] OR 33093663[uid] OR 33093149[uid] OR 33089395[uid] OR 33087490[uid] OR 33087489[uid] OR 33087331[uid] OR 33087057[uid] OR 33086324[uid] OR 33086318[uid] OR 33086318[uid] OR 33086310[uid] OR 33084990[uid] OR 33082211[uid] OR 33082106[uid] OR 33081716[uid] OR 33079429[uid] OR 33079423[uid] OR 33079303[uid] OR 33077384[uid] OR 33077383[uid] OR 33077382[uid] OR 33077381[uid] OR 33074907[uid] OR 33074899[uid] OR 33074853[uid] OR 33073341[uid] OR 33069583[uid] OR 33069084[uid] OR 33069083[uid] OR 33065644[uid] OR 33065029[uid] OR 33060404[uid] OR 33060404[uid] OR 33060017[uid] OR 33060017[uid] OR 33060017[uid] OR 33058868[uid] OR 33057860[uid] OR 33051739[uid] OR 33051307[uid] OR 33051146[uid]"> PubMed click here </a></p>
<p>To see these selected articles in <a href="https://www.lens.org/lens/scholar/search/results?q=pmid:33177357%20OR%20pmid:33177340%20OR%20pmid:33176750%20OR%20pmid:33174146%20OR%20pmid:33172395%20OR%20pmid:33169301%20OR%20pmid:33168600%20OR%20pmid:33168404%20OR%20pmid:33159698%20OR%20pmid:33158979%20OR%20pmid:33156465%20OR%20pmid:33156066%20OR%20pmid:33151547%20OR%20pmid:33148667%20OR%20pmid:33148667%20OR%20pmid:33148628%20OR%20pmid:33148205%20OR%20pmid:33148196%20OR%20pmid:33145705%20OR%20pmid:33142117%20OR%20pmid:33141373%20OR%20pmid:33139271%20OR%20pmid:33139201%20OR%20pmid:33136337%20OR%20pmid:33135147%20OR%20pmid:33135146%20OR%20pmid:33135144%20OR%20pmid:33132046%20OR%20pmid:33129823%20OR%20pmid:33129375%20OR%20pmid:33129276%20OR%20pmid:33128119%20OR%20pmid:33127392%20OR%20pmid:33124049%20OR%20pmid:33123857%20OR%20pmid:33123857%20OR%20pmid:33123857%20OR%20pmid:33122531%20OR%20pmid:33122530%20OR%20pmid:33122528%20OR%20pmid:33122527%20OR%20pmid:33122526%20OR%20pmid:33122525%20OR%20pmid:33122524%20OR%20pmid:33122523%20OR%20pmid:33122522%20OR%20pmid:33122521%20OR%20pmid:33122518%20OR%20pmid:33122516%20OR%20pmid:33122513%20OR%20pmid:33121946%20OR%20pmid:33121847%20OR%20pmid:33109735%20OR%20pmid:33109470%20OR%20pmid:33108683%20OR%20pmid:33097588%20OR%20pmid:33097431%20OR%20pmid:33097430%20OR%20pmid:33097020%20OR%20pmid:33093663%20OR%20pmid:33093149%20OR%20pmid:33089395%20OR%20pmid:33087490%20OR%20pmid:33087489%20OR%20pmid:33087331%20OR%20pmid:33087057%20OR%20pmid:33086324%20OR%20pmid:33086318%20OR%20pmid:33086318%20OR%20pmid:33086310%20OR%20pmid:33084990%20OR%20pmid:33082211%20OR%20pmid:33082106%20OR%20pmid:33081716%20OR%20pmid:33079429%20OR%20pmid:33079423%20OR%20pmid:33079303%20OR%20pmid:33077384%20OR%20pmid:33077383%20OR%20pmid:33077382%20OR%20pmid:33077381%20OR%20pmid:33074907%20OR%20pmid:33074899%20OR%20pmid:33074853%20OR%20pmid:33073341%20OR%20pmid:33069583%20OR%20pmid:33069084%20OR%20pmid:33069083%20OR%20pmid:33065644%20OR%20pmid:33065029%20OR%20pmid:33060404%20OR%20pmid:33060404%20OR%20pmid:33060017%20OR%20pmid:33060017%20OR%20pmid:33060017%20OR%20pmid:33058868%20OR%20pmid:33057860%20OR%20pmid:33051739%20OR%20pmid:33051307%20OR%20pmid:33051146&amp;toYear=2020&amp;fromYear=1950&amp;dateFilterField=year_published&amp;filterMap=%7B%7D&amp;preview=true"> Lens.org click here </a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<div style="page-break-after: always;"></div>
<div id="pancreas" class="section level2">
<h2>Pancreas</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33177357" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33177357</a></p>
<p>OBJECTIVE: To reappraise the optimal number of examined lymph nodes (ELN) in pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: The well-established threshold of 15 ELN in PD for PDAC is optimized for detecting one positive node (PLN) per the previous 7 edition of the AJCC staging manual. In the framework of the 8 edition, where at least four PLN are needed for an N2 diagnosis, this threshold may be inadequate for accurate staging. METHODS: Patients who underwent upfront PD at two academic institutions between 2000 and 2016 were analyzed. The optimal ELN threshold was defined as the cut-point associated with a 95% probability of identifying at least 4 PLN in N2 patients. The results were validated addressing the N-status distribution and stage migration. RESULTS: Overall, 1218 patients were included. The median number of ELN was 26 (IQR 17-37). ELN was independently associated with N2-status (OR 1.27, p &lt; 0.001). The estimated optimal threshold of ELN was 28. This cut-point enabled improved detection of N2 patients and stage III disease (58% versus 37%, p = 0.001). The median survival was 28.6 months. There was an improved survival in N0/N1 patients when ELN exceeded 28, suggesting a stage migration effect (47 versus 29 months, adjusted HR 0.649, p &lt; 0.001). In N2 patients, this threshold was not associated with survival on multivariable analysis. CONCLUSION: Examining at least 28 LN in PD for PDAC ensures optimal staging through improved detection of N2/stage III disease. This may have relevant implications for benchmarking processes and quality implementation.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004552" class="uri">https://doi.org/10.1097/SLA.0000000000004552</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33177340" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33177340</a></p>
<p>Assessment of the Ki67 index is critical for grading well-differentiated neuroendocrine tumors (WD-NETs), which can show a broad range of labeling that defines the WHO grade (G1-G3). Poorly differentiated neuroendocrine carcinomas (PD-NECs) have a relatively high Ki67 index, &gt;20% in all cases and commonly exceeding 50%. After anecdotally observing PD-NECs with an unexpectedly low and heterogeneous Ki67 index following chemotherapy in 5 cases, we identified 15 additional cases of treated high-grade neuroendocrine neoplasms (HG-NENs). The study cohort comprised 20 cases; 11 PD-NECs, 8 mixed adenoneuroendocrine carcinomas, and 1 WD-NET, G3 from various anatomic sites (gastrointestinal tract, pancreas, larynx, lung, and breast). The Ki67 index was evaluated on pretreatment (when available) and posttreatment samples. Topographic heterogeneity in the Ki67 index was expressed using a semi-quantitative score of 0 (no heterogeneity) to 5 (&gt;80% difference between maximal Ki67 and minimal Ki67 indices). Relative to the pretreatment group (n=9, mean Ki67 of 86.3%, range 80% to 100%), the neoplasms in the posttreatment group (n=20, mean Ki67 of 47.7%, range 1% to 90%) showed a significantly lower Ki67 index (18/20 cases). Of the 18 cases with a relatively low Ki67 index, 15 showed heterogeneous labeling (mean heterogeneity score of 2.3, range 1 to 5) and in 3 cases it was a homogeneously low. This phenomenon was observed in all subtypes of HG-NENs. In 6 cases, the alterations in Ki67 index following treatment were sufficient to place these HG-NENs in the WHO G1 or G2 grade, erroneously suggesting a diagnosis of WD-NET, and in 9 cases there was sufficient heterogeneity in the Ki67 index to suggest that a limited biopsy may sample an area of low Ki67, even though hotspot regions with a Ki67 index of &gt;20% persisted. In 7 cases, the alterations in the Ki67 index were accompanied by morphologic features resembling a WD-NET. These observations suggest that there is a potential for misinterpretation of previously treated PD-NECs as WD-NETs, or for assigning a lower grade in G3 WD-NETs. While the prognostic significance of treatment-associated alterations in Ki67 index is unknown, awareness of this phenomenon is important to avoid this diagnostic pitfall when evaluating treated NENs.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001602" class="uri">https://doi.org/10.1097/PAS.0000000000001602</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Efficacy of EUS-guided FNB using a Franseen needle for tissue acquisition and microsatellite instability evaluation in unresectable pancreatic lesions</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Nov;20(1):1094</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33176750" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33176750</a></p>
<p>BACKGROUND: The efficacy of immune checkpoint blockade in the treatment of microsatellite instability (MSI)-high tumors was recently reported. Therefore, the acquisition of histological specimens is desired in cases of unresectable solid pancreatic lesions (UR SPLs). This study investigated the efficacy of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) using a Franseen needle for UR SPL tissue acquisition and MSI evaluation. METHODS: A total of 195 SPL patients who underwent EUS-guided fine-needle aspiration (EUS-FNA) or EUS-FNB (EUS-FNAB) between January 2017 and March 2020 were enrolled in this study. Among them, 89 SPL patients (FNB: 28, FNA: 61) underwent EUS-FNAB using a 22-G needle (UR SPLs: 58, FNB: 22, FNA: 36) (UR SPLs after starting MSI evaluation: 23, FNB: 9, FNA: 14). RESULTS: The puncture number was significantly lower with FNB than with FNA (median (range): 3 (2-5) vs 4 (1-8), P &lt;  0.01, UR SPLs: 3 (2-5) vs 4 (1-8), P = 0.036). Histological specimen acquisition was more commonly achieved with FNB than with FNA (92.9% (26/28) vs 68.9% (42/61), P = 0.015, UR SPLs: 100% (22/22) vs 72.2% (26/36), P &lt;  0.01). The histological specimen required for MSI evaluation was acquired more often with FNB than with FNA (88.9% (8/9) vs 35.7% (5/14), P = 0.03). CONCLUSIONS: EUS-FNB using a Franseen needle is efficient for histological specimen acquisition and sampling the required amount of specimen for MSI evaluation in UR SPL patients.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07588-5" class="uri">https://doi.org/10.1186/s12885-020-07588-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33174146" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33174146</a></p>
<p>BACKGROUND: Neoadjuvant therapy (NAT) is increasingly being used in the management of patients with resectable pancreatic ductal adenocarcinoma (PDAC); however, there is a lack of evidence regarding the benefit among these patients. OBJECTIVE: The aim of this study was to evaluate overall survival (OS) in PDAC patients with resectable disease treated with NAT or upfront resection through instrumental variable (IV) analysis. DESIGN: A national cohort study of resectable PDAC patients in the National Cancer Data Base (2007-2015) treated with either upfront surgery or resection after NAT. Using multivariable modeling and IV methods, OS was compared between those treated with NAT and upfront resection. The IV was hospital-level NAT utilization in the most recent year prior to treatment. RESULTS: The cohort included 16,666 patients (14,012 upfront resection; 2654 NAT) treated at 779 hospitals. Among those treated with upfront resection, 59.9% received any adjuvant therapy. NAT patients had higher median (27.9 months, 95% confidence interval [CI] 26.2-29.1) and 5-year OS (24.1%, 95% CI 21.9-26.3%) compared with those treated with upfront surgery (median 21.2 months, 95% CI 20.7-21.6; 5-year survival 20.9%, 95% CI 20.1-21.7%). After multivariable modeling, NAT was associated with an approximately 20% decrease in the risk of death (hazard ratio [HR] 0.78, 95% CI 0.73-0.84), and this effect was magnified in the IV analysis (HR 0.61, 95% CI 0.47-0.79). CONCLUSIONS: In patients with resectable PDAC, NAT is associated with improved survival relative to upfront resection. Given the benefits of multimodality therapy and the challenges in receiving adjuvant therapy, consideration should be given to treating all PDAC patients with NAT.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09327-3" class="uri">https://doi.org/10.1245/s10434-020-09327-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33168600" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33168600</a></p>
<p>OBJECTIVE: The intestinal microbiome affects the prevalence and pathophysiology of a variety of diseases ranging from inflammation to cancer. A reduced taxonomic or functional diversity of the microbiome was often observed in association with poorer health outcomes or disease in general. Conversely, factors or manifest diseases that determine the long-term stability or instability of the microbiome are largely unknown. We aimed to identify disease-relevant phenotypes associated with faecal microbiota (in-)stability. DESIGN: A total of 2564 paired faecal samples from 1282 participants of the population-based Study of Health in Pomerania (SHIP) were collected at a 5-year (median) interval and microbiota profiles determined by 16S rRNA gene sequencing. The changes in faecal microbiota over time were associated with highly standardised and comprehensive phenotypic data to determine factors related to microbiota (in-)stability. RESULTS: The overall microbiome landscape remained remarkably stable over time. The greatest microbiome instability was associated with factors contributing to metabolic syndrome such as fatty liver disease and diabetes mellitus. These, in turn, were associated with an increase in facultative pathogens such as Enterobacteriaceae or Escherichia/Shigella. Greatest stability of the microbiome was determined by higher initial alpha diversity, female sex, high household income and preserved exocrine pancreatic function. Participants who newly developed fatty liver disease or diabetes during the 5-year follow-up already displayed significant microbiota changes at study entry when the diseases were absent. CONCLUSION: This study identifies distinct components of metabolic liver disease to be associated with instability of the intestinal microbiome, increased abundance of facultative pathogens and thus greater susceptibility toward dysbiosis-associated diseases.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-322753" class="uri">https://doi.org/10.1136/gutjnl-2020-322753</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>French reconnection: A conservative pancreato-enteric reconnection for disconnected pancreatic duct syndrome</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33168404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33168404</a></p>
<p>BACKGROUND/OBJECTIVES: Disconnectedpancreatic duct syndrome (DPDS), a severe complication of acute necrotizing pancreatitis (ANP), may require surgery, usually by distal splenopancreatectomy, thus increasing the risk of diabetes. We describe a new technique reconnecting the distal pancreas to the digestive tract. METHODS: This technique was proposed after failure of non-surgical treatment and at least 3 months after the onset of ANP in non-diabetic or non-insulin dependent diabetic patients with a distal pancreas of at least 5 cm. The ruptured zone was identified and the distal side was anastomosed to the stomach or the jejunum. RESULTS: From 2013 to June 2019, 36 patients (median age = 49 years) with DPDS underwent a “French reconnection” procedure, indicated for chronic pain/recurrent pancreatitis (n = 35; 97%), persistent pancreatic fistula (n = 33; 91%), or digestive compression/fistulisation (n = 9; 25%). Median preoperative weight loss was 10 kg (4-27), the median number of hospitalisations per patient was 5(1-8) and 24(67%) patients had received endoscopic/percutaneous treatment. Surgery was performed in median 279(90-2000) days after ANP, laparoscopically in 9(25%) patients. The remnant pancreas (median length = 70 mm; range = 50-130) was anastomosed to the stomach (n = 30) or the jejunum (n = 6). There were 13(36%) postoperative grade B/C pancreatic fistulas and 3(10%) bleedings including one death (mortality = 3%). The median hospital stay was 18 (7-121) days. After a median follow-up of 24 (4-53) months, all pancreatic fistulas had healed and the clinical success rate was 91%. Median BMI increased from 22 to 25 kg/m2. In patients with normal pancreatic function, postoperative de novo endocrine and severe exocrine insufficiencies were observed in 4/27 (15%) and 7/22 (32%), respectively. CONCLUSIONS: The “French reconnection” procedure, as an alternative to distal splenopancreatectomy for the treatment of DPDS, provides good control of symptoms and decreases the risk of pancreatic insufficiency.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.045" class="uri">https://doi.org/10.1016/j.pan.2020.10.045</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>The Journal of pathology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33159698" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33159698</a></p>
<p>Apical microvilli of polarized epithelial cells govern the absorption of metabolites and the transport of fluid in tissues. Previously, we reported that tall and dense basal microvilli present on the endothelial cells of pancreatic cancers, a lethal malignancy with a high metabolism and unusual hypomicrovascularity, contain nutrient trafficking vesicles and glucose; their length and density were related to the glucose uptake of pancreatic cancers in a small-scale analysis. However, the implications of basal microvilli on pancreatic cancers are unknown. Here, we evaluated the clinical implications of basal microvilli in 106 pancreatic cancers. We found that basal microvilli are a dominant change in pancreatic cancers. The presence of longer and denser basal microvilli on the microvessels in pancreatic cancer tissues positively correlated with increased glucose uptake and higher metastatic (or invasive) and proliferative potentials of neoplastic cells and vice versa. Clinically, postoperative patients with longer and denser basal microvilli were more prone to unfavorable pathological characteristics and dismal prognoses. They were even more refractory to adjuvant therapy than those with shorter and thinner basal microvilli were. Our findings show that basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancers. This article is protected by copyright. All rights reserved.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5588" class="uri">https://doi.org/10.1002/path.5588</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pain patterns in chronic pancreatitis: a nationwide longitudinal cohort study</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33158979" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33158979</a></p>
<p>OBJECTIVE: Pain in chronic pancreatitis is subdivided in a continuous or intermittent pattern, each thought to represent a different entity, requiring specific treatment. Because evidence is missing, we studied pain patterns in a prospective longitudinal nationwide study. DESIGN: 1131 patients with chronic pancreatitis (fulfilling M-ANNHEIM criteria) were included between 2011 and 2018 in 30 Dutch hospitals. Patients with continuous or intermittent pain were compared for demographics, pain characteristics, quality of life (Short-Form 36), imaging findings, disease duration and treatment. Alternation of pain pattern and associated variables were longitudinally assessed using a multivariable multinomial logistic regression model. RESULTS: At inclusion, 589 patients (52%) had continuous pain, 231 patients (20%) had intermittent pain and 311 patients (28%) had no pain. Patients with continuous pain had more severe pain, used more opioids and neuropathic pain medication, and had a lower quality of life. There were no differences between pain patterns for morphological findings on imaging, disease duration and treatment. During a median follow-up of 47 months, 552 of 905 patients (61%) alternated at least once between pain patterns. All alternations were associated with the Visual Analogue Scale pain intensity score and surgery was only associated with the change from pain to no pain. CONCLUSION: Continuous and intermittent pain patterns in chronic pancreatitis do not seem to be the result of distinctly different pathophysiological entities. The subjectively reported character of pain is not related to imaging findings or disease duration. Pain patterns often change over time and are merely a feature of how severity of pain is experienced.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-322117" class="uri">https://doi.org/10.1136/gutjnl-2020-322117</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospective Cohort Analysis</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33156465" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33156465</a></p>
<p>OBJECTIVES: The aim of this study was to assess the impact of clinically relevant postoperative pancreatic fistula (CR-POPF) on patient disease-specific survival and recurrence after curative distal pancreatectomy (DP) for pancreatic cancer. DESIGN: This was a retrospective case-control analysis. METHODS: We examined the data of adult patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) of the body and tail of the pancreas undergoing curative DP, over a 10-year period in 12 European surgical departments, from a prospectively implemented database. RESULTS: Among the 382 included patients, 283 met the strict inclusion criteria; 139 were males (49.1%) and the median age of the entire population was 70 years (range 37-88). A total of 121 POPFs were observed (42.8%), 42 (14.9%) of which were CR-POPFs. The median follow-up period was 24 months (range 3-120). Although poorer in the POPF group, overall survival (OS) and disease-free survival (DFS) did not differ significantly between patients with and without CR-POPF (p = 0.224 and p = 0.165, respectively). CR-POPF was not significantly associated with local or peritoneal recurrence (p = 0.559 and p = 0.302, respectively). A smaller percentage of patients benefited from adjuvant chemotherapy after POPF (76.2% vs. 83.8%), but the difference was not significant (p = 0.228). CONCLUSIONS: CR-POPF is a major complication after DP but it did not affect the postoperative therapeutic path or long-term oncologic outcomes. CR-POPF was not a predictive factor for disease recurrence and was not associated with an increased incidence of peritoneal or local relapse. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT04348084.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09310-y" class="uri">https://doi.org/10.1245/s10434-020-09310-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Early Patient Discharge in Selected Patients is Not Associated with Higher Readmission After Major Abdominal Operations</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33156066" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33156066</a></p>
<p>OBJECTIVE: Our objective was to examine the associations between early discharge and readmission after major abdominal operations. BACKGROUND: Advances in patient care resulted in earlier patient discharge after complex abdominal operations. Whether early discharge is associated with patient readmissions remains controversial. METHODS: Patients who had colorectal, liver, and pancreas operations abstracted in 2011-2017 ACS NSQIP Participant Use Data Files were included. Patient readmission was stratified by 6 operative groups. Patients who were discharged prior to median discharge date within each operative group were categorized as an early discharge. Analyses tested associations between early discharge and likelihood of 30-day postoperative unplanned readmission. RESULTS: 364,609 patients with major abdominal operations were included. Individual patient groups and corresponding median day of discharge were: laparoscopic colectomy (n = 152,575; median = 4), open colectomy (n = 137,462; median = 7), laparoscopic proctectomy (n = 12,238; median = 5), open proctectomy (n = 24,925; median = 6), major hepatectomy (n = 9,805; median = 6), pancreatoduodenectomy (n = 27,604; median = 8). Early discharge was not associated with an increase in proportion of readmissions in any operative group. Early discharge was associated with a decrease in average proportion of patient readmissions compared to patients discharged on median date in each of the operative groups: laparoscopic colectomy 6% versus 8%, open colectomy 11% versus 14%, laparoscopic proctectomy 13% versus 16%, open proctectomy 13% vs 17%, major hepatectomy 8% versus 12%, pancreatoduodenectomy 16% versus 20% (all p ≤ 0.02). Serious morbidity composite was significantly lower in patients who were discharged early than those who were not in each operative group (all p &lt; 0.001). CONCLUSIONS: Early discharge in selected patients after major abdominal operations is associated with lower, and not higher, rate of 30-day unplanned readmission.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004582" class="uri">https://doi.org/10.1097/SLA.0000000000004582</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Cardiometabolic risk factors and survival after cancer in the Women’s Health Initiative</strong></li>
</ul>
</summary>
<p><em>Cancer 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33151547" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33151547</a></p>
<p>BACKGROUND: Cardiometabolic abnormalities are a leading cause of death among women, including women with cancer. METHODS: This study examined the association between prediagnosis cardiovascular health and total and cause-specific mortality among 12,076 postmenopausal women who developed local- or regional-stage invasive cancer in the Women’s Health Initiative (WHI). Cardiovascular risk factors included waist circumference, hypertension, high cholesterol, and type 2 diabetes. Obesity-related cancers included breast cancer, colorectal cancer, endometrial cancer, kidney cancer, pancreatic cancer, ovarian cancer, stomach cancer, liver cancer, and non-Hodgkin lymphoma. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for important predictors of survival. RESULTS: After a median follow-up of 10.0 years from the date of the cancer diagnosis, there were 3607 total deaths, with 1546 (43%) due to cancer. Most participants (62.9%) had 1 or 2 cardiometabolic risk factors, and 8.1% had 3 or 4. In adjusted models, women with 3 to 4 risk factors (vs none) had a higher risk of all-cause mortality (HR, 1.99; 95% CI, 1.73-2.30), death due to cardiovascular disease (CVD) (HR, 4.01; 95% CI, 2.88-5.57), cancer-specific mortality (HR, 1.37; 95% CI, 1.1-1.72), and other-cause mortality (HR, 2.14; 95% CI, 1.70-2.69). A higher waist circumference was associated with greater all-cause mortality (HR, 1.17; 95% CI, 1.06-1.30) and cancer-specific mortality (HR, 1.22; 95% CI, 1.04-1.42). CONCLUSIONS: Among postmenopausal women diagnosed with cancer in the WHI, cardiometabolic risk factors before the cancer diagnosis were associated with greater all-cause, CVD, cancer-specific, and other-cause mortality. These results raise hypotheses regarding potential clinical intervention strategies targeting cardiometabolic abnormalities that require future prospective studies for confirmation. LAY SUMMARY: This study uses information from the Women’s Health Initiative (WHI) to find out whether cardiac risk factors are related to a greater risk of dying among older women with cancer. The WHI is the largest study of medical problems faced by older women in this country. The results show that women who have 3 or 4 risk factors are more likely to die of any cause, heart disease, or cancer in comparison with women with no risk factors. It is concluded that interventions to help to lower the burden of cardiac risk factors can have an important impact on survivorship among women with cancer.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.33295" class="uri">https://doi.org/10.1002/cncr.33295</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>PIPAC-OX: A Phase I study of Oxaliplatin-based Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Peritoneal Metastases</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33148667" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33148667</a></p>
<p>BACKGROUND: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel, laparoscopic intraperitoneal chemotherapy delivery technique aiming to improve drug distribution and tissue penetration to treat peritoneal metastases. Thus far, PIPAC oxaliplatin is conducted at an arbitrary dose of 92mg/m2. We conducted a phase 1 study to establish safety and tolerability. EXPERIMENTAL DESIGN: We used a 3+3 dose escalation design of PIPAC oxaliplatin for patients with peritoneal metastases from gastrointestinal tumors, after failure of at least first-line chemotherapy. Dose levels were planned at 45, 60, 90 and 120mg/m2. FINDINGS: This study included 16 patients with 24 PIPAC procedures (8 gastric, 5 colorectal and 1 gallbladder, pancreas and appendix cancer each). Median age and Peritoneal Cancer Index (PCI) score were 62 years and 17, respectively. Two patients developed pancreatitis (grade 2 and 3) at 45mg/m2, necessitating cohort expansion. Another patient developed grade 2 pancreatitis at 90mg/m2. There were no other dose limiting toxicities and the highest dose cohort (120 mg/m2) tolerated PIPAC well. Pharmacokinetic analyses demonstrated good linearity between dose and maximum concentration (r2=0.95) and area under the curve (AUC) (r2=0.99). Based on response evaluation criteria in solid tumors, 62.5% and 50% had stable disease after one and two PIPAC procedures, respectively. 8 patients underwent 2 PIPAC procedures, with improvement of median PCI and Peritoneal Regression Grade Score from 15 to 12 and 2.5 to 2.0, respectively. CONCLUSIONS: The recommended phase 2 dose is 120 mg/m2. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-2152" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-2152</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites</strong></li>
</ul>
</summary>
<p><em>Journal of clinical pathology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33148628" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33148628</a></p>
<p>AIMS: Breast neuroendocrine tumours (NETs) constitute a rare histologic subtype of oestrogen receptor (ER)-positive breast cancer, and their definition according to the WHO classification was revised in 2019. Breast NETs display histologic and transcriptomic similarities with mucinous breast carcinomas (MuBCs). Here, we sought to compare the repertoire of genetic alterations in breast NETs with MuBCs and NETs from other anatomic origins. METHODS: On histologic review applying the new WHO criteria, 18 breast tumours with neuroendocrine differentiation were reclassified as breast NETs (n=10) or other breast cancers with neuroendocrine differentiation (n=8). We reanalysed targeted sequencing or whole-exome sequencing data of breast NETs (n=10), MuBCs type A (n=12) and type B (n=11). RESULTS: Breast NETs and MuBCs were found to be genetically similar, harbouring a lower frequency of PIK3CA mutations, 1q gains and 16q losses than ER-positive/HER2-negative breast cancers. 3/10 breast NETs harboured the hallmark features of ER-positive disease (ie, PIK3CA mutations and concurrent 1q gains/16q losses). Breast NETs showed an enrichment of oncogenic/likely oncogenic mutations affecting transcription factors compared with common forms of ER-positive breast cancer and with pancreatic and pulmonary NETs. CONCLUSIONS: Breast NETs are heterogeneous and are characterised by an enrichment of mutations in transcription factors and likely constitute a spectrum of entities histologically and genomically related to MuBCs. While most breast NETs are distinct from ER-positive/HER2-negative IDC-NSTs, a subset of breast NETs appears to be genetically similar to common forms of ER-positive breast cancer, suggesting that some breast cancers may acquire neuroendocrine differentiation later in tumour evolution.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-207052" class="uri">https://doi.org/10.1136/jclinpath-2020-207052</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating ��-catenin</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Nov;20(1):1065</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33148205" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33148205</a></p>
<p>BACKGROUND: Pancreatic cancer is a malignant tumor with high mortality. Acidic nuclear phosphoprotein 32 family member E (ANP32E), a specific H2A.Z chaperone, has been shown to contribute to breast cancer development. However, the significance of ANP32E in pancreatic cancer is poorly understood. This study aimed to investigate the role of ANP32E in pancreatic cancer. METHODS: The expression of ANP32E in 179 pancreatic cancer tissues and 171 normal tissues, and the correlation between ANP32E expression and patients’ survival were analyzed from the TCGA database. ANP32E was over-expressed and silenced using lentivirus. siRNA was used to knock down β-catenin. CCK8, colony formation, cell cycle and transwell experiments were performed to determine cell proliferation and migration. qRT-PCR and Western blot were conducted to detect mRNA and protein expression. RESULTS: ANP32E was up-regulated in pancreatic cancer tissues and cells. Up-regulation of ANP32E predicted poor prognosis in pancreatic cancer patients. Lentivirus-mediated knockdown of ANP32E suppressed the proliferation, colony growth and migration of PANC1 and MIA cells. By contrast, ANP32E over-expression promoted the proliferation and migration of both cells. In addition, ANP32E accelerated the cell cycle progression in PANC1 and MIA cells. Molecular experiments showed that ANP32E activated β-catenin/cyclin D1 signaling. Silencing of β-catenin reduced cell proliferation and migration in ANP32E over-expressed cells. CONCLUSION: Our results propose that ANP32E functions as an oncogene in pancreatic cancer via activating β-catenin.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07556-z" class="uri">https://doi.org/10.1186/s12885-020-07556-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Decompositions of the Contribution of Treatment Disparities to Survival Disparities in Stage I-II Pancreatic Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33145705" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33145705</a></p>
<p>BACKGROUND: Higher socioeconomic status (SES) and non-Hispanic White (NHW) race/ethnicity are associated with higher treatment rates and longer overall survival (OS) among US patients with stage I-II pancreatic ductal adenocarcinoma. The proportion of OS disparities mediated through treatment disparities (PM) and the proportion predicted to be eliminated (PE) if treatment disparities were eliminated are unknown. METHODS: We analyzed 2007-2015 data from the Surveillance, Epidemiology, and End Results (SEER) census tract-level database and the National Cancer Database (NCDB) using causal mediation analysis methods to understand the extent to which treatment disparities mediate OS disparities. In the first set of decompositions, race/ethnicity was controlled for as a covariate proximal to SES, and lower SES strata were compared with the highest SES stratum. In the second set, an intersectional perspective was taken and each SES-race/ethnicity combination was compared with highest SES-NHW patients, who had the highest treatment rates and longest OS. RESULTS: The SEER and NCDB cohorts contained 16,921 patients and 44,638 patients, respectively. When race/ethnicity was controlled for, PMs ranged from 43 to 48% and PEs ranged from 46 to 50% for various lower SES strata. When separately comparing each SES-race/ethnicity combination with the highest SES-NHW patients, results were similar for lower SES-NHW patients but differed markedly for non-Hispanic Black and Hispanic patients, for whom PMs ranged from 60 to 80% and PEs ranged from 55 to 75% for most lower SES strata. CONCLUSIONS: These results suggest that efforts to reduce treatment disparities are worthwhile, particularly for NHB and Hispanic patients, and simultaneously point to the importance of non-treatment-related causal pathways.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09267-y" class="uri">https://doi.org/10.1245/s10434-020-09267-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Cell 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33142117" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33142117</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) tumors have a nutrient-poor, desmoplastic, and highly innervated tumor microenvironment. Although neurons can release stimulatory factors to accelerate PDAC tumorigenesis, the metabolic contribution of peripheral axons has not been explored. We found that peripheral axons release serine (Ser) to support the growth of exogenous Ser (exSer)-dependent PDAC cells during Ser/Gly (glycine) deprivation. Ser deprivation resulted in ribosomal stalling on two of the six Ser codons, TCC and TCT, and allowed the selective translation and secretion of nerve growth factor (NGF) by PDAC cells to promote tumor innervation. Consistent with this, exSer-dependent PDAC tumors grew slower and displayed enhanced innervation in mice on a Ser/Gly-free diet. Blockade of compensatory neuronal innervation using LOXO-101, a Trk-NGF inhibitor, further decreased PDAC tumor growth. Our data indicate that axonal-cancer metabolic crosstalk is a critical adaptation to support PDAC growth in nutrient poor environments.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2020.10.016" class="uri">https://doi.org/10.1016/j.cell.2020.10.016</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer?</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33141373" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33141373</a></p>
<p>OBJECTIVE: This study aims to define the role of surgery and assess different therapies for nonagenarians with localized, nonmetastatic pancreatic adenocarcinoma (PDAC). METHODS: The National Cancer Database (NCDB) was queried for patients ≥ 90 years of age with nonmetastatic, localized PDAC from 2004-2016. Postoperative mortality was assessed at 30 and 90 days in patients receiving pancreatoduodenectomy or total pancreatectomy. Overall survival (OS) was compared between three treatment groups: surgery alone, chemotherapy alone, and chemoradiation (chemoRT) alone. RESULTS: Of 380,524 patients with PDAC, 98 patients ≥ 90 years of age underwent curative-intent resection; 55% were female and 75% had a Charlson-Deyo comorbidity score of 0. A total of 17% received postoperative chemotherapy, 51.1% had poorly differentiated tumors with a median tumor size of 3 cm, 55.1% had positive lymph nodes, and 19.4% had positive resection margins. Postoperative median length of stay was 11 days. Postoperative 30- and 90-day mortality was 10.0% and 18.9%, respectively. Median OS for the surgery alone group was 11.6 months compared with 20.4 months in those receiving adjuvant therapy (p = 0.01). Among nonoperative PDAC patients, median OS in patients receiving chemotherapy only (n = 207) was 7.2 months, while chemoRT only (n = 100) was similar to surgery only (11 versus 11.6 months, p = 0.97). CONCLUSIONS: Even in well-selected nonagenarians, pancreatoduodenectomy or total pancreatectomy carries a high mortality rate. While adjuvant therapy after resection provides the best survival, it is seldom achieved, and chemoRT alone affords identical survival statistics as surgery alone. These data suggest it is reasonable to consider chemoRT as initial therapy, then reassess candidacy for resection if performance status allows.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09279-8" class="uri">https://doi.org/10.1245/s10434-020-09279-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33139271" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33139271</a></p>
<p>BACKGROUND: Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide. METHODS: The PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. RESULTS: 427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors were at greatest risk (SIR 12.1; 95% CI 9.6 to 15.1; SIR 7.3; 95% CI 5.9 to 9.0, respectively). The cumulative incidence increased the most steeply with increasing age for WT survivors, reaching 7.4% by age 55% and 9.6% by age 60 years (1.0% expected based on general population rates). Regarding colorectal SPNs, WT and HL survivors were at greatest risk; both seven times that expected. By age 55 years, 2.3% of both WT (95% CI 1.4 to 3.9) and HL (95% CI 1.6 to 3.2) survivors had developed a colorectal SPN-comparable to the risk among members of the general population with at least two first-degree relatives affected. CONCLUSIONS: Colonoscopy surveillance before age 55 is recommended in many European countries for individuals with a family history of colorectal cancer, but not for WT and HL survivors despite a comparable risk profile. Clinically, serious consideration should be given to the implementation of colonoscopy surveillance while further evaluation of its benefits, harms and cost-effectiveness in WT and HL survivors is undertaken.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-322237" class="uri">https://doi.org/10.1136/gutjnl-2020-322237</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Role of ultrasound shear wave elastography in preoperative prediction of pancreatic fistula after pancreaticoduodenectomy</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33139201" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33139201</a></p>
<p>BACKGROUND: Majority of predictors of postoperative pancreatic fistula (POPF) use intraoperative variables. We aimed to study the role of preoperative ultrasound shear wave elastography (USWE) to predict POPF. METHODS: The consecutive patients who underwent pancreaticoduodenectomy (PD) between January 2019 to March 2020 were prospectively enrolled. All patients underwent USWE assessment at the pancreatic neck level. Intraoperative variables including pancreatic texture, pancreatic duct diameter, blood loss and histological grading of fibrosis were also recorded. Associations between USWE and intraoperative variables and histological grading with the development of POPF were analyzed. RESULTS: Of the 62 patients assessed, 50 patients (mean age: 53 ± 14 years; 31 males) were included. POPF and clinically relevant POPF (CRPOPF) were observed in 22 (44%) and 7 (14%) patients respectively. Soft pancreas was an independent predictor of CRPOPF (p = 0.04). The mean USWE valve was significantly lower in patients with CRPOPF as compared to no CRPOPF (9.7 Kpa vs. 12.8Kpa, p = 0.016). At receiver operating characteristic curve analysis, USWE value of 12.65Kpa yielded sensitivity and specificity of 100% and 47%, respectively, for prediction of CRPOPF. USWE showed significant correlation with intraoperative pancreatic texture (Spearman’s rank correlation coefficient (ρ) = 0.565, p = 0.001). CONCLUSION: USWE helps in preoperative prediction of CRPOPF. This may further help to customize management strategy in high risk patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.047" class="uri">https://doi.org/10.1016/j.pan.2020.10.047</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Acinar cell induced autolysis is a frequent occurrence in CytoLyt-fixed pancreatic fine needle aspiration specimens: An analysis of 157 cytology samples</strong></li>
</ul>
</summary>
<p><em>Cancer cytopathology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33136337" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33136337</a></p>
<p>BACKGROUND: Although 10% formalin is a standard preservative in pancreatic FNAs, the effect of CytoLyt on pancreatic tissue preservation has not been systematically explored. METHODS: Smears and cell blocks from CytoLyt-fixed (CF-CBs) and formalin-fixed (FF-CBs) pancreatic FNAs were blindly reviewed without knowledge of the fixative used, and the presence of tissue/tumor autolysis was noted. Controls included FF-CBs from pancreatic FNAs, CF-CBs from nonpancreatic FNAs, and 4 pancreatic FNAs with matched CF-CBs and FF-CBs. RESULTS: We found that 62 of 85 (73%) pancreatic FNAs with CF-CBs showed significant autolysis, which was most pronounced in acinar cells and/or tumor cells with benign acinar cells in the background, compared with 2 of 46 (4%) FF-CBs (P &lt; .0001) and 3 of 26 (12%) CF-CBs from nonpancreatic FNAs (73% vs 12%; P &lt; .0001). Of the 4 pancreatic FNAs with matched CF-CBs and FF-CBs, all 4 CF-CBs showed marked autolysis versus none of the matched FF-CBs. Of the 23 (27%) pancreatic FNAs with CF-CBs that did not show autolysis, 10 had no acinar cells, and 7 had only minute tissue fragments on CB. CONCLUSION: While CytoLyt is a useful fixative for nonpancreatic FNAs it is a suboptimal fixative for pancreatic FNAs and is associated with tissue/tumor autolysis in the majority of cases, influencing morphologic evaluation, and potentially immunocytochemical staining. Autolysis appears to be due to acinar enzymes whose effect is likely interrupted/inhibited by formalin fixation. Cytopathologists and cytotechnologists should be mindful of this pitfall and should avoid using CytoLyt as a fixative for pancreatic FNAs.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22378" class="uri">https://doi.org/10.1002/cncy.22378</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33135144" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33135144</a></p>
<p>BACKGROUND: Disparities in pancreatic cancer outcomes between black and white patients are well documented. This study aimed to use a more novel index to examine the impact of racial segregation on the diagnosis, management, and outcomes of pancreatic cancer in black patients compared with white patients. METHODS: Black and white adults with pancreatic cancer in urban counties were identified using data from the 2018 submission of the Surveillance, Epidemiology and End Results (SEER) Program and the 2010 Census. The racial index of dissimilarity (IoD), a validated proxy of racial segregation, was used to assess the evenness with which whites and blacks are distributed across census tracts in each county. Multivariate Poisson regression was performed, and stepwise models were constructed for each of the outcomes. Overall survival was studied using the Kaplan-Meier method. RESULTS: The study enrolled 60,172 adults with a diagnosis of pancreatic cancer between 2005 and 2015. Overall, the black patients (13.8% of the cohort) lived in more segregated areas (IoD, 0.67 vs 0.61; p &lt; 0.05). They were less likely to undergo surgery for localized disease (relative risk [RR], 0.80; 95% confidence interval [CI], 0.76-0.83) and more frequently had a diagnosis of advanced-stage disease (RR, 1.09; 95% CI, 1.01-1.19) with increasing segregation. They also had shorter survival times (9.8 vs 11.4 months; p &lt; 0.05). CONCLUSIONS: Disparities in advanced-stage disease at diagnosis, surgery for localized disease, and overall survival are directly related to the degree of residential segregation, a proxy for structural racism. In searching for solutions to this problem, it is important to account for the historical marginalization of black Americans.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09218-7" class="uri">https://doi.org/10.1245/s10434-020-09218-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Divergent trends in lifetime drinking and smoking between Black and White Americans diagnosed with chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33132046" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33132046</a></p>
<p>BACKGROUND/OBJECTIVES: Black Americans are at increased risk of chronic pancreatitis (CP) compared to their White counterparts. We aimed to describe the race-specific smoking history and lifetime drinking in patients diagnosed with CP. METHODS: We analyzed data on 334 Black and White CP participants of the North American Pancreatitis Study 2 Continuation and Validation Study and Ancillary Study. Lifetime drinking history and lifetime smoking history were collected through in-person interviews. Intensity, frequency, duration and current status of drinking and smoking were compared between Black and White CP participants, stratified by physician-defined alcohol etiology. In addition, drinking levels at each successive decades in life (20s, 30s, 40s) were compared by race and graphically portrayed as heat diagrams. RESULTS: Among patients with alcoholic CP, current smoking levels were not different by race (67-70%), but a smaller proportion of Black patients reported having smoked 1 or more packs per day in the past (32%) as compared to White patients (58%, p &lt; 0.0001). Black patients were more likely to report current consumption of alcohol (31%), as opposed to White patients (17%, p = 0.016). Black patients also reported more intense drinking at age 35 and 45 years as compared to White patients, while age at CP onset were similar between the two groups. CONCLUSION: We found more intense drinking but less intense smoking history in Black CP patients as compared to White CP patients. Effective alcohol abstinence and smoking cessation program with sustained impact are needed in CP patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.031" class="uri">https://doi.org/10.1016/j.pan.2020.10.031</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Insulin’s centenary: the birth of an idea</strong></li>
</ul>
</summary>
<p><em>The lancet. Diabetes &amp; endocrinology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33129375" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33129375</a></p>
<p>At 2:00 h on Oct 31, 1920, Frederick G Banting, a surgeon practising in London, ON, Canada, conceived an idea to isolate the internal secretion of the pancreas. The following week, he met with noted scientist John J R Macleod in Toronto, ON, Canada, and they developed a research plan. By August, 1921, Banting and his student assistant Charles H Best had prepared an effective extract from a canine pancreas. In January, 1922, biochemist James B Collip isolated insulin that was sufficiently pure for human use. On Oct 25, 1923, Banting and Macleod received the Nobel Prize in Physiology or Medicine for the discovery of insulin. Here, we recount the most relevant events before and after the fateful early morning of Oct 31, 1920, which culminated in the discovery and clinical use of insulin.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(20)30337-5" class="uri">https://doi.org/10.1016/S2213-8587(20)30337-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33128119" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33128119</a></p>
<p>BACKGROUND: The clinical implications of pre- and postoperative KRAS-mutated circulating tumor DNA (ctDNA) present in patients with pancreatic ductal adenocarcinoma (PDAC) have remained an unresolved issue. This study sought to investigate the clinical significance of pre- and postoperative ctDNA analyses and their impact on the prognosis of PDAC patients. METHODS: Digital droplet polymerase chain reaction detected ctDNA in pre- and postoperative plasma samples prospectively obtained from patients with resectable and borderline-resectable PDAC. Its associations with recurrence-free survival (RFS) and overall survival (OS) were analyzed. The patients were sorted according to the presence of pre- and postoperative ctDNA, and its ability to stratify prognosis was evaluated. RESULTS: The study analyzed 97 patients. Both pre- and postoperative ctDNA were detected in 9 patients, and neither was detected in 55 patients. Whereas 15 patients harbored only preoperative ctDNA, 18 patients had only postoperative ctDNA. The multivariate analysis showed that the presence of preoperative ctDNA was associated with poorer OS (P = 0.008) and that postoperative ctDNA was not associated with either RFS or OS. Survival did not differ significantly between the patients with a positive shift in ctDNA status and those without detectable pre- or postoperative ctDNA. CONCLUSIONS: For the patients with PDAC, the presence of preoperative ctDNA was significantly associated poor OS, whereas postoperative ctDNA was not associated with poor survival. A positive change in ctDNA did not affect patients’ survival.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09278-9" class="uri">https://doi.org/10.1245/s10434-020-09278-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>How to Perform Total Laparoscopic Duodenum-Preserving Pancreatic Head Resection Safely and Efficiently with Innovative Techniques</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857</a></p>
<p>BACKGROUND: Although rapid progress has been achieved in laparoscopic pancreaticoduodenectomy (PD) over the last decade, laparoscopic duodenum-preserving pancreatic head resection (LDPPHR) remains a challenging surgery that has been rarely reported due to not only requiring complicated pancreaticojejunostomy (PJ) but also ensuring sufficient blood supplies to duodenum and common bile duct (CBD). We completed LDPPHR for 22 patients safely and efficiently with innovative techniques. PATIENTS AND METHODS: Clinical outcomes, including rate of conversion to laparotomy, time of residual pancreatic duct reconstruction, incidence of postoperative complications, and time of hospital stay, were collected for 22 consecutive patients who underwent LDPPHR with innovative techniques as follows: application of indocyanine green (ICG) to visualize and preserve CBD and the vessels supplying the duodenum and CBD, Hong’s PJ, and pancreatic duct end-to-end anastomosis (ETEA) for the residual pancreas. RESULTS: All surgeries were performed successfully under laparoscopy except for one case. The duration of ETEA was significantly shorter than PJ (18.2 ± 5.1 min versus 27.5 ± 8.3 min, p &lt; 0.05). There was no significant difference in incidence of postoperative complications between the Hong’s PJ and ETEA group. The overall incidence of postoperative pancreatic fistula (POPF) in the Hong’s PJ and ETEA group was 23.5% and 20%, respectively, without grade C fistula. All complications were resolved after conservative treatment. CONCLUSIONS: By utilizing intraoperative ICG navigation, LDPPHR is a minimally invasive, safe, and efficient approach for chronic pancreatitis with pancreatic head stones by using pancreatic duct ETEA and benign or low-grade malignant tumors of the pancreatic head by using Hong’s PJ.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09233-8" class="uri">https://doi.org/10.1245/s10434-020-09233-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Identification of Genomic Alterations in Sporadic Pancreatic Neurogenic Tumors</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1393-1397</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122531" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122531</a></p>
<p>Pancreatic neurogenic tumors, including schwannoma and neurofibroma, are rare, and their genetic aberrances have not been defined. The present study aimed at investigating the genomic alterations of pancreatic schwannoma and neurofibroma. Two patients with pancreatic schwannoma and 1 patient with neurofibroma, who underwent surgical resection at the First Affiliated Hospital, Sun Yat-sen University between June 2016 and April 2019, were recruited into the study. Their tumor tissues were analyzed by exome sequencing and genome sequencing. Exome sequencing revealed a MUTYH likely pathogenic germline variant in 1 schwannoma with somatic NF2del and NOTCH1 amplification. Pathway enrichment analysis on the other schwannoma case showed that the main abnormal function involved DNA damage repair, mitosis, and cell cycle. In addition, genome sequencing showed the inversion (INV) variant of SPIRE gene and multiple mitochondrial INV variants in both schwannoma cases. Furthermore, exome sequencing revealed NF1del, single nucleotide variation, TP53, and ERBB3 amplification in neurofibroma, whereas genomic duplication/deletion variants and mitochondrial abnormalities were much less than that in schwannoma. In conclusion, variants in NF1 and NF2 genes, amplification of key driver genes, and somatic and mitochondrial INV variants may play important roles in the development of pancreatic schwannoma and neurofibroma.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001680" class="uri">https://doi.org/10.1097/MPA.0000000000001680</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Successful Localization and Resection of Small Pancreatic Cystic Insulinoma Using Intraoperative Near-Infrared Fluorescence Imaging: A Case Report and Literature Review</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1388-1392</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122530" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122530</a></p>
<p>Pancreatic cystic insulinoma is an uncommon tumor. Perioperative localization remained challenging if the tumor is atypical with cystic feature or in small size. Near-infrared (NIR) imaging is a technique by injecting fluorescent dye intravenously, which accumulates to the target lesion and creating signal by laser sources. The signal helps surgeons to identify the lesion during operation, but little experience has been reported regarding the use of imaging NIR technique for localizing cystic insulinoma. We present a 29-year-old female patient with a symptomatic pancreatic cystic insulinoma (1.2 cm) as assessed by clinical symptom, laboratory evidence, and magnetic resonance cholangiopancreatography. With an aid of NIR imaging technique, this cystic tumor was localized easily at operation. Also, the fluorescence imaging visualized the tumor part, guided us to identify the safe margin, and preserved the normal pancreatic structure. Pathologic report confirmed that the tumor was a well-differentiated cystic insulinoma. This case demonstrates that pancreatic cystic insulinoma in small size can be intraoperatively localized by NIR imaging, a relatively safe and easy technique.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001678" class="uri">https://doi.org/10.1097/MPA.0000000000001678</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1378-1382</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122528" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122528</a></p>
<p>OBJECTIVE: In 2017 and 2019, the World Health Organization defined grade 3 neuroendocrine tumors (G3 NETs) and neuroendocrine carcinoma (G3 NEC) in the pancreas. The validity of this classification remains to be verified. METHODS: Clinical data were collected and analyzed for 39 G3 pancreatic neuroendocrine neoplasms (PanNENs) patients between 2009 and 2018. RESULTS: The tumor-node-metastasis stage (P = 0.0260), differentiation (P = 0.0115), and Ki-67 index (P = 0.0371) are prognostic factors for G3 PanNENs by Kaplan-Meier survival analysis. Among 39 patients, 18 had a Ki-67 index of less than 55% and well-differentiated morphology (G3 NET) and 16 had a Ki-67 index of 55% or greater and poorly differentiated morphology (G3 NEC). Grade 3 neuroendocrine tumor had a significant better prognosis than G3 NEC (median overall survival time, 25 months [95% confidence interval, 10.854-39.146 months] vs 12 months [95% confidence interval, 6.316-17.684 months], P = 0.0164). Based on Cox regression analyses, tumor-node-metastasis stage (P = 0.016) was identified as the independent prognostic factor for G3 PanNENs. CONCLUSIONS: The upper Ki-67 index cutoff of 55% might be the best cutoff value to define G3 NETs and G3 NECs for G3 PanNENs. The World Health Organization 2017 and 2019 classification system for G3 PanNENs can identify high-risk patients with G3 PanNENs.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001693" class="uri">https://doi.org/10.1097/MPA.0000000000001693</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1372-1377</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122527" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122527</a></p>
<p>OBJECTIVES: The multidrug regimen with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is widely used for recurrent pancreatic cancer after pancreatic resection. However, there are concerns about severe toxicities and poor tolerability of FOLFIRINOX in these patients because some suffer from surgery-associated malnutrition, weight loss, and diabetes mellitus. We evaluated the toxicity and tolerability of FOLFIRINOX in these patients. METHODS: This study was conducted as a secondary analysis of the Japan Adjuvant Study Group of Pancreatic Cancer 06 study, which was a multicenter observational study of FOLFIRINOX for pancreatic cancer in Japan. The toxicity and tolerability of FOLFIRINOX in recurrent disease correlated with those of both the locally advanced and the metastatic disease group. RESULTS: The major grades 3 and 4 toxicities observed in the recurrent and locally advanced or metastatic disease groups were neutropenia (68% vs 63%), febrile neutropenia (4% vs 15%, P = 0.007), thrombocytopenia (4% vs 3%), diarrhea (4% vs 8%), and sensory neuropathy (0% vs 2%). The dose modification and relative dose intensity did not differ markedly between the groups. CONCLUSIONS: The toxicity and tolerability of FOLFIRINOX for recurrence after pancreatic resection were similar to those for locally advanced or metastatic disease with appropriate patient selection and dose modifications.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001692" class="uri">https://doi.org/10.1097/MPA.0000000000001692</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1364-1371</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122526" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122526</a></p>
<p>OBJECTIVES: Pancreatic stellate cells (PSCs) play a key metabolic role within the tumor microenvironment (stroma) of pancreatic ductal adenocarcinoma (PDAC), being glycolytic and associated with protumorigenic acidification from excess lactate. This study investigates the clinical significance of glycolytic enzyme lactate dehydrogenase (LDH) and determines efficacy of the novel pan-LDH inhibitor Galloflavin. METHODS: An in vitro Transwell system was adopted for coculture of PSCs and 3 PDAC cell lines (MIA PaCa-2, PANC-1, and BxPC-3). Cells were treated with Galloflavin, and outcomes were analyzed regarding proliferation, apoptosis, lactate production, and glycolytic enzyme protein expression. Immunohistochemical staining for lactate dehydrogenase B (LDHB) was performed on 59 resected PDAC tumors annotated for clinical outcome. RESULTS: Galloflavin reduced PDAC proliferation in monoculture (P &lt; 0.01); however, in co-culture with PSCs, an antiproliferative effect was only evident in PANC-1 (P = 0.001). An apoptotic effect was observed in MIA PaCa-2 and BxPC-3 in coculture (P &lt; 0.05). A reduction in media lactate was observed in coculture (P &lt; 0.01) with PSCs. Immunohistochemistry revealed stromal and tumoral LDHB expression had no impact on survival. CONCLUSIONS: Galloflavin has the potential to neutralize the acidic PDAC microenvironment and thereby reduce tumor invasiveness and metastasis. Patients with lower LDHB expression are more likely to be beneficial responders.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001689" class="uri">https://doi.org/10.1097/MPA.0000000000001689</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Racial and Socioeconomic Disparities in the Treatments and Outcomes of Pancreatic Cancer Among Different Treatment Facility Types</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1355-1363</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122525" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122525</a></p>
<p>OBJECTIVES: The aim of this study was to investigate racial and socioeconomic disparities for patients with pancreatic cancer across different facility types. METHODS: The National Cancer Database was queried for pancreatic cancer cases from 2004 to 2015. Along with propensity score matching analysis, multivariate logistic and Cox model were used to assess effects of facility type, race, elements of socioeconomics on receipt of treatment, time to treatment, and overall survival, separately. RESULTS: Among 223,465 patients, 44.6%, 42.1%, and 13.3% were treated at academic, community, and integrated facilities, respectively. Private insurance was associated with more treatment (odds ratio, 1.41; P &lt; 0.001) and better survival [hazards ratio (HR), 0.84; P &lt; 0.001]. Higher education was associated with earlier treatment (HR, 1.09; P &lt; 0.001). African Americans had less treatment (odds ratio, 0.97; P = 0.04) and delayed treatment (HR, 0.89; P &lt; 0.001) despite later stage at diagnosis. After adjusting for socioeconomic status, African Americans had similar survival (HR, 0.99; P = 0.11) overall and improved survival (HR, 0.95; P = 0.016) at integrated facilities. CONCLUSIONS: Higher socioeconomic status was associated with better treatment and survival. After adjusting for socioeconomic disparities, race did not affect survival. Less racial disparity was observed at integrated facilities.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001688" class="uri">https://doi.org/10.1097/MPA.0000000000001688</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1348-1354</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122524" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122524</a></p>
<p>OBJECTIVES: The association of Lewis antigen phenotype with survival of patients with pancreatic ductal adenocarcinoma was investigated. METHODS: A total of 1187 patients diagnosed with pancreatic ductal adenocarcinoma were evaluated in a prospective cohort. Patients were classified into 3 different groups according to Lewis antigen phenotype: Lewis antigen (1) A positive [Le(a+b-)], (2) B positive [Le(a-b+)], and (3) negative [Le(a-b-)]. Risk of mortality was analyzed with Cox regression after adjusting for other predictors. RESULTS: The risk of mortality increased in the order of Le(a+b-), Le(a-b+), and Le(a-b-) [reference; hazard ratio (HR), 1.27; 95% confidence interval (CI)], 1.03-1.57; P = 0.02; and HR, 1.65; 95% CI, 1.31-2.09; P &lt; 0.001] after adjusting for other predictors. Among patients with serum carbohydrate antigen (CA) 19-9 lower than 37 U/mL, the association seemed more apparent (reference; HR, 1.50; 95% CI, 0.77-2.29; P = 0.22; and HR, 2.10; 95% CI, 1.10-4.02; P &lt; 0.02). CONCLUSIONS: The risk of mortality increased in the order of Le(a+b-), Le(a-b+), and Le(a-b-). The difference in prognosis according to the Lewis antigen phenotype was more pronounced in the low CA 19-9 group, which suggests that the Lewis antigen phenotype works as a biomarker predicting the prognosis of patients with pancreatic cancer with undetectable CA 19-9 level.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001687" class="uri">https://doi.org/10.1097/MPA.0000000000001687</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?: A Systematic Review and Meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1342-1347</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122523" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122523</a></p>
<p>OBJECTIVES: Ultrasound (US) elastography has been proposed for the non-invasive prediction of clinically relevant pancreatic fistula (CR-POPF) in patients undergoing pancreatic resection. We aimed to perform a systematic review with meta-analysis to assess the diagnostic value of US elastography in predicting CR-POPF. METHODS: MEDLINE via PubMed, Ovid Embase, Scopus, and Cochrane Library databases, and abstracts of international conference proceedings were searched up to April 20, 2020. Studies assessing the performance of abdominal US elastography in predicting CR-POPF in patients undergoing pancreatic resection were included. The quality of the studies was assessed using Quality Assessment of Diagnostic Accuracy Studies. RESULTS: Five studies, including 247 patients who underwent partial pancreatic resection of whom 72 patients experiencing CR-POPF, were selected. All studies performed US elastography in different pancreatic sites. The pooled mean strain value was lower in pancreatic segments of patients experiencing CR-POPF than in those without, with a pooled weighted mean difference of -0.187 (95% confidence intervals, -0.303 to -0.071; P = 0.002). There was low heterogeneity between studies (I = 7.6%), and all studies were at “high risk” or “unclear risk” of bias. CONCLUSIONS: This study provides evidence that US elastography values are statistically significantly lower in patients experiencing CR-POPF.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001685" class="uri">https://doi.org/10.1097/MPA.0000000000001685</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Inhibition of CHRM3 Alleviates Necrosis Via the MAPK-p38/miR-31-5p/RIP3 Axis in L-Arginine-Induced Severe Acute Pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1335-1341</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122522" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122522</a></p>
<p>OBJECTIVES: Pancreatic acinar necrosis is a typical feature in the early phase of severe acute pancreatitis (SAP). Muscarinic acetylcholine receptor M3 (CHRM3) has been reported to play important roles in promoting insulin secretion and tumor cell proliferation, but its effect on necrosis remains unknown. This study revealed the important role of CHRM3 in regulating L-arginine-induced SAP and the molecular mechanisms. METHODS: To verify the function of CHRM3, pancreatic tissues and primary acinar cells of CRISPR/Cas9-mediated Chrm3 knockout mice were used in CHRM3 knockdown experiments, and to ascertain the CHRM3 overexpression, PLV-EGFP-Chrm3 plasmids were transfected in acinar cells in vitro. RESULTS: In L-arginine-induced SAP, CHRM3 is activated and regulates SAP through the mitogen-activated protein kinase/p38 pathway. Moreover, the expression of miR-31-5p decreased in the SAP model both in vitro and in vivo. Mir-31-5p effects the necrosis of acinar cells in SAP by upregulating the target gene RIP3, and miR-31-5p is a downstream miRNA of CHRM3. CONCLUSIONS: Necrosis in L-arginine-induced SAP is promoted by CHRM3 through the mitogen-activated protein kinase-p38/miR-31-5p/RIP3 axis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001684" class="uri">https://doi.org/10.1097/MPA.0000000000001684</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Heat Shock Factor 1 in Relation to Tumor Angiogenesis and Disease Progression in Patients With Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1327-1334</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122521" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122521</a></p>
<p>OBJECTIVE: In this article, the aims were to study the expression of heat shock factor 1 (HSF1) in patients with pancreatic cancer and to elucidate the relevance between HSF1, angiogenesis, clinicopathological factors, and prognosis. METHODS: Pancreatic cancer, paracancerous, and normal pancreatic tissues were collected. The HSF1 RNA and protein expressions were identified using quantitative real-time reverse transcription polymerase chain reaction and immunohistochemical staining. Associations of HSF1 and cluster of differentiation 34 with clinical variables and disease outcomes were investigated. RESULTS: Compared with the normal pancreatic and paracancerous tissue, HSF1 RNA and protein significantly showed higher expression in the pancreatic cancer tissue and was significantly associated with microvessel density. The high expression of HSF1 did not correspond to the patients’ sex, age, carcinoembryonic antigen level, diameter of tumors, and locations; however, it corresponded significantly with carbohydrate antigen 19-9 level, lymph node metastasis, tumor node metastasis stage, differentiation degree, vascular invasion, and distant metastasis. The expression levels of HSF1 and cluster of differentiation 34 were significantly correlated with prognosis, disease specificity, and survival. The high expression of HSF1 would lead to worse prognosis and decrease in survival time and disease-free survival time. CONCLUSIONS: HSF1 expression level in pancreatic cancer tissue could be an ideal prognostic biomarker for risk stratification and a potential therapeutic target for patients with pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001683" class="uri">https://doi.org/10.1097/MPA.0000000000001683</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1307-1314</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122518" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122518</a></p>
<p>OBJECTIVES: The interferon-induced protein with multiple tetratricopeptide repeats 3 (IFIT3) seems to be associated with the prognosis in pancreatic cancer. Here we clarify whether the heterogeneity of IFIT3 expression affects previous IFIT3 analysis. METHODS: This retrospective study analyzes pancreatic cancer tissue samples retrieved by surgery from 2 independent patient cohorts. Patients underwent either primary surgery (n = 72) or received neoadjuvant chemotherapy (n = 12). Immunohistochemistry assessed IFIT3 expression and its heterogeneity. Complementarily, we analyzed publicly available transcriptomic data (n = 903). RESULTS: Of the primarily resected tumors, 16.4% were heterogeneous. Patients with IFIT3-negative tumors did not survive longer compared with patients with IFIT3-positive tumors. An analysis of publicly available data confirmed this result. Patients developing lung metastases had the best prognosis (4.8 years) with significantly lower IFIT3 expression compared with liver metastasis (P = 0.0117). Patients receiving neoadjuvant therapy who are IFIT3 negative had a longer disease-free survival (1.2 vs 0.3 years, P = 0.0081). CONCLUSIONS: Low IFIT3 expression is not associated with longer survival. Divergent results from tissue microarray analyses could be explained with tumor heterogeneity. As a single biomarker, IFIT3 is not suitable for predicting disease prognosis. Recurrence of lung metastases and response to neoadjuvant chemotherapy are associated with low IFIT3 expression.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001691" class="uri">https://doi.org/10.1097/MPA.0000000000001691</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1290-1296</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122516" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122516</a></p>
<p>OBJECTIVES: The objective of this study was to investigate the pattern and the oncologic impact of local recurrence after surgical resection of pancreatic cancer. METHODS: From July 1992 to December 2016, 388 patients who underwent curative-intent surgery for pancreatic ductal adenocarcinoma were retrospectively reviewed. RESULTS: At a median follow-up of 29.0 months, 286 (73.7%) of the 367 patients experienced recurrence, and the 5-year overall survival rate was 31.3%. The first recurrence pattern was local in 83 patients (22.0%), systemic in 152 patients (40.2%), and locosystemic in 51 patients (13.5%). There was no difference in overall survival between the patients who had either local or systemic recurrence (P &gt; 0.05). Remnant pancreas, common hepatic artery, celiac trunk, and para-aortic area were the common local recurrence sites in both head and body/tail cancer. However, the superior mesenteric artery (P = 0.050) and portal vein (P = 0.001) were more frequent local recurrence sites for a head tumor, and the surgical bed was a common recurrence site for body/tail tumor (P &lt; 0.001). CONCLUSIONS: Our study shows the importance of local recurrence on overall survival and that preferred sites of local recurrence according to tumor location are predictable.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001679" class="uri">https://doi.org/10.1097/MPA.0000000000001679</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(10):1264-1275</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33122513" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33122513</a></p>
<p>Historically, locally advanced pancreatic adenocarcinoma (LAPDAC) was considered a palliative condition. Advances in treatment have resulted in studies reporting survival after neoadjuvant treatment and surgery similar to earlier disease stages. However, there is no consensus on optimal LAPDAC management. Our aim was a systematic review of published evidence on LAPDAC treatment strategies with curative intent. Twenty-eight studies defining LAPDAC as per established criteria and reporting outcomes after neoadjuvant treatment with a view to resection were included. Primary outcomes were resection rate and proportion of curative resections. Secondary outcomes were postoperative mortality, progression-free survival, and overall survival. Neoadjuvant treatment varied significantly, most common being the combination of folinic acid, fluorouracil, irontecan, and oxaliplatin. Median percentage of patients proceeding to surgery after completion of neoadjuvant pathway was 33.5%. Median resection rate was 25%. Median R0 resection was 80% of resected patients. These outcomes ranged 0% to 100% across studies. Ninety-day postoperative mortality ranged from 0% to 5%. Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post-neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001694" class="uri">https://doi.org/10.1097/MPA.0000000000001694</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>PANCREATIC BETA CELLS COMMUNICATE WITH VAGAL SENSORY NEURONS</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33121946" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33121946</a></p>
<p>BACKGROUND AND AIMS: Destroying visceral sensory nerves impacts pancreatic islet function, glucose metabolism and diabetes onset, but how islet endocrine cells interact with sensory neurons has not been studied. METHODS: We characterized the anatomical pattern of pancreatic sensory innervation by combining viral tracing, immunohistochemistry, and reporter mouse models. To assess the functional interactions of beta cells with vagal sensory neurons, we recorded Ca2+ responses in individual nodose neurons in vivo while selectively stimulating beta cells with chemogenetic and pharmacologic approaches. RESULTS: We found that pancreatic islets are innervated by vagal sensory axons expressing Phox2b, substance P, calcitonin-gene related peptide, and the serotonin receptor 5HT3R. Centrally, vagal neurons projecting to the pancreas terminate in the commissural nucleus of the solitary tract. Nodose neurons responded in vivo to chemogenetic stimulation of beta cells and to pancreas infusion with serotonin, but were not sensitive to insulin. Responses to chemogenetic and pharmacological stimulation of beta cells were blocked by a 5HT3R antagonist and were enhanced by increasing serotonin levels in beta cells. We further confirmed directly in living pancreas slices that sensory terminals in the islet were sensitive to serotonin. CONCLUSIONS: Our study establishes that pancreatic beta cells communicate with vagal sensory neurons, likely using serotonin signaling as a transduction mechanism. Serotonin is co-released with insulin and may therefore convey information about the secretory state of beta cells via vagal afferent nerves.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.10.034" class="uri">https://doi.org/10.1053/j.gastro.2020.10.034</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? - A systematic review with meta-analysis of randomized-controlled trials</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33121847" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33121847</a></p>
<p>OBJECTIVE: Postoperative pancreatic fistula/POPF is the most feared complication in pancreatic surgery. Although several systematic reviews investigated the impact of somatostatin analogues on POPF, no stratification was performed regarding type of pancreatic resection (pancreaticoduodenectomy/PD; distal pancreatectomy/DP) and different somatostatin analogues. METHODS: This study was planed according to the Preferred-Reporting-Items-for-Systematic -Review-and-Meta-Analysis/PRISMA-guidelines. After screening databases for randomized controlled trials/RCT, studies were stratified into pancreatic resection techniques and data were pooled in meta-analyses containing subgroups of octreotide, somatostatin, lanreotide, pasireotide and vapreotide. RESULTS: The meta-analysis of studies with a mixed cohort of patients after pancreatic resection revealed a protective effect of somatostatin analogues for morbidity (RR: 0.71, p &lt; .00001) but not for mortality (RR: 1.07, = 0.78) or intra-abdominal abscesses (RR: 1.00, p = 1.00). Moreover, no effect was visible for mortality (RR: 1.57, p = .15), morbidity (RR: 0.87, p = .15) and intra-abdominal abscesses (RR: 0.92, p = .48) after PD. The meta-analysis of patients after PD revealed no impact of somatostatin analogues on POPF (RR: 0.87, p = .19) and clinically relevant POPF (RR: 0.69, p = .30). However, treatment with somatostatin analogues in the mixed cohort showed less POPF (RR: 0.60, p &lt; .00001) and clinically relevant POPF (RR: 0.47, p = .02), which was also the case after DP (RR: 0.41, p = .03). CONCLUSION: Somatostatin analogues did not affect POPF and clinically relevant POPF after PD, but seemed to be associated with less POPF after DP. As no sufficiently powered RCT could be identified by the systematic review, further RCTs are urgently needed to investigate the effect of somatostatin analogues after DP. STUDY REGISTRATION: CRD42018099808.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.043" class="uri">https://doi.org/10.1016/j.pan.2020.10.043</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Age is in the eye of the beholder: Distinguishing molecular signatures in early-onset pancreatic adenocarcinomas</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33109735" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33109735</a></p>
<p>Pancreatic adenocarcinoma (PDAC) is more prevalent in older patients, but early-onset cases (&lt;55 years) may be a distinct genetic subpopulation. Differential expression of CDKN2A and transcription factor FOXC2 were found in early-onset cases. This finding opens the door to investigating additional features that distinguish PDAC tumors in this age group.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-3683" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-3683</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pilot study examining the impact of a specialist multidisciplinary team clinic for patients with chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33109470" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33109470</a></p>
<p>OBJECTIVE: -To assess the efficacy of a pilot Chronic Pancreatitis (CP) Multidisciplinary (MDT) clinic. METHODS: - 60 patients referred to a pilot MDT CP clinic were analysed. Anthropometric data, nutrition status, malabsorption evidence, glycaemic control, opiate use, bone mineral density (BMD) assessment and quality of life (QoL) were examined. RESULTS: -The average age was 51.27 (±12.75). The commonest aetiology was alcohol (55%). Ninety one point five percent had evidence of ongoing pancreatic exocrine insufficiency, with 88.1% requiring initiation or up-titration of pancreatic enzyme replacement (PERT). Up to half of the patients exhibited micronutrient deficiency. Twenty eight percent were diagnosed with type IIIc diabetes. There was an average daily reduction of 6 mg of morphine usage per patient with a concurrent decline in median pain scores from 83.3 to 63.3, which was non-significant. The median QoL score was 33.3 compared to a score of 75 from the reference population. QoL scores increased from 31.0 to 37.3 at follow up appointments. Seventy two point five percent of patients had undiagnosed low BMD. CONCLUSION: The data suggest that CP patients have significant nutritional deficiencies as well as undiagnosed diabetes, poor pain and glycaemic control which negatively impacts QoL. Assessment in a multi-disciplinary clinic ensures appropriate management.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.041" class="uri">https://doi.org/10.1016/j.pan.2020.10.041</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries</strong></li>
</ul>
</summary>
<p><em>Cancer cytopathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33108683" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33108683</a></p>
<p>BACKGROUND: To the authors’ knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS: Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS: Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P &lt; .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P &lt; .05). An overall increase of 5.56% (95% CI, 3.77%-7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS: The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.</p>
<p>doi: <a href="https://doi.org/10.1002/cncy.22373" class="uri">https://doi.org/10.1002/cncy.22373</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Journal of clinical pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33097588" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33097588</a></p>
<p>AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies. Hence, there is a need for new markers and treatment strategies. P68/DEAD box protein 5 (DDX5) is an ATP-dependent RNA helicase of the DEAD box protein family. It is a prognostic marker for several cancers. In this study, we aimed to evaluate the expression and clinical relevance of DDX5 in PDAC. METHODS: DDX5 expression in tissue microarray blocks containing 230 PDAC samples was examined using immunohistochemical analysis. DDX5 expression was considered high when more than 50% of the cells were stained and low when less than 50% of the cells were stained. We investigated the association between DDX5 expression and clinicopathological parameters, including patient survival. RESULTS: The nuclei of normal pancreatic ducts, normal acinar cells and PDAC cells were stained positive for DDX5 although the intensity and distribution of DDX5 expression varied. Islet cells showed strong and diffuse staining of DDX5. DDX5 expression was low and high in 148 (64.3%) and 82 cases (35.7%), respectively. Low DDX5 expression was significantly associated with an advanced pT factor (pT2-pT3: tumour size,&gt;20 mm), lymphatic involvement, advanced tumour-node-metastasis (TNM) stage (stages IIB, III, and IV), and venous involvement. In addition, the multivariate analysis revealed that DDX5 expression is an independent prognostic factor for PDAC. CONCLUSION: These results suggest that DDX5 plays an important role in tumour invasiveness and PDAC prognosis.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-207002" class="uri">https://doi.org/10.1136/jclinpath-2020-207002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The histopathology of SPINK1-associated chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33097431" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33097431</a></p>
<p>BACKGROUND: The identification of genetic risk factors for chronic pancreatitis, such as PRSS1, CFTR and SPINK1, provides the opportunity to define key pathologic hallmarks and etiologic-specific changes. For example, pancreata from PRSS1 and CFTR patients exhibit progressive lipomatous atrophy without significant fibrosis. Considering the pathology of SPINK1-associated pancreatitis is ill-defined, we examined the pancreata of SPINK1 patients with chronic pancreatitis. METHODS: Histologic sections after total pancreatectomy with islet autotransplantation and associated clinicopathologic data were collected from 28 patients with SPINK1 germline alterations. Clinical findings, germline data, anatomic anomalies and pathologic findings were descriptively evaluated. RESULTS: Patients ranged in age from 5 to 48 years (median, 21.6 years) with abdominal pain between 2 and 25 years (median, 5.8 years). Most patients were SPINK1 heterozygous and 14 (50%) had co-occurring CFTR (n = 12) and CTRC (n = 2) mutations. Other pancreatitis risk factors included anatomic anomalies (n = 9) and tobacco use (n = 1). Overall, 24 (86%) patients had additional pancreatitis-associated germline alterations, SPINK1 homozygosity, anatomic anomalies or environmental factors. Examination of pancreata revealed a sequential pattern of exocrine parenchymal loss and replacement by prominent fibrosis, dependent on the duration of abdominal pain. No malignancies were identified, but low-grade pancreatic intraepithelial neoplasia was present for 2 cases. CONCLUSIONS: Within this descriptive study, SPINK1-associated pancreatitis is characterized by parenchymal fibrosis and suggests divergent pathophysiologic mechanisms from PRSS1 and CFTR-associated pancreatitis. Moreover, SPINK1 patients frequently had additional etiologic factors that did not impact the development of pancreatic fibrosis and may implicate SPINK1 as a disease modifier gene.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.030" class="uri">https://doi.org/10.1016/j.pan.2020.10.030</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Experimental pancreatitis is characterized by rapid T cell activation, Th2 differentiation that parallels disease severity, and improvement after CD4+ T cell depletion</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33097430" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33097430</a></p>
<p>BACKGROUND: Acute pancreatitis is a gastrointestinal disorder of high incidence resulting in life threatening complications in up to 20% of patients. Its severe form is characterized by an extensive and systemic immune response. We investigated the role of the adaptive immune response in two experimental models of pancreatitis. METHODS: In C57BI/6-mice mild pancreatitis was induced by 8-hourly injections of caerulein and severe pancreatitis by additional, partial pancreatic duct ligation. T-cell-activation was determined by flow-cytometry of CD25/CD69, T-cell-differentiation by nuclear staining of the transcription-factors Tbet, Gata3 and Foxp3. In vivo CD4+ T-cells were depleted using anti-CD4 antibody. Disease severity was determined by histology, serum amylase and lipase activities, lung MPO and serum cytokine levels (IL-6, TNFα, IL-10). RESULTS: In both models T-cells were activated. Th1-differentiation (Tbet) was absent during pancreatitis but we detected a pronounced Th2/Treg (Gata3/Foxp3) response which paralleled disease severity in both models. The complete depletion of CD4+ T-cells via anti-CD4 antibody, surprisingly, reduced disease severity significantly, as well as granulocyte infiltration and pro- and anti-inflammatory cytokine levels. Co-incubation of acini and T-cells did not lead to T-cell-activation by acinar cells but to acinar damage by T-cells. During pancreatitis no significant T-cell-infiltration into the pancreas was observed. CONCLUSION: T cells orchestrate the early local as well as the systemic immune responses in pancreatitis and are directly involved in organ damage. The Th2 response appears to increase disease severity, rather than conferring an immunological protection.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.044" class="uri">https://doi.org/10.1016/j.pan.2020.10.044</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions��in pancreatic cancer cells</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):1024</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33097020" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33097020</a></p>
<p>BACKGROUND: For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspases), exerts synergistic killing of PANC-1 human pancreatic adenocarcinoma cells. METHODS: To investigate potential mechanisms underlying this synergistic pharmacodynamic interaction, data capturing PANC-1 cell growth, apoptosis kinetics, and cell cycle distribution were integrated with high-quality IonStar-generated proteomic data capturing changes in the relative abundance of more than 3300 proteins as the cells responded to the two drugs, alone and combined. RESULTS: PTX alone (15 nM) elicited dose-dependent G2/M-phase arrest and cellular polyploidy. Combined BRP/PTX (150/15 nM) reduced G2/M by 35% and polyploid cells by 45%, and increased apoptosis by 20%. Whereas BRP or PTX alone produced no change in the pro-apoptotic protein pJNK, and a slight increase in the anti-apoptotic protein Bcl2, the drug combination increased pJNK and decreased Bcl2 significantly compared to the vehicle control. A multi-scale, mechanism-based mathematical model was developed to investigate integrated birinapant/paclitaxel effects on temporal profiles of key proteins involved in kinetics of cell growth, death, and cell cycle distribution. CONCLUSIONS: The model, consistent with the observed reduction in the Bcl2/BAX ratio, suggests that BRP-induced apoptosis of mitotically-arrested cells is a major contributor to the synergy between BRP and PTX. Coupling proteomic and cellular response profiles with multi-scale pharmacodynamic modeling provides a quantitative mechanistic framework for evaluating pharmacodynamically-based drug-drug interactions in combination chemotherapy, and could potentially guide the development of promising drug regimens.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07398-9" class="uri">https://doi.org/10.1186/s12885-020-07398-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors</strong></li>
</ul>
</summary>
<p><em>Nature reviews. Gastroenterology &amp; hepatology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33093663" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33093663</a></p>
<p>The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.</p>
<p>doi: <a href="https://doi.org/10.1038/s41575-020-00366-5" class="uri">https://doi.org/10.1038/s41575-020-00366-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Detection of Chemotherapy-Resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33093149" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33093149</a></p>
<p>PURPOSE: A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a glycan biomarker for PDAC called sTRA could be used for this purpose. EXPERIMENTAL DESIGN: We tested for differences between PDACs classified by glycan expression in multiple systems: sets of cell lines, organoids, and isogenic cell lines; primary tumors; and blood plasma from human subjects. RESULTS: The sTRA-expressing models tended to have stem-like gene expression and the capacity for mesenchymal differentiation, in contrast to the non-expressing models. The sTRA cell lines also had significantly increased resistance to seven different chemotherapeutics commonly used against pancreatic cancer. Patients with primary tumors that were positive for a gene-expression classifier for sTRA received no statistically significant benefit from adjuvant chemotherapy, in contrast to those negative for the signature. In another cohort, based on direct measurements of sTRA in tissue microarrays, the patients who were high in sTRA again had no statistically significant benefit from adjuvant chemotherapy. Furthermore, a blood-plasma test for the sTRA glycan identified the PDACs that showed rapid relapse following neoadjuvant chemotherapy. CONCLUSIONS: This research demonstrates that a glycan biomarker could have value to detect chemotherapy-resistant PDAC in clinical settings. This capability could aid in the development of stratified treatment plans and facilitate biomarker-guided trials targeting resistant PDAC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-2475" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-2475</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Landmark Series: Mitigation of the Postoperative Pancreatic Fistula</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33089395" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33089395</a></p>
<p>Pancreatic fistula has been the defining complication and challenge of pancreatic surgery. Better awareness and mitigation of postoperative pancreatic fistulas has led to significant improvements in morbidity and mortality of pancreatic surgery. The definition and management of pancreatic fistulas has sequentially progressed over the last three decades; the literature ranges from retrospective, observational studies to prospective multicenter randomized controlled trials. The landmark literature contributions driving the perioperative management of pancreatic fistulas are detailed in this article.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09251-6" class="uri">https://doi.org/10.1245/s10434-020-09251-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33087490" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33087490</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is the deadliest cancer. Cancer-associated thrombosis/thromboembolism (CAT), frequently observed in PDAC, is known as a poor prognostic factor. Here, we investigated the underlying mechanisms between PDAC and CAT, and performed a trial of therapeutic approach for PDAC using a genetically engineered mouse model, PKF (Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2flox/flox ). DESIGN: Presence of CAT in PKF mice was detected by systemic autopsy. Plasma cytokines were screened by cytokine antibody array. Murine and human plasma atrial natriuretic peptide (ANP) and soluble vascular cell adhesion molecule 1 (sVCAM-1) were determined by ELISA. Distribution of VCAM-1 in PKF mice and human autopsy samples was detected by immunohistochemistry. PKF mice were treated with anti-VCAM-1 antibody and the effects on survival, distribution of CAT and the tumour histology were analysed. RESULTS: We found spontaneous CAT with cardiomegaly in 68.4% PKF mice. Increase of plasma ANP and sVCAM-1 was observed in PKF mice and PDAC patients with CAT. VCAM-1 was detected in the activated endothelium and thrombi. Administration of anti-VCAM-1 antibody to PKF mice inhibited tumour growth, neutrophil/macrophage infiltration, tumour angiogenesis and progression of CAT; moreover, it dramatically extended survival (from 61 to 253 days, p&lt;0.01). CONCLUSION: Blocking VCAM-1/sVCAM-1 might be a potent therapeutic approach for PDAC as well as CAT, which can contribute to the prognosis. Increase of plasma ANP and sVCAM-1 might be a diagnostic approach for CAT in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-320608" class="uri">https://doi.org/10.1136/gutjnl-2020-320608</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>FXR in the dorsal vagal complex is sufficient and necessary for upper small intestinal microbiome-mediated changes of TCDCA to alter insulin action in rats</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33087489" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33087489</a></p>
<p>OBJECTIVE: Conjugated bile acids are metabolised by upper small intestinal microbiota, and serum levels of taurine-conjugated bile acids are elevated and correlated with insulin resistance in people with type 2 diabetes. However, whether changes in taurine-conjugated bile acids are necessary for small intestinal microbiome to alter insulin action remain unknown. DESIGN: We evaluated circulating and specifically brain insulin action using the pancreatic-euglycaemic clamps in high-fat (HF) versus chow fed rats with or without upper small intestinal healthy microbiome transplant. Chemical and molecular gain/loss-of-function experiments targeting specific taurine-conjugated bile acid-induced changes of farnesoid X receptor (FXR) in the brain were performed in parallel. RESULTS: We found that short-term HF feeding increased the levels of taurochenodeoxycholic acid (TCDCA, an FXR ligand) in the upper small intestine, ileum, plasma and dorsal vagal complex (DVC) of the brain. Transplantation of upper small intestinal healthy microbiome into the upper small intestine of HF rats not only reversed the rise of TCDCA in all reported tissues but also enhanced the ability of either circulating hyperinsulinaemia or DVC insulin action to lower glucose production. Further, DVC infusion of TCDCA or FXR agonist negated the enhancement of insulin action, while genetic knockdown or chemical inhibition of FXR in the DVC of HF rats reversed insulin resistance. CONCLUSION: Our findings indicate that FXR in the DVC is sufficient and necessary for upper small intestinal microbiome-mediated changes of TCDCA to alter insulin action in rats, and highlight a previously unappreciated TCDCA-FXR axis linking gut microbiome and host insulin action.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-321757" class="uri">https://doi.org/10.1136/gutjnl-2020-321757</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33087331" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33087331</a></p>
<p>PURPOSE: Concurrent gemcitabine and nab-paclitaxel treatment is one of the preferred chemotherapy regimens for metastatic and locally-advanced pancreatic ductal adenocarcinoma (PDAC). Previous studies demonstrate that caveolin-1 (Cav-1) expression is critical for nab-paclitaxel uptake into tumors and correlates with response. Gemcitabine increases nab-paclitaxel uptake by increasing Cav-1 expression. Thus, we hypothesized that pre-treatment with gemcitabine would further enhance the sensitivity of PDAC to nab-paclitaxel by increasing Cav-1 expression and nab-paclitaxel uptake. EXPERIMENTAL DESIGN: We investigated the sensitivity of different gemcitabine and nab-paclitaxel treatment regimens in a panel of PDAC cell lines and orthotopic xenograft models. The sensitivity of different treatment regimens was compared to the standard concurrent treatment. RESULTS: Pre-treatment with gemcitabine before nab-paclitaxel increased Cav-1 and albumin uptake and significantly decreased proliferation and clonogenicity compared to concurrent treatment, which correlated with increased levels of apoptosis. Cav-1 silencing reduced the uptake of albumin and therapeutic advantage observed when cells were pre-treated with gemcitabine prior to nab-paclitaxel. Additionally, we observed that pre-treatment with gemcitabine resulted in partial synchronization of cells in the G2/M phase at the time of nab-paclitaxel treatment, providing another mechanism for the benefit of altered scheduling. In heterotopic and orthotopic xenograft models, the altered schedule of gemcitabine prior to nab-paclitaxel significantly delayed tumor growth compared to concurrent delivery without added toxicity. CONCLUSIONS: Pre-treatment with gemcitabine significantly increased nab-paclitaxel uptake and correlated with an increased treatment efficacy and survival benefit in preclinical models, compared to standard concurrent treatment. These results justify preclinical and clinical testing of this altered scheduling combination.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1422" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1422</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Distinct clinicopathological differences between early gastric cardiac and non-cardiac carcinomas: a single-center retrospective study of 329 radical resection cases</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):351</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33087057" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33087057</a></p>
<p>BACKGROUND: Early gastric carcinoma is heterogeneous and can be divided into early gastric cardiac carcinoma (EGCC) and early gastric non-cardiac carcinoma (EGNCC) groups. At present, differences in clinicopathology remains obscure between EGCC and EGNCC fundus-corpus and antrum-angularis-pylorus subgroups, especially between EGCC with and without oesophageal invasion. METHODS: In this study, we studied 329 consecutive early gastric carcinoma radical gastrectomies with 70 EGCCs and 259 EGNCCs. RESULTS: Compared to the EGNCC antrum-angularis-pylorus (n = 181), but not fundus-corpus (n = 78), sub-group, EGCC showed significantly older age, lower prevalence of the grossly depressed pattern, better tumor differentiation, higher percentage of tubular/papillary adenocarcinoma, but lower frequency of mixed poorly cohesive carcinoma with tubular/papillary adenocarcinoma, and absence of lymph node metastasis (LNM) in tumors with invasion up to superficial submucosa (SM1). In contrast, pure poorly cohesive carcinoma was less frequently seen in EGCCs than in EGNCCs, but mixed poorly cohesive carcinoma with tubular/papillary adenocarcinomas was significantly more common in the EGNCC antrum-angularis-pylorus sub-group than in any other group. No significant differences were found between EGCC and EGNCC sub-groups in gender, tumor size, H. pylori infection rate, and lymphovascular/perineural invasion. EGCC with oesophageal invasion (n = 22), compared to EGCC without (n = 48), showed no significant differences in the H. pylori infection rate and oesophageal columnar, intestinal, or pancreatic metaplasia, except for a higher percentage of the former in size &gt; 2 cm and tubular differentiation. CONCLUSIONS: There exist distinct clinicopathologic differences between EGCC and EGNCC sub-groups; EGCC was indeed of gastric origin. Further investigations with larger samples are needed to validate these findings.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01498-3" class="uri">https://doi.org/10.1186/s12876-020-01498-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33086324" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33086324</a></p>
<p>OBJECTIVE: To describe PNI and to evaluate its impact on disease-free (DFS) and overall survival (OS) in patients with resected pancreatic ductal adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: Although PNI is a prognostic factor for survival in many GI cancers, there is limited knowledge regarding its impact on tumor recurrence, especially in “early stage disease” (PDAC ≤20 mm, R0/N0 PDAC). METHODS: This multicenter retrospective study included patients undergoing PDAC resection between 2009 and 2014. The association of PNI with DFS and OS was analyzed using Cox proportional-hazards models. RESULTS: PNI was found in 87% of 778 patients included in the study, with lower rates in PDAC ≤20 mm (78.7%) and in R0/N0 tumors (70.6%). PNI rate did not differ between patients who underwent neoadjuvant therapy and upfront surgery (88% vs 84%, P = 0.08). Although not significant at multivariate analysis (P = 0.07), patients with PNI had worse DFS at univariate analysis (median DFS: 20 vs 15 months, P &lt; 0.01). PNI was the only independent predictor of DFS in R0/N0 tumors (hazard ratio [HR]: 2.2) and in PDAC ≤20 mm (HR: 1.8). PNI was an independent predictor of OS in the entire cohort (27 vs 50 months, P = 0.01), together with G3 tumors, pN1 status, carbohydrate antigen (CA) 19.9 &gt;37 and pain. CONCLUSIONS: PNI represents a major determinant of tumor recurrence and patients’ survival in pancreatic cancer. The role of PNI is particularly relevant in early stages, supporting the hypothesis that invasion of nerves by cancer cells has a driving role in pancreatic cancer progression.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004464" class="uri">https://doi.org/10.1097/SLA.0000000000004464</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Biliary Stricture after Necrotizing Pancreatitis: An Underappreciated Challenge</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33086318" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33086318</a></p>
<p>OBJECTIVE: Biliary stricture in necrotizing pancreatitis (NP) has not been systematically categorized; therefore, we sought to define the incidence and natural history of biliary stricture caused by NP. SUMMARY/BACKGROUND DATA: Benign biliary stricture occurs secondary to bile duct injury, anastomotic narrowing, or chronic inflammation and fibrosis. The profound loco-regional inflammatory response of NP creates challenging biliary strictures. METHODS: NP patients treated between 2005-2019 were reviewed. Biliary stricture was identified on cholangiography as narrowing of the extrahepatic biliary tree to &lt; 75% of the diameter of the unaffected duct. Biliary stricture risk factors and outcomes were evaluated. RESULTS: Among 743 NP patients, 64 died, 13 were lost to follow up; therefore, a total of 666 patients were included in the final cohort. Biliary stricture developed in 108 (16%) patients. Mean follow up was 3.5 ± 3.3 years. Median time from NP onset to biliary stricture diagnosis was 4.2 months (IQR, 1.8-10.9). Presentation was commonly clinical or biochemical jaundice, n = 30 (28%) each. Risk factors for stricture development were splanchnic vein thrombosis and pancreatic head parenchymal necrosis. Median time to stricture resolution was 6.0 months after onset (2.8-9.8). A mean of 3.3 ± 2.3 procedures were performed. Surgical intervention was required in 22 (20%) patients. Endoscopic treatment failed in 17% (17/99) of patients and was not associated with stricture length. Operative treatment of biliary stricture was more likely in patients with infected necrosis or NP disease duration ≥6 months. CONCLUSION: Biliary stricture occurs frequently after necrotizing pancreatitis and is associated with splanchnic vein thrombosis and pancreatic head necrosis. Surgical correction was performed in 20%.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004470" class="uri">https://doi.org/10.1097/SLA.0000000000004470</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33086310" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33086310</a></p>
<p>OBJECTIVE: The objective of this study was to characterize the patterns of first recurrence after curative-intent resection for pancreatic adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: We evaluated the first site of recurrence after neoadjuvant treatment as locoregional (LR) or distant metastasis (DM). To validate our findings, we evaluated the pattern from two phase II clinical trials evaluating neoadjuvant chemotherapy (NAC) in PDAC. METHODS: We identified site of first recurrence from a retrospective cohort of patients from 2011-2017 treated with neoadjuvant chemotherapy followed by chemoradiation and then an operation or an operation first followed by adjuvant therapy, as well as two separate prospective cohorts of patients derived from two phase II clinical trials evaluating patients treated with neoadjuvant chemotherapy in borderline-resectable and locally advanced PDAC RESULTS:: In the retrospective cohorts, 160 out of 285 patients (56.1%) recurred after a median disease-free survival (mDFS) of 17.2 months. The pattern of recurrence was DM in 81.9% of patients, versus LR in 11.1%. This pattern was consistent in patients treated with upfront resection and adjuvant chemotherapy (DM 83.0%, LR 16.9%) regardless of margin-involvement (DM 80.1%, LR 19.4%). The use of NAC did not alter pattern of recurrence; 81.7% had DM and 18.3% had LR. This pattern also remained consistent regardless of margin-involvement (DM 94.1%, LR 5.9%). In the Phase II borderline-resectable trial (NCI# 01591733) cohort of 32 patients, the mDFS was 34.2 months. Pattern of recurrence remained predominantly DM (88.9%) versus LR (11.1%). In the Phase II locally-advanced trial (NCI# 01821729) cohort of 34 patients, the mDFS was 30.7 months. Although there was a higher rate of local recurrence in this cohort, pattern of first recurrence remained predominantly DM (66.6%) versus LR (33.3%) and remained consistent independent of margin-status. CONCLUSIONS: The pattern of recurrence in PDAC is predominantly DM rather than LR, and is consistent regardless of the use of NAC and margin involvement.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004585" class="uri">https://doi.org/10.1097/SLA.0000000000004585</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Modified Appleby Procedure, Distal Splenopancreatectomy with Celiac Axis Resection</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33084990" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33084990</a></p>
<p>BACKGROUND: Modified Appleby procedure could be indicated in stage III locally advanced body pancreatic ductal adenocarcinoma (PDAC) involving the celiac axis after neoadjuvant treatment. PATIENTS AND METHODS: We report the case of a 38-year-old woman presenting a tumor arising from the body of the pancreas, involving the celiac trunk with the common hepatic artery and having contact with the anterior surface of the superior mesenteric artery. A fine-needle aspirate biopsy confirmed the diagnosis of PADC. Eight cycles of FOLFIRINOX followed by chemoradiotherapy (50.4 Gy) were conducted. After 6 months, the CA19-9 levels were normalized, and the tumor remained stable without local growth or distant metastasis. To reduce the risk of ischemia-related complications and develop the pancreaticoduodenal arcades, a preoperative embolization of the common hepatic artery was performed. Then, surgical resection was considered 4 weeks after embolization. RESULTS: The patient underwent a modified Appleby procedure including distal splenopancreatectomy with en bloc celiac axis resection combined with lateral portal vein resection. Venous reconstruction was carried out using peritoneal patch.1 Pathologic evaluation revealed a 2.5-cm PDAC with negative resection margins. Postoperative course was marked by acute ischemic cholecystitis requiring reoperation at postoperative day 3. The treatment was completed with four cycles of FOLFIRINOX, and she was free of disease 6 months after surgery. CONCLUSIONS: Nowadays, modified Appleby procedure is more frequently performed due to improvements in responses to chemotherapy and radiotherapy which have led to better local control and more aggressive approaches in highly selected patients.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09212-z" class="uri">https://doi.org/10.1245/s10434-020-09212-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33082211" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33082211</a></p>
<p>PURPOSE: To evaluate somatic mutations, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the PDAC patients with pathological complete response (pCR) to neoadjuvant therapy (NAT) and find their associations with outcome. DESIGN: Thirty-six PDAC patients with pCR were identified from 2009 to 2017. Macro-dissection was performed on resected specimens to isolate DNA from 332 regions of interest including fibrosis, normal duct, normal parenchyma, and undefined ductal cells (UDCs). Cell-free DNA (cfDNA) and CTCs were also extracted. Next-generation sequencing (NGS) was used to detect mutations of KRAS, CDKN2A, SMAD4, TP53, GNAS, and BRAF Results: KRAS mutation was detected in UDCs and fibrosis while SMAD4, TP53 and GNAS were only seen in UDCs. Patients with TP53 mutation showed relatively worse overall survival (OS) (HR=3.596, 95%=0.855-15.130, P=0.081). Five patients available for CTCs data were all positive for CTCs and seven of 16 pCR patients were detected with ctDNA at surgery. We proposed a new concept of regression assessment combining genomic analysis of resected specimens and liquid biopsy data for PDAC, namely molecular complete response (mCR). Three of six mCR patients recurred as compared with six in fifteen non-mCR patients. Seven of 15 non-mCR patients died during follow-up while there was only one in six mCR patients. CONCLUSIONS: This study firstly reports that somatic mutations, CTCs and ctDNA existed even in PDAC patients with pCR to NAT, which could possibly predict early recurrence and reduced survival. The current regression evaluation system of PDAC needs to be re-assessed at a molecular level.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1746" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1746</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33082106" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33082106</a></p>
<p>BACKGROUND AND AIMS: Despite recent advances, patients with pancreaticobiliary cancers have a poor prognosis. We previously demonstrated the efficacy of endoscopic ultrasound (EUS) guided acquisition of portal vein (PV) blood for enumeration of circulating tumor cells (CTCs). The aim of this study was to assess PV-CTCs as potential biomarkers for the assessment of progression-free (PFS) and overall survival (OS) in patients with pancreaticobiliary cancers. METHODS: 17 patients with biopsy-proven pancreaticobiliary malignancy were enrolled. CTCs were enumerated from both peripheral and PV blood. All patients were followed until death. PFS and OS were evaluated with the log-rank test and summarized with the use of Kaplan-Meier methods. Unadjusted and adjusted Cox-proportional hazards models were fitted to study the relationship between PV-CTCs and PFS and OS. RESULTS: After 3.5 years of follow-up, all patients had expired. PV-CTCs were detected in all patients (median PV-CTCs 62.0/7.5 mL (interquartile range [IQR] 17-132). The mean PFS in patients with PV-CTCs &lt;185/7.5 mL was significantly longer than patients with PV-CTCs ≥185/7.5 mL (43.3 weeks vs. 12.8 weeks, log-rank p = 0.002). The mean OS in patients with PV-CTCs &lt;185/7.5 mL was significantly longer than patients with PV-CTCs ≥185/7.5 mL (75.8 weeks vs. 29.5 weeks, log-rank p = 0.021). In an adjusted Cox-proportional hazards model, PV-CTCs were significant predictors of both PFS and OS (HR 1.004, p = 0.037; HR 1.004, p = 0.044 respectively). CONCLUSION: In this pilot and feasibility study, EUS-acquired PV-CTCs predicted PFS and OS. Our findings suggest that PV-CTCs can help provide important prognostic data for both providers and patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.039" class="uri">https://doi.org/10.1016/j.pan.2020.10.039</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions</strong></li>
</ul>
</summary>
<p><em>The Journal of pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33079429" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33079429</a></p>
<p>Cystic neoplasms of the pancreas are an increasingly important public health problem. The majority of these lesions are benign but some progress to invasive pancreatic ductal adenocarcinoma (PDAC). There is a dearth of mouse models of these conditions. The orphan nuclear receptor NR5A2 regulates development, differentiation, and inflammation. Germline Nr5a2 heterozygosity sensitizes mice to the oncogenic effects of mutant Kras in the pancreas. Here, we show that - unlike constitutive Nr5a2+/- mice - conditional Nr5a2 heterozygosity in pancreatic epithelial cells, combined with mutant Kras, (KPN+/- ) leads to a dramatic replacement of the pancreatic parenchyma with cystic structures and an accelerated development of high grade PanINs and PDAC. Timed histopathological analyses indicated that in KPN+/- mice PanINs precede the formation of cystic lesions and the latter precede PDAC. A single episode of acute caerulein pancreatitis is sufficient to accelerate the development of cystic lesions in KPN+/- mice. Epithelial cells of cystic lesions of KPN+/- mice express MUC1, MUC5AC, and MUC6 but lack expression of MUC2, CDX2 and acinar markers, indicative of a pancreato-biliary/gastric phenotype. In accordance with this, in human samples we found a non-significantly decreased expression of NR5A2 in mucinous tumours, compared with conventional PDAC. These results highlight that the effects of loss of one Nr5a2 allele are time- and cell context-dependent. KPN+/- mice represent a new model to study the formation of cystic pancreatic lesions and their relationship with PanINs and classical PDAC. Our findings suggest that pancreatitis could also contribute to acceleration of cystic tumour progression in patients. This article is protected by copyright. All rights reserved.</p>
<p>doi: <a href="https://doi.org/10.1002/path.5570" class="uri">https://doi.org/10.1002/path.5570</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Novel Technique for Single-Layer Pancreatojejunostomy is Not Inferior to Modified Blumgart Anastomosis in Robotic Pancreatoduodenectomy: Results of a Randomized Controlled Trial</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33079303" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33079303</a></p>
<p>BACKGROUND: A novel technique of single-layer continuous suturing (SCS) for pancreaticojejunostomy (PJ) during robotic pancreaticoduodenectomy (RPD), a technically straightforward procedure, has been shown to produce promising results in a previous study. The present RCT aims to show that SCS during RPD does not increase the incidence of clinically relevant postoperative pancreatic fistula (CR-POPF) when compared with modified Blumgart anastomosis (MBA). PATIENTS AND METHODS: Between January 2019 and September 2019, consecutive patients (ASA score ≤ 2) who underwent RPD were enrolled and randomized to the SCS or the MBA group. The primary endpoint was the rate of CR-POPF. A noninferiority margin of 10% was chosen. RESULTS: Of the 186 patients, 4 were excluded because PJ was not performed. The remaining 182 patients were randomized to the SCS group (n = 89) or MBA group (n = 93). CR-POPF rate was not inferior in the SCS group [SCS: 6.7%, MBA: 11.8%; 95% confidence interval (- 0.76, - 0.06), P = 0.0002]. PJ duration was significantly lower in the SCS group (P &lt; 0.01). No significant differences were found between the two groups in operative time, estimated blood loss, postoperative hospital stay, or rates of conversion to laparotomy, morbidity, reoperation, or mortality. On subgroup analysis of patients with a soft pancreas and small main pancreatic duct, SCS significantly reduced the duration of PJ. CONCLUSIONS: This study showed that SCS was not inferior to MBA in terms of the CR-POPF rate during RPD. Registration number: ChiCTR1800020086 ( www.Chictr.org.cn ).</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09204-z" class="uri">https://doi.org/10.1245/s10434-020-09204-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: A meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33077384" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33077384</a></p>
<p>BACKGROUND/OBJECTIVES: Consensus guidelines recommend surveillance of high-risk individuals (HRIs) for pancreatic cancer (PC) using endoscopic ultrasonography (EUS) and/or magnetic resonance imaging (MRI). This study aims to assess the yield of PC surveillance programs of HRIs and compare the detection of high-grade dysplasia or T1N0M0 adenocarcinoma by EUS and MRI. METHODS: The MEDLINE and Embase (Ovid) databases were searched for prospective studies published up to April 11, 2019 using EUS and/or MRI to screen HRIs for PC. Baseline detection of focal pancreatic abnormalities, cystic lesions, solid lesions, high-grade dysplasia or T1N0M0 adenocarcinoma, and all pancreatic adenocarcinoma were recorded. Weighted pooled proportions of outcomes detected were compared between EUS and MRI using random effects modeling. RESULTS: A total of 1097 studies were reviewed and 24 were included, representing 2112 HRIs who underwent imaging. The weighted pooled proportion of focal pancreatic abnormalities detected by baseline EUS (0.34, 95% CI 0.30-0.37) was significantly higher (p = 0.006) than by MRI (0.31, 95% CI 0.28-0.33). There were no significant differences between EUS and MRI in detection of other outcomes. The overall weighted pooled proportion of patients with high-grade dysplasia or T1N0M0 adenocarcinoma detected at baseline (regardless of imaging modality) was 0.0090 (95% CI 0.0022-0.016), corresponding to a number-needed-to-screen (NNS) of 111 patients to detect one high-grade dysplasia or T1N0M0 adenocarcinoma. CONCLUSIONS: Surveillance programs are successful in detecting high-risk precursor lesions. No differences between EUS and MRI were noted in the detection of high-grade dysplasia or T1N0M0 adenocarcinoma, supporting the use of either imaging modality.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.025" class="uri">https://doi.org/10.1016/j.pan.2020.10.025</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Fatty acid ethyl ester (FAEE) associated acute pancreatitis: An ex-vivo study using human pancreatic acini</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33077383" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33077383</a></p>
<p>BACKGROUND &amp; AIM: Fatty acid ethyl esters (FAEEs), are produced by non-oxidative alcohol metabolism and can cause acinar cell damage and subsequent acute pancreatitis in rodent models. Even though experimental studies have elucidated the FAEE mediated early intra-acinar events, these mechanisms have not been well studied in humans. In the present study, we evaluate the early intra-acinar events and inflammatory response in human pancreatic acinar tissues and cells in an ex-vivo model. METHODS: Experiments were conducted using normal human pancreatic tissues exposed to FAEE. Subcellular fractionation was performed on tissue homogenates and trypsin and cathepsin B activities were estimated in these fractions. Acinar cell injury was evaluated by histology and immunohistochemistry. Cytokine release from exposed acinar cells was evaluated by performing Immuno-fluorescence. Serum was collected from patients with AP within the first 72 h of symptom onset for cytokine estimation using FACS. RESULTS: We observed significant trypsin activation and acinar cell injury in FAEE treated tissue. Cathepsin B was redistributed from lysosomal to zymogen compartment at 30 min of FAEE exposure. IHC results indicated the presence of apoptosis in pancreatic tissue at 1 &amp; 2hrs of FAEE exposure. We also observed a time dependent increase in secretion of cytokines IL-6, IL-8, TNF-α from FAEE treated acinar tissue. There was also a significant elevation in plasma cytokines in patents with alcohol associated AP within 72 h of symptom onset. CONCLUSION: Our data suggest that alcohol metabolites can cause acute acinar cell damage and subsequent cytokine release which could eventually culminant in SIRS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.027" class="uri">https://doi.org/10.1016/j.pan.2020.10.027</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>What should we trust to define, predict and assess pancreatic fistula after pancreatectomy?</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33077382" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33077382</a></p>
<p>OBJECTIVE: The ISGPF postoperative pancreatic fistula (POPF) definition using amylase drain concentration is widely used. However, the interest of lipase drain concentration, daily drain output and absolute enzyme daily production (concentration x daily drain volume) have been poorly investigated. MATERIAL AND METHODS: These predictive on postoperative day (POD) 1, 3, 5 and 7 were analyzed in a development cohort, and subsequently tested in an independent validation cohort. RESULTS: Of the 227 patients of the development cohort, 17% developed a biochemical fistula and 34% a POPF (Grade B/C). Strong correlation was found between amylase/lipase drain concentration at all postoperative days (ρ = 0.90; p = 0.001). Amylase and lipase were both significantly higher in patients with a POPF (p &lt; 0.001) presenting an equivalent under the ROC curve area (0.85 vs 0.84; p = 0.466). Combining POD1 and POD3 threefold enzyme cut-off value increased significantly POPF prediction sensibility (97.4% vs 77.8%) and NPV (97.1% vs 86.3%). These results were also confirmed in the validation cohort of 554 patients. Finally, absolute enzyme daily production and daily drain output were significantly higher in patients with a POPF (p &lt; 0.001) but did not add clinical value when compared to drain enzyme concentration. CONCLUSION: Lipase is as effective as amylase drain concentration to define POPF. Absolute enzyme daily production or daily drain output do not help to better predict clinically significant POPF occurrence and severity. Lipase and amylase should mainly be used for their negative predictive value to predict the absence of clinically significant POPF and could allow early drain removal and hospital discharge.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.036" class="uri">https://doi.org/10.1016/j.pan.2020.10.036</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Novel techniques for management of portal system hemorrhage in acute pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33077381" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33077381</a></p>
<p>Current management of infected pancreatic necrosis is focused on a minimally invasive step-up approach. The step-up approach consists of initial percutaneous or endoscopic drainage of infected pancreatic necrosis, followed, if necessary, by minimally invasive surgical or endoscopic debridement. While there is reduced morbidity and mortality, vascular complications can be life-threatening. Reported vascular complications have been limited to arterial bleeding. Venous bleeding has not been previously reported. We present two cases of portal venous bleeding in patients who underwent treatment for infected pancreatic necrosis with a step-up approach. We discuss the clinical presentation, diagnosis, and initial management. Moreover, we present two different techniques that can be used to successfully manage venous bleeding in patients who have percutaneous drains in place as part of a step-up approach. These techniques involve tamponading the cavity or drain tract with topical hemostatics and direct embolization of the bleeding vein. These experiences can serve as a guide for managing portal venous bleeding in patients with infected pancreatic necrosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.022" class="uri">https://doi.org/10.1016/j.pan.2020.09.022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Is Hospital Occupancy Rate Associated with Postoperative Outcomes Among Patients Undergoing Hepatopancreatic Surgery?</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33074907" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33074907</a></p>
<p>OBJECTIVE: To define the association between hospital occupancy rate and postoperative outcomes among patients undergoing hepatopancreatic (HP) resection. SUMMARY BACKGROUND DATA: Previous studies have sought to identify hospital-level characteristics associated with optimal surgical outcomes and decreased expenditures. The present study utilized a novel hospital quality metric coined “occupancy rate” based on publicly available data to assess differences in postoperative outcomes among Medicare beneficiaries undergoing HP procedures. METHODS: Medicare beneficiaries who underwent an elective HP surgery between 2013 and 2017 were identified. Occupancy rate was calculated and hospitals were categorized into quartiles. Multivariable logistic regression was utilized to assess the association between occupancy rate and clinical outcomes. RESULTS: Among 33,866 patients, the majority underwent a pancreatic resection (58.5%; n = 19,827), were male (88.4%; n = 7,488), or white (88.4%; n = 29,950); median age was 72 years [interquartile range (IQR): 68-77] and median Charleston Comorbidity Index was 3 (IQR 2-8). Hospitals were categorized into quartiles based on hospital occupancy rate (cutoffs: 48.1%, 59.4%, 68.2%). Most patients underwent an HP operation at a hospital with an above average occupancy rate (n = 20,865, 61.6%), whereas only a small subset of patients had an HP procedure at a low occupancy rate hospital (n = 1,218, 3.6%). On multivariable analysis, low hospital occupancy rate was associated with increased odds of a complication [(OR) 1.35, 95% confidence interval (CI) 1.18-1.55) and 30-day mortality (OR 1.58, 95% CI 1.27-1.97). Even among only high-volume HP hospitals, patients operated on at hospitals that had a low occupancy rate were at markedly higher risk of complications (OR 1.42, 95% CI 1.03-1.97), as well as 30 day morality (OR 2.20, 95% CI 1.27-3.83). CONCLUSIONS: Among Medicare beneficiaries undergoing an elective HP resection, more than 1 in 4 hospitals performing HP surgeries utilized less than half of their beds on average. There was a monotonic relationship between hospital occupancy rate and the odds of experiencing a complication, as well as 30-day mortality, independent of other hospital level characteristics including procedural volume.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004418" class="uri">https://doi.org/10.1097/SLA.0000000000004418</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Are Volume Pledge Standards Worth the Travel Burden for Major Abdominal Cancer Operations?</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33074899" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33074899</a></p>
<p>OBJECTIVE: The study objective is to determine the association between travel distance and surgical volume on outcomes after esophageal, pancreatic, and rectal cancer resections. SUMMARY OF BACKGROUND DATA: “Take the Volume Pledge” aims to centralize esophagectomies, pancreatectomies, and proctectomies to hospitals meeting minimum volume standards. The impact of travel, and possible care fragmentation, on potential benefits of centralized surgery is not well understood. METHODS: Using the National Cancer Database (2004-2016), patients who underwent esophageal, pancreatic, or rectal resections at far HVH meeting volume standards versus local intermediate (IVH) and low-volume (LVH) hospitals were identified. Perioperative outcomes and 5-year OS were compared. RESULTS: Of 49,454 patients, 17,544 (34.5%) underwent surgery at far HVH, 11,739 (23.7%) at local IVH, and 20,171 (40.8%) at local LVH. The median (interquartile range) travel distances were 77.1 (51.1-125.4), 13.2 (5.8-27.3), and 7.8 (3.1-15.5) miles to HVH, IVH, and LVH, respectively. By multivariable analysis, LVH was associated with increased 30-day mortality for all resections compared to HVH, but IVH was associated with mortality only for proctectomies [odds ratio 1.90, 95% confidence interval (CI) 1.31-2.75]. Compared to HVH, both IVH (hazard ratio 1.25, 95% CI 1.19-1.31) and LVH (hazard ratio 1.35, 95% CI 1.29-1.42) were associated with decreased 5-year OS. CONCLUSIONS: Compared to far HVH, 30-day mortality was higher for all resections at LVH, but only for proctectomies at IVH. Five-year OS was consistently worse at local LVH and IVH. Improving long-term outcomes at IVH may provide opportunities for greater access to quality cancer care.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004361" class="uri">https://doi.org/10.1097/SLA.0000000000004361</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33074853" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33074853</a></p>
<p>Currently, there is no consensus on the optimal tumor response score (TRS) system to assess regression in pancreatic cancers resected after neoadjuvant therapy. We developed a novel TRS (Royal North Shore [RNS] system) based on estimating the percentage of tumor bed occupied by viable cancer and categorized into 3 tiers: grade 1 (≤10%), grade 2 (11% to 75%), and grade 3 (&gt;75%). We assessed 147 resected carcinomas with this and other TRS systems (College of American Pathologists [CAP], MD Anderson Cancer Center [MDACC], and Evans). The 3-tiered RNS system predicted median survival after surgery for grades 1, 2, and 3 of 54, 23, and 9 months, respectively (P&lt;0.05). The CAP, MDACC, and Evans systems also predicted survival (P&lt;0.05) but less consistently. The median survival for MDACC and CAP grade 0 (complete regression) was less than MDACC grade 1 and CAP grades 1 and 2. There was no difference in survival between CAP grades 2 and 3 (P=0.960), Evans grades 1 and 2a (P=0.395), and Evans grades 2a and 2b (P=0.587). Interobserver concordance was weak for CAP (κ=0.431), moderate for MDACC (κ=0.691), minimal for Evans (κ=0.307), and moderate to strong for RNS (κ=0.632 to 0.84). Of age, sex, size, stage, grade, perineural and vascular invasion, extrapancreatic extension, margin status, and RNS score, only RNS score, vascular invasion, and extrapancreatic extension predicted survival in univariate analysis. Only extrapancreatic extension (P=0.034) and RNS score (P&lt;0.0001) remained significant in multivariate analysis. We conclude that the RNS system is a reproducible and powerful predictor of survival after resection for pancreatic cancers treated with neoadjuvant therapy and should be investigated in larger cohorts.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001601" class="uri">https://doi.org/10.1097/PAS.0000000000001601</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33073341" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33073341</a></p>
<p>INTRODUCTION: CRS/HIPEC is thought to confer a survival advantage for patients with malignant peritoneal mesothelioma (MPM). However, the impact of nonperitoneal organ resection is not clearly defined. We evaluated the impact of major organ resection (MOR) on postoperative outcomes and overall survival (OS). PATIENTS AND METHODS: The US HIPEC collaborative database (2000-2017) was reviewed for MPM patients who underwent CRS/HIPEC. MOR was defined as total or partial resection of diaphragm, stomach, spleen, pancreas, small bowel, colon, rectum, kidney, ureter, bladder, and/or uterus. MOR was categorized as 0, 1, or 2+ organs. RESULTS: A total of 174 patients were identified. Median PCI was 16 (3-39). The distribution of patients with MOR-0, MOR-1, and MOR-2+ was 94, 45, and 35 patients, respectively. MOR-1 and MOR-2+ groups had a higher frequency of any complication compared with MOR-0 (57.8%, 74.3%, and 48.9%, respectively, p = 0.035), but Clavien 3/4 complications were similar. Median length of stay was slightly higher in the MOR-1 and MOR-2+ groups (10 and 11 days) compared with the MOR-0 cohort (9 days, p = 0.005). Incomplete cytoreduction, ASA class 4, and male gender were associated with increased mortality on unadjusted analysis; however, their impact on OS was attenuated on multivariable analysis. MOR was not associated with OS based on these data (MOR-1: HR 1.67, 95% CI 0.59-4.74; MOR-2+ : HR 0.77, 95% CI 0.22-2.69). CONCLUSIONS: MOR was not associated with an increase in major complications or worse OS in patients undergoing CRS/HIPEC for MPM and should be considered, if necessary, to achieve complete cytoreduction for MPM patients.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09232-9" class="uri">https://doi.org/10.1245/s10434-020-09232-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33069583" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33069583</a></p>
<p>BACKGROUND: Compliance with national guidelines on pancreatic cancer management could improve patient outcomes. Early compliance with the Dutch guideline was poor. The aim was to assess compliance with this guideline during six years after publication. MATERIALS AND METHODS: Nationwide guideline compliance was investigated for three subsequent time periods (2012-2013 vs. 2014-2015 vs. 2016-2017) in patients with pancreatic cancer using five quality indicators in the Netherlands Cancer Registry: 1) discussion in multidisciplinary team meeting (MDT), 2) maximum 3-week interval from final MDT to start of treatment, 3) preoperative biliary drainage when bilirubin &gt;250 μmol/L, 4) use of adjuvant chemotherapy, and 5) chemotherapy for inoperable disease (non-metastatic and metastatic). RESULTS: In total, 14 491 patients were included of whom 2290 (15.8%) underwent resection and 4561 (31.5%) received chemotherapy. Most quality indicators did not change over time: overall, 88.8% of patients treated with curative intent were discussed in a MDT, 42.7% were treated with curative intent within the 3-week interval, 62.7% with a resectable head tumor and bilirubin &gt;250 μmol/L underwent preoperative biliary drainage, 57.2% received chemotherapy after resection, and 36.6% with metastatic disease received chemotherapy. Only use of chemotherapy for non-metastatic, non-resected disease improved over time (23.4% vs. 25.6% vs. 29.7%). CONCLUSION: Nationwide compliance to five quality indicators for the guideline on pancreatic cancer management showed little to no improvement during six years after publication. Besides critical review of the current quality indicators, these outcomes may suggest that a nationwide implementation program is required to increase compliance to guideline recommendations.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.032" class="uri">https://doi.org/10.1016/j.pan.2020.10.032</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Hyalinized stroma is a characteristic feature of pancreatic intraductal oncocytic papillary neoplasm: An immunohistochemical study</strong></li>
</ul>
</summary>
<p><em>Annals of diagnostic pathology 2020 Oct;49():151639</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33069084" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33069084</a></p>
<p>Hyalinized stroma (HS) is a dense, eosinophilic, and amorphous extracellular material in the stroma. HS is observed in several tumors; however, it has not been comprehensively studied in pancreatic intraductal papillary mucinous neoplasm (IPMN) or intraductal oncocytic papillary neoplasm (IOPN). Here, we aimed to evaluate the immunohistochemical and microscopic characteristics of HS in IPMN and IOPN. The prevalence of HS was determined in 168 cases of IPMN, including intestinal type (IPMN-I), gastric type (IPMN-G), and pancreatobiliary type (IPMN-PB), as well as in 11 cases of IOPN. Immunohistochemical staining for laminin and collagen (types I, II, III, IV, and V), as well as Congo red staining were performed in IPMN and IOPN cases containing HS. The prevalence of HS among the IPMN and IOPN specimens was 1.2% (2/168 cases) and 45.5% (5/11 cases), respectively. The prevalence rates of HS in each IPMN subtype were as follows: 2.2% (2/91 cases) in IPMN-G, and 0% in IPMN-PB and IPMN-I. All seven HS cases were positive for collagen I, III, IV, and V but were negative for Congo red staining. Most cases showed negative, focal, or weak expression of laminin and type II collagen. These findings indicate that HS is associated with IOPN and is primarily composed of collagen fibers.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2020.151639" class="uri">https://doi.org/10.1016/j.anndiagpath.2020.151639</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-Label Multicenter Prospective Trial (JASPAC05)</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33065644" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33065644</a></p>
<p>OBJECTIVE: This study assessed whether neoadjuvant chemoradiotherapy (CRT) with S-1 increases the R0 resection rate in borderline resectable pancreatic cancer (BRPC). SUMMARY BACKGROUND DATA: Although a multidisciplinary approach that includes neoadjuvant treatment has been shown to be a better strategy for BRPC than upfront resection, a standard treatment for BRPC has not been established. METHODS: A multicenter, single-arm, phase II study was performed. Patients who fulfilled the criteria for BRPC received S-1 (40 mg/m bid) and concurrent radiotherapy (50.4 Gy in 28 fractions) before surgery. The primary endpoint was the R0 resection rate. At least 40 patients were required, with a one-sided α = 0.05 and β = 0.05 and expected and threshold values for the primary endpoint of 30% and 10%, respectively. RESULTS: Fifty-two patients were eligible, and 41 were confirmed to have definitive BRPC by a central review. CRT was completed in 50 (96%) patients and was well tolerated. The rate of grade 3/4 toxicity with CRT was 43%. The R0 resection rate was 52% among the 52 eligible patients and 63% among the 41 patients who were centrally confirmed to have BRPC. Postoperative grade III/IV adverse events according to the Clavien-Dindo classification were observed in 7.5%. Among the 41 centrally confirmed BRPC patients, the 2-year overall survival rate and median overall survival duration were 58% and 30.8 months, respectively. CONCLUSIONS: S-1 and concurrent radiotherapy appear to be feasible and effective at increasing the R0 resection rate and improving survival in patients with BRPC. TRIAL REGISTRATION: UMIN000009172.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004535" class="uri">https://doi.org/10.1097/SLA.0000000000004535</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients</strong></li>
</ul>
</summary>
<p><em>Cell 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33065029" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33065029</a></p>
<p>KRAS mutations are among the most common genetic alterations in lung, colorectal, and pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit in precision oncology, one established shortly after the discovery of RAS mutations in human cancer cells nearly 40 years ago. Recent advances in medicinal chemistry have established inhibitors targeting KRAS(G12C), a mutation found in ∼13% of lung adenocarcinomas and, at a lower frequency, in other cancers. Preclinical studies describing their discovery and mechanism of action, coupled with emerging clinical data from patients treated with these drugs, have sparked a renewed enthusiasm in the study of KRAS and its therapeutic potential. Here, we discuss how these advances are reshaping the fundamental aspects of KRAS oncoprotein biology and the strides being made toward improving patient outcomes in the clinic.</p>
<p>doi: <a href="https://doi.org/10.1016/j.cell.2020.09.044" class="uri">https://doi.org/10.1016/j.cell.2020.09.044</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Mural Intracholecystic Neoplasms Arising in Adenomyomatous Nodules of the Gallbladder: An Analysis of 19 Examples of a Clinicopathologically Distinct Entity</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33060404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33060404</a></p>
<p>Intracholecystic neoplasms (ICNs) (pyloric gland adenomas and intracholecystic papillary neoplasms, collectively also called intracholecystic papillary/tubular neoplasms) form multifocal, extensive proliferations on the gallbladder mucosa and have a high propensity for invasion (&gt;50%). In this study, 19 examples of a poorly characterized phenomenon, mural papillary mucinous lesions that arise in adenomyomatous nodules and form localized ICNs, were analyzed. Two of these were identified in 1750 consecutive cholecystectomies reviewed specifically for this purpose, placing its incidence at 0.1%. Median age was 68 years. Unlike other gallbladder lesions, these were slightly more common in men (female/male=0.8), and 55% had documented cholelithiasis. All were characterized by a compact multilocular, demarcated, cystic lesion with papillary proliferations and mucinous epithelial lining. The lesions’ architecture, distribution, location, and typical size were suggestive of evolution from an underlying adenomyomatous nodule. All had gastric/endocervical-like mucinous epithelium, but 5 also had a focal intestinal-like epithelium. Cytologic atypia was graded as 1 to 3 and defined as 1A: mucinous, without cytoarchitectural atypia (n=3), 1B: mild (n=7), 2: moderate (n=2), and 3: severe atypia (n=7, 3 of which also had invasive carcinoma, 16%). Background gallbladder mucosal involvement was absent in all but 2 cases, both of which had multifocal papillary mucosal nodules. In conclusion, these cases highlight a distinct clinicopathologic entity, that is, mural ICNs arising in adenomyomatous nodules, which, by essentially sparing the “main” mucosa, not displaying “field-effect/defect” phenomenon, and only rarely (16%) showing carcinomatous transformation, are analogous to pancreatic branch duct intraductal papillary mucinous neoplasms.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001603" class="uri">https://doi.org/10.1097/PAS.0000000000001603</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The use of immunohistochemistry for IgG4 in the diagnosis of autoimmune pancreatitis: A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017</a></p>
<p>BACKGROUND: The diagnosis of autoimmune pancreatitis (AIP) remains challenging, especially when serum IgG4 is normal or imaging features are indeterminate. We performed a systematic review and meta-analysis to evaluate the performance of IgG4 immunostaining of pancreatic, biliary, and ampullary tissues as a diagnostic aid for AIP. METHODS: A comprehensive literature search of the PubMed, EMBASE, and Ovid MEDLINE databases was conducted until February 2020. The methodological quality of each study was assessed according to the Quality Assessment of Diagnostic Accuracy Studies checklist. A random-effects model was used to summarize the diagnostic odds ratio and other measures of accuracy. RESULTS: The meta-analysis included 20 studies comprising 346 patients with AIP and 590 patients with other pancreatobiliary diseases, including 371 pancreatobiliary malignancies. The summary estimates for tissue IgG4 in discriminating AIP and controls were as follows: diagnostic odds ratio 38.86 (95% confidence interval (CI), 18.70-80.75); sensitivity 0.64 (95% CI, 0.59-0.69); specificity 0.93 (95% CI, 0.91-0.95). The area under the curve was 0.939 for tissue IgG4 in discriminating AIP and controls. Subgroup analysis revealed no significant difference in diagnostic accuracy according to control groups (pancreatobiliary cancer versus other chronic pancreatitis) and sampling site (pancreas versus bile duct/ampulla). CONCLUSIONS: Current data demonstrate that IgG4 immunostaining of pancreatic, biliary, and ampullary tissue has a high specificity but moderate sensitivity for diagnosing AIP. IgG4 immunostaining may be useful in supporting a diagnosis of AIP when AIP is clinically suspected, but a combination of imaging and serology does not provide a conclusive diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.028" class="uri">https://doi.org/10.1016/j.pan.2020.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33058868" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33058868</a></p>
<p>BACKGROUND &amp; AIMS: We evaluated global and regional burdens of, risk factors for, and epidemiologic trends in pancreatic cancer among groups of different sexes and ages. METHODS: We used data from the GLOBOCAN database to estimate pancreatic cancer incidence and mortality in 184 countries. We examined the association between lifestyle and metabolic risk factors, extracted from the World Health Organization Global Health Observatory database, and pancreatic cancer incidence and mortality by univariable and multivariable linear regression. We retrieved country-specific on age-standardized rates (ASRs) of incidence and mortalities from cancer registries from 48 countries through 2017 for trend analysis by joinpoint regression analysis. RESULTS: The highest incidence and mortality of pancreatic cancer were in regions with very high (ASRs, 7.7 and 4.9) and high HDIs (ASRs, 6.9 and 4.6) in 2018. Countries with higher incidence and mortality were more likely to have higher prevalence of smoking, alcohol drinking, physical inactivity, obesity, hypertension, and high cholesterol. From 2008 to 2017, 2007 to 2016, or 2003 to 2012, depending on the availability of the data, there were increases in incidence among men and women in 14 (average annual percent changes [AAPCs], 8.85 to 0.41) and 17 (AAPCs, 6.04 to 0.87) countries, respectively. For mortality, the increase was observed in eight (AAPCs, 4.20 to 0.55) countries among men and 14 (AAPCs, 5.83 to 0.78) countries among women. While the incidence increased in 18 countries (AAPCs, 7.83 to 0.91) among individuals 50 years or older, an increasing trend in pancreatic cancer was also identified among individuals younger than 50 years and 40 years in eight (AAPCs, 8.75 to 2.82) and four (AAPCs, 11.07 to 8.31) countries, respectively. CONCLUSIONS: In an analysis of data from 48 countries, we found increasing incidence and mortality trends in pancreatic cancer, especially among women and populations 50 years or older, but also among younger individuals. More preventive efforts are recommended for these populations.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.10.007" class="uri">https://doi.org/10.1053/j.gastro.2020.10.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Race/Ethnicity and County-Level Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33057860" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33057860</a></p>
<p>BACKGROUND: Integration of palliative care services into the surgical treatment plan is important for holistic patient care. We sought to examine the association between patient race/ethnicity and county-level vulnerability relative to patterns of hospice utilization. PATIENTS AND METHODS: Medicare Standard Analytic Files were used to identify patients undergoing lung, esophageal, pancreatic, colon, or rectal cancer surgery between 2013 and 2017. Data were merged with the Centers for Disease Control and Prevention’s social vulnerability index (SVI). Logistic regression was utilized to identify factors associated with overall hospice utilization among deceased individuals. RESULTS: A total of 54,256 Medicare beneficiaries underwent lung (n = 16,645, 30.7%), esophageal (n = 1427, 2.6%), pancreatic (n = 6183, 11.4%), colon (n = 26,827, 49.4%), or rectal (n = 3174, 5.9%) cancer resection. Median patient age was 76 years (IQR 71-82 years), and 28,887 patients (53.2%) were male; the majority of individuals were White (91.1%, n = 49,443), while a smaller subset was Black or Latino (racial/ethnic minority: n = 4813, 8.9%). Overall, 35,416 (65.3%) patients utilized hospice services prior to death. Median SVI was 52.8 [interquartile range (IQR) 30.3-71.2]. White patients were more likely to utilize hospice care compared with minority patients (OR 1.24, 95% CI 1.17-1.31, p &lt; 0.001). Unlike White patients, there was reduced odds of hospice utilization (OR 0.97, 95% CI 0.96-0.99) and early hospice initiation (OR 0.94, 95% CI 0.91-0.97) as SVI increased among minority patients. CONCLUSIONS: Patients residing in counties with high social vulnerability were less likely to be enrolled in hospice care at the time of death, as well as be less likely to initiate hospice care early. The effects of increasing social vulnerability on hospice utilization were more profound among minority patients.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09227-6" class="uri">https://doi.org/10.1245/s10434-020-09227-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR)</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33051739" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33051739</a></p>
<p>BACKGROUND: Modern chemotherapeutics have led to improved systemic disease control for patients with locally advanced pancreatic cancer (LAPC). Surgical strategies such as distal pancreatectomy with celiac axis resection (DP-CAR) are increasingly entertained. Herein we review procedure-specific outcomes and assess biologic rationale for DP-CAR. METHODS: A prospectively maintained single-institution database of all pancreatectomies was queried for patients undergoing DP-CAR. We excluded all patients for whom complete data were not available and those who were not treated with contemporary multi-agent therapy. Data were supplemented with dedicated chart review and outreach for long-term oncologic outcomes. RESULTS: Fifty-four patients underwent DP-CAR between 2008 and 2018. The median age was 62.7 years. Ninety-eight percent received induction chemotherapy. Arterial reconstruction was performed in 17% and concomitant visceral resection in 30%. The R0 resection rate was 87%. Postoperative complications were common (43%) with chyle leak being the most frequent (17%). Length of stay was 8 days, readmission occurred in one-third, and 90-day mortality was 2%. Disease recurrence occurred in 74% during a median follow up of 17.4 months. Median recurrence-free (RFS) and overall survival (OS) were 9 and 25 months, respectively. CONCLUSIONS: Following modern induction paradigms, DP-CAR can be performed with low mortality, manageable morbidity, and excellent rates of margin-negative resection in high-volume settings. The profile of complications of DP-CAR is distinct from pancreaticoduodenectomy and simple distal pancreatectomy. OS and RFS are similar to those undergoing resection of borderline resectable and resectable disease. Improved systemic disease control will likely lead to increasing utilization of aggressive surgical approaches to LAPC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09201-2" class="uri">https://doi.org/10.1245/s10434-020-09201-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33051307" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33051307</a></p>
<p>Background RNA-sequencing-based subtyping of pancreatic ductal adenocarcinoma (PDAC) has been reported by multiple research groups, each using different methodologies and patient cohorts. ‘Classical’ and ‘basal-like’ PDAC subtypes are associated with survival differences, with basal-like tumors associated with worse prognosis. We amalgamated various PDAC subtyping tools to evaluate the potential of such tools to be reliable in clinical practice. Methods Sequencing data for 574 PDAC tumors was obtained from prospective trials and retrospective public databases. Six published PDAC subtyping strategies (Moffitt regression tools, clustering-based Moffitt, Collisson, Bailey, and Karasinska subtypes) were employed on each sample, and results were tested for subtype call consistency and association with survival. Results Basal-like and classical subtype calls were concordant in 88% of patient samples, and survival outcomes were significantly different (p&lt;0.05) between prognostic subtypes. 12% of tumors had subtype-discordant calls across the different methods, showing intermediate survival in univariate and multivariate survival analyses. Transcriptional profiles compatible with that of a hybrid subtype signature were observed for subtype-discordant tumors, in which classical and basal-like genes were concomitantly expressed. Subtype-discordant tumors showed intermediate molecular characteristics, including subtyping gene expression (p&lt;0.0001) and mutant KRAS allelic imbalance (p&lt;0.001). Conclusions Nearly one in six patients with PDAC have tumors that fail to reliably fall into the classical or basal-like PDAC subtype categories, based on two regression tools aimed towards clinical practice. Rather, these patient tumors show intermediate prognostic and molecular traits. We propose close consideration of the non-binary nature of PDAC subtypes for future incorporation of subtyping into clinical practice.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-2831" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-2831</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33051146" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33051146</a></p>
<p>BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) harbors mutant KRAS as the most common driver mutation. Studies on mouse models have uncovered the tumorigenic characteristics of the Kras oncogene driving pancreatic carcinogenesis. Similarly, Ewing sarcoma predominantly depends on the occurrence of the EWSR1-FLI1 fusion oncogene. The expression of EWSR1-FLI1 affects pro-tumorigenic pathways and induces cell transformation. In this study, we investigated whether mutant Kras could be exchanged by another potent oncogene, such as EWSR1-FLI1, to initiate pancreatic cancer development. METHODS: We generated two conditional mouse models expressing mutant KrasG12D (KC) or the EWSR1-FLI1 oncogene (E/F) in pancreas cells. Pancreatic tissue was collected from the mice at 4-6 weeks and 11-13 weeks of age as well as from survival cohorts to determine the development of spontaneous acinar-to-ductal metaplasia (ADM) and neoplastic lesions. Immunohistochemistry and immunofluorescence staining were performed to characterize and quantify changes in tissue morphology. RESULTS: The expression of the EWSR1-FLI1 fusion protein in pancreas cells was confirmed by positive FLI1 immunohistochemistry staining. Notably, the EWSR1-FLI1 expression in pancreas cells resulted in a strong depletion of the acinar cell mass and an extensive lipomatosis. Although the E/F mice exhibited spontaneous ADM formation and a shorter overall survival rate compared to KC mice, no development of neoplastic lesion was observed in aging E/F mice. CONCLUSIONS: The expression of the EWSR1-FLI1 oncogene leads to a strong pancreatic atrophy and lipomatosis. ADM formation indicates that pancreatic acinar cells are susceptible for EWSR1-FLI1-mediated oncogenic transformation to a limited extent. However, the EWSR1-FLI1 oncogene is insufficient to induce pancreatic cancer development.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.033" class="uri">https://doi.org/10.1016/j.pan.2020.10.033</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33046515" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33046515</a></p>
<p>PURPOSE: Cancer-associated fibroblasts have emerged to be highly heterogenous and can play multifaced roles in dictating pancreatic ductal adenocarcinoma (PDAC) progression, immunosuppression and therapeutic response, highlighting the need for a deeper understanding of stromal heterogeneity between patients and even within a single tumor. We hypothesized that image analysis of fibroblast subpopulations and collagen in PDAC tissues might guide stroma-based patient stratification to predict clinical outcomes and tumor characteristics. EXPERIMENTAL DESIGN: A novel multiplex immunohistochemistry-based image analysis system was established to digitally differentiate fibroblast subpopulations. Using whole-tissue slides from 215 treatment-naïve PDACs, we performed concurrent quantification of principal fibroblast subpopulations and collagen and defined three stroma types: collagen-rich stroma, fibroblast activation protein a (FAP)-dominant fibroblast-rich stroma and a smooth muscle actin (ACTA2)-dominant fibroblast-rich stroma. These stroma types were assessed for the associations with cancer-specific survival by multivariable Cox regression analyses, and with clinicopathological factors including CD8+ cell density. RESULTS: FAP-dominant fibroblasts and ACTA2-dominant fibroblasts represented the principal distinct fibroblast subpopulations in tumor stroma. Stroma types were associated with patient survival, SMAD4 status and transcriptome signatures. Compared with FAP-dominant fibroblast-rich stroma, collagen-rich stroma correlated with prolonged survival (HR, 0.57; 95% CI, 0.33-0.99), while ACTA2-dominant fibroblast-rich stroma exhibited poorer prognosis (HR, 1.65; 95% CI, 1.06-2.58). FAP-dominant fibroblast-rich stroma was additionally characterized by restricted CD8+-cell infiltrates and intense neutrophil infiltration. CONCLUSIONS: This study identified three distinct stroma types differentially associated with survival, immunity and molecular features, thereby underscoring the importance of stromal heterogeneity in subtyping pancreatic cancers and supporting the development of anti-stromal therapies.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-2298" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-2298</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Safety and Oncological Benefit of Hepatopancreatoduodenectomy for Advanced Extrahepatic Cholangiocarcinoma with Horizontal Tumor Spread: Shinshu University Experience</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33044629" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33044629</a></p>
<p>BACKGROUND: Although hepatopancreatoduodenectomy (HPD) is the only means of achieving R0 resection of widespread extrahepatic cholangiocarcinoma, its safety and oncological benefit remain controversial because of its inherent high risk of mortality and morbidity. OBJECTIVE: The aim of this study was to retrospectively analyze short- and long-term outcomes and evaluate the safety and oncological benefit of this advanced procedure. METHODS: The study cohort comprised 37 consecutive patients who had undergone major HPD. Portal vein embolization was performed before surgery in 20 (54%) patients with future remnant liver volume &lt; 35%. RESULTS: The median operative time and blood loss were 866 min and 1000 mL, respectively. Concomitant vascular resection was performed in five patients (14%). The overall morbidity and mortality rates were 100% and 5.4% (n = 2), respectively. Nineteen patients (51%) had major (Clavien-Dindo grade III or higher) complications, the most common being intra-abdominal infection (49%) and post-hepatectomy liver failure (46%, grade B/C: 32%/5%), followed by postoperative pancreatic fistula (30%, grade B/C). R0 resection was achieved in 31 patients (84%). The 1-, 3-, and 5-year overall survival (OS) rates were 83%, 48%, and 37%, respectively. In patients with R0 resection, 5-year OS was comparable between patients who had undergone major HPD and major hepatectomy alone (41% vs. 40%, p = non-significant). CONCLUSIONS: HPD is a valid treatment option for extensive cholangiocarcinoma, offering long-term survival benefit at the cost of relatively high but acceptable morbidity and mortality rates. HPD is advocated in selected patients provided that it is considered possible to achieve R0 resection.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09209-8" class="uri">https://doi.org/10.1245/s10434-020-09209-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33041332" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33041332</a></p>
<p>Histopathologically scoring the response of pancreatic ductal adenocarcinoma (PDAC) to neoadjuvant treatment can guide the selection of adjuvant therapy and improve prognostic stratification. However, several tumor response scoring (TRS) systems exist, and consensus is lacking as to which system represents best practice. An international consensus meeting on TRS took place in November 2019 in Amsterdam, The Netherlands. Here, we provide an overview of the outcomes and consensus statements that originated from this meeting. Consensus (≥80% agreement) was reached on a total of seven statements: (1) TRS is important because it provides information about the effect of neoadjuvant treatment that is not provided by other histopathology-based descriptors. (2) TRS for resected PDAC following neoadjuvant therapy should assess residual (viable) tumor burden instead of tumor regression. (3) The CAP scoring system is considered the most adequate scoring system to date because it is based on the presence and amount of residual cancer cells instead of tumor regression. (4) The defining criteria of the categories in the CAP scoring system should be improved by replacing subjective terms including “minimal” or “extensive” with objective criteria to evaluate the extent of viable tumor. (5) The improved, consensus-based system should be validated retrospectively and prospectively. (6) Prospective studies should determine the extent of tissue sampling that is required to ensure adequate assessment of the residual cancer burden, taking into account the heterogeneity of tumor response. (7) In future scientific publications, the extent of tissue sampling should be described in detail in the “Materials and methods” section.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-00683-9" class="uri">https://doi.org/10.1038/s41379-020-00683-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33039466" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33039466</a></p>
<p>BACKGROUND AND AIMS: Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage response (DDR), replication stress and novel therapeutic response in PC to develop a biomarker driven therapeutic strategy targeting DDR and replication stress in PC. METHODS: We interrogated the transcriptome, genome, proteome and functional characteristics of 61 novel PC patient-derived cell lines to define novel therapeutic strategies targeting DDR and replication stress. Validation was done in patient derived xenografts and human PC organoids. RESULTS: Patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, co-segregates with response to platinum (P &lt; 0.001) and PARP inhibitor therapy (P &lt; 0.001) in vitro and in vivo. We generated a novel signature of replication stress with which predicts response to ATR (P &lt; 0.018) and WEE1 inhibitor (P &lt; 0.029) treatment in both cell lines and human PC organoids. Replication stress was enriched in the squamous subtype of PC (P &lt; 0.001) but not associated with DDR deficiency. CONCLUSIONS: Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR proficient PC, and post-platinum therapy.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.09.043" class="uri">https://doi.org/10.1053/j.gastro.2020.09.043</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Focal parenchymal atrophy of pancreas: An important sign of underlying high-grade pancreatic intraepithelial neoplasia without invasive carcinoma, i.e., carcinoma in situ</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33039293" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33039293</a></p>
<p>OBJECTIVES: Diagnosing high-grade intraepithelial neoplasia without invasion, traditionally referred to as carcinoma in situ (CIS), is essential for improving prognosis. We examined the imaging findings of patients with and without CIS to identify significant aspects for the diagnosis of CIS. METHODS: Forty-six patients strongly suspected of early pancreatic cancer without nodule on imaging (CIS group, n = 27; non-malignant group, n = 19) were retrospectively evaluated according to ten factors of computed tomography/magnetic resonance imaging (CT/MRI), endoscopic ultrasonography (EUS), and endoscopic retrograde cholangiopancreatography (ERCP) using hierarchical cluster and univariate analyses. RESULTS: Two clusters were formed by hierarchical cluster analysis. One cluster consisted of 83.3% CIS cases with similar image findings such as focal pancreatic parenchymal atrophy (FPPA) on CT/MRI, main pancreatic duct (MPD) stricture surrounded by hypoechoic areas on EUS, and MPD stricture with upstream MPD dilation on ERCP. On univariate analysis, the CIS and non-malignant groups had FPPA on CT/MRI in 15 (55.6%) and 3 (15.8%) cases (p = 0.013), and MPD stricture surrounded by hypoechoic areas on EUS in 20 (74.1%) and 4 (21.1%) cases (p = 0.001), respectively. MPD stricture surrounded by hypoechoic areas was observed in 80% (12/15) of CIS cases with FPPA on CT/MRI and correlated with FPPA. Moreover, FPPA and MPD stricture surrounded by hypoechoic areas had histopathologically observed fibrosis or fat replacement due to pancreatic parenchymal atrophy. CONCLUSIONS: FPPA and MPD stricture surrounded by hypoechoic areas are significant findings for the diagnosis of CIS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.020" class="uri">https://doi.org/10.1016/j.pan.2020.09.020</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33039292" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33039292</a></p>
<p>BACKGROUND: We recently reported prostate apoptosis response 4 (Par-4), a potential tumor suppressor protein restrains epithelial-mesenchymal transition (EMT) properties and promotes mesenchymal-epithelial transition (MET) in invasive cancer cells by repressing Twist-1 promoter activity. Here, we demonstrate that genetic as well as pharmacological modulation of Par-4 by NGD16 (a small molecule antimetastatic agent), limits EMT-induced chemoresistance in aggressive cancer cells by suppressing MDM-2, a downstream effector of Twist-1. METHODS: Matrigel invasion assay, gelatin degradation assay, cell scattering assay, MTT assay and colony formation assay were used to study the proliferation and migration abilities of invasive cancer cells. Immunoblotting, immunocytochemistry, and immunoprecipitation analysis were utilized for determining protein expression and protein-protein interaction. 4T1 aggressive mouse carcinoma model was employed to evaluate tumor growth and lung metastasis. RESULTS: Treatment of gemcitabine (nucleoside analogue anticancer agent) to pancreatic cancer (Panc-1, MiaPaca-2) and breast cancer (MDA-MB-231) cells amplified MDM-2 expression along with increase in EMT properties. Conversely, NGD16 boosted expression of tumor suppressor Par-4 and inhibited invasion and migration abilities of these cells. Moreover, induction of Par-4 effectively diminished MDM-2 along with pro-EMT markers, whereas, augmented the expression of epithelial markers. Furthermore, siRNA-mediated silencing of Par-4 divulged that NGD16 exerts its EMT inhibitory effects in a Par-4-dependent manner. Mechanistically, Par-4 activation provokes p53 by disrupting MDM-2-p53 interaction, which restored epithelial characteristics in cancer cells. Additionally, partial knockdown of MDM-2 through siRNA pronounced the anti-proliferative and anti-invasive effects of NGD16. Finally, NGD16 efficiently inhibited tumor growth and lung metastasis in mouse mammary carcinoma model without showing any undesirable effects. CONCLUSION: Our findings unveil Par-4 as a key therapeutic target and NGD16 (the pharmacological modulator of Par-4) are potential tools to suppress EMT and associated chemoresistance, which could be exploited clinically for the treatment of aggressive cancers.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.021" class="uri">https://doi.org/10.1016/j.pan.2020.09.021</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas</strong></li>
</ul>
</summary>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33037322" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33037322</a></p>
<p>Pancreatic cancer (PaCa) is the third leading cause of cancer-related deaths in the United States. There is an unmet need to develop strategies to detect PaCa at an early, operable stage and prevent its progression. Intraductal papillary mucinous neoplasms (IPMNs) are cystic PaCa precursors that comprise nearly 50% of pancreatic cysts detected incidentally via cross-sectional imaging. Since IPMNs can progress from low- and moderate-grade dysplasia to high-grade dysplasia and invasion, the study of these lesions offers a prime opportunity to develop early detection and prevention strategies. Organoids are an ideal preclinical platform to study IPMNs, and the objective of the current investigation was to establish a living biobank of patient-derived organoids (PDO) from IPMNs. IPMN tumors and adjacent normal pancreatic tissues were successfully harvested from 15 patients with IPMNs undergoing pancreatic surgical resection at Moffitt Cancer Center &amp; Research Institute (Tampa, FL) between May of 2017 and March of 2019. Organoid cultures were also generated from cryopreserved tissues. Organoid count and size were determined over time by both Image-Pro Premier 3D Version 9.1 digital platform and Matlab application of a Circular Hough Transform algorithm, and histologic and genomic characterization of a subset of the organoids was performed using immunohistochemistry and targeted sequencing, respectively. The success rates for organoid generation from IPMN tumor and adjacent normal pancreatic tissues were 81% and 87%, respectively. IPMN organoids derived from different epithelial subtypes showed different morphologies in vitro, and organoids recapitulated histologic and genomic characteristics of the parental IPMN tumor. In summary, this preclinical model has the potential to provide new opportunities to unveil mechanisms of IPMN progression to invasion and to shed insight into novel biomarkers for early detection and targets for chemoprevention.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-020-00494-1" class="uri">https://doi.org/10.1038/s41374-020-00494-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A single center randomized double blind controlled trial of pentoxifylline in acute pancreatitis: Challenges and opportunities</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33036921" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33036921</a></p>
<p>OBJECTIVES: Despite substantial morbidity and mortality associated with acute pancreatitis (AP), only one small randomized controlled drug trial (RCT) is available in the past few decades from the United States. Hence, we conducted a single-center, double-blind, placebo-controlled RCT of pentoxifylline in AP. METHODS: A total of 9 doses of oral pentoxifylline 400 mg or placebo tablet, three times daily, was administered within 72 h of diagnosis, using randomization blocks by pharmacy. Primary outcome was a composite outcome including any of the following: death, peripancreatic and/or pancreatic necrosis, infected pancreatic necrosis, persistent organ failure, persistent systemic inflammatory response syndrome, hospital stay longer than 4 days, need for intensive care, and need for intervention for necrosis. RESULTS: Between July 7, 2015, and April 4, 2017, we identified 685 patients with AP, 233 met eligibility criteria and 176 were approached for the study. Of these, 91 (51.7%) declined and finally 45 in pentoxifylline group and 38 in placebo group (83 total) were compared. There were no significant differences in primary outcome (27 [60.0%] vs 15 [39.5%]; P = .06). Pentoxifylline group was not associated with any benefit, but withlonger stay (42% vs. 21%; P = .04) and higher readmission rates (16 %vs 3%; P = .047). CONCLUSIONS: We could not demonstrate superiority of pentoxifylline over placebo. Smaller sample size and inclusion of all types of severity might be the reasons for lack of efficacy. The challenges observed in the present study indicate that, in order to conduct a successful drug trial in AP, a multi center collaboration is essential.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.023" class="uri">https://doi.org/10.1016/j.pan.2020.09.023</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33032924" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33032924</a></p>
<p>BACKGROUND: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of patients with blood type O is better for pancreatic adenocarcinoma, although this has not been extensively explored in pancreatic neuroendocrine tumors (PanNET). OBJECTIVE: To assess the influence of the ABO and Rhesus blood types on the risk of recurrence in patients who underwent curative intent PanNET surgical resection. METHODS: All consecutive patients operated on for well-differentiated panNET in an expert center from 2003 to 2018 were retrospectively included. Blood group, Rhesus system, demographic and clinical data were collected. The primary endpoint was recurrence free survival (RFS). Factors associated with RFS were explored using Cox proportional hazard models. RESULTS: Overall, 300 patients (male 43%) were included, median age 54 years old (IQR 45-64). The ABO blood group distribution was similar to that of the French population. There was no association between blood group and tumor features. The median postoperative follow-up was 43.9 months (17.0-77.8). The 5- and 10-year RFS rates were 85 ± 4% and 71 ± 13% in O RhD + patients, versus 72 ± 4% and 63 ± 6% otherwise, respectively (p = 0.035). The O RhD + blood group was associated with a decreased risk of recurrence (HR 0.34, 95% CI [0.15-0.75]), p = 0.007 in multivariable analysis adjusted for age, ki67, functioning syndrome, resection margins, tumor size, lymph node status, oncogenetic syndrome. CONCLUSIONS: After curative-intent surgical resection for PanNET, patients with a non-O RhD + blood group may have an increased risk of recurrence and could benefit from closer follow-up.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.014" class="uri">https://doi.org/10.1016/j.pan.2020.09.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial</strong></li>
</ul>
</summary>
<p><em>The lancet. Diabetes &amp; endocrinology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33031736" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33031736</a></p>
<p>BACKGROUND: The pancreas is small and irregular in shape in people with type 2 diabetes. If these abnormalities are caused by the disease state itself rather than being a predisposing factor, remission of type 2 diabetes should restore normal pancreas morphology. The objective of this study was to determine whether changes in pancreas volume and shape occurred during 2 years of remission. METHODS: For this post-hoc analysis, we included a subset of adult participants of the Diabetes Remission Clinical Trial (DiRECT), who had type 2 diabetes and were randomly assigned to a weight management intervention or routine diabetes management. Intervention group participants were categorised as responders (HbA1c &lt;6·5% [48 mmol/mol] and fasting blood glucose &lt;7·0 mmol/L, off all anti-diabetes medication) and non-responders, who were classified as remaining diabetic. Data on pancreas volume and irregularity of pancreas border at baseline, 5 months, 12 months, and 24 months after intervention were compared between responders and non-responders; additional comparisons were made between control group participants with type 2 diabetes and a non-diabetic comparator (NDC) group, who were matched to the intervention group by age, sex, and post-weight-loss weight, to determine the extent of any normalisation. We used a mixed-effects regression model based on repeated measures ANOVA with correction for potential confounding. Magnetic resonance techniques were employed to quantify pancreas volume, the irregularity of the pancreas borders, and intrapancreatic fat content. β-cell function and biomarkers of tissue growth were also measured. FINDINGS: Between July 25, 2015, and Aug 5, 2016, 90 participants with type 2 diabetes in the DiRECT subset were randomly assigned to intervention (n=64) or control (n=26) and were assessed at baseline; a further 25 non-diabetic participants were enrolled into the NDC group. At baseline, mean pancreas volume was 61·7 cm3 (SD 16·0) in all participants with type 2 diabetes and 79·8 cm3 (14·3) in the NDC group (p&lt;0·0001). At 24 months, pancreas volume had increased by 9·4 cm3 (95% CI 6·1 to 12·8) in responders compared with 6·4 cm3 (2·5 to 10·3) in non-responders (p=0·0008). Pancreas borders at baseline were more irregular in participants with type 2 diabetes than in the NDC group (fractal dimension 1·138 [SD 0·027] vs 1·097 [0·025]; p&lt;0·0001) and had normalised by 24 months in responders only (1·099 [0·028]). Intrapancreatic fat declined by 1·02 percentage points (95% CI 0·53 to 1·51) in 32 responders and 0·51% (-0·17 to 1·19) in 13 non-responders (p=0·23). INTERPRETATION: These data show for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of type 2 diabetes by weight loss-induced remission. FUNDING: Diabetes UK.</p>
<p>doi: <a href="https://doi.org/10.1016/S2213-8587(20)30303-X" class="uri">https://doi.org/10.1016/S2213-8587(20)30303-X</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33028669" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33028669</a></p>
<p>OBJECTIVE: Intraductal papillary mucinous neoplasms (IPMNs) are non-invasive precursor lesions that can progress to invasive pancreatic cancer and are classified as low-grade or high-grade based on the morphology of the neoplastic epithelium. We aimed to compare genetic alterations in low-grade and high-grade regions of the same IPMN in order to identify molecular alterations underlying neoplastic progression. DESIGN: We performed multiregion whole exome sequencing on tissue samples from 17 IPMNs with both low-grade and high-grade dysplasia (76 IPMN regions, including 49 from low-grade dysplasia and 27 from high-grade dysplasia). We reconstructed the phylogeny for each case, and we assessed mutations in a novel driver gene in an independent cohort of 63 IPMN cyst fluid samples. RESULTS: Our multiregion whole exome sequencing identified KLF4, a previously unreported genetic driver of IPMN tumorigenesis, with hotspot mutations in one of two codons identified in &gt;50% of the analyzed IPMNs. Mutations in KLF4 were significantly more prevalent in low-grade regions in our sequenced cases. Phylogenetic analyses of whole exome sequencing data demonstrated diverse patterns of IPMN initiation and progression. Hotspot mutations in KLF4 were also identified in an independent cohort of IPMN cyst fluid samples, again with a significantly higher prevalence in low-grade IPMNs. CONCLUSION: Hotspot mutations in KLF4 occur at high prevalence in IPMNs. Unique among pancreatic driver genes, KLF4 mutations are enriched in low-grade IPMNs. These data highlight distinct molecular features of low-grade and high-grade dysplasia and suggest diverse pathways to high-grade dysplasia via the IPMN pathway.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-321217" class="uri">https://doi.org/10.1136/gutjnl-2020-321217</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33028668" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33028668</a></p>
<p>OBJECTIVE: The diagnosis of autoimmune pancreatitis (AIP) is challenging. Sonographic and cross-sectional imaging findings of AIP closely mimic pancreatic ductal adenocarcinoma (PDAC) and techniques for tissue sampling of AIP are suboptimal. These limitations often result in delayed or failed diagnosis, which negatively impact patient management and outcomes. This study aimed to create an endoscopic ultrasound (EUS)-based convolutional neural network (CNN) model trained to differentiate AIP from PDAC, chronic pancreatitis (CP) and normal pancreas (NP), with sufficient performance to analyse EUS video in real time. DESIGN: A database of still image and video data obtained from EUS examinations of cases of AIP, PDAC, CP and NP was used to develop a CNN. Occlusion heatmap analysis was used to identify sonographic features the CNN valued when differentiating AIP from PDAC. RESULTS: From 583 patients (146 AIP, 292 PDAC, 72 CP and 73 NP), a total of 1 174 461 unique EUS images were extracted. For video data, the CNN processed 955 EUS frames per second and was: 99% sensitive, 98% specific for distinguishing AIP from NP; 94% sensitive, 71% specific for distinguishing AIP from CP; 90% sensitive, 93% specific for distinguishing AIP from PDAC; and 90% sensitive, 85% specific for distinguishing AIP from all studied conditions (ie, PDAC, CP and NP). CONCLUSION: The developed EUS-CNN model accurately differentiated AIP from PDAC and benign pancreatic conditions, thereby offering the capability of earlier and more accurate diagnosis. Use of this model offers the potential for more timely and appropriate patient care and improved outcome.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-322821" class="uri">https://doi.org/10.1136/gutjnl-2020-322821</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33028596" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33028596</a></p>
<p>PURPOSE: To compare the clinical characteristics and overall survival (OS) of germline mutation carriers in homologous recombination repair (HRR) genes and noncarriers with pancreatic ductal adenocarcinoma (PDAC). METHODS: Germline DNA from 3,078 patients with PDAC enrolled in a prospective registry at Mayo Clinic between 2000 and 2017 was analyzed for mutations in 37 cancer predisposition genes. Characteristics and OS of patients with mutations in eight genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, PALB2, RAD51C, and RAD51D) involved in HRR were compared with patients testing negative for mutations in all 37 genes. RESULTS: The 175 HRR mutation carriers and 2,730 noncarriers in the study had a median duration of follow-up of 9.9 years. HRR mutation carriers were younger (median age at diagnosis: 63 vs. 66 years, P &lt; 0.001) and more likely to have metastatic disease at diagnosis (46% vs. 36%, P = 0.004). In a multivariable model adjusting for sex, age at diagnosis, and tumor staging, patients with germline HRR mutations had a significantly longer OS compared with noncarriers [HR, 0.83; 95% confidence interval (CI), 0.70-0.97; P = 0.02]. Further gene-level analysis demonstrated that germline ATM mutation carriers had longer OS compared with patients without germline mutations in any of the 37 genes (HR, 0.72; 95% CI, 0.55-0.94; P = 0.01). CONCLUSIONS: This study demonstrates that germline mutation carrier status in PDAC is associated with longer OS compared with noncarriers. Further research into tumor biology and response to platinum-based chemotherapy in germline mutation carriers with PDAC are needed to better understand the association with longer OS.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1788" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1788</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comparison of prognostic impact of anatomic location of the pancreas on postoperative pancreatic fistula in laparoscopic and open gastrectomy</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):325</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33023478" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33023478</a></p>
<p>BACKGROUND: Postoperative pancreatic fistula (POPF) is a serious complication after gastric cancer surgery. The current study aimed to investigate the significance of the anatomic location of the pancreas as a predictor for POPF in both laparoscopic gastrectomy (LG) and open gastrectomy (OG). METHODS: In total, 233 patients with gastric cancer were assessed retrospectively. We measured the maximum vertical (P-L height; PLH) and horizontal length (P-L depth; PLD) between the upper border of pancreas and the root of left gastric artery on a preoperative CT in the sagittal direction. The maximum length of the vertical line between the surface of the pancreas and the aorta (P-A length), previously reported as prognostic factor of POPF, was also measured. We investigated the correlations between these parameters and the incidence of POPF in LG and OG groups. RESULTS: Among the patients in this study, 118 underwent OG and 115 underwent LG. In LG, the median PLH and P-A length in patients with POPF were significantly longer compared with those without POPF (p = 0.026, 0.034, respectively), but not in OG. There was no significant difference in the median PLD between the patients with or without POPF in both LG and OG. The multivariate analysis demonstrated that PLH (odds ratio [OR] 4.19, 95% confidence interval [CI] 1.57-11.3, P = 0.004) and P-A length (OR 4.06, 95%CI 1.05-15.7, P = 0.042] were independent factors for predicting POPF in LG. However, intraoperative blood loss (OR 2.55, 95%CI 1.05-6.18, P = 0.038) was extracted as an independent factor in OG. The median amylase level in the drained fluid (D-Amy) were significantly higher in patients with high PLH(≥12.4 mm) or high P-A length (≥45 mm) compared with those with low PLH or low P-A length in LG. However, there were no differences in the D-Amy levels by PLH or P-A length in OG patients. CONCLUSIONS: The anatomic location of the pancreas is a specific and independent predictor of POPF in LG but not in OG. PLH is a simple parameter that can evaluate the anatomic position of the pancreas, and it may be useful for preventing POPF after LG.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01476-9" class="uri">https://doi.org/10.1186/s12876-020-01476-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33011748" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33011748</a></p>
<p>Currently there is no highly specific and sensitive marker to identify breast cancer-the most common malignancy in women. Breast cancer can be categorized as estrogen receptor (ER)/progesterone receptor (PR)-positive luminal, human epidermal growth factor receptor 2 (HER2)-positive, or triple-negative breast cancer (TNBC) types based on the expression of ER, PR, and HER2. Although GATA3 is the most widely used tumor marker at present to determine the breast origin, which has been shown to be an excellent marker for ER-positive and low-grade breast cancer, but it does not work well for TNBC with sensitivity as low as &lt;20% in metaplastic breast carcinoma. In the current study, through TCGA data mining we identified trichorhinophalangeal syndrome type 1 (TRPS1) as a specific gene for breast carcinoma across 31 solid tumor types. Moreover, high mRNA level of TRPS1 was found in all four subtypes of breast carcinoma including ER/PR-positive luminal A and B types, HER2-positive type, and basal-type/TNBC. We then analyzed TRPS1 expression in 479 cases of various types of breast cancer using immunochemistry staining, and found that TRPS1 and GATA3 had comparable positive expression in ER-positive (98% vs. 95%) and HER2-positive (87% vs. 88%) breast carcinomas. However, TRPS1 which was highly expressed in TNBC, was significantly higher than GATA3 expression in metaplastic (86% vs. 21%) and nonmetaplastic (86% vs. 51%) TNBC. In addition, TRPS1 expression was evaluated in 1234 cases of solid tumor from different organs. In contrast to the high expression of GATA3 in urothelial carcinoma, TRPS1 showed no or little expression in urothelial carcinomas or in other tumor types including lung adenocarcinoma, pancreatic adenocarcinoma, colon and gastric adenocarcinoma, renal cell carcinoma, melanoma, and ovarian carcinoma. These findings suggest that TRPS1 is a highly sensitive and specific marker for breast carcinoma and can be used as a great diagnostic tool, especially for TNBC.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-00692-8" class="uri">https://doi.org/10.1038/s41379-020-00692-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33009500" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33009500</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States. Despite the high prevalence of Kras mutations in pancreatic cancer patients, murine models expressing the oncogenic mutant Kras (Krasmut) in mature pancreatic cells develop PDAC at a low frequency. Independent of cell of origin, a second genetic hit (loss of tumor suppressor TP53 or PTEN) is important for development of PDAC in mice. We hypothesized ectopic expression and elevated levels of oncogenic mutant Kras would promote PanIN arising in pancreatic ducts. To test our hypothesis, the significance of elevating levels of K-Ras and Ras activity has been explored by expression of a CAG driven LGSL-KrasG12V allele (cKras) in pancreatic ducts, which promotes ectopic Kras expression. We predicted expression of cKras in pancreatic ducts would generate neoplasia and PDAC. To test our hypothesis, we employed tamoxifen dependent CreERT2 mediated recombination. Hnf1b:CreERT2;KrasG12V (cKrasHnf1b/+) mice received 1 (Low), 5 (Mod) or 10 (High) mg per 20 g body weight to recombine cKras in low (cKrasLow), moderate (cKrasMod), and high (cKrasHigh) percentages of pancreatic ducts. Our histologic analysis revealed poorly differentiated aggressive tumors in cKrasHigh mice. cKrasMod mice had grades of Pancreatic Intraepithelial Neoplasia (PanIN), recapitulating early and advanced PanIN observed in human PDAC. Proteomics analysis revealed significant differences in PTEN/AKT and MAPK pathways between wild type, cKrasLow, cKrasMod, and cKrasHigh mice. In conclusion, in this study, we provide evidence that ectopic expression of oncogenic mutant K-Ras in pancreatic ducts generates early and late PanIN as well as PDAC. This Ras rheostat model provides evidence that AKT signaling is an important early driver of invasive ductal derived PDAC.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-020-00490-5" class="uri">https://doi.org/10.1038/s41374-020-00490-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Changing trends in the clinicopathological features, practices and outcomes in the surgical management for cystic lesions of the pancreas and impact of the international guidelines: Single institution experience with 462 cases between 1995-2018</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008749" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008749</a></p>
<p>INTRODUCTION: The impact on clinical practice of the international guidelines including the Sendai Guidelines (SG06) and Fukuoka Guidelines (FG12) on the management of cystic lesions of the pancreas (CLP) has not been well-studied. The primary aim was to examine the changing trends and outcomes in the surgical management of CLP in our institution over time and to determine the impact of these guidelines on our institution practice. METHODS: 462 patients with surgically-treated CLP were retrospectively reviewed and classified under the 2 guidelines. The cohort was divided into 3 time periods: 1998-2006, 2007-2012 and 2013 to 2018. RESULTS: Comparison across the 3 time periods demonstrated significantly increasing frequency of older patients, asymptomatic CLP, male gender, smaller tumor size, elevated Ca 19-9, use of magnetic resonance imaging (MRI) and use of endoscopic ultrasound (EUS) prior to surgery. There was also significantly increasing frequency of adherence to the international guidelines as evidenced by the increasing proportion of HRSG06 and HRFG12 CLP with a corresponding lower proportion of LRSG06 and LRFG12 being resected. This resulted in a significantly higher proportion of resected CLP whereby the final pathology confirmed that a surgery was actually indicated. CONCLUSIONS: Over time, there was increasing adherence to the international guidelines for the selection of patients for surgical resection as evidenced by the significantly increasing proportion of HRSG06 and HRFG06 CLPs undergoing surgery. This was associated with a significantly higher proportion of patients with a definitive indication for surgery. These suggested that over time, there was a continuous improvement in our selection of appropriate CLP for surgical treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.019" class="uri">https://doi.org/10.1016/j.pan.2020.09.019</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Integrated analysis identifies a pathway-related competing endogenous RNA network in the progression of pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):958</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008376" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008376</a></p>
<p>BACKGROUND: It is well acknowledged that cancer-related pathways play pivotal roles in the progression of pancreatic cancer (PC). Employing Integrated analysis, we aim to identify the pathway-related ceRNA network associated with PC progression. METHODS: We divided eight GEO datasets into three groups according to their platform, and combined TCGA and GTEx databases as a group. Additionally, we screened out the differentially expressed genes (DEGs) and performed functional enrichment analysis in each group, and recognized the top hub genes in the most enriched pathway. Furthermore, the upstream of miRNAs and lncRNAs were predicted and validated according to their expression and prognostic roles. Finally, the co-expression analysis was applied to identify a pathway-related ceRNA network in the progression of PC. RESULTS: A total of 51 significant pathways that common enriched in all groups were spotted. Enrichment analysis indicated that pathway in cancer was greatly linked with tumor formation and progression. Next, the top 20 hug genes in this pathway were recognized, and stepwise prediction and validation from mRNA to lncRNA, including 11 hub genes, 4 key miRNAs, and 2 key lncRNAs, were applied to identify a meaningful ceRNA network according to ceRNA rules. Ultimately, we identified the PVT1/miR-20b/CCND1 axis as a promising pathway-related ceRNA axis in the progression of PC. CONCLUSION: Overall, we elucidate the pathway-related ceRNA regulatory network of PVT1/miR-20b/CCND1 in the progression of PC, which can be considered as therapeutic targets and encouraging prognostic biomarkers for PC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07470-4" class="uri">https://doi.org/10.1186/s12885-020-07470-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):950</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008332" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008332</a></p>
<p>BACKGROUND: In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to guide the individual patient to the most beneficial therapeutic strategy, simple and easily available prognostic and predictive markers are needed. METHODS: The potential prognostic value of a range of blood/serum parameters, patient-, and tumour characteristics was explored in a retrospective cohort of 75 patients treated with gemcitabine/nab-paclitaxel (Gem/NabP) for advanced pancreatic ductal adenocarcinoma (PDAC) in the South Eastern Region of Sweden. Primary outcome was overall survival (OS) while progression free survival (PFS) was the key secondary outcome. RESULT: Univariable Cox regression analysis revealed that high baseline serum albumin (&gt; 37 g/L) and older age (&gt; 65) were positive prognostic markers for OS, and in multivariable regression analysis both parameters were confirmed to be independent prognostic variables (HR 0.48, p = 0.023 and HR = 0.47, p = 0.039,). Thrombocytopenia at any time during the treatment was an independent predictor for improved progression free survival (PFS) but not for OS (HR 0.49, p = 0.029, 0.54, p = 0.073), whereas thrombocytopenia developed under cycle 1 was neither related with OS nor PFS (HR 0.87, p = 0.384, HR 1.04, p = 0.771). Other parameters assessed (gender, tumour stage, ECOG performance status, myelosuppression, baseline serum CA19-9, and baseline serum bilirubin levels) were not significantly associated with survival. CONCLUSION: Serum albumin at baseline is a prognostic factor with palliative Gem/NabP in advanced PDAC, and should be further assessed as a tool for risk stratification. Older age was associated with improved survival, which encourages further studies on the use of Gem/NabP in the elderly.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07426-8" class="uri">https://doi.org/10.1186/s12885-020-07426-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):324</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008295" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008295</a></p>
<p>BACKGROUND: Hypercalcemia of malignancy is not uncommon in patients with advanced stage cancer. In rare cases the cause of the hypercalcemia is excessive production of calcitriol, the active form of vitamin D. Although inappropriate tumoral secretion of calcitriol is typically associated with lymphomas and some ovarian germ cell tumors, we present a case of calcitriol overproduction-induced hypercalcemia due to a pancreatic neuroendocrine tumor. The high expression of somatostatin receptors on this neuroendocrine neoplasm opened up the opportunity to treat the patient with radiolabelled somatostatin analogs, which successfully controlled the refractory hypercalcaemia and calcitriol levels. This case documents a rare finding of refractory hypercalcaemia of underlying malignancy due to a calcitriol-producing pancreatic neuroendocrine tumor, responding to peptide receptor radionuclide therapy (PRRT). CASE PRESENTATION: A 57 years-old patient presented with back pain, general discomfort, polydipsia, polyuria, fatigue and recent weight loss of 10 kg. Clinical examination was normal and there was no relevant medical history. Biochemical evaluation showed hypercalcemia with markedly increased calcitriol levels. CT-thorax-abdomen and ultrasound guided biopsy revealed a pancreatic neuroendocrine tumor with multifocal liver metastases, suggesting that excessive overproduction of calcitriol by this neuroendocrine tumor was the cause of the refractory hypercalcemia. The patient was eligible for PRRT. Four cycles of 177Lu-DOTATATE PRRT resulted in a morphological response and a normalization of serum calcium levels, confirming the hypothesis of a calcitriol producing pancreatic neuroendocrine tumor. Progression of liver metastases warranted further therapy and temozolomide-capecitabine was started with morphological and biochemical (serum calcium, calcitriol) stabilization. CONCLUSION: Although up to 30-40% of gastroenteropancreatic neuroendocrine tumors are known to be functional (i.e. producing symptoms associated with the predominant hormone/peptide secreted), calcitriol secreting pancreatic neuroendocrine tumors are very rare. However, treatment with PRRT resulted in normalization of calcium and calcitriol levels, strongly supporting the hypothesis of a calcitriol-producing pancreatic neuroendocrine tumor.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01470-1" class="uri">https://doi.org/10.1186/s12876-020-01470-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33007300" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33007300</a></p>
<p>BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibroblast-rich desmoplastic stroma. Cancer-associated fibroblasts (CAFs) have been shown to display a high degree of interconvertible states including quiescent, inflammatory and myofibroblastic phenotypes, however, the mechanisms by which this plasticity is achieved are poorly understood. Here, we aim to elucidate the role of CAF plasticity and its impact on PDAC biology. METHODS: To investigate the role of mesenchymal plasticity in PDAC progression, we generated a PDAC mouse model in which CAF plasticity is modulated by genetical depletion of the transcription factor Prrx1. Primary pancreatic fibroblasts from this mouse model were further characterized by functional in vitro assays. To characterize the impact of CAFs on tumor differentiation and response to chemotherapy various co-culture experiments were performed. In vivo, tumors were characterized by morphology, extracellular matrix composition as well as tumor dissemination and metastasis. RESULTS: Our in vivo findings demonstrated that Prrx1-deficient CAFs remain constitutively activated. Importantly, this CAF phenotype determines tumor differentiation and disrupts systemic tumor dissemination. Mechanistically, co-culture experiments of tumor organoids and CAFs revealed that CAFs shape the epithelial-to-mesenchymal phenotype and confer gemcitabine resistance of PDAC cells induced by CAF-derived hepatocyte growth factor. Furthermore, gene expression analysis revealed that pancreatic cancer patients with high stromal expression of Prrx1 display the squamous, most aggressive, subtype of PDAC. CONCLUSION: Here, we define that the Prrx1 transcription factor is critical for tuning CAF activation, allowing a dynamic switch between a dormant and an activated state. This work demonstrates that Prrx1-mediated CAF plasticity has significant impact on PDAC biology and therapeutic resistance.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.09.010" class="uri">https://doi.org/10.1053/j.gastro.2020.09.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33005981" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33005981</a></p>
<p>Recently, the term mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) has been proposed as an umbrella definition covering different possible combinations of mixed neuroendocrine-exocrine neoplasms. Among these, the adenoma plus neuroendocrine tumor (NET) combination is among the rarest and not formally recognized by the 2019 WHO Classification. In this setting, the debate between either collision tumors or true mixed neoplasms is still unsolved. In this report, a pancreatic intraductal papillary mucinous neoplasm (IPMN) plus a NET is described, and the molecular investigations showed the presence in both populations of the same KRAS, GNAS, and CDKN2A mutations and the amplification of the CCND1 gene. These data prove clonality and support a common origin of both components, therefore confirming the true mixed nature. For this reason, mixed neuroendocrine-exocrine neoplasms, in which the exocrine component is represented by a glandular precursor lesion (adenoma/IPMN) only, should be included into the MiNEN family.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02942-1" class="uri">https://doi.org/10.1007/s00428-020-02942-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33004046" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33004046</a></p>
<p>BACKGROUND: Radiotherapy is known to improve local tumor control in locally advanced pancreatic cancer (LAPC), although there is a lack of convincing data on a potential overall survival benefit of chemoradiotherapy over chemotherapy alone. To improve efficacy of radiotherapy, new approaches need to be evolved. Carbon ion radiotherapy is supposed to be more effective than photon radiotherapy due to a higher relative biological effectiveness (RBE) and due to a steep dose-gradient making dose delivery highly conformal. METHODS: The present Phase II PACK-study investigates carbon ion radiotherapy as definitive treatment in LAPC as well as in locally recurrent pancreatic cancer. A total irradiation dose of 48 Gy (RBE) will be delivered in twelve fractions. Concurrent chemotherapy is accepted, if indicated. The primary endpoint is the overall survival rate after 12 months. Secondary endpoints are progression free survival, safety, quality of life and impact on tumor markers CA 19-9 and CEA. A total of twenty-five patients are planned for recruitment over 2 years. DISCUSSION: Recently, Japanese researches could show promising results in a Phase I/II-study evaluating chemoradiotherapy of carbon ion radiotherapy and gemcitabine in LAPC. The present prospective PACK-study investigates the efficacy of carbon ion radiotherapy in pancreatic cancer at Heidelberg Ion Beam Therapy Center (HIT) in Germany. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov: NCT04194268 (Retrospectively registered on December, 11th 2019).</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07434-8" class="uri">https://doi.org/10.1186/s12885-020-07434-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):946</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33004032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33004032</a></p>
<p>BACKGROUND: Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC. Therefore, we conducted multicenter retrospective study to investigate the efficacy of chemotherapy in patients with UC of the pancreas. METHODS: This multicenter retrospective cohort study was conducted at 17 institutions in Japan between January 2007 and December 2017. A total of 50 patients treated with chemotherapy were analyzed. RESULTS: The median overall survival (OS) in UC patients treated with chemotherapy was 4.08 months. The details of first-line chemotherapy were as follows: gemcitabine (n = 24), S-1 (n = 12), gemcitabine plus nab-paclitaxel (n = 6), and other treatment (n = 8). The median progression-free survival (PFS) was 1.61 months in the gemcitabine group, 2.96 months in the S-1 group, and 4.60 months in the gemcitabine plus nab-paclitaxel group. Gemcitabine plus nab-paclitaxel significantly improved PFS compared with gemcitabine (p = 0.014). The objective response rate (ORR) was 4.2% in the gemcitabine group, 0.0% in the S-1 group, and 33.3% in the gemcitabine plus nab-paclitaxel group. Gemcitabine plus nab-paclitaxel also showed a significantly higher ORR compared with both gemcitabine and S-1 (gemcitabine plus nab-paclitaxel vs. gemcitabine: p = 0.033; gemcitabine plus nab-paclitaxel vs. S-1: p = 0.034). A paclitaxel-containing first-line regimen significantly improved OS compared with a non-paclitaxel-containing regimen (6.94 months vs. 3.75 months, respectively; p = 0.041). After adjustment, use of a paclitaxel-containing regimen in any line was still an independent predictor of OS (hazard ratio for OS, 0.221; 95% confidence interval, 0.076-0.647; p = 0.006) in multiple imputation by chained equation. CONCLUSIONS: The results of the present study indicate that a paclitaxel-containing regimen would offer relatively longer survival, and it is considered a reasonable option for treating patients with unresectable UC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07462-4" class="uri">https://doi.org/10.1186/s12885-020-07462-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Efficacy of Early Percutaneous Catheter Drainage in Acute Pancreatitis of Varying Severity Associated With Sterile Acute Inflammatory Pancreatic Fluid Collection</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1246-1254</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33003087" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33003087</a></p>
<p>OBJECTIVE: The aim of the study was to evaluate the efficacy of early percutaneous catheter drainage (PCD) for sterile acute inflammatory pancreatic fluid collection (AIPFC) in acute pancreatitis (AP) of varying severity. METHODS: Retrospective analyses were performed based on the presence of sterile AIPFC and different AP severities according to 2012 Revised Atlanta Classification. RESULTS: Early PCD contributed to obvious decreases in operation rate (OR, P = 0.006), infection rate (IR, P = 0.020), and mortality (P = 0.009) in severe AP (SAP). In moderate SAP with sterile AIPFCs, however, early PCD was associated with increased OR (P = 0.009) and IR (P = 0.040). Subgroup analysis revealed that early PCD led to remarkable decreases in OR for patients with persistent organ failure (OF) within 3 days (P = 0.024 for single OF, P = 0.039 for multiple OF) and in mortality for patients with multiple OF (P = 0.041 for OF within 3 days and P = 0.055 for 3-14 days). Moreover, lower mortality was found in SAP patients with early PCD-induced infections than with spontaneous infections (P = 0.027). CONCLUSIONS: Early PCD may improve the prognosis of SAP with drainable sterile AIPFCs by reducing the OR, IR, and mortality.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001666" class="uri">https://doi.org/10.1097/MPA.0000000000001666</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic Angiopathy Associated With Islet Amyloid and Type 2 Diabetes Mellitus</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1232-1239</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33003086" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33003086</a></p>
<p>OBJECTIVES: Type 2 diabetes (T2D) is histopathologically characterized by islet amyloid and is closely connected with vascular complications. Here, we explore the presence of pancreatic angiopathy (PA) associated with islet amyloid and T2D. METHODS: From a total of 172 autopsy cases who had a history of T2D diagnosis, we randomly selected 30 T2D autopsy cases with islet amyloid (DA+) in comparison with islet amyloid-free (DA-) 30 T2D cases and 60 nondiabetic (ND) controls. Amyloid deposits and PA including atherosclerosis of pancreatic interlobar arteries, arterial calcification, atheroembolism, hyaline arteriosclerosis of small arterioles, and islet capillary density were detected in all groups. RESULTS: Pancreatic angiopathy was found in 91.7% of patients with T2D and in 68.3% of ND controls (P &lt; 0.01). Furthermore, 100% of DA+ patients and 83.3% of DA- subjects showed PA. The intraislet capillary density was significantly lower in DA+ subjects than DA- subjects (mean [standard deviation], DA+: 205 [82] count/mm; DA-: 344 [76] count/mm; ND: 291 [94] count/mm; P &lt; 0.01). Finally, interlobar arteriosclerosis (R = 0.603, P &lt; 0.01) was linearly correlated with the severity of islet amyloid deposits. CONCLUSIONS: Pancreatic angiopathy might be both a cause and a consequence of islet amyloid and T2D.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001664" class="uri">https://doi.org/10.1097/MPA.0000000000001664</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1141-1152</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33003085" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33003085</a></p>
<p>Pancreatic cancer is the fourth leading cause of cancer death in the United States. Pancreatic cancer presents dismal clinical outcomes in patients, and the incidence of pancreatic cancer has continuously increased to likely become the second most common cause of cancer-related deaths by as early as 2030. One of main reasons for the high mortality rate of pancreatic cancer is the lack of tools for early-stage detection. Current practice in detecting and monitoring therapeutic response in pancreatic cancer relies on imaging analysis and invasive endoscopic examination. Liquid biopsy-based analysis of genetic alterations in biofluids has become a fundamental component in the diagnosis and management of cancers. There is an urgent need for scientific and technological advancement to detect pancreatic cancer early and to develop effective therapies. The development of a highly sensitive and specific liquid biopsy tool will require extensive understanding on the characteristics of circulating tumor DNA in biofluids. Here, we have reviewed the current status of liquid biopsy in detecting and monitoring pancreatic cancers and our understanding of circulating tumor DNA that should be considered for the development of a liquid biopsy tool, which will greatly aid in the diagnosis and healthcare of people at risk.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001662" class="uri">https://doi.org/10.1097/MPA.0000000000001662</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Total Neoadjuvant Therapy for Operable Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33000372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33000372</a></p>
<p>BACKGROUND: Overall survival (OS) for operable pancreatic cancer (PC) is optimized when 4-6 months of nonsurgical therapy is combined with pancreatectomy. Because surgery renders the delivery of postoperative therapy uncertain, total neoadjuvant therapy (TNT) is gaining popularity. METHODS: We performed a retrospective cohort study of patients with operable PC and compared TNT with shorter course neoadjuvant therapy (SNT). Primary outcomes of interest included completion of neoadjuvant therapy (NT) and resection of the primary tumor, receipt of 5 months of nonsurgical therapy, and median OS. RESULTS: We reviewed 541 consecutive patients from 2009 to 2019 including 226 (42%) with resectable PC and 315 (58%) with borderline resectable (BLR) PC. The median age was 66 years (IQR [59, 72]), and 260 (48%) patients were female. TNT was administered to 89 (16%) patients and SNT was administered to 452 (84%). Both groups were equally likely to complete intended NT and surgery (p = 0.90). Patients who received TNT and surgical resection were more likely to have a complete pathologic response (8% vs 4%, p &lt; 0.01) and were more likely to receive at least 5 months of nonsurgical therapy (67% vs 45%, p &lt; 0.01). The median OS was 26 months [IQR (15, 57)]; not reached among patients treated with TNT, and 25 months [IQR (15, 56)] among patients treated with SNT (p = 0.19). CONCLUSIONS: TNT ensures the delivery of intended systemic therapy prior to a complicated operation without decreasing the chance of successful surgery; a window of operability was not lost. Patients who can tolerate SNT will likely benefit from TNT.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09149-3" class="uri">https://doi.org/10.1245/s10434-020-09149-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Tumor quiescence: elevating SOX2 in diverse tumor cell types downregulates a broad spectrum of the cell cycle machinery and inhibits tumor growth</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Oct;20(1):941</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32998722" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32998722</a></p>
<p>BACKGROUND: Quiescent tumor cells pose a major clinical challenge due to their ability to resist conventional chemotherapies and to drive tumor recurrence. Understanding the molecular mechanisms that promote quiescence of tumor cells could help identify therapies to eliminate these cells. Significantly, recent studies have determined that the function of SOX2 in cancer cells is highly dose dependent. Specifically, SOX2 levels in tumor cells are optimized to promote tumor growth: knocking down or elevating SOX2 inhibits proliferation. Furthermore, recent studies have shown that quiescent tumor cells express higher levels of SOX2 compared to adjacent proliferating cells. Currently, the mechanisms through which elevated levels of SOX2 restrict tumor cell proliferation have not been characterized. METHODS: To understand how elevated levels of SOX2 restrict the proliferation of tumor cells, we engineered diverse types of tumor cells for inducible overexpression of SOX2. Using these cells, we examined the effects of elevating SOX2 on their proliferation, both in vitro and in vivo. In addition, we examined how elevating SOX2 influences their expression of cyclins, cyclin-dependent kinases (CDKs), and p27Kip1. RESULTS: Elevating SOX2 in diverse tumor cell types led to growth inhibition in vitro. Significantly, elevating SOX2 in vivo in pancreatic ductal adenocarcinoma, medulloblastoma, and prostate cancer cells induced a reversible state of tumor growth arrest. In all three tumor types, elevation of SOX2 in vivo quickly halted tumor growth. Remarkably, tumor growth resumed rapidly when SOX2 returned to endogenous levels. We also determined that elevation of SOX2 in six tumor cell lines decreased the levels of cyclins and CDKs that control each phase of the cell cycle, while upregulating p27Kip1. CONCLUSIONS: Our findings indicate that elevating SOX2 above endogenous levels in a diverse set of tumor cell types leads to growth inhibition both in vitro and in vivo. Moreover, our findings indicate that SOX2 can function as a master regulator by controlling the expression of a broad spectrum of cell cycle machinery. Importantly, our SOX2-inducible tumor studies provide a novel model system for investigating the molecular mechanisms by which elevated levels of SOX2 restrict cell proliferation and tumor growth.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07370-7" class="uri">https://doi.org/10.1186/s12885-020-07370-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The efficacy of pancreatic juice cytology with liquid-based cytology for evaluating malignancy in patients with intraductal papillary mucinous neoplasm</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):319</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32993498" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32993498</a></p>
<p>BACKGROUND: Pancreatic juice cytology (PJC) is a tool for diagnosing malignant intraductal papillary mucinous neoplasm (IPMN); however, the accuracy is insufficient using the conventional method. Liquid-based cytology (LBC) improves the cell recovery rate, and almost all cells can be evaluated. We evaluated the efficacy of PJC with LBC for malignant IPMN. METHODS: We retrospectively analyzed 90 patients with suspected malignant IPMN who underwent PJC before pancreatectomy. PJC with smear and LBC methods was conducted in 52 patients (between June 2003 to December 2011) and 38 patients (between January 2012 to December 2018). Based on the imaging studies, all of the patients were classified according to the international consensus guidelines for IPMN revised in 2017. RESULTS: Of the 90 patients, 43 (48%) had malignant IPMN (high-grade dysplasia or invasive carcinoma), and the remaining patients had non-malignant IPMN (intermediate- or low-grade dysplasia). LBC increased the accuracy of PJC for the diagnosis of malignant IPMN (smear method: 56% [29/52] vs. LBC method: 76% [29/38]; P = 0.044). In a multivariate analysis, LBC was a significant factor influencing the accurate diagnosis of PJC (odds ratio: 3.52; P = 0.021). Furthermore, LBC increased the accuracy of PJC for malignant IPMN in patients with worrisome features (smear method: 66% [19/29] vs. LBC method: 93% [14/15]; P = 0.043). CONCLUSIONS: LBC increases the accuracy of PJC for diagnosing malignant IPMN compared with the conventional smear method.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01465-y" class="uri">https://doi.org/10.1186/s12876-020-01465-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32991341" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32991341</a></p>
<p>Retiform and composite hemangioendotheliomas (CHEs) are both locally aggressive, rarely metastasizing vascular neoplasms characterized by arborizing vascular channels lined by endothelial cells with a hobnail morphology. CHE displays additional cytologic and architectural components, including often vacuolated epithelioid cells, solid areas, or features reminiscent of well-differentiated angiosarcoma. Triggered by an index case of a soft tissue retiform hemangioendothelioma (RHE) which revealed a YAP1-MAML2 gene fusion by targeted RNA sequencing, we sought to investigate additional cases in this morphologic spectrum for this genetic abnormality. A total of 24 cases, 13 RHE and 11 CHE involving skin and soft tissue were tested by fluorescence in situ hybridization using custom BAC probes for rearrangements involving these genes. An additional visceral CHE with neuroendocrine differentiation was tested by targeted RNA sequencing. Among the soft tissue cohort, 5/13 (38%) RHE and 3/11 (27%) CHE showed YAP1 gene rearrangements, with 5 cases showing a YAP1-MAML2 fusion, including all 3 CHE. The single neuroendocrine CHE showed the presence of a PTBP1-MAML2 fusion. All YAP1-positive CHE lesions occurred in female children at acral sites, compared with fusion-negative cases which occurred in adults, with a wide anatomic distribution. YAP1-positive RHE occurred preferentially in males and lower limb, compared with negative cases. These results suggest that RHE and CHE represent a morphologic continuum, sharing abnormalities in YAP1 and MAML2 genes. In contrast, the neuroendocrine CHE occurring in a 37-year-old male harbored a distinct PTBP1-MAML2 fusion and showed aggressive clinical behavior (pancreatic mass with multiple liver and lung metastases). These preliminary findings raise the possibility that neuroendocrine CHE may be genetically distinct from the conventional RHE/CHE spectrum. Further studies are needed to investigate the pathogenetic relationship of fusion-negative cases with this subset and, less likely, with other members of the HE family of tumors.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001575" class="uri">https://doi.org/10.1097/PAS.0000000000001575</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32973069" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32973069</a></p>
<p>Acute pancreatitis (AP), an acute inflammatory disorder of the exocrine pancreas, is one of the most common gastrointestinal diseases encountered in emergency departments with no specific treatments. Laboratory-based research has formed the cornerstone of endeavours to decipher the pathophysiology of AP, because of the limitations of such study in human beings. While this has provided us with substantial understanding, we cannot answer several pressing questions. These are: (a) Why is it that only a minority of individuals with gallstones, or who drink alcohol excessively, or are exposed to other causative factors develop AP? (b) Why do only some develop more severe manifestations of AP with necrosis and/or organ failure? (c) Why have we been unable to find an effective therapeutic for AP? This manuscript provides a state-of-the-art review of our current understanding of the pathophysiology of AP providing insights into the unanswered clinical questions. We describe multiple protective factors operating in most people, and multiple stressors that in a minority induce AP, independently or together, via amplification loops. We present testable hypotheses aimed at halting progression of severity for the development of effective treatments for this common unpredictable disease.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-322163" class="uri">https://doi.org/10.1136/gutjnl-2020-322163</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Outcomes of limited resection for patients with intraductal papillary mucinous neoplasm of the pancreas: A single-center experience</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1399-1405</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32972836" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32972836</a></p>
<p>BACKGROUND: /ObjectivesThe aim of this study was to clarify the oncological outcomes of patients with intraductal papillary mucinous neoplasm (IPMN) who underwent limited resection (LR). METHODS: This retrospective study analyzed the data of 110 patients with IPMN. Patients with IPMN without a history of pancreatitis who had neither tumor infiltration nor regional lymph node swelling on imaging findings underwent LR. We assessed the oncological outcomes of LR for patients with IPMN by comparing the surgical outcomes of LR and standard resection. RESULTS: LR was performed in 50 patients (45.5%), including duodenum-preserving pancreatic head resection (n = 31), middle-pancreatectomy (n = 12), spleen-preserving distal pancreatectomy (n = 3), total parenchymal pancreatectomy (n = 3), and partial resection (n = 1). In the LR group, 18 patients had postoperative complications of Clavien-Dindo classification ≥ IIIa. After histopathological examination, the presence of high-grade dysplasia (HGD) and invasive carcinoma (IC) were observed in nine and three patients, respectively, in the LR group, and eight and 22 patients, respectively, in the standard resection group. There was a significant difference in the histopathological diagnosis of IC between the two groups (p &lt; 0.001). Finally, in the LR group, postoperative recurrences occurred in three patients, and the 5-, 10-, and 15-year disease-specific survival rates were all 97.0%. CONCLUSIONS: For patients with IPMN judged to have no infiltrating lesions based on the detailed imaging examination, LR is acceptable and may be considered as an alternative to standard resection.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.008" class="uri">https://doi.org/10.1016/j.pan.2020.09.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prediction of clinically relevant pancreatic fistula after pancreatic surgery using preoperative CT scan: A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1558-1565</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32972835" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32972835</a></p>
<p>BACKGROUND: Body composition analysis has emerged as a practical tool for predicting outcomes following pancreatic surgery. However, the impact of body composition disorders on clinically relevant postoperative pancreatic fistula (CR-POPF) remains inconclusive. The aim of this study was to review and analyse whether radiographically assessed body composition is predictive of CR-POPF. METHODS: PubMed, MEDLINE, Web of Science, and the Cochrane Library databases were searched up to January 2020 to identify relevant studies. CR-POPF was defined according to the definition and grading system proposed by the International Study Group on Pancreatic Surgery (ISGPS). Pooled odds ratios (OR) for CR-POPF were calculated to evaluate the predictive values of radiographically assessed body composition. RESULTS: Fifteen studies published between 2008 and 2019 with a total of 3136 patients were included. There was a significant increase in the incidence of CR-POPF in patients with visceral obesity (OR 2.97, 95% CI 2.05-4.29, P &lt; 0.00001) and sarcopenic obesity (OR 2.88, 95% CI 1.31-6.34, P = 0.009). Conversely, the impact of sarcopenia (OR 0.91, 95% CI 0.65-1.28, P = 0.59) and low muscle attenuation (MA) on CR-POPF did not reach statistical significance. CONCLUSION: Preoperative visceral obesity and sarcopenic obesity are more effective at predicting CR-POPF than decreased muscle quantity and quality. This finding may lead to appropriate management and early intervention of patients at risk of CR-POPF.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.009" class="uri">https://doi.org/10.1016/j.pan.2020.09.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1519-1525</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32972834" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32972834</a></p>
<p>BACKGROUND: Data on FOLFIRINOX as a second-line chemotherapy for advanced pancreatic cancer are limited. In the JASPAC06 study-a nationwide, multicenter, observational study-FOLFIRINOX for patients with unresectable or recurrent pancreatic cancer as any line of treatment showed favorable efficacy and safety in Japanese clinical practice. METHODS: We performed exploratory analyses of patients with unresectable or recurrent pancreatic cancer who received FOLFIRINOX as the second-line chemotherapy in Japanese clinical settings. RESULTS: Of the 399 evaluable patients, 44 were eligible for inclusion in the analysis. The patients’ characteristics were as follows: median age, 62 years; men, 26 (59%); Eastern Cooperative Oncology Group-Performance status 0/1, 30 (68%)/14 (32%); disease status, recurrent/local/metastatic: 4 (9%)/8 (18%)/32 (73%). The initial dose was reduced in 28 (64%) patients. The median time to treatment failure and number of cycles were 4.5 (range, 0.2-19.1) months and 6 cycles (range, 1-13 or more), respectively. The major grade 3/4 adverse events were neutropenia in 29 (66%), leucopenia in 17 (39%), anorexia in 7 (16%), febrile neutropenia in 5 (11%), and anemia in 5 (11%) patients. The median overall survival, progression-free survival, and 1-year survival rates were 10.3 (95% confidence interval [CI], 7.2-13.3), 4.1 (95% CI, 2.6-5.5) months, and 30%, respectively. CONCLUSION: Our findings suggest that FOLFIRINOX as a second-line chemotherapy for advanced pancreatic cancer was effective in patients with a good performance status. It displayed toxicity similar to that observed with its use as a first-line treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.006" class="uri">https://doi.org/10.1016/j.pan.2020.07.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32968957" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32968957</a></p>
<p>BACKGROUND: Overall survival (OS) has increased in recent adjuvant clinical trials of pancreatic ductal adenocarcinoma (PDAC). Although oncologists have taken notice, the root causes have not been fully examined. METHODS: All phase 3 adjuvant PDAC clinical trials were screened (n = 13), and eight trials (2007-2019) that met a study requirement of having a gemcitabine monotherapy arm to serve as a uniform comparative anchor across trials were identified. Patient enrollment eligibility criteria were compared across trials and categorized as tumor- or patient-related factors. Disease-free survival (DFS) and OS in the gemcitabine-only and non-gemcitabine arms were plotted and compared over time using linear regression. RESULTS: In the non-gemcitabine arms, OS increased over time, but the slope did not achieve statistical significance (p = 0.0815). Interestingly, OS improved for patients receiving only gemcitabine (slope, 1.99 months; p = 0.0018), whereas DFS remained constant (p = 0.897). Carbohydrate antigen (CA) 19-9 values and pathologic profiles of tumors were only marginally different across all cohorts. Recent adjuvant trials had stricter inclusion criteria (i.e., more patients were excluded for medical reasons; linear regression, p = 0.010). CONCLUSION: Survival for patients with resected PDAC has roughly doubled in phase 3 adjuvant trials during the past decade. Improved outcomes likely are attributable to improved adjuvant therapeutic regimens, but also reflect healthier patients enrolled in the more recent trials.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08859-y" class="uri">https://doi.org/10.1245/s10434-020-08859-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Low serum trypsinogen levels in chronic pancreatitis: Correlation with parenchymal loss, exocrine pancreatic insufficiency, and diabetes but not CT-based cambridge severity scores for fibrosis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1368-1378</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32967795" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32967795</a></p>
<p>BACKGROUND: Chronic pancreatitis (CP) is a complex inflammatory disorder of the pancreas affecting acinar cells, duct cells, islet cells and inflammatory cells including fibrosis-producing stellate cells. Serum trypsinogen is a biomarkers of acinar cell function. AIM: To define the degree of correlation between low trypsinogen levels as a marker of acinar cell function and variable features of CP. METHODS: Serum samples from previously ascertained and well phenotyped case and control subjects from the North American Pancreatitis Study II (NAPS2) were used to measure serum trypsinogen levels in a commercial laboratory. Control samples were used to define normal ranges and compared with levels in CP patients with defined features. RESULTS: A final cohort of 279 CP patients and 262 controls from the NAPS2 studies were evaluated. In controls trypsinogen had a mean of 34.96 ng/ml and SD = 11.99. Cut-off values for low trypsinogen ranged from &lt;20 to 10 ng/ml and very low trypsinogen at &lt;10 ng/ml. Compared to controls, CP was associated with very low trypsinogen levels (p &lt; 0.0001). Within CP, very low trypsinogen levels correlated with parenchymal loss (pancreatic surgery [p &lt; 0.05]; atrophy with calcifications, [p &lt; 0.001]), EPI (p &lt; 0.01, trend p &lt; 0.001) and diabetes (trend p &lt; 0.01) but not CT-based criteria for fibrosis (pancreatic duct dilation, irregularity, strictures). CONCLUSIONS: Very low serum trypsinogen levels correlate with measures of acinar cell loss including surgical resection, atrophic-calcific CP, diabetes and functional symptoms EPI but not duct morphology criteria. Serum trypsinogen levels correlate with decreased acinar cell function and therefore have biomarker utility clinical management.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.025" class="uri">https://doi.org/10.1016/j.pan.2020.08.025</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The economic burden of metastatic pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1434-1441</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32967794" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32967794</a></p>
<p>BACKGROUND: Objectives: Pancreatic cancer (PC) is a costly disease with a limited life-expectancy as it generally presents as an advanced, metastatic disease. Though current literature suggests cost varies by first line treatment, there is limited real-world knowledge about the economic burden of pancreatic cancer. This study describes the economic burden of pancreatic cancer patients overall and by observed first line treatments. METHODS: The IBM MarketScan databases were used to identify adult metastatic PC patients from January 1, 2010 through 3/31/2017. Those without other primary cancers, pregnancy, or prior PC treatment, and with 6 months of continuous enrollment prior to PC were included. Treatment patterns and healthcare utilization and expenditures were measured during the variable-length follow-up period. Continuous measures were presented as per patient per month (PPPM). RESULTS: A total of 6,360 patients met all inclusion criteria. Almost half (46.8%) of patients were untreated. Gemcitabine alone (15.6%) and FOLFIRINOX (11.4%) were the most commonly observed first line regimens. Treated patients incurred $17,513 PPPM (Gemcitabine alone) to $27,889 PPPM (FOLFIRINOX) during follow-up. Untreated patients incurred the highest unadjusted ($30,777 PPPM) and adjusted ($20,392 PPPM) cost. CONCLUSIONS: Metastatic PC patients incur a high economic burden driven by high utilization of healthcare resources, which varies by first line treatment. Also, the high proportion of untreated patients is alarming as these patients may be the most expensive of all patients. There is an unmet need in these patients for effective treatments that also reduce their economic burden.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.002" class="uri">https://doi.org/10.1016/j.pan.2020.09.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Sep;20(1):913</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32967656" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32967656</a></p>
<p>BACKGROUND: Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β). METHODS: BxPC-3, CFPAC-1, and Panc-1 cells were pre-treated with IFN-β followed by gemcitabine monotherapy. The effect on cell growth, colony formation, and cell cycle was determined. RT-qPCR was used to measure gene expression. BxPC-3 cells were used in a heterotopic subcutaneous mouse model. RESULTS: IFN-β increased sensitivity to gemcitabine (4-, 7.7-, and 1.7-fold EC50 decrease in BxPC-3, CFPAC-1, and Panc-1, respectively; all P &lt; 0.001). Findings were confirmed when assessing colony formation. The percentage of cells in the S-phase was significantly increased after IFN-β treatment only in BxPC-3 and CFPAC-1 by 12 and 7%, respectively (p &lt; 0.001 and p &lt; 0.05, respectively). Thereby, IFN-β upregulated expression of the drug transporters SLC28A1 in BxPC-3 (252%) and SLC28A3 in BxPC-3 (127%) and CFPAC-1 (223%) (all p &lt; 0.001). In vivo, combination therapy reduced tumor volume with 45% (P = 0.01). Both ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells, whereas apoptosis was increased. CONCLUSIONS: For the first time, we validated the chemosensitising effects of IFN-β when combined with gemcitabine in vitro, ex vivo, and in vivo. This was driven by cell cycle modulation and associated with an upregulation of genes involving intracellular uptake of gemcitabine. The use of IFN-β in combination with gemcitabine seems promising in patients with pancreatic cancer and needs to be further explored.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07420-0" class="uri">https://doi.org/10.1186/s12885-020-07420-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Sep;20(1):909</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32967636" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32967636</a></p>
<p>BACKGROUND: Various parameters have been considered for predicting survival in pancreatic ductal adenocarcinoma. Information about western population is missing. The aim of this study is to assess the association between Glucose transporter type 1 (GLUT-1) expression and prognosis for patients with PDAC submitted for surgical resection in a European cohort. METHODS: Retrospective analysis of PDAC specimens after pancreatoduodenectomy assessing GLUT-1 expression according to intensity (weak vs strong) and extension (low if &lt; 80% cells were stained, high if &gt; 80%) was performed. Statistical analysis was performed using the exact Fisher test, Student t test or the Mann-Whitney U test. Survival was analysed using the Kaplan-Meier method and compared with the Log-rank test. The differences were considered significant at a two-sided p value of &lt; 0.05. All statistical analyses were performed using SPSS® 23.0 for Windows (SPSS Inc., Chicago, IL, USA). RESULTS: Our study consisted of 39 patients of which 58.9% presented with weak and 41.1% with strong intensity. The median extension was 90%: 28.2% cases presented with a low extension and 71.8% with a high extension. No significant differences related to intensity were found. The high-extension group showed a higher percentage of T3 PDAC (92.9% vs 63.6%, p = 0.042) and LNR20 (35.7% vs 0%, p = 0.037) as well as shorter disease-free survival (17.58 vs 54.46 months; p = 0.048). CONCLUSIONS: Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07409-9" class="uri">https://doi.org/10.1186/s12885-020-07409-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study</strong></li>
</ul>
</summary>
<p><em>The Lancet. Oncology 2020 Nov;21(11):1489-1499</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32966810" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32966810</a></p>
<p>BACKGROUND: Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the efficacy and safety of surufatinib in patients with advanced pancreatic NETs. METHODS: SANET-p was a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, done in 21 hospitals across China. Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease. Patients were randomly assigned (2:1) via an interactive web response system to receive 300 mg of surufatinib or placebo, taken orally once per day in consecutive 4-week treatment cycles until disease progression, intolerable toxicity, withdrawal of consent, poor compliance, use of other antitumour medication, pregnancy, loss to follow-up, or if the investigator deemed discontinuation in the patient’s best interest. Randomisation was done centrally using stratified block randomisation (block size three), stratified by pathological grade, previous systemic antitumour treatment, and ECOG performance status score. Patients, investigators, research staff, and the sponsor study team were masked to treatment allocation. Crossover to surufatinib was permitted for patients in the placebo group with disease progression. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, which included all patients in randomisation. A pre-planned interim analysis was done at 70% of the predicted progression-free survival events. This study is registered at ClinicalTrials.gov, NCT02589821. FINDINGS: Between Feb 18, 2016, and Nov 11, 2019, of 264 patients who were screened, 172 (65%) patients were randomly assigned to receive surufatinib (n=113) or placebo (n=59). The median follow-up was 19·3 months (95% CI 9·3-19·4) in the surufatinib group and 11·1 months (5·7-35·9) in the placebo group. The median investigator-assessed progression-free survival was 10·9 months (7·5-13·8) for surufatinib versus 3·7 months (2·8-5·6) for placebo (hazard ratio 0·49, 95% CI 0·32-0·76; p=0·0011). The trial met the early stopping criteria at the interim analysis and was terminated on recommendation from the independent data monitoring committee. The most common grade 3 or worse treatment-related adverse events were hypertension (43 [38%] of 113 with surufatinib vs four [7%] of 59 with placebo), proteinuria (11 [10%] vs one [2%]), and hypertriglyceridaemia (eight [7%] vs none). Treatment-related serious adverse events were reported in 25 (22%) patients in the surufatinib group and four (7%) patients in the placebo group. There were three on-treatment deaths in the surufatinib group, including two deaths due to adverse events (gastrointestinal haemorrhage [possibly treatment-related] and cerebral haemorrhage [unlikely to be treatment-related]), and one death attributed to disease progression. One on-treatment death in the placebo group was attributed to disease progression. INTERPRETATION: Surufatinib significantly improves progression-free survival and has an acceptable safety profile in patients with progressive, advanced pancreatic NETs, and could be a potential treatment option in this patient population. FUNDING: Hutchison MediPharma.</p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(20)30493-9" class="uri">https://doi.org/10.1016/S1470-2045(20)30493-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Sep;20(1):906</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32962649" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32962649</a></p>
<p>BACKGROUND: Pancreatic neuroendocrine neoplasms (p-NENs) are a group of highly heterogeneous tumors with distinct clinicopathological features and long-term prognosis. In 2017, in order to better stratify patients into prognostic groups and predicting their outcomes, World Health Organization (WHO) officially updated its grading system for p-NENs which distinguished these neoplasms among Grading 1 (G1) pancreatic neuroendocrine tumors (p-NETs), G2 p-NETs, G3 p-NETs and G3 pancreatic neuroendocrine carcinomas (p-NECs). However, this new grading classification for p-NENs has not yet been rigorously validated. METHODS: Data of patients who were surgically treated and histopathologically diagnosed as p-NENs at West China Hospital of Sichuan University from January 2002 to December 2018 were retrospectively collected and analyzed according the novel WHO 2017 grading classification. RESULTS: We eventually enrolled 480 eligible patients with p-NENs in our present study, in which 150 patients with WHO 2017 G1 p-NETs, 158 with G2 p-NETs, 64 with G3 p-NETs and 108 with G3 p-NECs were identified. The estimated 5-year overall survival for patients with G1 p-NETs, G2 p-NETs, G3 p-NETs and G3 p-NECs was 75.8, 58.4, 35.1 and 11.1%, with a median survival time of 85.3mons, 67.4mons, 51.3mons and 26.8mons, respectively. Patients with G2 p-NETs present notably worse survival than those with G1 p-NETs (P = 0.03). Survival of G3 p-NETs were significantly worse than that of G1 p-NETs or G2 p-NETs (P &lt; 0.001, P = 0.023, respectively), as well as that when comparing G3 p-NECs with G1 p-NETs or G2 p-NETs (P &lt; 0.001, P &lt; 0.001, respectively). Patients with G3 p-NECs showed statistically shorter survival than those with G3 p-NETs (P &lt; 0.001). Both WHO 2017 and 2010 grading criteria could be independent predictor for the OS of p-NENs (P = 0.016, P = 0.022; respectively). The 95% confidence intervals of WHO 2017 grading classification (0.983-9.454) was slightly smaller than that of WHO 2010 criteria (0.201-13.374), indicating a relatively more accurate predicting ability for the prognosis of p-NENs. CONCLUSION: The WHO 2017 grading classification for p-NENs could successfully allocate patients into four groups with distinct clinical features and significant survival differences, which might be superior to the WHO 2010 criteria for its better prognostic stratification and more accurate predicting ability.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07356-5" class="uri">https://doi.org/10.1186/s12885-020-07356-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Delving into Early Onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32958704" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32958704</a></p>
<p>PURPOSE: With the rising incidence of early-onset pancreatic cancer (EOPC), molecular characteristics that distinguish early onset pancreatic ductal adenocarcinoma (PDAC) tumors from those arising at a later age are not well understood. EXPERIMENTAL DESIGN: We performed bioinformatic analysis of genomic and transcriptomic data generated from 269 advanced (metastatic or locally advanced) and 277 resectable PDAC tumor samples. Patient samples were stratified into EOPC (age of onset ≤55 years; n=117), intermediate (age of onset 55-70 years; n=264) and average (age of onset ≥70 years; n=165) groups. Frequency of somatic mutations affecting genes commonly implicated in PDAC, as well as gene expression patterns, were compared between EOPC and all other groups. RESULTS: EOPC tumors showed significantly lower frequency of somatic SNV/indels in CDKN2A (p=0.0017), and were more likely to achieve bi-allelic mutation of CDKN2A through homozygous copy loss as opposed to heterozygous copy loss coupled with a loss-of-function SNV/indel mutation, the latter of which was more common for tumors with later ages of onset (p=1.5e-4). Transcription factor FOXC2 was significantly up-regulated in EOPC tumors (p=0.032). Genes significantly correlated with FOXC2 in PDAC samples were enriched for gene sets related to epithelial-mesenchymal transition (EMT) and included VIM (p=1.8e-8), CDH11 (p=6.5e-5) and CDH2 (p=2.4e-2). CONCLUSIONS: Our comprehensive analysis of sequencing data generated from a large cohort of PDAC patient samples highlights a distinctive pattern of bi-allelic CDKN2A mutation in EOPC tumors. Increased expression of FOXC2 in EOPC, with the correlation between FOXC2 and EMT pathways, represent novel molecular characteristics of EOPC.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1042" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1042</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors</strong></li>
</ul>
</summary>
<p><em>The New England journal of medicine 2020 09;383(13):1207-1217</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32955176" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32955176</a></p>
<p>BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa1917239" class="uri">https://doi.org/10.1056/NEJMoa1917239</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: A multicenter prospective trial</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1428-1433</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32952043" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32952043</a></p>
<p>OBJECTIVES: Preoperative grading of pancreatic neuroendocrine tumors (PanNET) is challenging. The aim of this study was to prospectively evaluate the use of a 25-gauge needle with a core trap for diagnosis and grading of PanNET. METHODS: This multicenter prospective trial was registered with the University Hospital Medical Information Network (UMIN000021409). Consecutive patients with suspected PanNET between June 2016 and November 2017 were enrolled. All patients underwent endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) using a 25-gauge needle with a core trap. Samples obtained after the first needle pass were used for central pathological review. EUS-FNB was evaluated in terms of (i) technical success rate, (ii) adequacy for histological evaluation, (iii) complication rate during the procedure, and (iv) concordance between PanNET grading on EUS-FNB and that after analysis of the resected tumor. RESULTS: Fifty-two patients were enrolled. Of the 36/52 patients who underwent surgical resection, 31 were finally diagnosed with PanNET and were eligible for analysis. The technical success rate of EUS-FNB was 100%. The rate of adequacy for histological evaluation was 90.3%. There were no complications related to EUS-FNB. The concordance rate between PanNET grading on EUS-FNB and that after analysis of the resected tumor was 82.6% (95% confidence interval = 61.22-95.05, P = 0.579). CONCLUSIONS: EUS-FNB using a 25-gauge needle with a core trap is feasible, providing histological samples are of sufficient quality for diagnosis and grading of PanNET.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.023" class="uri">https://doi.org/10.1016/j.pan.2020.08.023</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Analysis of T lymphocyte-related biomarkers in pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1502-1510</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32952042" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32952042</a></p>
<p>BACKGROUND: Pancreatic cancer remains one of the most lethal cancers. OBJECTIVE: This study aimed to analyze T cell-related biomarkers and their molecular network in pancreatic cancer. METHODS: RNAseq sequencing data and clinical data of pancreatic cancer were obtained from TCGA database. The STromal and Immune cells in MAlignant Tumours using Expression data (ESTIMATE) algorithm was used to screen the DEGs related to the tumor immune cells. The pearson correlation analysis were used to analyze the relationships between DEGs and T cells. Additionally, the T cell-related DEGs were subjected to protein-protein interaction, competing endogenous RNA (ceRNA), and chemical small molecule-target network construction. Furthermore, the prognosis-associated DEGs were screened. RESULTS: A total of 412 stromal score-associated and 312 immune score-associated DEGs were obtained. From these DEGs, 50 CD4+ T cell-related genes and 13 CD8+ T cell-related genes were selected. The PPI networks associated with immune cell-related genes were constructed and found that CD22, SELL, and OLR1 had higher degrees in the PPI network. The number of ceRNA regulatory relation pairs obtained from CD4+ T cells and CD8+ T cells were 59 and 48, respectively. Additionally, both CD4+ T cell- and CD8+ T cell-related genes predicted 29 small molecules. CXCL9 and GIMAP7 were screened out from CD4+ T cell-related genes, which were related with the survival of pancreatic cancer. CONCLUSION: We mapped T cell-related gene profile in pancreatic cancer and constructed their potential regulatory network.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.005" class="uri">https://doi.org/10.1016/j.pan.2020.09.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The quality of pain management in pancreatic cancer: A prospective multi-center study</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1511-1518</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32952041" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32952041</a></p>
<p>BACKGROUND/OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with severe pain. Given the almost inevitably fatal nature of the disease, pain control is crucial. However, data on quality of pain management in PDAC is scarce. METHODS: This is a multi-center, prospective study to evaluate the quality of pain management in PDAC. Insufficient pain treatment (undertreatment) was prevalent if there was an incongruence between the patients level of pain and the potency of analgesic drug therapy. Determinants of pain and undertreatment were identified using multivariable logistic regression. RESULTS: 139 patients with histologically confirmed PDAC were analyzed. The prevalence of pain was 63%, with approximately one third of the patients grading their pain as moderate to severe. Palliative stage (OR: 3.37, 95%CI: 1.23-9.21, p = 0.018) and localization of the primary tumor in the body or tail (OR: 2.57, 95%CI: 1.05-6.31, p = 0.039) were independent determinants of pain. Of those reporting pain, 60% were undertreated and in 89% pain interfered with activities and emotions. Age ≥ 70 years (OR: 3.20, 95%CI: 1.09-9.41, p = 0.035) was an independent predictor of undertreatment. Patients with longer-known PDAC ( ≥ 30 days) showed improved pain management compared to new cases (OR: 0.19, 95%CI: 0.05-0.81, p = 0.025). Treatment by gastroenterologists (OR: 0.22, 95%CI: 0.05-0.89, p = 0.034) was associated with less undertreatment. CONCLUSIONS: The results show a high proportion of PDAC patients with pain, pain interference and undertreatment, whose characteristics could help to identify patients at risk in the future. Several changes in the management of cancer-related pain are necessary to overcome barriers to optimal treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.017" class="uri">https://doi.org/10.1016/j.pan.2020.08.017</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic resections in patients who refuse blood transfusions. The application of a perioperative protocol for a true bloodless surgery</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1550-1557</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32950387" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32950387</a></p>
<p>BACKGROUND: The refusal of blood transfusions compels surgeons to face ethical and clinical issues. A single-institution experience with a dedicated perioperative blood management protocol was reviewed to assess feasibility and short-term outcomes of true bloodless pancreatic surgery. METHODS: The institutional database was reviewed to identify patients who refused transfusion and were scheduled for elective pancreatic surgery from 2010 through 2018. A protocol to optimize the hemoglobin values by administration of drugs stimulating erythropoiesis was systematically used. RESULTS: Perioperative outcomes of 32 Jehovah’s Witnesses patients were included. Median age was 67 years (range, 31-77). Nineteen (59.4%) patients were treated with preoperative erythropoietin. Twenty-four (75%) patients underwent pylorus-preserving pancreaticoduodenectomy, 4 (12.5%) distal pancreatectomy (DP) with splenectomy, 3 (9.4%) spleen-preserving DP, and 1 (3.1%) total pancreatectomy. Median estimated blood loss and surgical duration were 400 mL (range, 100-1000) and 470 min (range, 290-595), respectively. Median preoperative hemoglobin was 13.9 g/dL (range, 11.7-15.8) while median postoperative nadir hemoglobin was 10.5 g/dL (range, 7.1-14.1). The most common histological diagnosis (n = 15, 46.9%) was pancreatic ductal adenocarcinoma. Clavien-Dindo grade I-II complications occurred in fourteen (43.8%) patients while one (3.1%) patient had a Clavien-Dindo grade IIIa complication wich was an abdominal collection that required percutaneous drainage. Six (18.8%) patients presented biochemical leak or postoperative pancreatic fistula grade B. Median hospital stay was 16 days (range, 8-54) with no patient requiring transfusion or re-operation and no 90-day mortality. CONCLUSIONS: A multidisciplinary approach and specific perioperative management allowed performing pancreatic resections in patients who refused transfusion with good short-term outcomes.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.020" class="uri">https://doi.org/10.1016/j.pan.2020.08.020</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospective study</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1495-1501</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32950386" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32950386</a></p>
<p>BACKGROUND: The frequency, nature and timeline of changes on thin-slice (≤3 mm) multi-detector computerized tomography (CT) scans in the pre-diagnostic phase of pancreatic ductal adenocarcinoma (PDAC) are unknown. It is unclear if identifying imaging changes in this phase will improve PDAC survival beyond lead time. METHODS: From a cohort of 128 subjects (Cohort A) with CT scans done 3-36 months before diagnosis of PDAC we developed a CTgram defining CT Stages (CTS) I through IV in the radiological progression of pre-diagnostic PDAC. We constructed Cohort B of PDAC resected at CTS I and II and compared survival in CTS I and II in Cohort A (n = 22 each; control natural history cohort) vs Cohort B (n = 33 and 72, respectively; early interception cohort). RESULTS: CTs were abnormal in 16% and 85% at 24-36 and 3-6 months respectively, before PDAC diagnosis. The PDAC CTgram stages, findings and median lead times (months) to clinical diagnosis were: CTS I: Abrupt duct cut-off/duct dilatation (-12.8); CTS II: Low density mass confined to pancreas (-9.5), CTS III: Peri-pancreatic infiltration (-5.8), CTS IV: Distant metastases (only at diagnosis). PDAC survival was better in cohort B than in cohort A despite inclusion of lead time in Cohort A: CTS I (36 vs 17.2 months, p = 0.03), CTS II (35.2 vs 15.3 months, p = 0.04). CONCLUSION: Starting 12-18 months before PDAC diagnosis, progressive and increasingly frequent changes occur on CT scans. Resection of PDAC at the time of pre-diagnostic CT changes is likely to provide survival benefit beyond lead time.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.410" class="uri">https://doi.org/10.1016/j.pan.2020.07.410</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Landmark Series: Pancreatic Neuroendocrine Tumors</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32948965" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32948965</a></p>
<p>Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of neoplasms arising from pancreatic islet cells that remain relatively rare but are increasing in incidence worldwide. While significant advances have been made in recent years with regard to systemic therapies for patients with advanced disease, surgical resection remains the standard of care for most patients with localized tumors. Although formal pancreatectomy with regional lymphadenectomy is the standard approach for most PNETs, pancreas-preserving approaches without formal lymphadenectomy are acceptable for smaller tumors at low risk for lymph node metastases. Furthermore, observation of small, asymptomatic, low-grade PNETs is a safe, initial strategy and is generally recommended for tumors &lt; 1 cm in size. In this Landmark Series review, we highlight the critical studies that have defined the surgical management of PNETs.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09133-x" class="uri">https://doi.org/10.1245/s10434-020-09133-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Overexpression of transmembrane protein 2 (TMEM2), a novel hyaluronidase, predicts poor prognosis in pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1479-1485</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32948431" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32948431</a></p>
<p>BACKGROUND: Abnormal metabolism of hyaluronan (HA), a major component of extracellular matrix, is a hallmark of cancer. Our previous studies have shown the importance of enzymes responsible for HA degradation in the aggressive phenotype of pancreatic ductal adenocarcinoma (PDAC). In the present study, we investigated the expression and function of transmembrane protein 2 (TMEM2), a recently identified HA-degrading enzyme, in PDAC. MATERIALS &amp; METHODS: We used immunohistochemistry to investigate expression patterns of TMEM2 in archival tissues obtained from 100 patients with PDAC who underwent surgical resection from 1982 to 2012. The correlations between TMEM2 expression and clinicopathological variables, including survival, were determined using univariate and multivariate analyses. The effect of TMEM2 on proliferation and migratory ability (measured using transwell cell migration assay) of PDAC cells was determined by TMEM2 knockdown with small-interfering RNA (siRNA). RESULTS: Immunohistochemical analysis revealed high expression of TMEM2 in 22 (22%) of 100 patients. The overall survival was significantly shorter in patients with high TMEM2 expression than in those with low expression (P = 0.013). Multivariate analysis identified high TMEM2 expression as an independent factor predicting poor prognosis (P = 0.011). Unexpectedly, knockdown of TMEM2 resulted in increased migratory ability of PDAC cells, which was associated with increased expression of KIAA1199, a potent HA-degrading enzyme shown to enhance cell migration. CONCLUSION: TMEM2 overexpression is associated with poor prognosis in PDAC patients. Targeted disruption of this molecule, however, could enhance the aggressiveness of PDAC cells through a possible interaction with KIAA1199.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.026" class="uri">https://doi.org/10.1016/j.pan.2020.08.026</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1486-1494</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32948429" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32948429</a></p>
<p>OBJECTIVES: Venous invasion is a poor prognostic factor for pancreatic ductal adenocarcinoma (PDAC). However, our understanding of various features of venous invasion is limited. Our aim is to comprehensively evaluate various histopathologic features of venous invasion, including status, type (lymphatic or venous), number of invasion foci, and histologic pattern (pancreatic intraepithelial neoplasia [PanIN]-like, conventional) in PDACs. METHODS: Various features of venous invasion, including status, number of invasion foci, histologic patterns [pancreatic intraepithelial neoplasia (PanIN)-like, conventional], and size of involved vessels in 471 surgically resected PDACs were evaluated with all available hematoxylin and eosin (H&amp;E)-stained slides. RESULTS: Venous invasion was observed in 319 cases (67.7%) and was more frequently associated with increased tumor size, extrapancreatic extension, resection margin involvement, diffuse tumor distribution, lymph node metastasis, and perineural invasion (all Ps &lt; .05). High frequency (≥3 foci) of venous invasion was associated with shorter overall survival both in the entire group and in the early stage subgroup (stage I; all Ps &lt; .05). Multivariate analysis indicated that a high frequency (≥3 foci) of venous invasion, large tumor size (&gt;4 cm), higher histologic grade, and lymph node metastasis, were independent prognostic factors of worse overall survival (all Ps &lt; .05). CONCLUSION: Precise evaluation of venous invasion status, including foci number of invasion, can provide additional prognostic information for patients undergoing surgical resection of PDAC, especially for those with early disease stage.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.015" class="uri">https://doi.org/10.1016/j.pan.2020.08.015</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prolonged operating time is a significant perioperative risk factor for arterial pseudoaneurysm formation and patient death following hemorrhage after pancreaticoduodenectomy</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1540-1549</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32943343" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32943343</a></p>
<p>BACKGROUND: Arterial pseudoaneurysm is a rare but potentially fatal complication after pancreaticoduodenectomy (PD). This study aimed to evaluate the incidence and predictors associated with pseudoaneurysm formation and patient death caused by its rupture. PATIENTS AND METHOD: We retrospectively reviewed the data of 453 patients who underwent PD from April 2007 to February 2019. Uni- and multivariate analysis and receiver operating characteristic (ROC) curve analysis were performed to identify risk factors and optimal cutoff values. RESULTS: Among the 453 patients, 22 (4.9%) developed pseudoaneurysm after PD. Median duration from surgery to detection of pseudoaneurysm was 17.0 (1-51) days. The locations of pseudoaneurysms were hepatic artery in 8, splenic artery in 3, gastroduodenal artery in 4, gastric artery in 2 and others in 5 patients, and 72.7% (16/22) of patients presented with hemorrhage. All pseudoaneurysms were treated using angioembolization. Lower age (&lt;65.5 years, p = 0.004), prolonged operation time (Cutoff ˃610 min, p = 0.026) and postoperative pancreatic fistula (POPF) (p = 0.013) were the independent risk factors for development of pseudoaneurysm. 6 (27.3%) patients died due to rupture of pseudoaneurysm and prolonged operation time (Cutoff ˃657 min, p = 0.043) was a significant risk factor for death related to pseudoaneurysm. CONCLUSION: Prolonged operating time was identified as a risk factor for both pseudoaneurysm formation and patient death following pseudoaneurysm bleeding. Interventional radiology treatment offered a central role in the treatment of pseudoaneurysms after PD. Therefore, it is important to have a high index of suspicion in high risk patients of the possibility of pseudoaneurysm formation and bleeding.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.021" class="uri">https://doi.org/10.1016/j.pan.2020.08.021</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction</strong></li>
</ul>
</summary>
<p><em>Human pathology 2020 Sep;105():67-73</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32941964" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32941964</a></p>
<p>Increasing evidence suggests that bile reflux (BR) plays a major role in mucosal injury, leading to adenocarcinoma of the proximal stomach and distal esophagus. However, gastric BR is difficult to diagnose and investigate. Reactive gastropathy (RG), in the absence of nonsteroidal anti-inflammatory drugs (NSAIDs) and other known causes, likely represents bile-mediated injury to the gastric mucosa. The goal of this study is to explore the association between antral RG and gastroesophageal junction (GEJ) mucosal inflammation and intestinal metaplasia (IM). The pathology database was searched for patients who had gastric biopsies with a diagnosis of antral RG and concurrent gastric cardia/GEJ/distal esophagus biopsies from 2013 to 2015. Age- and sex-matched patients with normal gastric antral biopsies served as controls. Biopsies from the GEJ region were evaluated for histological changes, including inflammation, antral and pancreatic metaplasia, RG, the type of gastric glands, proton pump inhibitor (PPI) changes, and IM. Detailed clinical history and medication use (including PPIs and NSAIDs) were recorded. IM in the GEJ region was more frequent in patients with antral RG than in controls (33.0% vs. 5.2%, 95% confidence interval [18.3-37.3%]). In addition, inflammation, other mucosal changes around the GEJ (RG and foveolar hyperplasia), antral IM, and PPI-associated mucosal changes were also more frequently seen in patients with antral RG. Our results show that antral RG is associated with mucosal injury and IM around GEJ, suggesting a role of BR. Further studies are needed to study duodenogastric-esophageal BR and its role in development of proximal gastric and distal esophageal adenocarcinoma.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.08.007" class="uri">https://doi.org/10.1016/j.humpath.2020.08.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32941274" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32941274</a></p>
<p>OBJECTIVE: This study evaluated the associated factors and prognosis according to pathology and margin after surgical resection of intraductal papillary mucinous neoplasms (IPMN). BACKGROUND: There is limited information on recurrence patterns according to pathology and margin in IPMN. METHODS: Total 577 patients who underwent operation for IPMN at a tertiary center were included. Factors associated with recurrence, survival and recurrence outcomes according to pathology and margin were analyzed. RESULTS: Among 548 patients analyzed, 353 had low-grade dysplasia (LGD); 78, high-grade dysplasia (HGD); and 117, invasive IPMN. Total 50 patients developed recurrences, with four resection margins, eight remnant pancreas, 11 locoregional, and 35 distant recurrences. Invasive IPMN showed worse 5-year cumulative recurrence risk (LGD vs HGD vs invasive: 0.7% vs 4.3% vs 37.6%, p &lt; 0.001) and 5-year survival rate (89.0% vs 84.0% vs 48.4%, p &lt; 0.001). Recurrence risk increased after 5 years, even in LGD and HGD. Malignant margin (HGD and invasive) had worse 5-year cumulative recurrence rate (R0 vs LGD vs malignant: 8.3% vs 5.9% vs 50.6%, p &lt; 0.001) and 5-year survival rate (80.7% vs 83.0% vs 30.8%, p &lt; 0.001). CA19-9 &gt; 37 (p = 0.003), invasive IPMN (p &lt; 0.001), and malignant margin (p = 0.036) were associated with recurrence. CONCLUSIONS: Invasive IPMN developed more recurrences and had worse survival than LGD or HGD, indicating the need for more efficient postoperative treatment strategies. Patients with LGD and HGD also need regular follow-up for recurrence after 5 years. Malignant margins need additional resection to achieve negative or at least LGD margin.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004478" class="uri">https://doi.org/10.1097/SLA.0000000000004478</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32941267" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32941267</a></p>
<p>OBJECTIVE: To elucidate the role of surgery in patients with high-grade neuroendocrine neoplasms (hg-NENs) and Ki-67 &gt; 20%. BACKGROUND: Although surgery is the first treatment choice in patients with low-grade NENs, whether it increases the survival of patients with hg-NENs is debatable. METHODS: Between 2005 and 2018, 63 patients pathologically diagnosed with hg-NENs treated at our institution were retrospectively analyzed. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed, and OS was compared between each treatment group. RESULTS: The median observation time was 21.2 months, and the median Ki-67 value was 52%. Patients with hg-NENs were classified into low Ki-67 (Ki-67 &lt; 52%) and high Ki-67 (Ki-67 ≥ 52%) groups. Multivariate analysis for OS identified surgery (P = 0.013) and low Ki-67 value (P = 0.007) as independent risk factors, while morphological differentiation defined by the WHO 2017 criteria showed no association with OS. Patients with low Ki-67 value subjected to R0/1, R2, and chemotherapy had a median survival time (MST) of 83.8, 16.6, and 28.1 months, respectively. The MST for R0/1 group was significantly longer than that for chemotherapy group (P = 0.001). However, no difference in survival was reported between patients from R0/1 and chemotherapy groups with high Ki-67. Ki-67 value could determine RFS (P = 0.006) in patients that underwent R0/1 surgery for pancreatic hg-NENs. CONCLUSION: R0/1 surgery predicted prognoses in the low Ki-67 group. The indication of surgery for patients with hg-NENs did not depend on tumor differentiation.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004495" class="uri">https://doi.org/10.1097/SLA.0000000000004495</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The European evidence-based guidelines on pancreatic cystic neoplasms (PCN) in clinical practice: The development of relative and absolute indications for surgery during prospective IPMN surveillance</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1393-1398</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938553" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938553</a></p>
<p>INTRODUCTION: The European evidence-based guidelines on PCN recommend surveillance for IPMN patients who are fit for surgery but who have no indication for immediate surgery. Our aim was to demonstrate the feasibility of the new guidelines in clinical practice. METHODS: This is a prospective cohort study of patients included in the IPMN register in Tampere University Hospital, Finland. IPMN was diagnosed from January 1, 2013 to December 31, 2018. Patients were analyzed for surveillance and indications for surgery according to the European guidelines on PCN. RESULTS: Out of 128 patients in register 23 was decided to operate upfront and 105 patients were included in the surveillance programme. Invasive carcinoma was found in 4/23 of operated patients. Median follow-up time was 26 months (6-69). Median size of the cyst at the beginning and end of the surveillance was 16 mm (4-58 mm). During surveillance 0/105 (0.0%) patients had or developed an absolute indication for surgery. Relative indication for surgery was present in 8/105 (7.6%) patients in the beginning surveillance and 9/105 (8.6%) patients developed at least one relative indication for surgery during surveillance. From the surveillance cohort 2/105 patients were operated. Surveillance was abandoned in 15/105 (14.1%) patients all due to poor general condition or other medical conditions. CONCLUSIONS: In clinical practice, surveillance of IPMN according to the European guidelines on PCN is feasible. Among our patients 16% were detected to have relative indications for surgery during the median 26 (range 3-135) months of surveillance. Nearly 15% became surgically unfit during surveillance period.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.003" class="uri">https://doi.org/10.1016/j.pan.2020.09.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Early laboratory biomarkers for severity in acute pancreatitis; A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1302-1311</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938552" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938552</a></p>
<p>BACKGROUND/OBJECTIVES: Acute pancreatitis is complicated by local and systemic complications in 20-30% of the patients. Accurate prediction of severity may be important for clinical decision making. Our aim is to identify and compare the accuracy of laboratory biomarkers that predict severity and complications in adult patients. METHODS: Medline, EMBASE, Web of Science and Cochrane Library (1993 to August 2020) were searched for studies with an unselected population of patients with acute pancreatitis, that contains accuracy data for ≥1 laboratory biomarker(s) and/or APACHE-II score for the prediction of a patient outcomes of interest during the first 48 h of admission. The primary outcome is moderate severe or severe acute pancreatitis (MSAP/SAP). Secondary outcomes are severe acute pancreatitis, pancreatic necrosis and organ failure. Risk of bias was assed using QUADAS-2. Biomarkers extracted from ≥3 unique sources, were analyzed using hierarchical summary receiver operating characteristic (HSROC) and bivariate model analysis. RESULTS: In total, 181 studies were included in the qualitative analysis reporting on 29 biomarkers. For the primary outcome at admission, summary sensitivities and specificities were, respectively, 87% (95% CI 69-95%) and 88% (95% CI 80-93%) for IL-6 at a threshold of &gt;50 pg/ml, 72% (95% CI 64-79%) and 76% (95% CI 67-84%) for an APACHE-II score of ≥8, and 53% (95% CI 35-71%) and 82% (95% CI 74-88%) for CRP &gt;150 mg/l. HSROC curve analysis confirmed these results. CONCLUSION: This study indicates superiority of IL-6 for the early prediction of MSAP/SAP and may be used for to guide clinical decision making.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.007" class="uri">https://doi.org/10.1016/j.pan.2020.09.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Protruded duodenal tumor arising from Santorini’s duct of the pancreas: a rare case of intraductal papillary mucinous neoplasm mimicking a duodenal polypoid tumor</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):303</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938427" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938427</a></p>
<p>BACKGROUND: We experienced a rare case of intraductal papillary mucinous neoplasm arising from Santorini’s duct (SD) forming a tumor protruding into the duodenum . CASE PRESENTATION: A 71-year-old woman was incidentally diagnosed with a 3 cm type Isp polypoid tumor in the second portion of the duodenum at another hospital. Enhanced CT and endoscopic ultrasound revealed that the origin of this protruding tumor was arising from SD and that the tumor mimicked a pedunculated duodenal tumor. Our preoperative diagnosis was a malignant pancreatic tumor arising from SD with invasion into the duodenum. She underwent a subtotal stomach-preserving pancreaticoduodenectomy, and the resected specimen showed a 25 mm tumor protruding into the duodenum with a villous surface. The pathological findings revealed that the tumor was intraductal papillary mucinous adenoma (IPMA) arising from SD. CONCLUSIONS: To the best of our knowledge, this is the first case of IPMA protruding into the duodenal lumen from SD, although most of the tumors arising from SD have been reported to be malignant.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01449-y" class="uri">https://doi.org/10.1186/s12876-020-01449-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Intraductal papillary mucinous neoplasm complicated with intraductal bleeding in a young woman mimicked a cystic solid pseudo-papillary tumor: a case report</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):304</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938404</a></p>
<p>BACKGROUND: There are only 6 cases of intraductal papillary mucinous neoplasm (IPMN) complicated with intraductal hemorrhage have been reported in English literatures. All these 6 cases of IPMN occurred in the old people. The present rare case of IPMN complicated with intraductal hemorrhage occurred in a young woman, and mimicked a cystic solid pseudo-papillary neoplasm (SPN) on preoperative imaging findings. CASE PRESENTATION: A 29-year-old young woman complained of a sustained mild right upper quadrant abdominal pain. CT and MRI showed a lobulated, partly ill-defined cystic lesion located in the pancreatic head. Spotted calcification within cystic wall was seen on CT. The lesion was demonstrated as predominantly homogeneous hyperattenuation on CT and homogeneous high signal without decreased signal on fat suppression sequence on T1WI. After contrast administration, the cystic wall and septa of lesion was showed gradually mild to moderate degree of enhancement over time both on CT and MRI. No communication between lesion and the main duct was found on MRCP and the main pancreatic duct and common bile duct were not dilated. Considering patient’s age, gender and manifestations of lesion on CT and MRI (calcification, bleeding and gradually enhanced pattern), the present case mimicked as a cystic SPN. The lesion was pathologically confirmed a branch type IPMN after surgical resection. CONCLUSION: We propose that IPMN may need to be taken into account in the differential diagnosis when pancreatic cystic lesions occur in young women with bleeding, calcification, progressive enhancement of cystic wall and no communication with the main pancreatic duct.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01436-3" class="uri">https://doi.org/10.1186/s12876-020-01436-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Effect of Pancreatoduodenectomy Plus Intraperitoneal Hyperthermic Perfusion on Resectable Pancreatic Head Cancer: Cohort Study</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32935266" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32935266</a></p>
<p>BACKGROUND: Intraperitoneal hyperthermic perfusion (IPHP) has achieved positive results in treating various abdominal cancers but infrequently reported in resectable pancreatic head cancer. This study was designed to explore the safety and efficacy of pancreaticoduodenectomy plus intraperitoneal hyperthermic perfusion (PD + IPHP) in patients with pancreatic cancer. METHODS: Data of pancreatic cancer patients undergoing pancreaticoduodenectomy were retrospectively analyzed, including PD + IPHP (n = 28) and PD group (n = 29). IPHP was performed during surgery, on postoperative day (POD) 2, and POD 4 with normal saline as the perfusion solution. Complications and overall survival of these patients were observed and recorded. RESULTS: There was no significant difference in the incidence of major postoperative complications between PD + IPHP group and PD group. The median overall survival (OS) time of the PD + IPHP group was 19.0 months, the 1-year survival rate was 82.35%, and the 2-year survival rate was 49.41%. The median OS time of the PD group was 13.0 months, the 1-year survival rate was 51.00%, and the 2-year survival rate was 27.33% (Log-rank, P = 0.030; Breslow, P = 0.039). Cox proportional risk model showed that IPHP was an independent factor to improve survival outcomes of these patients (hazard ratio = 0.363, 95% confidence interval: 0.14-0.94; P = 0.038). CONCLUSIONS: Intraperitoneal hyperthermic perfusion significantly improves the survival outcomes of pancreatic head cancer patients undergoing PD and does not bring extra risks of complications.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09095-0" class="uri">https://doi.org/10.1245/s10434-020-09095-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours</strong></li>
</ul>
</summary>
<p><em>Journal of clinical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32934105" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32934105</a></p>
<p>AIMS: Determining the site of origin of a metastatic neuroendocrine tumour (NET) can be challenging and has important prognostic and therapeutic implications. An immunohistochemical (IHC) panel consisting of TTF1, CDX2, PAX8/PAX6 and Islet1 is often employed. However, there can be a significant IHC overlap among different primary sites. Herein, we sought to determine the utility of including Special AT-rich sequence binding protein-2 (SATB2) in the IHC panel that is used for determining the site of origin of a metastatic NET. METHODS: Paraffin tissue microarrays consisting of 137 primary NETs (26 lung, 22 jejunoileal, 8 appendix, 5 stomach, 4 duodenum, 17 rectum and 55 pancreas) were stained for SATB2, in addition to the well-described lineage-associated markers, such as TTF1, CDX2, PAX6 and Islet1. Additionally, a tissue microarray consisting of 21 metastatic NETs (1 lung, 1 stomach, 8 jejunoileal and 11 pancreas) was stained for TTF1, CDX2, SATB2 and Islet1. The results were recorded as no staining, weak staining and moderate to strong staining. RESULTS: All appendiceal NETs and majority (88%) of the rectal NETs were positive for SATB2. All primary foregut NETs (stomach, pancreas, duodenum and lung) were negative for SATB2, except for one pulmonary NET with weak staining. However, among the metastatic tumours, 5 of 11 pancreatic NETs, 1 stomach NET, 1 lung NET and 2 of 8 jejunoileal NETs showed weak staining. Receiver operating characteristic analysis incorporating sensitivity and specificity data of IHC panel, considering moderate to strong staining as truly positive cases, showed that inclusion of SATB2 to the previously described NET IHC panel outperformed the panel without SATB2, raising the specificity for pancreaticoduodenal NETs from 81.2% to 100%, with a positive predictive value (PPV) of 100% and negative predictive value (NPV) of 82.22% (p&lt;0.0001); for appendiceal NETs the specificity changed from 99.1% to 98.5% and sensitivity increased from 11.8% to 80%, with a PPV and NPV of 66.67% and 99.26%, respectively (p&lt;0.0001); and for rectal NETs the specificity increased from 97.6% to 99.3% and sensitivity raised from 7.1% to 66.7%, with a PPV and NPV of 80% and 98.53%, respectively (p&lt;0.0001). CONCLUSIONS: SATB2 stain is useful in differentiatingIslet1/PAX6 positive pancreatic and rectal NETs, as rectal NETs are typically moderately to strongly positive for SATB2 and pancreatic NETs are usually negative or weakly positive for SATB2. Moderate to strong staining for SATB2 is suggestive of an appendiceal or a rectal primary. SATB2 may complement the panel of CDX2, TTF1 and Islet1 in determining the site of origin of an NET in a metastatic setting.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-206645" class="uri">https://doi.org/10.1136/jclinpath-2020-206645</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32933996" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32933996</a></p>
<p>PURPOSE: Pancreatic cancer is among the most aggressive malignancies and is rarely discovered early. However, pancreatic “incidentalomas,” particularly cysts, are frequently identified in asymptomatic patients through anatomic imaging for unrelated causes. Accurate determination of the malignant potential of cystic lesions could lead to life-saving surgery or spare patients with indolent disease undue risk. Current risk assessment of pancreatic cysts requires invasive sampling, with attendant morbidity and sampling errors. Here, we sought to identify imaging biomarkers of high-risk pancreatic cancer precursor lesions. EXPERIMENTAL DESIGN: Translocator protein (TSPO) expression, which is associated with cholesterol metabolism, was evaluated in premalignant and pancreatic cancer lesions from human and genetically engineered mouse (GEM) tissues. In vivo imaging was performed with [18F]V-1008, a TSPO-targeted PET agent, in two GEM models. For image-guided surgery (IGS), V-1520, a TSPO ligand for near-IR optical imaging based upon the V-1008 pharmacophore, was developed and evaluated. RESULTS: TSPO was highly expressed in human and murine pancreatic cancer. Notably, TSPO expression was associated with high-grade, premalignant intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanIN) lesions. In GEM models, [18F]V-1008 exhibited robust uptake in early pancreatic cancer, detectable by PET. Furthermore, V-1520 localized to premalignant pancreatic lesions and advanced tumors enabling real-time IGS. CONCLUSIONS: We anticipate that combined TSPO PET/IGS represents a translational approach for precision pancreatic cancer care through discrimination of high-risk indeterminate lesions and actionable surgery.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1214" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1214</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32933947" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32933947</a></p>
<p>OBJECTIVE: To describe the clinical, pathological and genomic characteristics of pancreatic cancer with DNA mismatch repair deficiency (MMRD) and proficiency (MMRP). DESIGN: We identified patients with MMRD and MMRP pancreatic cancer in a clinical cohort (N=1213, 519 with genetic testing, 53 with immunohistochemistry (IHC)) and a genomic cohort (N=288 with whole-genome sequencing (WGS)). RESULTS: 12 out of 1213 (1.0%) in the clinical cohort were MMRD by IHC or WGS. Of the 14 patients with Lynch syndrome, 3 (21.4%) had an MMRP pancreatic cancer by IHC, and 4 (28.6%) were excluded because tissue was unavailable for testing. MMRD cancers had longer overall survival after surgery (weighted HR after coarsened exact matching 0.11, 95% CI 0.02 to 0.78, p=0.001). One patient with an unresectable MMRD cancer has an ongoing partial response 3 years after starting treatment with PD-L1/CTLA-4 inhibition. This tumour showed none of the classical histopathological features of MMRD. 9 out of 288 (3.1%) tumours with WGS were MMRD. Despite markedly higher tumour mutational burden and neoantigen loads, MMRD cancers were significantly less likely to have mutations in usual pancreatic cancer driver genes like KRAS and SMAD4, but more likely to have mutations in genes that drive cancers with microsatellite instability like ACV2RA and JAK1. MMRD tumours were significantly more likely to have a basal-like transcriptional programme and elevated transcriptional markers of immunogenicity. CONCLUSIONS: MMRD pancreatic cancers have distinct clinical, pathological and genomic profiles. Patients with MMRD pancreatic cancer should be considered for basket trials targeting enhanced immunogenicity or the unique genomic drivers in these malignancies.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-320730" class="uri">https://doi.org/10.1136/gutjnl-2020-320730</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreaticoduodenectomy: Outcomes of a complex surgical procedure from a developing country</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1534-1539</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32928685" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32928685</a></p>
<p>BACKGROUND: Pancreaticoduodenectomy (PD) plays an integral part in the management of pancreatic, periampullary and duodenal cancers, along with a few other pathologies of this region. Despite advances in surgery PD continues to have significant morbidity and noteworthy mortality. The aim of this study is to provide an in-depth report on the patient characteristics, indications and the outcomes of PD) in a tertiary cancer hospital in Pakistan. MATERIALS AND METHODS: The study population included patients who underwent PD between January 1, 2014 and march 31, 2019, at Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH&amp;RC) in Pakistan. The data was retrospectively analyzed from the Hospital Information System (HIS), which is a prospectively maintained patient electronic database of SKMCH&amp;RC. Patient characteristics, procedural details and post-operative outcomes according to internationally accepted definitions were reported. RESULTS: A total of 161 patients underwent PD at our hospital in the study period at a median age of 53 years, ranging from 19 to 78 years. 62% of the patients were males while 37% were females. Jaundice was the most common presenting symptom (64.6%), followed by abdominal pain (26.7%). PD with pancreaticogastrostomy was performed in 110 patients (68.3%), while pancreaticojejunostomy was performed in the rest of the cohort. Surgical site infection (SSI) was observed in 64 patients (40%). The incidence of Pancreatic Fistula grade C based on the International Study Group on Pancreatic Fistula (ISGPF) definition was 7.45% (n = 12). The 30 days mortality rate was 3.1%. Median survival of the cohort was 21 ±1.13 months and disease-free survival was 16±2.62 months. CONCLUSION: PD can be performed with acceptable morbidity and mortality in a resource constrained country, as long as it is undertaken in a high-volume center. This is in keeping with data published from other well-reputed international centers.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.013" class="uri">https://doi.org/10.1016/j.pan.2020.08.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Can Early Postoperative Complications Predict High Morbidity and Decrease Failure to Rescue Following Major Abdominal Surgery?</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 11;272(5):834-839</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32925252" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32925252</a></p>
<p>OBJECTIVE: To assess whether specific patterns of early postoperative complications may predict overall severe morbidity after major surgery, warranting early escalation of care and prevention of failure to rescue. SUMMARY OF BACKGROUND DATA: It is unclear whether early postoperative complications predict a poor outcome. Detailed knowledge of the chronology and type of early complications after major surgery may alert clinicians when to expect higher risk for subsequent major negative events. METHODS: All 90-day postoperative events following complex pancreas, liver, and rectal surgeries, and liver transplantation were analyzed over a 3-year period in a single tertiary center. Each complication was recorded regarding severity, type (cardiac, infectious, etc), etiology (surgical/medical), and timing of occurrence. The Comprehensive Complication Index (CCI), covering the first 7 postoperative days, was calculated as a measure for early cumulative postoperative morbidity. The statistical analysis (descriptive, sequence pattern analyses, and logistic regression analyses) aimed to detect any combinations of events predicting poor outcome as defined by a cumulative CCI ≥37.1 at 90-days. RESULTS: The occurrence of ≥2 complications, irrespective of severity, type or etiology, was strongly associated with a severe postoperative course (P &lt; 0.001). Even 2 mild complications (≤ grade II) greatly increased the chance for high morbidity compared to patients with 0 or 1 complication within the first postoperative week (odds ratio 10.2, 95% confidence interval 5.82-17.98). The CCI at postoperative day 7 strongly predicted high 90-day morbidity (odds ratio 3.96 per 10 CCI points, P &lt; 0.001). CONCLUSION: Multiple complications of any cause or severity within the first postoperative days represents a “warning-signal” for overall high morbidity by 90 days, which should be used to trigger an escalation of care to prevent failure to rescue and eventually poor outcome.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004254" class="uri">https://doi.org/10.1097/SLA.0000000000004254</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32925194" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32925194</a></p>
<p>Identification of the primary site of cancer is essential for the treatment of patients with cancer. Numerous immunohistochemical markers have been developed to determine the differentiation of tumor cells and suggest possible primary sites, but markers of gastric and pancreatic adenocarcinomas are still lacking. Claudin-18 is a tight-junction protein uniquely expressed in gastric epithelial cells and has been shown to be expressed in gastric and pancreatic adenocarcinoma. Whether claudin-18 can be used as a marker for identifying the primary site of cancer is still unclear. In this study, we used the immunohistochemical method to stain claudin-18 in tissue arrays containing 575 carcinomas from different anatomic sites and representative sections of 157 metastatic adenocarcinomas. In the group of primary tumors, claudin-18 was frequently expressed in gastric, pancreatic, and pulmonary mucinous adenocarcinomas. Half of cholangiocarcinomas and ovarian mucinous carcinomas and some colorectal and pulmonary adenocarcinomas were also positive for claudin-18. In the metastatic cohort, 15 of 17 (88%) gastric adenocarcinomas, 18 of 23 (78%) pancreatic adenocarcinomas, and 4 of 7 (57%) cholangiocarcinomas and gallbladder adenocarcinomas were positive for claudin-18. Only 4 tumors that originated outside the stomach and pancreatobiliary tract were positive for claudin-18. After normalization to the tumor frequency, the sensitivity of claudin-18 for identifying the stomach and pancreatobiliary tract as primary tumor sites was 79%, and the specificity was 93%. The positive and negative predictive values were 76% and 94%, respectively. In conclusion, claudin-18 represents a sensitive and specific marker for stomach and pancreatobiliary adenocarcinoma that may be a useful diagnostic tool in routine surgical pathology.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001583" class="uri">https://doi.org/10.1097/PAS.0000000000001583</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32920722" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32920722</a></p>
<p>BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related death in the USA. A wealth of evidence has demonstrated the chemopreventive activity of aspirin, statins, and metformin against PDAC. The aim of this study is to investigate the effect of aspirin, statins, and metformin on disease-free survival (DFS) and disease-specific survival (DSS) in a large population of PDAC patients undergoing pancreatic resection. PATIENTS AND METHODS: All patients who underwent pancreatic resections between January 2015 and September 2018 were retrospectively reviewed. The potentially “chemopreventive agents” considered for the analysis were aspirin, statins, and metformin. Drug use was defined in case of regular assumption at least 6 months before diagnosis and regularly after surgery along the follow-up period. RESULTS: A total of 430 patients were enrolled in this study, with median DFS and DSS of 21 months (IQR 13-30) months and 34 (IQR 26-52) months, respectively. On multivariable analysis, use of aspirin was associated with better DFS (HR: 0.62; p = 0.038). Metformin was associated with better DFS, without reaching statistical significance (p = 0.083). Use of statins did not influence DFS in the studied population. Aspirin, metformin, and statins were not associated with better DSS on multivariable analysis. Factors influencing DSS were pT3/pT4, N1, N2, no adjuvant treatment, G3, and ASA score &gt; 3. CONCLUSIONS: The results suggest that chronic use of aspirin is associated with increased DFS but not with better DSS after surgical resection in patients with PDAC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09097-y" class="uri">https://doi.org/10.1245/s10434-020-09097-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32920720" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32920720</a></p>
<p>BACKGROUND: International consensus criteria (ICC) have redefined borderline resectability for pancreatic ductal adenocarcinoma (PDAC) according to three dimensions: anatomical (BR-A), biological (BR-B), and conditional (BR-C). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumour and vessels but that biological and conditional dimensions also are important. METHODS: Patients’ tumours were retrospectively defined borderline resectable according to ICC. The study cohort was grouped into either BR-A or BR-B and compared with patients considered primarily resectable (R). Differences in postoperative complications, pathological reports, overall (OS), and disease-free survival were assessed. RESULTS: A total of 345 patients underwent resection for PDAC. By applying ICC in routine preoperative assessment, 30 patients were classified as stage BR-A and 62 patients as stage BR-B. In total, 253 patients were considered R. The cohort did not contain BR-C patients. No differences in postoperative complications were detected. Median OS was significantly shorter in BR-A (15 months) and BR-B (12 months) compared with R (20 months) patients (BR-A vs. R: p = 0.09 and BR-B vs. R: p &lt; 0.001). CA19-9, as the determining factor of BR-B patients, turned out to be an independent prognostic risk factor for OS. CONCLUSIONS: Preoperative staging defining surgical resectability in PDAC according to ICC is crucial for patient survival. Patients with PDAC BR-B should be considered for multimodal neoadjuvant therapy even if considered anatomically resectable.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09100-6" class="uri">https://doi.org/10.1245/s10434-020-09100-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The utility of intracystic glucose levels in differentiating mucinous from non-mucinous pancreatic cysts</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1386-1392</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32919884" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32919884</a></p>
<p>BACKGROUND: Differentiating benign non-mucinous from potentially malignant mucinous pancreatic cysts is still a challenge. This study aims to improve this distinction with cyst fluid analysis. METHODS: A cohort study of pancreatic cyst undergoing EUS/FNA was performed from a prospectively maintained database between 2014 and 2018 was performed. RESULTS: 113 patients were analyzed (40 non-mucinous and 73 mucinous). For differentiating mucinous from non-mucinous cyst: intracyst glucose ≤41 mg/dl had a sensitivity of 92% and a specificity of 92%; positive predictive value (PPV) of 96 and negative predictive value (NPV) of 86. Glucose ≤21 mg/dl had a sensitivity of 88%, specificity of 97%, PPV of 98 and NPV of 81. CEA ≥192 ng/mL had a sensitivity of 50% and a specificity of 92%; PPV of 92 and NPV of 50. Glucose ≤21 mg/dl or CEA ≥192 ng/mL combined had a sensitivity of 93%, specificity of 92%, PPV of 96 and NPV of 87 (Fig. 1, Table 1). CONCLUSION: Intra-cyst glucose levels (≤41 mg/dl) outperforms classic CEA testing for differentiation of mucinous from non-mucinous pancreatic cysts. It was found to be an excellent diagnostic test with an AUC of 0.95 (95% CI: 0.81, 0.97).</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.024" class="uri">https://doi.org/10.1016/j.pan.2020.08.024</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Zinc: Roles in pancreatic physiology and disease</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1413-1420</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32917512" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32917512</a></p>
<p>Zinc is an essential trace element. Deficiencies are frequently seen with gastrointestinal diseases, including chronic pancreatitis, nutritional deficiency, and reduced intestinal absorption. Additionally, reduced zinc levels have been linked to cellular changes associated with acute pancreatitis such as enhanced inflammation with increased macrophage activation and production of inflammatory cytokines such as IL-1β, impaired autophagy, and modulation of calcium homeostasis. Preliminary data suggest that zinc deficiency may lead to pancreatic injury in animal models. The purpose of this review is to explore the biologic effects of zinc deficiency that could impact pancreatic disease. MESH KEYWORDS: Malnutrition, inflammation, trace element.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.016" class="uri">https://doi.org/10.1016/j.pan.2020.08.016</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm</strong></li>
</ul>
</summary>
<p><em>Diagnostic pathology 2020 Sep;15(1):108</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32917216" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32917216</a></p>
<p>BACKGROUND: Chromogranin A (CgA), synaptophysin (Syn) and the Ki-67 index play significant roles in diagnosis or the evaluation of the proliferative activity of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). However, little is known about whether these biological markers change during tumor metastasis and whether such changes have effect on prognosis. METHODS: We analyzed 35 specimens of both primary and metastatic tumor from 779 patients who had been diagnosed as GEP-NENs at Wuhan Union Hospital from August 2011 to October 2019. The heterogeneity of CgA, Syn and Ki-67 index was evaluated by immunohistochemical analysis. RESULTS: Among these 779 patients, the three most common sites of NENs in the digestive tract were the pancreas, rectum and stomach. Metastases were found in 311 (39.9%) patients. Among the 35 patients with both primary and metastatic pathological specimens, differences in the Ki-67 level were detected in 54.3% of the patients, while 37.1% showed a difference in CgA and only 11.4% showed a difference in Syn. Importantly, due to the difference in the Ki-67 index between primary and metastatic lesions, the WHO grade was changed in 8.6% of the patients. In addition, a Kaplan-Meier survival analysis showed that patients with Ki-67 index variation had a shorter overall survival (p = 0.0346), while neither Syn variation nor CgA variation was related to patient survival (p = 0.7194, p = 0.4829). CONCLUSIONS: Our data indicate that primary and metastatic sites of GEP-NENs may exhibit pathological heterogeneity. Ki-67 index variation is closely related to the poor prognosis of patients with tumor metastasis, but neither Syn variation nor CgA variation is related to patient prognosis. Therefore, clinicopathologic evaluation of the primary tumor and metastatic sites could be helpful for predicting the prognosis.</p>
<p>doi: <a href="https://doi.org/10.1186/s13000-020-01030-x" class="uri">https://doi.org/10.1186/s13000-020-01030-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Simultaneous Discordant B-Lymphoblastic Lymphoma and Follicular Lymphoma</strong></li>
</ul>
</summary>
<p><em>American journal of clinical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32915189" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32915189</a></p>
<p>OBJECTIVES: We report a rare case of B-lymphoblastic lymphoma (B-LBL) and low-grade follicular lymphoma (FL) identified concurrently in biopsies from different sites at the initial diagnosis in a 39-year-old man. The clonal relationship between the 2 histologic subtypes was investigated. METHODS: A diagnosis of FL grade 1/2 (low grade) was made by bone marrow (BM) biopsy. B-LBL was identified in biopsies from the testis and pancreas. Cytogenetic and molecular analyses were performed to investigate their clonal relationship. RESULTS: Interphase fluorescence in situ hybridization analyses and G-banding karyotype analyses identified the BCL2-IGH and MYC-IGH translocation in tumor cells from both the BM and testis. The tumor cells from the BM and testis shared the same IGH VDJ usage and a high degree of somatic mutations. These findings suggest that acquisition of MYC gene rearrangement is a critical event for lymphoblastic transformation of FL. Of note, the presence of intraclonal diversity in the B-LBL sample further suggests an earlier or concurrent event of MYC translocation than the somatic IGH mutation in the germinal center and the dedifferentiation of lymphoma cells to a precursor stage of B-cell development. CONCLUSIONS: B-lymphoblastic transformation of FL can occur with MYC gene rearrangement.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqaa126" class="uri">https://doi.org/10.1093/ajcp/aqaa126</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins</strong></li>
</ul>
</summary>
<p><em>American journal of clinical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32914850" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32914850</a></p>
<p>OBJECTIVES: Special AT-rich binding protein 2 (SATB2) immunohistochemistry (IHC) has high sensitivity and specificity for colorectal adenocarcinoma (CRC), but data on its expression in specific subsets of pulmonary, gastric, small bowel, and pancreatobiliary adenocarcinomas (ADCAs) are relatively limited or discordant. We assessed SATB2 expression in a large cohort of ADCAs from these sites to determine its reliability in distinguishing CRC from them. METHODS: SATB2 IHC was performed on 335 neoplasms, including 40 lung ADCAs, 165 pancreatobiliary neoplasms (34 intraductal papillary mucinous neoplasms [IPMNs], 19 pancreatic ADCAs, 112 cholangiocarcinomas [CCs]), and 35 gastric, 13 small bowel, 36 ampullary (AMP), and 46 CRC ADCAs. The cases were evaluated for positivity (defined as ≥5% nuclear staining), and an H-score was calculated based on the percentage of SATB2+ cells and staining intensity. Analysis was performed to determine the optimal H-score threshold to separate CRC and non-CRC. RESULTS: SATB2 was positive in 3% of lung, 2% of CC, 17% of gastric, 38% of small bowel, and 6% of AMP ADCAs. All pancreatic ADCA/IPMNs were negative, and 87% CRCs were positive. CONCLUSIONS: SATB2 is not entirely specific for colorectal origin and can be expressed in a subset of gastrointestinal ADCAs. It is most useful in the differential of CRC vs lung and pancreatobiliary ADCAs.</p>
<p>doi: <a href="https://doi.org/10.1093/ajcp/aqaa118" class="uri">https://doi.org/10.1093/ajcp/aqaa118</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis</strong></li>
</ul>
</summary>
<p><em>Nature 2020 09;585(7825):426-432</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32908310" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32908310</a></p>
<p>Endothelial cells adopt tissue-specific characteristics to instruct organ development and regeneration1,2. This adaptability is lost in cultured adult endothelial cells, which do not vascularize tissues in an organotypic manner. Here, we show that transient reactivation of the embryonic-restricted ETS variant transcription factor 2 (ETV2)3 in mature human endothelial cells cultured in a serum-free three-dimensional matrix composed of a mixture of laminin, entactin and type-IV collagen (LEC matrix) ‘resets’ these endothelial cells to adaptable, vasculogenic cells, which form perfusable and plastic vascular plexi. Through chromatin remodelling, ETV2 induces tubulogenic pathways, including the activation of RAP1, which promotes the formation of durable lumens4,5. In three-dimensional matrices-which do not have the constraints of bioprinted scaffolds-the ‘reset’ vascular endothelial cells (R-VECs) self-assemble into stable, multilayered and branching vascular networks within scalable microfluidic chambers, which are capable of transporting human blood. In vivo, R-VECs implanted subcutaneously in mice self-organize into durable pericyte-coated vessels that functionally anastomose to the host circulation and exhibit long-lasting patterning, with no evidence of malformations or angiomas. R-VECs directly interact with cells within three-dimensional co-cultured organoids, removing the need for the restrictive synthetic semipermeable membranes that are required for organ-on-chip systems, therefore providing a physiological platform for vascularization, which we call ‘Organ-On-VascularNet’. R-VECs enable perfusion of glucose-responsive insulin-secreting human pancreatic islets, vascularize decellularized rat intestines and arborize healthy or cancerous human colon organoids. Using single-cell RNA sequencing and epigenetic profiling, we demonstrate that R-VECs establish an adaptive vascular niche that differentially adjusts and conforms to organoids and tumoroids in a tissue-specific manner. Our Organ-On-VascularNet model will permit metabolic, immunological and physiochemical studies and screens to decipher the crosstalk between organotypic endothelial cells and parenchymal cells for identification of determinants of endothelial cell heterogeneity, and could lead to advances in therapeutic organ repair and tumour targeting.</p>
<p>doi: <a href="https://doi.org/10.1038/s41586-020-2712-z" class="uri">https://doi.org/10.1038/s41586-020-2712-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1472-1478</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32900632" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32900632</a></p>
<p>BACKGROUND: The clinical characteristic differences at the initial recurrence site after resection for pancreatic ductal adenocarcinoma (PDAC) remain unknown. We investigated the clinical characteristics in patients with lung recurrence after surgical resection and evaluated the outcome of resection for isolated lung recurrence. METHODS: Of 442 consecutive PDAC patients who underwent surgical resection between 2002 and 2018, 229 had recurrence on imaging. Initial recurrence sites were the liver, lung, local, peritoneal, multiple organs, and others. We analyzed the clinicopathologic factors and outcomes, comparing by initial recurrence site, and investigated the outcomes of resection for isolated lung recurrence. RESULTS: Liver recurrences were the most frequent (n = 60, 26%), followed by lung recurrence (n = 48, 21%). The interval from surgery to recurrence was significantly longer in lung recurrence (P = 0.0001). Patients with lung recurrence had significantly longer overall survival after diagnosis (P &lt; 0.0001). Patients who underwent surgical resection of lung recurrence had a significantly prolonged overall survival rate after recurrence diagnosis (P = 0.004). CONCLUSIONS: Patients with lung recurrence had significantly prolonged survival than those with other recurrence patterns. Resection for isolated lung recurrence represented relatively good prognosis, and possibly may be beneficial in highly-selected patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.019" class="uri">https://doi.org/10.1016/j.pan.2020.08.019</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical outcomes of acute pancreatitis in elderly patients: An experience of single tertiary center</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1296-1301</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32900631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32900631</a></p>
<p>BACKGROUND: Although well understanding the course of diseases in geriatric population is of paramount importance in order to provide the optimal treatment, there is only a few studies with controversial results that have been conducted about the course and outcomes of acute pancreatitis (AP) in elderly. We aimed to compare clinical outcomes of AP disease in geriatric age group and to evaluate the risk factors affecting outcomes. METHODS: A total of 336 patients diagnosed with AP, hospitalized and followed-up in our hospital between July/2013-February/2019 were included in this study. Patients aged 65 years and over were assessed as elderly population. Patients’ demographic data, comorbidities, duration of hospitalization, local systemic complications, and mortality rates were documented. RESULTS: 196(58.3%) of the patients were female with a mean age of 54.1 ± 17.9 years. The number of patients was 114(33.9%) in the elderly group and 222(66.1%) in the non-elderly group. Although there was no significant difference between both groups in terms of abscess, pseudocyst and necrosis, pancreatic necrosis and systemic complications were higher in the elderly group (p &lt; 0.05). The durations of oral intake and hospitalization were longer, the mortality rate and severity of AP according to the Ranson and Atlanta criteria were significantly higher in the geriatric population (p &lt; 0.05). In addition, age and severity of AP were found to be independent predictive factors of developing complications. CONCLUSIONS: Early recognition of AP is important in the geriatric population. Clinical and laboratory investigations, and early diagnosis in severe patients will be largely helpful in providing close follow-up and the optimal treatment.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.06.006" class="uri">https://doi.org/10.1016/j.pan.2020.06.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Acute Phase Response and Postprocedural Evaluation of Open and Laparoscopic Cryoablation Procedures in Porcine Pancreases</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1255-1262</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898011" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898011</a></p>
<p>OBJECTIVES: Cryoablation is a potentially less invasive locoregional ablation modality. Although cryoablation has been used to treat malignancy in various organs, a limited application of this modality in the pancreas has been reported. METHODS: Acute phase response assessments and postprocedural course evaluations of 2 experimental locoregional ablation methods were conducted. In one method, open and laparoscopic cryoablation of a porcine pancreas using an argon-helium gas-based cryoablation system and monitoring of tissue temperature during the procedure were performed. In the other method, open cryoablation of a porcine pancreas using liquid nitrogen was performed. The animals were evaluated postoperatively. RESULTS: The size of the cryolesion was larger in the second treatment than in the first. Laparoscopic cryoablation was associated with the formation of an iceball, which possibly affected the surrounding structures. The ablated region was adequately cooled with 10 minutes of freeze/repeat cycles. The area cooled to a temperature of less than -40°C was approximately half the size of the cryolesion in diameter. The swine used for the evaluation of the postprocedural course survived 3 weeks after the procedure with a temporal elevation of the serum lipase level. CONCLUSIONS: Cryoablation of the pancreas was experimentally practicable without severe complications under direct or laparoscopic vision.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001668" class="uri">https://doi.org/10.1097/MPA.0000000000001668</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1240-1245</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898010" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898010</a></p>
<p>OBJECTIVES: Neoadjuvant chemotherapy (NAC) has improved overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but its effects on immune gene signatures are unknown. Here, we examined the immune transcriptome after NAC for PDAC. METHODS: Resected tumor specimens were obtained from 140 patients with PDAC who received surgery first (n = 93) or NAC (n = 47). Six patients were randomly selected from each group, and RNA was extracted from tumor tissues. We compared 770 immune-related genes among the 2 groups using nCounterPanCancer Immune Profiling (NanoString Technologies, Seattle, Wash). Gene clusters were classified into 14 immune function groups based on gene ontology argolism by nSolver 4.0 software (NanoString Technologies), and corresponding immune cell function scores were compared. RESULTS: Eleven genes (LY86, SH2D1A, CD247, TIGIT, CR2, CD83, LAMP3, CXCR4, DUSP4, SELL, and IL2RA) were significantly downregulated in the NAC group. Gene expression analysis showed that the functions of regulatory T cells, B cells, and natural killer CD56 dim cells were significantly decreased in the NAC group. CONCLUSIONS: Neoadjuvant chemotherapy may suppress regulatory T cells and B-cell function in the PDAC microenvironment. The 11 identified genes could be useful for predicting the efficacy of NAC and could be therapeutic targets for PDAC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001665" class="uri">https://doi.org/10.1097/MPA.0000000000001665</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1213-1219</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898008" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898008</a></p>
<p>OBJECTIVES: Pancreatic cancer (PC) is a highly malignant tumor with poor detection sensitivity and specificity in biomarkers and diagnosis. Previous research indicated that serum Ephrin type-A receptor 2 in exosomes (Exo-EphA2) was highly expressed and might have facilitated cell migration in PC cells. However, the dynamics of clinical performance of serum Exo-EphA2 in PC patients are unknown. Thus, this study evaluated serum Exo-EphA2 as a potential diagnostic biomarker in PC. METHODS: The expressions of serum Exo-EphA2 were assessed by enzyme-linked immunosorbent assay for N = 353 serum samples, including from 204 PC patients, 75 patients with benign pancreatic disease, and 74 healthy control patients. Carbohydrate antigen 19-9 (CA 19-9) and carbohydrate antigen 242 (CA 242) were measured by automated immunoassay. RESULTS: Serum Exo-EphA2 levels were significantly higher in PC patients than in benign pancreatic disease and healthy control patients. Receiver operating characteristic curve analysis suggested that using combined diagnoses of Exo-EphA2 with CA 19-9 and CA 242 was more effective to discriminate early stage (stage I and II) in PC than in healthy controls and benign disease patients. CONCLUSIONS: Novel findings suggest that serum Exo-EphA2 is a potential early diagnostic biomarker complementing CA 19-9 and CA 242 in PC.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001660" class="uri">https://doi.org/10.1097/MPA.0000000000001660</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The Epidemiology of Pancreatic Cancer and the Association With Acetylsalicylic Acid in the United States: A Population-Based Study</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1207-1212</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898007" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898007</a></p>
<p>OBJECTIVES: Pancreatic cancer (PaC) is the third leading cause of cancer-related death in the United States. Multiple studies have investigated the epidemiology and the association between PaC and acetylsalicylic acid (ASA) use, revealing mixed results. Using a large database, we sought to investigate the epidemiology of PaC. METHODS: Using a commercial database (Explorys Inc, Cleveland, Ohio), which includes electronic health record data from 26 major integrated US health care systems, all patients 18 years and older diagnosed with PaC for 5 years were identified based on Systematized Nomenclature Of Medicine-Clinical Terms. We determined the prevalence of PaC and the potential associated factors using univariable and multivariable analysis. RESULTS: Of the 32,970,850 individuals, we identified 30,250 individuals with PaC with an overall prevalence of 0.08%. Individuals with PaC were more likely to be males, seniors (age, &gt;65 years), and White, compared with patients without PaC. In subgroup analysis of chronic pancreatitis, individuals on ASA, individuals &gt;65 years, White, and White males were less likely to have PaC, and non-White females were more likely to have PaC. CONCLUSIONS: This is the largest population-based study evaluating the epidemiology of PaC. We observed a protective association of ASA on a subgroup of patients with PaC and chronic pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001659" class="uri">https://doi.org/10.1097/MPA.0000000000001659</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Impact of the Human Immunodeficiency Viruses Status on Outcomes in Patients Hospitalized With Acute Pancreatitis: A Propensity-Matched Analysis</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1195-1201</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898004" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898004</a></p>
<p>OBJECTIVES: We aimed to examine the clinical characteristics and outcomes of patients admitted for acute pancreatitis (AP) in the population with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). METHODS: The National Inpatient Sample from 2010 to 2014 was used to identify adult patients admitted with AP. Patients were grouped based on the HIV status. Primary outcomes were mortality, length of stay (LOS), disposition and total hospitalization charges. Secondary outcomes included acute kidney injury, septic shock, respiratory failure and pancreatic procedures. RESULTS: After matching and weighting, a total of 14,152 HIV-positive patients (6904 with AIDS and 7248 with asymptomatic HIV [aHIV]) with AP were identified. Acute pancreatitis with AIDS were associated with a higher rate of acute kidney injury, longer LOS, higher hospitalization charges, and less routine disposition compared with HIV-negative AP. Patients with aHIV had less septic shock, shorter LOS, and less hospitalization charges compared with HIV-negative patients and less respiratory failure, shorter LOS, and less hospitalization charges compared with AIDS patients. CONCLUSIONS: Patients admitted for AP with AIDS have worse outcomes. On the contrary, aHIV status was not only associated with better outcomes when compared with AIDS, but to HIV-negative status as well.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001656" class="uri">https://doi.org/10.1097/MPA.0000000000001656</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1187-1194</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898003" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898003</a></p>
<p>OBJECTIVES: The purpose of this study was to investigate the association of syndecan-1 (SDC1) and KRAS molecular characteristics with patient survival in pancreatic cancer. METHODS: Both SDC1 mRNA and methylation and KRAS mRNA and somatic mutations, as well as clinical data were retrieved from The Cancer Genome Alta pancreatic cancer data set for survival analyses. Kyoto Encyclopedia of Gene and Genomes pathway analysis for coexpressed genes for either SDC1 or KRAS was performed, respectively. RESULTS: A significantly negative correlation existed between SDC1 mRNA and DNA methylation. Patients with KRAS somatic mutations had a significantly higher SDC1 mRNA but lower methylation than those without the mutations. Compared with patients with KRASSDC1 signature, those with a high level of KRAS and SDC1 alone or both had a significantly elevated mortality. The adjusted hazard ratios (95% confidence interval) were 2.30 (1.16-4.54, P = 0.017) for KRASSDC1, 2.85 (1.48-5.49, P = 0.002) for KRASSDC1, and 2.48 (1.31-4.70, P = 0.005) for KRASSDC1, respectively. Several Kyoto Encyclopedia of Gene and Genomes pathways were shared, whereas there were distinct pathways between KRAS and SDC1 coexpressed genes. CONCLUSIONS: SDC1 interplays with KRAS, and targeting both KRAS and SDC1 in combination may be more beneficial to pancreatic cancer patients.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001654" class="uri">https://doi.org/10.1097/MPA.0000000000001654</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Real-world Evidence of Diffusion-weighted Imaging Combined With Magnetic Resonance Cholangiopancreatography for Pancreatic Tumor Screening: A Cross-Sectional Diagnostic Accuracy Study</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1182-1186</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898002" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898002</a></p>
<p>OBJECTIVES: The aim was to clarify the sensitivity and specificity of diffusion-weighted imaging, as well as of that in combination with magnetic resonance cholangiopancreatography for pancreatic tumor diagnosis in real-world clinical setting. METHODS: Subjects were 217 consecutive patients who underwent both magnetic resonance imaging and contrast-enhanced ultrasound sonography. Cases positive for a pancreatic tumor were confirmed based on pathological diagnosis, whereas negative cases were defined when no solid pancreatic tumor was detected by contrast-enhanced ultrasound sonography or a solid mass was detected but the diagnosis was ultimately denied based on pathological results. Diffusion-weighted imaging-positive was defined as a case with high signals and magnetic resonance cholangiopancreatography-positive when localized main pancreatic duct stenosis with caudal dilation was detected.We calculated sensitivity and specificity of each modality and those in combination based on sequential use for pancreatic tumor diagnosis. RESULTS: Diffusion-weighted imaging showed a sensitivity of 94.4% and specificity of 94.5%, whereas those values for magnetic resonance cholangiopancreatography alone were 83.3% and 99.0%, respectively, and for the modalities in combination were 100% and 94.5%, respectively. CONCLUSIONS: Diffusion-weighted imaging was more sensitive than magnetic resonance cholangiopancreatography, whereas those used in combination resulted in increased sensitivity.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001653" class="uri">https://doi.org/10.1097/MPA.0000000000001653</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Inflammatory Bowel Diseases Elevate the Risk of Developing Acute Pancreatitis: A Meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1174-1181</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898001" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898001</a></p>
<p>OBJECTIVES: Increasing data suggest that acute pancreatitis (AP) occurs more frequently among patients with inflammatory bowel diseases (IBDs) than in the non-IBD population; however, currently no comprehensive meta-analysis is available. METHODS: Systematic literature search was conducted in 4 major databases. We included observational studies sampling from the general population. Basic study characteristics and crude incidences of AP were extracted. Pooled odds ratios (ORs) with 95% confidence interval (CIs) were calculated using the random-effects model. Subgroups were set up by Crohn disease and ulcerative colitis. Heterogeneity was tested with I statistics. RESULTS: Eight studies were eligible for the analysis. The odds of AP were 3 times higher in IBD (OR, 3.11; 95% CI, 2.93-3.30; I, 0.0%), significantly higher in Crohn disease than in ulcerative colitis (P &lt; 0.001; OR, 4.12 vs OR, 2.61; I, 0.0%). The pooled annual incidence of AP in IBD was 210/100,000 person-years (95% CI, 84-392/100,000 person-years; I, 98.66%). CONCLUSIONS: We confirmed that IBD elevates the risk of AP and of 100,000 IBD patients 210 AP cases are to be expected annually. Therefore, it is important to include pancreatic enzyme level measurements and radiological investigations in the workup of IBD patients with acute abdominal pain.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001650" class="uri">https://doi.org/10.1097/MPA.0000000000001650</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Safety and Feasibility of Electrochemotherapy of the Pancreas in a Porcine Model</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1168-1173</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32898000" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32898000</a></p>
<p>OBJECTIVES: The use of thermal ablative therapies in the pancreatic tumors is limited because of the risk of the vessel injury and potential pancreatitis or fistula formation. Electrochemotherapy (ECT) is an ablative therapy with an established role in the treatment of cutaneous and liver tumors. This study was designed to evaluate the safety and feasibility of ECT of the pancreas in a porcine survival model. METHODS: In the first group, 4 animals underwent computed tomography (CT)-guided percutaneous ECT with bleomycin of the pancreatic tail. In the second group (4 animals), the intraoperative ECT with bleomycin of pancreatic tail and head was performed. Animals were followed for 7 days and then killed. Clinical parameters, CT imaging, laboratory, and histologic analysis were performed. RESULTS: All pigs survived the ECT procedure and none of them developed clinical signs of acute pancreatitis or related complications. There were no signs of acute pancreatitis or damage to the large vessels present in the follow-up CT scans. No significant change in laboratory parameters was obtained after procedure. CONCLUSIONS: This study shows that ECT with bleomycin is feasible and safe in the pancreatic parenchyma. Clinical studies are needed to evaluate the efficacy of ECT in pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001642" class="uri">https://doi.org/10.1097/MPA.0000000000001642</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1153-1160</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32897998" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32897998</a></p>
<p>OBJECTIVE: For many patients whose pancreatic ductal adenocarcinoma (PDAC) is locally advanced, neoadjuvant therapy has been proposed as a way to decrease tumor burden. Pancreatic ductal adenocarcinoma is generally thought to be resistant to chemotherapy and radiation, however, response to neoadjuvant therapy in PDAC has been described in a subset of patients. The SMAD4 status is considered to be an important molecular feature which distinguishes two subsets of PDAC, SMAD4-positive and -negative tumors. The objective of this study was to evaluate the neoadjuvant treatment response rate as well as compare the different clinicopathologic variables between SMAD4-positive and -negative tumors. METHODS: We analyzed the data of patients who underwent surgical resection for PDAC from 2009-2019. Our cohort from a single institution included 233 patients. RESULTS: Of the 233 cases, 143 (61.4%) were SMAD4-negative and 90 (38.6%) were SMAD4-positive. Overall, SMAD4-positive tumors with neoadjuvant therapy had better treatment response and better tumor regression scores. In addition, SMAD4-positive tumors had a significantly lower lymph node metastasis rate in both the neoadjuvant and nonneoadjuvant setting. CONCLUSIONS: Further characterization of the role of SMAD4 within the context of neoadjuvant therapy will lead to improved personalized therapeutic strategies.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001636" class="uri">https://doi.org/10.1097/MPA.0000000000001636</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Endoscopic ultrasound-guided fine needle aspiration of pancreatic mass</strong></li>
</ul>
</summary>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32894783" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32894783</a></p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12912" class="uri">https://doi.org/10.1111/cyt.12912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Bayesian copy number detection and association in large-scale studies</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Sep;20(1):856</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32894098" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32894098</a></p>
<p>BACKGROUND: Germline copy number variants (CNVs) increase risk for many diseases, yet detection of CNVs and quantifying their contribution to disease risk in large-scale studies is challenging due to biological and technical sources of heterogeneity that vary across the genome within and between samples. METHODS: We developed an approach called CNPBayes to identify latent batch effects in genome-wide association studies involving copy number, to provide probabilistic estimates of integer copy number across the estimated batches, and to fully integrate the copy number uncertainty in the association model for disease. RESULTS: Applying a hidden Markov model (HMM) to identify CNVs in a large multi-site Pancreatic Cancer Case Control study (PanC4) of 7598 participants, we found CNV inference was highly sensitive to technical noise that varied appreciably among participants. Applying CNPBayes to this dataset, we found that the major sources of technical variation were linked to sample processing by the centralized laboratory and not the individual study sites. Modeling the latent batch effects at each CNV region hierarchically, we developed probabilistic estimates of copy number that were directly incorporated in a Bayesian regression model for pancreatic cancer risk. Candidate associations aided by this approach include deletions of 8q24 near regulatory elements of the tumor oncogene MYC and of Tumor Suppressor Candidate 3 (TUSC3). CONCLUSIONS: Laboratory effects may not account for the major sources of technical variation in genome-wide association studies. This study provides a robust Bayesian inferential framework for identifying latent batch effects, estimating copy number, and evaluating the role of copy number in heritable diseases.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07304-3" class="uri">https://doi.org/10.1186/s12885-020-07304-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1421-1427</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32891532" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32891532</a></p>
<p>BACKGROUND/OBJECTIVES: Pancreatic neuroendocrine carcinoma (PanNEC)-G3 often presents along with genetic abnormalities such as KRAS, RB1, and TP53 mutations. However, the association between these genetic findings and response to chemotherapy and prognosis has not been clarified. This study aimed to clarify the clinicopathological features of PanNEC-G3. METHODS: We performed a subgroup analysis of the Japanese PanNEN-G3 study (multicenter, retrospective study), which revealed that Rb loss and KRAS mutation were predictors of the response to platinum-based regimen in PanNEN-G3. We re-classified WHO grades of PanNENs using the 2017 WHO classification and then analyzed the clinicopathological features and prognostic factors in 49 patients with PanNEC-G3. RESULTS: The rates of Rb loss and KRAS mutation in PanNEC-G3 were 54.5% and 48.7%, respectively. Patients with Rb loss and/or KRAS mutation showed a higher response rate to first-line platinum-based regimen than those without Rb loss or KRAS mutation (object response rate 70.0% vs 33.3%, odds ratio 9.22; 95% CI 1.26-67.3, P = 0.029), but tended to have shorter overall survival rates than those without Rb loss or KRAS mutation (median 239 vs 473 days, hazard ratio 2.11; 95% CI 0.92-4.86, P = 0.077). CONCLUSIONS: Patients with PanNEC-G3 have varied clinical outcomes for platinum-based regimen. When grouped based on Rb loss and KRAS mutation, there seemed to be two groups with distinct prognoses and responses to the platinum-based regimen. PanNEC-G3 could, therefore, be classified into two distinct groups based on immunohistochemical and genetic findings.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.400" class="uri">https://doi.org/10.1016/j.pan.2020.07.400</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Acute pancreatitis</strong></li>
</ul>
</summary>
<p><em>Lancet (London, England) 2020 09;396(10252):726-734</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32891214" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32891214</a></p>
<p>Acute pancreatitis is an unpredictable and potentially lethal disease. The prognosis mainly depends on the development of organ failure and secondary infection of pancreatic or peripancreatic necrosis. In the past 10 years, treatment of acute pancreatitis has moved towards a multidisciplinary, tailored, and minimally invasive approach. Despite improvements in treatment and critical care, severe acute pancreatitis is still associated with high mortality rates. In this Seminar, we outline the latest evidence on diagnostic and therapeutic strategies for acute pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(20)31310-6" class="uri">https://doi.org/10.1016/S0140-6736(20)31310-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 11;272(5):731-737</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32889866" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32889866</a></p>
<p>OBJECTIVE: The aim of this study was to establish clinically relevant outcome benchmark values using criteria for pancreatoduodenectomy (PD) with portomesenteric venous resection (PVR) from a low-risk cohort managed in high-volume centers. SUMMARY BACKGROUND DATA: PD with PVR is regarded as the standard of care in patients with cancer involvement of the portomesenteric venous axis. There are, however, no benchmark outcome indicators for this population which hampers comparisons of patients undergoing PD with and without PVR resection. METHODS: This multicenter study analyzed patients undergoing PD with any type of PVR in 23 high-volume centers from 2009 to 2018. Nineteen outcome benchmarks were established in low-risk patients, defined as the 75th percentile of the median outcome values of the centers (NCT04053998). RESULTS: Out of 1462 patients with PD and PVR, 840 (58%) formed the benchmark cohort, with a mean age was 64 (SD11) years, 413 (49%) were females. Benchmark cutoffs, among others, were calculated as follows: Clinically relevant pancreatic fistula rate (International Study Group of Pancreatic Surgery): ≤14%; in-hospital mortality rate: ≤4%; major complication rate Grade≥3 and the CCI up to 6 months postoperatively: ≤36% and ≤26, respectively; portal vein thrombosis rate: ≤14% and 5-year survival for patients with pancreatic ductal adenocarcinoma: ≥9%. CONCLUSION: These novel benchmark cutoffs targeting surgical performance, morbidity, mortality, and oncological parameters show relatively inferior results in patients undergoing vascular resection because of involvement of the portomesenteric venous axis. These benchmark values however can be used to conclusively assess the results of different centers or surgeons operating on this high-risk group.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004267" class="uri">https://doi.org/10.1097/SLA.0000000000004267</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic perfusion imaging method that reduces radiation dose and maintains image quality by combining volumetric perfusion CT with multiphasic contrast enhanced-CT</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1406-1412</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32888809" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32888809</a></p>
<p>OBJECTIVES: The aim of this study is to propose and evaluate a new method of volumetric perfusion computed tomography (PCT) incorporated into pancreatic multiphasic contrast enhanced (CE)-CT in the clinical setting. METHODS: In this ethically approved study, PCT was incorporated into our existing scanning protocol in 17 patients and effective doses related to PCT were evaluated. CT values and signal-to-noise ratio (SNR) of anatomical structure were compared in diagnostic images that were acquired using 320-detector volumetric scan mode and 64-detector helical scan mode. In addition, focal lesion depiction was qualitatively assessed in the two groups. Perfusion parameters in normal pancreas were measured by two radiologists and the interobserver-reliability was assessed. RESULTS: The effective dose of PCT was 5.1 ± 0.3 mSv. The actual effective dose (AED) including the dose used in volumetric scans for diagnostic imaging was 22.8 ± 5.3 mSv and the putative effective dose (PED) was 21.9 ± 9.1 mSv on average. There was no significant difference between AED and PED (p = 0.404). Compared with conventional helical scans, volumetric scans did not decrease CT values or SNR, but rather significantly increased those of the aorta in the arterial phase. Both groups had acceptable qualitatively assessed image quality with no significant difference in the depiction of each structure. There was almost perfect interobserver agreement in the measurement of perfusion parameters (mean ICCs &gt; 0.9). CONCLUSIONS: Our scanning protocol for pancreatic perfusion CT provides high-quality images while requiring lower radiation doses than conventional methods.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.010" class="uri">https://doi.org/10.1016/j.pan.2020.08.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy</strong></li>
</ul>
</summary>
<p><em>The Lancet. Oncology 2020 09;21(9):e431-e443</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32888472" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32888472</a></p>
<p>Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocrine tumours (NETs). Some of the key challenges in its use are the prediction of efficacy and toxicity, patient selection, and response optimisation. In this Review, we assess current knowledge on the molecular profile of NETs and the strategies and tools used to predict, monitor, and assess the toxicity of PRRT. The few mutations in tumour genes that can be evaluated (eg, ATM and DAXX) are limited to pancreatic NETs and are most likely not informative. Assays that are transcriptomic or based on genes are effective in the prediction of radiotherapy response in other cancers. A blood-based assay for eight genes (the PRRT prediction quotient [PPQ]) has an overall accuracy of 95% for predicting responses to PRRT in NETs. No molecular markers exist that can predict the toxicity of PRRT. Candidate molecular targets include seven single nucleotide polymorphisms (SNPs) that are susceptible to radiation. Transcriptomic evaluations of blood and a combination of gene expression and specific SNPs, assessed by machine learning with algorithms that are tumour-specific, might yield molecular tools to enhance the efficacy and safety of PRRT.</p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(20)30323-5" class="uri">https://doi.org/10.1016/S1470-2045(20)30323-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Factors Influencing Exercise Following Pancreatic Tumor Resection</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32886288" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32886288</a></p>
<p>BACKGROUND: We previously demonstrated associations between exercise during pancreatic cancer treatment and quality of life and physical fitness prior to pancreatectomy. In this study, we quantified exercise among survivors following pancreatic tumor resection and characterized concordance with established guidelines. METHODS: We quantified exercise frequency, duration, and intensity among survivors who underwent pancreatectomy for adenocarcinoma or a neuroendocrine tumor at our center from 2000 to 2017 and compared them with American College of Sports Medicine Guidelines for Cancer Survivors. Additional surveys measured motivation to exercise, barrier self-efficacy, quality of life, and fatigue. Multivariable models were constructed to evaluate associations between clinicodemographic and psychosocial variables and guideline concordance, and between guideline concordance and quality of life and fatigue. RESULTS: Of 504 eligible survivors, 262 (52%) returned surveys. Only 62 participants (24%) reported meeting both aerobic and strengthening guidelines; 103 (39%) reported meeting neither. Adjusted analyses demonstrated that higher autonomous motivation was associated with higher aerobic and strengthening guideline concordance (both p &lt; 0.01). Higher barrier self-efficacy and older age were associated with higher aerobic guideline concordance (p &lt; 0.01). We identified no significant associations between guideline concordance and tumor type, time since surgery, or recent cancer therapy (all p &gt; 0.05). We found favorable associations between aerobic guideline concordance and both quality of life and fatigue (both p &lt; 0.001). CONCLUSIONS: Less than one-quarter of participants exercised sufficiently to meet national exercise guidelines following pancreatectomy. To maximize exercise and related benefits, interventions should help survivors increase intrinsic motivation and overcome barriers to exercise.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09062-9" class="uri">https://doi.org/10.1245/s10434-020-09062-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Association of malnutrition with geriatric assessment impairments and health-related quality of life among older adults with gastrointestinal malignancies</strong></li>
</ul>
</summary>
<p><em>Cancer 2020 Dec;126(23):5147-5155</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32885848" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32885848</a></p>
<p>BACKGROUND: A majority of older adults with cancer develop malnutrition; however, the implications of malnutrition among this vulnerable population are poorly understood. The goal of this study was to quantify the prevalence of nutrition related-symptoms and malnutrition among older adults with gastrointestinal (GI) malignancies and the association of malnutrition with geriatric assessment (GA) impairment, health-related quality of life (HRQoL), and health care utilization. METHODS: We performed a cross-sectional study of older adults (≥60 years) who were referred to the GI Oncology clinic at the University of Alabama at Birmingham. Participants underwent the Cancer &amp; Aging Resilience Evaluation survey that includes the abbreviated Patient-Generated Subjective Global Assessment of nutrition. Nutrition scores were dichotomized into normal (0-5) and malnourished (≥6), and multivariate analyses adjusted for demographics, cancer type, and cancer stage were used to examine associations with GA impairment, HRQoL, and health care utilization. RESULTS: A total of 336 participants were included (men, 56.8%; women, 43.2%), with a mean age of 70 years (standard deviation, ±7.2 years) and colorectal cancer (33.6%) and pancreatic cancer (24.4%) being the most common diagnoses. Overall, 52.1% of participants were identified as malnourished. Malnutrition was associated with a higher prevalence of several GA impairments, including 1 or more falls (adjusted odds ratio [aOR], 2.1), instrumental activities of daily living impairment (aOR, 4.1), and frailty (aOR, 8.2). Malnutrition was also associated with impaired HRQoL domains; both physical (aOR, 8.7) and mental (aOR, 5.0), and prior hospitalizations (aOR, 2.2). CONCLUSION: We found a high prevalence of malnutrition among older adults with GI malignancies that was associated with increased GA impairments, reduced HRQoL, and increased health care utilization.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.33122" class="uri">https://doi.org/10.1002/cncr.33122</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32883872" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32883872</a></p>
<p>OBJECTIVE: A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify potential therapeutic vulnerabilities in this disease. DESIGN: Differential expression analysis of 600 immune-related genes was performed on 207 PanNET samples, comprising a training cohort (n=72) and two validation cohorts (n=135) from multiple transcriptome profiling platforms. Different immune-related and subtype-related phenotypes, cell types and pathways were investigated using different in silico methods and were further validated using spatial multiplex immunofluorescence. RESULTS: The study identified an immune signature of 132 genes segregating PanNETs (n=207) according to four previously defined molecular subtypes: metastasis-like primary (MLP)-1 and MLP-2, insulinoma-like and intermediate. The MLP-1 subtype (26%-31% samples across three cohorts) was strongly associated with elevated levels of immune-related genes, poor prognosis and a cascade of tumour evolutionary events: larger hypoxic and necroptotic tumours leading to increased damage-associated molecular patterns (viral mimicry), stimulator of interferon gene pathway, T cell-inflamed genes, immune checkpoint targets, and T cell-mediated and M1 macrophage-mediated immune escape mechanisms. Multiplex spatial profiling validated significantly increased macrophages in the MLP-1 subtype. CONCLUSION: This study provides novel data on the immune microenvironment of PanNETs and identifies MLP-1 subtype as an immune-high phenotype featuring a broad and robust activation of immune-related genes. This study, with further refinement, paves the way for future precision immunotherapy studies in PanNETs to potentially select a subset of MLP-1 patients who may be more likely to respond.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-321016" class="uri">https://doi.org/10.1136/gutjnl-2020-321016</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32883742" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32883742</a></p>
<p>PURPOSE: GEP-NENs are rare malignancies with increasing incidence. Their molecular characteristics are still undefined. We explored the underlying biology of GEP-NENs and the differences between gastrointestinal (GI) and pancreatic (PNEN), high-grade (HG), and low-grade (LG) tumors. EXPERIMENTAL DESIGN: GEP-NENs were analyzed using next-generation sequencing (NGS; MiSeq on 47 genes, NextSeq on 592 genes), IHC, and in situ hybridization. Tumor mutational burden (TMB) was calculated on the basis of somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci. RESULTS: In total, 724 GEP-NENs were examined: GI (N = 469), PNEN (N = 255), HG (N = 135), and LG (N = 335). Forty-nine percent were female, and median age was 59. Among LG tumors, the most frequently mutated genes were ATRX (13%), ARID1A (10%), and MEN1 (10%). HG tumors showed TP53 (51%), KRAS (30%), APC (27%), and ARID1A (23%). Immune-related biomarkers yielded a lower prevalence in LG tumors compared with HG [MSI-H 0% vs. 4% (P = 0.04), PD-L1 overexpression 1% vs. 6% (P = 0.03), TMB-high 1% vs. 7% (P = 0.05)]. Compared with LG, HG NENs showed a higher mutation rate in BRAF (5.4% vs. 0%, P &lt; 0.0001), KRAS (29.4% vs. 2.6%, P &lt; 0.0001), and PI3KCA (7% vs. 0.3%, P &lt; 0.0001). When compared with GI, PNEN carried higher frequency of MEN1 (25.9% vs. 0.0%, P &lt; 0.0001), FOXO3 (8.6% vs. 0.8%, P = 0.005), ATRX (20.6% vs. 2.0%, P = 0.007), and TSC2 (6.3% vs. 0.0%, P = 0.007), but lower frequency of mutations in APC (1.0% vs. 13.8%, P &lt; 0.0001). CONCLUSIONS: Significant molecular differences were observed in GEP-NENs by tumor location and grade, indicating differences in carcinogenic pathways and biology.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1804" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1804</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Surgeon-Placed Continuous Wound Infusion Pain Catheters Markedly Decrease Narcotic Use and Improve Outcomes After Pancreatic Tumor Resection</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32880771" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32880771</a></p>
<p>BACKGROUND: Pancreatectomy results in significant postoperative pain and typically requires opioid analgesia for adequate pain control. Local anesthetics may decrease postoperative pain and opioid requirements but can be limited by onset of action, duration of effect, and inability to titrate dosing after administration. This can be overcome by surgeon placement of tunneled peri-incisional catheters with continuous wound infusion (CWI). METHODS: This retrospective cohort study analyzed patients undergoing open pancreatic tumor resection. All the patients received patient-controlled analgesia (PCA), enabling an objective comparison of opioid requirements, and underwent the same recovery pathway. The patients received CWI (n = 45), PCA alone (n = 11), or epidural analgesia (EA) (n = 9). The primary outcome was total opioid use in terms of intravenous morphine milligram equivalents (MMEs) and patient-reported pain scores on a numeric rating scale (NRS) of 0 to 10. RESULTS: No differences in baseline patient or tumor characteristics were observed. In both the uni- and multivariate analyses, CWI was associated with lower opioid use than PCA (MME, 83 vs 207 mg; p = 0.004) or EA (MME, 83 vs 156 mg; p &lt; 0.001) without having a negative impact on pain scores. Furthermore, CWI was associated with a greater percentage of time that patients experienced optimal pain control (NRS, ≤ 4: 63% vs 50%; p = 0.033) and a shorter time to PCA independence (4.0 vs 4.9 days; p = 0.004) than PCA alone. In addition, CWI was associated with earlier ambulation [EA vs CWI: odds ratio (OR), 0.05; p = 0.021], improved spirometry performance (CWI vs PCA: regression coefficient (coef), 267; p = 0.013), and earlier urinary catheter removal (EA vs CWI: coef, 1.30; p = 0.013). The findings showed no differences in time to return of bowel function, antiemetic use, or hospital length of stay. CONCLUSIONS: After open pancreatic tumor resection, CWI is safe and associated with decreased opioid requirements and improved functional outcomes without a negative impact on pain scores, supporting its potential for preferred use over PCA or EA alone.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09067-4" class="uri">https://doi.org/10.1245/s10434-020-09067-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Drug-induced acute pancreatitis: Prevalence, Causative agents, and Outcomes</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1281-1286</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32878711" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32878711</a></p>
<p>BACKGROUND: We sought to study the causative drugs, prevalence and outcomes of drug-induced acute pancreatitis (DIAP). METHODS: Retrospective study of DIAP patients at a tertiary teaching hospital. The diagnosis and severity of pancreatitis were determined based on the Revised Atlanta Classification. The cases were further subclassified using the Badalov et al., 2008 classification, and Naranjo score to evaluate and determine the odds of drug-related adverse reaction as a causative factor for AP. RESULTS: Out of 841 AP patients, a total of 31 patients (3.6%) with DIAP were included. The mean age was 52.9 years, 51.6% were male. The most common causative drugs are listed in Table 3. Most cases were mild in severity (87%), moderate AP occurred in 2 patients (6.5%) and severe AP in 2 patients (6.5%). 19.3% had systemic inflammatory response syndrome at presentation, but it persisted beyond 48 h in only 9.6%. 9.6% developed acute kidney injury. One patient with valproate induced DIAP had pancreatic necrosis, splenic vein thrombus, and sub occlusive superior mesenteric vein thrombus on abdominal imaging. Three patients had recurrent AP, and two (6.5%) of them eventually developed chronic pancreatitis. Notably, none of our patients developed complications such as shock, acute respiratory distress syndrome, bacteremia, or death. 1 patient had an acute peripancreatic fluid collection on initial imaging and another patient developed a pseudocyst on follow up imaging. None of them required drainage. CONCLUSION: Our study showed a prevalence of DIAP of (3.6%) and hydrochlorothiazide, azathioprine, and doxycycline were the most common culprit drugs.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.401" class="uri">https://doi.org/10.1016/j.pan.2020.07.401</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32875467" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32875467</a></p>
<p>BACKGROUND: The clinical role of peritoneal lavage cytology (CY) in pancreatic ductal adenocarcinoma (PDAC) remains controversial, partly due to its low sensitivity. This study aimed to develop a new biomarker, defined as peritoneal lavage tumor DNA (ptDNA), using DNAs extracted from peritoneal lavage samples from patients with PDAC. METHODS: Samples were collected intraoperatively from 89 PDAC patients who underwent pancreatectomy between 2012 and 2017. Droplet digital polymerase chain reaction (PCR) was used to measure ptDNA for detection of KRAS mutations. The ptDNA status and clinical characteristics were retrospectively evaluated. RESULTS: Positive ptDNA was found in 41 patients, including all 9 patients positive for CY (CY+) and 32 patients negative for CY (CY-). The mutant allele frequency was significantly higher in the CY+ patients than in the CY- patients. The disease-free survival (DFS) and overall survival (OS) were significantly poorer in the high-ptDNA group than in the low-ptDNA group (median DFS, 11.0 vs. 18.8 months; p = 0.007; median OS, 28.7 vs not reached; p = 0.001). The survival curves of DFS and OS in the CY+ group were almost equal to those in the CY- and high-ptDNA group. In a multivariable analysis, ptDNA was an independent predictive factor for DFS (p = 0.025) and OS (p = 0.047). The estimated cumulative incidence of peritoneal recurrence was 45.5% in the high-ptDNA group. The ptDNA biomarker had a much higher sensitivity for peritoneal recurrence than CY, whereas CY had higher specificity. CONCLUSIONS: As a promising biomarker, ptDNA may predict poor prognosis and peritoneal recurrence in PDAC, resolving the controversy surrounding CY.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08990-w" class="uri">https://doi.org/10.1245/s10434-020-08990-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32873698" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32873698</a></p>
<p>OBJECTIVE: ATM serine/threonine kinase (ATM) is the most frequently mutated DNA damage response gene, involved in homologous recombination (HR), in pancreatic ductal adenocarcinoma (PDAC). DESIGN: Combinational synergy screening was performed to endeavour a genotype-tailored targeted therapy. RESULTS: Synergy was found on inhibition of PARP, ATR and DNA-PKcs (PAD) leading to synthetic lethality in ATM-deficient murine and human PDAC. Mechanistically, PAD-induced PARP trapping, replication fork stalling and mitosis defects leading to P53-mediated apoptosis. Most importantly, chemical inhibition of ATM sensitises human PDAC cells toward PAD with long-term tumour control in vivo. Finally, we anticipated and elucidated PARP inhibitor resistance within the ATM-null background via whole exome sequencing. Arising cells were aneuploid, underwent epithelial-mesenchymal-transition and acquired multidrug resistance (MDR) due to upregulation of drug transporters and a bypass within the DNA repair machinery. These functional observations were mirrored in copy number variations affecting a region on chromosome 5 comprising several of the upregulated MDR genes. Using these findings, we ultimately propose alternative strategies to overcome the resistance. CONCLUSION: Analysis of the molecular susceptibilities triggered by ATM deficiency in PDAC allow elaboration of an efficient mutation-specific combinational therapeutic approach that can be also implemented in a genotype-independent manner by ATM inhibition.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319970" class="uri">https://doi.org/10.1136/gutjnl-2019-319970</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32873697" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32873697</a></p>
<p>OBJECTIVE: The gut microbiota are the main source of infections in necrotising pancreatitis. We investigated the effect of disruption of the intestinal microbiota by a Western-type diet on mortality and bacterial dissemination in necrotising pancreatitis and its reversal by butyrate supplementation. DESIGN: C57BL/6 mice were fed either standard chow or a Western-type diet for 4 weeks and were then subjected to taurocholate-induced necrotising pancreatitis. Blood and pancreas were collected for bacteriology and immune analysis. The cecum microbiota composition of mice was analysed using 16S rRNA gene amplicon sequencing and cecal content metabolites were analysed by targeted (ie, butyrate) and untargeted metabolomics. Prevention of necrotising pancreatitis in this model was compared between faecal microbiota transplantation (FMT) from healthy mice, antibiotic decontamination against Gram-negative bacteria and oral or systemic butyrate administration. Additionally, the faecal microbiota of patients with pancreatitis and healthy subjects were analysed. RESULTS: Mortality, systemic inflammation and bacterial dissemination were increased in mice fed Western diet and their gut microbiota were characterised by a loss of diversity, a bloom of Escherichia coli and an altered metabolic profile with butyrate depletion. While antibiotic decontamination decreased mortality, Gram-positive dissemination was increased. Both oral and systemic butyrate supplementation decreased mortality, bacterial dissemination, and reversed the microbiota alterations. Paradoxically, mortality and bacterial dissemination were increased with FMT administration. Finally, patients with acute pancreatitis demonstrated an increase in Proteobacteria and a decrease of butyrate producers compared with healthy subjects. CONCLUSION: Butyrate depletion and its repletion appear to play a central role in disease progression towards necrotising pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-320430" class="uri">https://doi.org/10.1136/gutjnl-2019-320430</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32873571" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32873571</a></p>
<p>PURPOSE: The cytokine milieu in pancreatic ductal adenocarcinoma (PDAC) promotes tumor progression and immune suppression, contributing to the dismal prognosis of patients with PDAC. The roles of many of these cytokines, however, have not been thoroughly investigated in PDAC. EXPERIMENTAL DESIGN: PDAC microarray and The Cancer Genome Atlas datasets were analyzed to identify cytokines and cognate receptors overexpressed in PDAC and associated with survival. Pathway and CIBERSORT analyses were used to elucidate potential mechanisms of altered patient survival. Comparative analysis of cytokine expression in KPC (K-rasG12D; TP53R172H; Pdx-1cre) and KC (K-rasG12D; Pdx-1cre) PDAC models and multicolor immunofluorescence (IF) staining of human PDAC-resected samples were used to validate these findings. RESULTS: CXCL9 and CXCL10 were among the most highly overexpressed cytokines by bioinformatics analyses, while their receptor, CXCR3, was significantly overexpressed by IHC analysis. Higher CXCR3 ligand expression was associated with shorter overall survival, while high CXCR3 expression was associated with better survival. The CXCR3 ligands, CXCL4, 9, and 10, were overexpressed in KPC compared with KC mice. Pathway analysis of CXCR3- and CXCR3 ligand-associated genes showed that CXCR3 is a marker of antitumor immunity, while its ligands may promote immunosuppression. CIBERSORT and IF studies of PDAC tissues demonstrated that high CXCR3 expression was associated with increased CD8+ T-cell and naïve B-cell signatures and loss of plasma cell signatures. CXCR3 ligand expression was associated with increased CD8+ T-cell signatures and loss of natural killer-cell signatures. CONCLUSIONS: CXCR3 ligands are overexpressed in PDAC and are associated with poor survival likely related to alterations in tumor immune infiltrate/activity.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1359" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1359</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1379-1385</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32873485" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32873485</a></p>
<p>BACKGROUND/OBJECTIVES: Intraductal papillary mucinous neoplasms (IPMNs) are classified into main duct (MD)-type IPMNs, branch duct (BD)-type IPMNs, and mixed type IPMNs. While MD-type IPMN has a high risk of malignancy and should therefore be considered for resection if the patient is fit, BD-type IPMN needs to be carefully judged for surgical indication. The decision to resect BD-type IPMN is often based on international consensus Fukuoka guidelines 2017, but further investigation is required. In this study, we focused on whether the location of the mural nodule (MN) could be an indicator of malignancy. METHODS: We enrolled 17 cases who had been diagnosed BD-type IPMNs which were surgically resected from January 2016 to December 2019. These cases were classified into benign and malignant group. Subsequently, a clinicopathological study was conducted based on the localization of MN (MN-central type or MN-peripheral type). RESULTS: Although MN was found in 57% (4/11) in the benign group, 88% (7/8) was noted in the malignant group, indicating the presence of MN to be more common in the malignant group. Those with MN consisted of 6 cases of MN-central type and 5 cases of MN-peripheral type. All cases of central type were malignant compared to only one case of the peripheral group being confirmed on histology as cancer. CONCLUSION: BD-IPMN with central mural nodule should be considered high risk for malignancy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.006" class="uri">https://doi.org/10.1016/j.pan.2020.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1465-1471</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32873483" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32873483</a></p>
<p>BACKGROUND/OBJECTIVES: Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is important as PDAC can lead to mortality; however, no specific biomarker has been identified for its early diagnosis. We previously identified fibrinogen α chain as a promising biomarker for differentiating between patients with and without PDAC using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Here, we aimed to validate the clinical usefulness of serum fibrinogen as a biomarker for PDAC. METHODS: From 2009 to 2011, blood samples of 67 PDAC patients and 43 healthy adults (controls) were prospectively collected. Serum fibrinogen levels and their clinical significances were evaluated. RESULTS: Mean fibrinogen levels were significantly higher in the PDAC group than in the control group (3.08 ± 0.565 vs. 2.54 ± 0.249 log10 ng/mL, P &lt; 0.001). In the receiver operating characteristic analysis, overall sensitivity, and specificity of serum fibrinogen levels for differentiating PDAC patients from control patients were 67.4% and 83.6%, respectively, with a 427-ng/mL cutoff value. Serum fibrinogen levels were significantly higher in PDAC patients with distant metastasis than in those without distant metastasis (3.38 ± 0.581 vs. 2.93 ± 0.499 log10 ng/mL, P = 0.002). Median overall survival was significantly longer in PDAC patients with low fibrinogen levels (&lt;1000 ng/mL) than in those with high fibrinogen levels (≥1000 ng/mL) [489 days (95% confidence interval, 248.1-729.9) vs. 172 days (58.4-285.6) (P = 0.008)]. Although serum fibrinogen levels were poorly correlated with carbohydrate antigen 19-9 levels, these two biomarkers together predicted survival better. CONCLUSIONS: Serum fibrinogen levels may be a useful biomarker for diagnosing and predicting PDAC prognosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.06.010" class="uri">https://doi.org/10.1016/j.pan.2020.06.010</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin</strong></li>
</ul>
</summary>
<p><em>Cancer 2020 Nov;126(22):4936-4947</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32870522" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32870522</a></p>
<p>BACKGROUND: LMB-100 is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity. The objective of the current first-in-human phase 1 study was to determine the maximum tolerated dose (MTD) and safety in patients with advanced solid tumors expressing mesothelin. METHODS: Cohorts of 1 to 7 patients received intravenous LMB-100 at 7 dose levels from 40 µg/kg to 250 µg/kg intravenously on days 1, 3, and 5 of a 21-day cycle. RESULTS: Of the 25 patients accrued, 17 had mesothelioma, 3 each had ovarian or pancreatic cancer, and 2 patients had gastric cancer. Dose-limiting toxicities occurred in 2 of 4 patients treated at a dose of 250 µg/kg (capillary leak syndrome) and in 3 of 7 patients treated at a dose of 170 µg/kg (creatinine increase). The MTD of LMB-100 was 140 µg/kg. Of the 10 patients with mesothelioma who were treated at doses of 170 µg/kg or 140 µg/kg, 8 had stable disease and 2 developed progressive disease. Peak LMB-100 plasma concentrations were dose-dependent during cycle 1. The development of antidrug antibodies decreased LMB-100 blood levels in 8 of 21 patients (38%) who received cycle 2 and 9 of 11 patients (81.8%) who received cycle 3. CONCLUSIONS: The MTD for single-agent LMB-100 was found to be 140 µg/kg given on a schedule of every other day for 3 doses every 3 weeks. Although less immunogenic than the first-generation antimesothelin immunotoxin SS1P, the majority of patients developed antidrug antibodies after 2 cycles, indicating that LMB-100 has limited antitumor efficacy as a single agent. Phase 2 studies of LMB-100 plus pembrolizumab currently are ongoing for patients with mesothelioma and lung cancer. LAY SUMMARY: Mesothelin, a cell surface antigen, is an attractive target for cancer therapy given its limited expression in normal human tissues and high expression in many human cancers. LMB-100 is a recombinant antimesothelin immunotoxin consisting of a humanized antimesothelin antibody fragment fused to a truncated Pseudomonas exotoxin A. In the current study, the authors determined the safety, maximum tolerated dose, and pharmacokinetics of LMB-100, as well as the generation of antidrug antibodies. Ongoing phase 2 clinical trials are evaluating the combination of LMB-100 plus pembrolizumab in patients with treatment-refractory mesothelioma and non-small cell lung cancer.</p>
<p>doi: <a href="https://doi.org/10.1002/cncr.33145" class="uri">https://doi.org/10.1002/cncr.33145</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1458-1464</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32868184" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32868184</a></p>
<p>BACKGROUND: Serum CA19-9 concentration may be useful in triaging patients with pancreatic cancer for more intensive staging investigations. Our aim was to identify the CA19-9 cut-point with the greatest accuracy for detecting unresectable features not identified by CT scan, and to examine the performance of this and other cut-points in predicting the outcome of staging laparoscopy (SL). METHODS: Patients with pancreatic cancer were drawn from two state-wide cancer registries between 2009 and 2011. We used classification and regression tree (CART) analysis to identify the CA19-9 cut-point which best predicted the presence of imaging-occult unresectable features, and compared its performance with that of a number of alternative cut-points. We then used logistic regression to test the association between CA19-9 concentration and detection of unresectable features in patients who underwent SL. RESULTS: From the CART analysis, the optimal CA19-9 cut-point was 440 U/mL. CA19-9 ≥ 150 U/mL had a similar Youden Index, but greater sensitivity (69% versus 47%). This remained true for those who had obstructive jaundice at the time of CA19-9 sampling. CA19-9 concentration greater than or equal to 110 U/mL, 150 U/mL and 200 U/mL was associated with significantly greater odds of unresectable features being detected during SL. CONCLUSION: Elevated serum CA19-9 concentration is a valid marker for CT-occult unresectable features; the most clinically appropriate cut-point appears to be ≥ 150 U/mL irrespective of the presence of jaundice. Clinical trials which evaluate the value of CA19-9 in the staging algorithm for pancreatic cancer are needed before it is routinely used in clinical practice.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.405" class="uri">https://doi.org/10.1016/j.pan.2020.07.405</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic body and tail cancer and favorable metastatic lymph node behavior on the left edge of the aorta</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1451-1457</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32868183" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32868183</a></p>
<p>BACKGROUND: Lymph node (LN) metastasis in pancreatic body-tail cancer is a poor prognostic factor and the optimal LN dissection area for distal pancreatectomy (DP) remains unclear. Lymphatic flow from the tumors is thought to depend on the tumor sites. We examined LN metastasis frequency based on tumor site and recurrent patterns post-DP. METHODS: With a retrospective, single institutional study, we examined 100 patients who underwent DP as an upfront surgery for pancreatic cancer over 17 years. Tumor sites were classified as tumor confined to pancreatic body (and neck) (Pb(n)); and pancreatic tail (Pt). We compared metastatic LN and recurrence patterns based on tumor site. The median overall survival (OS) and disease-free survival (DFS) were analyzed. RESULTS: LN metastasis occurred in 59/100 (59.0%), with 23 and 25 tumors located in the Pb(n), and Pt, respectively. Those with the tumor in Pt had metastases to #10, #11d/p, and #18 LN mainly. However, the patients with the Pb(n) tumor had metastases to #8a/p, #11p, and #14p/d LN. There was no metastasis to #10 and #11d LN. The OS and DFS were 34 and 15 months, respectively. No significant difference was found in the OS, DFS, and recurrence patterns based on tumor sites. CONCLUSION: Differences in metastatic LN sites were observed in pancreatic body-tail cancer when tumors were confined to the left or right of the left aortic edge. Although it is necessary to validate this finding with a large-scale study, organ-preserving DP might be a treatment option for selected patients depending on the tumor sites.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.014" class="uri">https://doi.org/10.1016/j.pan.2020.08.014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Early on-demand drainage versus standard management among acute necrotizing pancreatitis patients complicated by persistent organ failure: The protocol for an open-label multi-center randomized controlled trial</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1268-1274</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32868182" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32868182</a></p>
<p>INTRODUCTION/AIM: Pancreatic necrosis occurs in a quarter of patients with acute pancreatitis, many of whom form an acute necrotic collection (ANC). The current standard treatment is to defer percutaneous catheter drainage (PCD) until the latter becomes “walled off,” which takes approximately four weeks. The majority of patients that develop persistent organ failure (POF), the primary determinant of mortality, do so within four weeks. To defer PCD until after four weeks may result in a worse outcome because of a missed opportunity to treat early infection and thereby reduce the severity and/or duration of POF. This study is aimed to compare the clinical outcome of the current standard approach with early on-demand PCD in acute necrotizing pancreatitis (ANP) patients with ANC and POF. METHODS/DESIGN: This is an open-label, multi-center, parallel, randomized, controlled trial. All patients with ANP who develop POF during the first week of onset will be screened for eligibility. In total, 120 study subjects will be randomized to either early on-demand PCD or standard care. Patients assigned to the former will receive PCD when they show signs of decompensation like new-onset OF, aggravation of pre-existent OF, and persistent OF for more than a week. The primary composite endpoint is major complication and/or death. Patients will be followed until discharge or death with an additional follow-up 90 days after randomization. DISCUSSION: This study challenges the standard 4-week delay before PCD and will answer the question whether early on-demand PCD is associated with a lower incidence of major complications and/or death.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.012" class="uri">https://doi.org/10.1016/j.pan.2020.08.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32862372" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32862372</a></p>
<p>BACKGROUND: A consensus regarding the optimal extent of lymph node dissection for pancreatic cancer has not yet been achieved. The purpose of this study was to evaluate the efficacy of lymph node dissection according to the location for pancreatic cancer. METHODS: A total of 495 patients diagnosed with invasive ductal carcinoma of the pancreas who had undergone a pancreatectomy between October 2002 and December 2015 were analyzed. The efficacy index (EI) was calculated for each lymph node station via multiplication of the frequency of metastasis to the station and the 5-year survival rate of the patients with metastasis to that station. RESULTS: For pancreatic head (Ph) tumors, mesocolon lymph nodes had a high EI, although not regional. For pancreatic body (Pb) tumors, peri-Ph lymph nodes had a high EI, although not regional. For pancreatic tail (Pt) tumors, lymph nodes along the celiac axis and common hepatic artery had a zero EI, although regional. When the Ph was segmented into the pancreatic neck (Ph-neck), uncinate process (Ph-up), and periampullary regions, hepatoduodenal ligament lymph nodes had a zero EI for Ph-up, although regional; the mesojejunum lymph node also had a zero EI, even for Ph-up, regardless of a high incidence of metastasis. Regarding lymph node recurrence after surgery, recurrence was most frequently found at the peri-Ph lymph node (12%) in patients with Pb tumors who had undergone a distal pancreatectomy. CONCLUSIONS: The optimal extent of lymph node dissection should be estimated in regard to the tumor location.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09066-5" class="uri">https://doi.org/10.1245/s10434-020-09066-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Predicting Positive Margins in Pancreatic Head Adenocarcinoma After Neoadjuvant Therapy: Investigating Disparities in Quality Care Using the National Cancer Database</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32856228" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32856228</a></p>
<p>BACKGROUND: In pancreatic cancer, surgical resection with neoadjuvant therapy improves survival, but survival relies significantly on the margin status of the resected tissue. This study aimed to develop a model that predicts margin positivity, and then to identify facility-specific factors that influence the observed-to-expected (O/E) ratio for positive margins among facilities. METHODS: This retrospective review analyzed patients in the National Cancer Database (2004-2016) with pancreatic head adenocarcinoma [tumor-node-metastasis (TNM) stage 1 or 2] who received neoadjuvant therapy for a pancreaticoduodenectomy. Logistic regression was used to develop a model that predicts margin positivity. This model then was used to identify outlier facilities with regard to the O/E ratio. Hospital volume was defined as the total number of pancreaticoduodenectomies per year. RESULTS: The study enrolled 4085 patients, and 16.8% of these patients had positive margins. Most of the patients (64%) had a tumor size of 2 to 4 cm, and approximately 51% of the patients did not have positive lymph nodes at resection. A logistic regression model showed that the predictors of positive margins after resection with neoadjuvant therapy were male sex, larger tumor size, and positive lymph nodes. This model was validated to yield a bootstrap-corrected concordance index of 0.632. The study calculated O/E ratios with the model, identifying 12 low- and 17 high O/E-ratio outlier facilities among 401 studied hospitals. The outlier hospitals did not differ in facility type (i.e., academic vs integrated network), but did differ significantly in terms of yearly hospital volume (low outlier of 20.6 vs high outlier of 10.7; p = 0.008). CONCLUSIONS: An association of lower-volume facilities with higher than expected rates of positive margins was found to indicate a disparity in care. This disparity was identified via an O/E ratio as a quality indicator for facilities. Facilities can gauge the efficiency of their own practices by referencing their O/E ratios, and they also can improve their practices by analyzing the framework of low O/E-ratio facilities.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08766-2" class="uri">https://doi.org/10.1245/s10434-020-08766-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32855305" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32855305</a></p>
<p>Complex rearrangement patterns and mitotic errors are hallmarks of most pancreatic ductal adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic advances in recent years. DNA double-strand breaks (DSB) bear the greatest risk of provoking genomic instability, and DNA damage repair (DDR) pathways are crucial in preserving genomic integrity following a plethora of damage types. Two major repair pathways dominate DSB repair for safeguarding the genome integrity: non-homologous end joining and homologous recombination (HR). Defective HR, but also alterations in other DDR pathways, such as BRCA1, BRCA2, ATM and PALB2, occur frequently in both inherited and sporadic PDAC. Personalised treatment of pancreatic cancer is still in its infancy and predictive biomarkers are lacking. DDR deficiency might render a PDAC vulnerable to a potential new therapeutic intervention that increases the DNA damage load beyond a tolerable threshold, as for example, induced by poly (ADP-ribose) polymerase inhibitors. The Pancreas Cancer Olaparib Ongoing (POLO) trial, in which olaparib as a maintenance treatment improved progression-free survival compared with placebo after platinum-based induction chemotherapy in patients with PDAC and germline BRCA1/2 mutations, raised great hopes of a substantially improved outcome for this patient subgroup. This review summarises the relationship between DDR and PDAC, the prevalence and characteristics of DNA repair mutations and options for the clinical management of patients with PDAC and DNA repair deficiency.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-319984" class="uri">https://doi.org/10.1136/gutjnl-2019-319984</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Evaluation of allowable pancreatic resection rate depending on preoperative risk factors for new-onset diabetes mellitus after distal pancreatectomy</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1526-1533</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32855059" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32855059</a></p>
<p>BACKGROUND: Although more patients have long-term survival after pancreatectomy, the details of pancreatogenic diabetes mellitus (DM) are still unclear. We aimed to investigate the incidence of new-onset DM (NODM) after distal pancreatectomy (DP) and to clarify the risk factors, including allowable pancreatic resection rate (PR), for NODM. METHODS: The incidence, onset time, and risk factors for NODM were retrospectively evaluated in 150 patients who underwent DP without preoperative DM and with &gt;5 years of postoperative follow-up between 2005 and 2015. RESULTS: The incidence rate of NODM was 39%, and 60% of this incidence was noted within 6 months postoperatively. In the multivariate analysis, hemoglobin A1c ≥ 5.8% (odds ratio [OR] 7.6), impaired glucose tolerance and/or impaired fasting glucose (OR 4.2), homeostasis model assessment of insulin resistance ≥1.4 (OR 5.5), and insulinogenic index &lt;0.7 (OR 3.9) were the preoperative risk factors for NODM. Based on these four preoperative risk factors of NODM, we made the new scoring system to predict the NODM after DP. The NODM incidence was 0%, 8%, 48%, 60%, and 86% in patients with risk scores 0 (n = 25), 1 (n = 36), 2 (n = 33), 3 (n = 35), and 4 (n = 21), respectively. PRs ≥42.1% and ≥30.9% were allowable in the preoperative risk-score 0-1 and 2-4 groups. In the former group, the NODM incidence for PR ≥ 42.1% and &lt;42.1% was significantly different (20% vs 0%, P &lt; 0.05). In the latter group, the NODM incidence for PR ≥ 30.9% vs &lt;30.9% was significantly different (75% vs 23%, P &lt; 0.05). CONCLUSIONS: We clarified the preoperative risk factors and allowable PR for NODM and recommended the use of a risk scoring system for predicting NODM preoperatively.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.005" class="uri">https://doi.org/10.1016/j.pan.2020.08.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Metastatic pancreatic adenocarcinomas could be classified into M1a and M1b category by the number of metastatic organs</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):289</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32854631" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32854631</a></p>
<p>BACKGROUND: With the improvement of treatment and prognosis for patients with late malignant diseases, certain malignancies with distant metastasis (M1 category) have been further classified into M1a (single metastatic site) and M1b (multiple metastatic sites) category in the staging system. We aimed to assess the feasibility of sub-classifying metastatic pancreatic adenocarcinoma (mPA) into M1a and M1b category depending on the number of metastatic organs. METHODS: Patient records were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015). Univariable and multivariable analyses were performed using the Cox regression model. Then survival analysis was determined using the Kaplan-Meier method. RESULTS: A total of 11,885 patients were included in this analysis, including 9425 patients with single metastasis and 2460 patients with multiple metastases. Multivariable analysis showed that gender, age, marital status, grade, surgery, chemotherapy, and radiotherapy were independent prognostic factors for patients with single metastasis; gender, age, marital status, grade, chemotherapy and radiotherapy were independent prognostic factors for patients with multiple metastases. Notably, surgery was an independent prognostic factor for patients with single metastasis (P &lt; 0.001) but not for patients with multiple metastases (P = 0.134). Kaplan-Meier analysis showed that patients with single metastasis (M1a) had better survival outcomes than patients with multiple metastases (M1b) (P &lt; 0.001). CONCLUSIONS: PA patients with M1 diseases could be divided into M1a (single metastasis) category and M1b (multiple metastases) category by the number of metastatic organs. The subclassification would facilitate individualized treatment for late PA patients. Surgery was associated with lower mortality in M1a patients but not significantly in M1b patients.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01431-8" class="uri">https://doi.org/10.1186/s12876-020-01431-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Therapeutic Potentials of MicroRNAs for Curing Diabetes Through Pancreatic ��-Cell Regeneration or Replacement</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 10;49(9):1131-1140</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32852323" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32852323</a></p>
<p>MicroRNAs are a type of noncoding RNAs that regulates the expression of target genes at posttranscriptional level. MicroRNAs play essential roles in regulating the expression of different genes involved in pancreatic development, β-cell mass maintenance, and β-cell function. Alteration in the level of miRNAs involved in β-cell function leads to the diabetes. Being an epidemic, diabetes threatens the life of millions of patients posing a pressing demand for its urgent resolve. However, the currently available therapies are not substantial to cure the diabetic epidemic. Thus, researchers are trying to find new ways to replenish the β-cell mass in patients with diabetes. One promising approach is the in vivo regeneration of β-cell mass or increasing the efficiency of β-cell function. Another clinical strategy is the transplantation of in vitro developed β-like cells. Owing to their role in pancreatic β-cell development, maintenance, functioning and their involvement in diabetes, overexpression or attenuation of different miRNAs can cause β-cell regeneration in vivo or can direct the differentiation of various kinds of stem/progenitor cells to β-like cells in vitro. Here, we will summarize different strategies used by researchers to investigate the therapeutic potentials of miRNAs, with focus on miR-375, for curing diabetes through β-cell regeneration or replacement.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001655" class="uri">https://doi.org/10.1097/MPA.0000000000001655</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Undertreatment of Pancreatic Cancer: Role of Surgical Pathology</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32851518" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32851518</a></p>
<p>BACKGROUND: Current guidelines recommend treatment of early-stage pancreatic cancer with surgical resection and chemotherapy. Undertreatment can occur after resection when patients fail to receive adjuvant chemotherapy. Final pathologic results have the potential to bias providers to omit adjuvant chemotherapy, however, the association of surgical pathology and adjuvant chemotherapy is unknown. METHODS: Data from the National Cancer Database identified patients who underwent surgery for stage I or II pancreatic cancer. Chi-square tests and logistic regression were used to determine differences between patients receiving surgery followed by chemotherapy and those who had resection alone. Survival analysis of subgroups with favorable pathology (node-negative disease, tumor size ≤ 2 cm, well-differentiated histology) was performed by the Kaplan-Meier method and the Cox proportional hazards model. RESULTS: Of the 22,131 patients included in this study, 28% were considered undertreated (surgery alone). Favorable pathologic traits of negative lymph nodes, tumor 2 cm in size or smaller, and well-differentiated histology were associated with a 15-35% lower probability that adjuvant chemotherapy would be given than less favorable pathologic results (p &lt; 0.001). Multivariable survival analysis showed significantly lower odds of mortality for patients who received resection and chemotherapy than for those who were undertreated among two subgroups: patients with node-negative disease (hazard ratio [HR] 0.774) and those with a tumor 2 cm in size or smaller (HR 0.771). CONCLUSION: The patients who had early-stage pancreatic cancer with favorable pathology after pancreatectomy were less likely than those with unfavorable pathology to receive adjuvant chemotherapy. This omission had significant survival consequences for subgroups with node-negative disease and tumors 2 cm in size or smaller. Recognition of patients with favorable pathology as an undertreated group is required for efforts to be directed toward encouraging guideline-concordant care and to combat undertreatment of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09043-y" class="uri">https://doi.org/10.1245/s10434-020-09043-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Intraductal papillary squamous neoplasm of the pancreas: Cyto-histologic correlation of a novel entity</strong></li>
</ul>
</summary>
<p><em>Annals of diagnostic pathology 2020 Oct;48():151583</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32847795" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32847795</a></p>
<p>We correlate the cytologic and histologic features of a squamous-lined pancreatic cystic lesion with a complex papillary architecture and an associated KRAS mutation, which to our knowledge has not been previously described. A 69 year-old woman presented with intermittent left upper quadrant pain. CT imaging revealed a 1 cm solid lesion in the pancreatic tail with peripheral calcification. Endoscopic ultrasound-guided fine needle biopsy showed a proliferation of epithelial cells with fibrovascular cores. An immunohistochemical stain for p40 was positive in the lesional cells. A distal pancreatectomy revealed a unilocular, cystic, well-circumscribed, soft and friable mass measuring 1.0 × 1.0 × 0.8 cm. Histologically, the cyst was lined by nonkeratinizing stratified squamous epithelium with a complex papillary architecture, filling the cyst lumen. Molecular sequencing revealed a KRAS G12V missense mutation. While the lesion shared some histologic features with the previously described “squamoid cyst of the pancreatic ducts”, the complex papillary architecture and presence of a KRAS mutation are unique to the entity we describe herein and we propose the name “intraductal papillary squamous neoplasm of the pancreas.” Reporting the cytomorphologic features of this novel entity may help in identification of similar lesions and understanding of the clinicopathologic significance.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2020.151583" class="uri">https://doi.org/10.1016/j.anndiagpath.2020.151583</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes</strong></li>
</ul>
</summary>
<p><em>The New England journal of medicine 2020 08;383(9):836-845</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32846062" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32846062</a></p>
<p>BACKGROUND: A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes. METHODS: In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented insulin pump (control group). The primary outcome was the percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter, as measured by continuous glucose monitoring. RESULTS: A total of 101 children underwent randomization (78 to the closed-loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 to 10.1%. The mean (±SD) percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter increased from 53±17% at baseline to 67±10% (the mean over 16 weeks of treatment) in the closed-loop group and from 51±16% to 55±13% in the control group (mean adjusted difference, 11 percentage points [equivalent to 2.6 hours per day]; 95% confidence interval, 7 to 14; P&lt;0.001). In both groups, the median percentage of time that the glucose level was below 70 mg per deciliter was low (1.6% in the closed-loop group and 1.8% in the control group). In the closed-loop group, the median percentage of time that the system was in the closed-loop mode was 93% (interquartile range, 91 to 95). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either group. CONCLUSIONS: In this 16-week trial involving children with type 1 diabetes, the glucose level was in the target range for a greater percentage of time with the use of a closed-loop system than with the use of a sensor-augmented insulin pump. (Funded by Tandem Diabetes Care and the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number, NCT03844789.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa2004736" class="uri">https://doi.org/10.1056/NEJMoa2004736</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A case of inflammatory pseudotumour of the gallbladder presenting as a big mass of uncertain behavior</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):282</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747</a></p>
<p>BACKGROUND: Inflammatory pseudotumour has been used to describe an inflammatory or fibrosing tumoral process of an undetermined cause that may involve a variety of organ systems, including the lungs, spleen, liver, lymph nodes, pancreas and extrahepatic bile duct with potential for recurrence and persistent local growth. In this article, we report a patient with a big mass of uncertain nature and behavior. CASE PRESENTATION: A 60-year-old woman presented with a 1-week history of abdominal pain, fever and jaundice. Six months before she had had right upper quadrant pain that was interpreted as biliary colic. A contrast-enhanced CT scan showed a big mass of soft tissue with diffuse infiltration of the gallbladder, displacement of the transverse colon, hepatic flexure and duodenum. For diagnostic distinction between a chronic inflammatory disease or a neoplasm, exploratory laparotomy was required. Intraoperative exploration disclosed a big mass of hard texture involving the gallbladder, with multiple concrements, hepatoduodenal ligament, right and transverse mesocolon, stomach and duodenum. Cholecystectomy was performed, preserving adjacent organs with macroscopic desmoplastic reaction. Histopathologic examination of the gallbladder showed a spindle cell proliferation with diffuse chronic inflammatory infiltrate of lymphocytes, plasma cells and hyalinized fibrous stroma. No vascular invasion or cellular atypia were evident. CONCLUSION: Inflammatory pseudotumour is a rare condition and diagnostic distinction from a chronic inflammatory disease or other neoplasm is only possible by histopathologic examination. There is a limited number of case reports in the literature indicating tumor location in the gallbladder.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01408-7" class="uri">https://doi.org/10.1186/s12876-020-01408-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Depression Before and After a Diagnosis of Pancreatic Cancer: Results From a National, Population-Based Study</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1117-1122</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833946" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833946</a></p>
<p>OBJECTIVES: The aim of this study was to evaluate depression in pancreatic cancer (PC) patients before and after a cancer diagnosis using a US-based healthcare database. We also sought to study the impact of treatment of depression in PC patients on all-cause mortality. METHODS: Pancreatic cancer patients with comorbid depression in Explorys (1999-2019) were compared with controls using odds ratios with 95% confidence intervals. Rates of depression diagnosed within 6 months, 1 year, and 3 years before and after a PC diagnosis were recorded. Patients who developed depression after a PC diagnosis were further categorized into those treated for depression using mental health professionals (MHPs), pharmacologic treatment, or both (2015-2019). RESULTS: Of the 62,450 PC patients, 10,220 (16.4%) were diagnosed with depression before PC and 8130 (13%) were diagnosed with depression after PC. Patients diagnosed with depression after PC had a significantly higher all-cause mortality than patients with PC alone (P &lt; 0.0001). Involvement of MHP significantly improved all-cause mortality (P = 0.0041). CONCLUSIONS: Most post-PC depression is diagnosed in the first 6 months after a PC diagnosis. Although depression significantly increases PC mortality, integrating MHP in the care of PC patients with depression improves outcomes.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001635" class="uri">https://doi.org/10.1097/MPA.0000000000001635</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1109-1116</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833945" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833945</a></p>
<p>OBJECTIVES: A limited repertoire of good pancreatic ductal adenocarcinoma (PDAC) models is one of the main barriers in developing effective new PDAC treatments. We aimed to characterize 6 commonly used PDAC cell lines and compare them with PDAC patient tumor samples using proteomics. METHODS: Proteomic methods were used to generate an extensive catalog of proteins from 10 PDAC surgical specimens, 9 biopsies of adjacent normal tissue, and 6 PDAC cell lines. Protein lists were interrogated to determine what extent the proteome of the cell lines reflects the proteome of primary pancreatic tumors. RESULTS: We identified 7973 proteins from the cell lines, 5680 proteins from the tumor tissues, and 4943 proteins from the adjacent normal tissues. We identified 324 proteins unique to the cell lines, some of which may play a role in survival of cells in culture. Conversely, a list of 63 proteins expressed only in the patient samples, whose expression is lost in culture, may place limitations on the degree to which these model systems reflect tumor biology in vivo. CONCLUSIONS: Our work offers a catalog of proteins detected in each of the PDAC cell lines, providing a useful guide for researchers seeking model systems for PDAC functional studies.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001633" class="uri">https://doi.org/10.1097/MPA.0000000000001633</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Impact of a Prior Nonpancreatic Malignancy on Survival Outcomes of Patients With Stage IV Pancreatic Neuroendocrine Tumor: A Population-Based and Propensity Score Matching Study</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1090-1098</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833943" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833943</a></p>
<p>OBJECTIVE: The aim of the study was to investigate the impact of a previous nonpancreatic malignancy on the survival outcomes in patients with a stage IV pancreatic neuroendocrine tumor (PanNET). METHODS: The Surveillance, Epidemiology, and End Results database was reviewed, and patients diagnosed with a stage IV PanNET between 2004 and 2015 were selected. Patients were divided into 2 groups according to the presence or absence of a previous nonpancreatic malignancy. Clinicopathological characteristics and survival outcomes were compared. RESULTS: A total of 1582 patients with stage IV PanNET were identified, of whom 116 (7.3%) had a prior malignancy. Prostate (33.62%), breast (17.24%), and gastrointestinal (12.07%) malignancies were the most common. Most prior malignancies (84.48%) were localized and regional. Patients with intervals of 36 months or less, 36 to 60 months, 60 to 120 months, and more than 120 months account for 25.86%, 14.66%, 31.03%, and 28.45% of all cases, respectively. Before and after propensity score matching, there was no significant difference detected regarding survival outcomes. CONCLUSIONS: Stage IV PanNET patients with a history of a prior cancer had comparable survival outcomes with patients without such history. These patients could be candidates for clinical trials if otherwise appropriate, and aggressive and potentially curative therapies should be offered.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001630" class="uri">https://doi.org/10.1097/MPA.0000000000001630</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Role of the Immune System and the Circadian Rhythm in the Pathogenesis of Chronic Pancreatitis: Establishing a Personalized Signature for Improving the Effect of Immunotherapies for Chronic Pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1024-1032</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833942" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833942</a></p>
<p>Pancreatitis, in both acute and chronic forms, poses a major therapeutic challenge and is associated with great morbidity and several complications. The nature of pancreatic injury in chronic pancreatitis (CP) and the wide range of causative processes that lead to CP have made effective therapy a true unmet need. Multiple physiological, genetic, environmental, and behavioral factors contribute to the development of CP. As a result, several fields of research are aimed at identifying and addressing the factors that contribute to pancreatic injury. In this article, we review the current understanding of the pathogenesis and natural history of CP. We focus on the autonomous nervous system, immune system, and role of a chronobiological therapeutic approach to alleviate symptoms and prevent or reverse pancreatic injury associated with CP. We aim to demonstrate that individualizing chronopharmacological treatments for CP is a promising direction for future treatment using immune, nervous, and circadian systems.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001626" class="uri">https://doi.org/10.1097/MPA.0000000000001626</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>T-Cell Immunity in Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1014-1023</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833941" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833941</a></p>
<p>Worldwide, approximately half a million people are diagnosed with pancreatic cancer every year, with mortality rates of more than 90%. T cells within pancreatic tumors are generally infrequent and incapable of eliciting antitumor immunity. Thus, pancreatic cancer is considered an “immunologically cold” tumor. However, recent studies clearly show that when T-cell immunity in pancreatic cancer is sufficiently induced, T cells become effective weapons. This fact suggests that to improve pancreatic cancer patients’ clinical outcomes, we need to unveil the complex immune biology of this disease. In this review, we discuss the elements of tumor immunogenicity in the specific context of pancreatic malignancy.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001621" class="uri">https://doi.org/10.1097/MPA.0000000000001621</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Fifty Years of Surgery for Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Pancreas 2020 09;49(8):1005-1013</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833940" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833940</a></p>
<p>The surgical treatment of pancreatic cancer (PDAC) has seen sweeping changes during the past 5 decades. Up to the middle of the 20th century resection rates were below 5%, but the numbers of curative resections for PDAC are now continuously increasing due to improved neoadjuvant treatment concepts as well as progress in surgical techniques and perioperative management. During the same period, mortality rates after pancreatic surgery have decreased considerably and are now less than 5%. One of the most important cornerstones of reduced mortality has been the concentration of PDAC surgery in specialized centers. In addition, the management of postoperative complications has improved greatly as a result of optimized interdisciplinary teamwork. Adjuvant chemotherapy has become the reference treatment in resected PDAC, achieving significantly prolonged survival. Moreover, the concept of borderline resectable PDAC has emerged to characterize tumors with increased risk for tumor-positive resection margins or worse outcome. The best treatment strategy for borderline resectable PDAC is currently under debate, whereas neoadjuvant therapy has become established as a beneficial treatment option for patients with locally advanced PDAC, enabling conversion surgery in up to 60% of cases. This review article summarizes the principal changes in PDAC surgery during the past 50 years.</p>
<p>doi: <a href="https://doi.org/10.1097/MPA.0000000000001634" class="uri">https://doi.org/10.1097/MPA.0000000000001634</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic Inflammation and Proenzyme Activation Are Associated With Clinically Relevant Postoperative Pancreatic Fistulas After Pancreas Resection</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 11;272(5):863-870</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833754" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833754</a></p>
<p>OBJECTIVE: We investigated the activation of pancreatic proenzymes and signs of peripancreatic inflammation in patients with clinically relevant postoperative pancreatic fistulas (POPFs). SUMMARY BACKGROUND DATA: An increase of systemic amylase concentration was associated with POPFs. This suggested parallels in the pathomechanisms between the development of POPFs and pancreatitis. METHODS: Trypsinogen, procathepsin B, and IL-6 concentrations as well as cathepsin B, myeloperoxidase and trypsin activities were determined throughout the first 7 postoperative days in drain fluids of 128 consecutive patients after pancreas resection. Histology and immunohistochemistry were performed in pancreatic specimens after total pancreatectomy due to complications and after placing experimental pancreatic sutures in the pancreatic tail of C57/Bl6 mice. RESULTS: Trypsin activity, cathepsin B activity and myeloperoxidase activity on the first postoperative day were elevated and predictive for clinically relevant pancreatic fistulas. Drain fluid stabilized trypsin activity and prevented the activation of the cascade of digestive enzymes. Leukocytes were the source of cathepsin B in drain fluid. Findings differed between fistulas after distal pancreatectomy and pancreatoduodenectomy. Immunohistochemistry of the pancreatic remnant revealed an inflammatory infiltrate expressing cathepsin B, independent of the presence of pancreatic fistulas. The infiltrate could be reproduced experimentally by sutures placed in the pancreatic tail of C57/Bl6 mice. CONCLUSIONS: Trypsinogen activation, increased cathepsin B activity and inflammation around the pancreato-enteric anastomosis on post operative day 1 are associated with subsequent clinically relevant POPFs after pancreatoduodenectomy. The parenchymal damage seems to be induced by placing sutures in the pancreatic parenchyma during pancreatic surgery.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004257" class="uri">https://doi.org/10.1097/SLA.0000000000004257</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Insulitis and lymphoid structures in the islets of Langerhans of a 66-year-old patient with long-standing type 1 diabetes</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32833039" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32833039</a></p>
<p>Insulitis is a characteristic inflammatory lesion consisting of immune cell infiltrates around and within the pancreatic islets of patients with recent-onset type 1 diabetes (T1D). The infiltration is typically mild, both in terms of the number of infiltrating cells and the number of islets affected. Here, we present an unusual histopathological case study of a 66-year-old female patient with long-standing T1D, insulitis, and islet-associated lymphoid tissue. Most islets in the head of the pancreas of this patient were insulin-deficient, whereas the islets in the tail appeared normal. Insulitis was present in 0.84% of the insulin-containing islets and three islets had large lymphocytic infiltrates resembling tertiary lymphoid structures (TLS). Of note, this is the first description of potential TLS in the endocrine pancreas of a patient with T1D. Their association with a marked residual beta cell mass is of interest and may hint at new insights into disease progression and regulation of autoimmunity.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02915-4" class="uri">https://doi.org/10.1007/s00428-020-02915-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A case report of pancreatic panniculitis due to acute pancreatitis with intraductal papillary mucinous neoplasm</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):286</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32831035" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32831035</a></p>
<p>BACKGROUND: Pancreatic panniculitis is a rare skin manifestation in pancreatic disease patients that most frequently develops on the lower legs. We report the unique case of a 68-year-old man who suffered from pancreatic panniculitis on his trunk associated with acute pancreatitis due to an intraductal papillary mucinous neoplasm. CASE PRESENTATION: A 68-year-old man complained of a 2-day history of a tender subcutaneous nodule on his trunk. Laboratory tests and abdominal contrast computed tomography were consistent with acute pancreatitis due to an intraductal papillary mucinous neoplasm. A skin biopsy of the nodule histologically displayed lobular panniculitis with characteristic “ghost cells”, which indicated pancreatic panniculitis. CONCLUSIONS: In order to avoid a missed or delayed diagnosis, clinicians should bear in mind that pancreatic panniculitis can be the first manifestation of pancreatic disease when encountering subcutaneous nodules on the trunk.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01430-9" class="uri">https://doi.org/10.1186/s12876-020-01430-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic duct guidewire placement for biliary cannulation as a risk factor for stone residue after endoscopic transpapillary stone removal</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):285</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32831030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32831030</a></p>
<p>BACKGROUND: Recent improvements in stone extraction implements and apparatus have lessened the complexity of the endoscopic bile duct stone treatment. However, despite confirmation of complete removal, cases of residual stones have been reported, which can result in recurrent biliary symptoms, cholangitis, and pancreatitis and considerably increase cost given the need for repeat imaging and/or procedures. To date, risk factors for residual bile duct stones following endoscopic retrograde cholangiopancreatography (ERCP) extraction have not been thoroughly evaluated. This study retrospectively investigated the incidence and risk factors of residual bile duct stones following extraction via ERCP. METHODS: We retrospectively reviewed all ERCP cases that underwent endoscopic bile duct stone extraction between April 2014 and March 2019. A total of 505 patients were enrolled and evaluated for the incidence and risk factors of residual bile duct stones after ERCP. RESULTS: The rate of residual stones was 4.8% (24/505). Residual stones were detected by computed tomography (12/24) or magnetic resonance cholangiopancreatography (12/24). In univariate analyses, a large number of stones (P = 0.01), long procedure time (P = 0.005), and performance of the pancreatic duct guidewire placement method (P-GW) for selective bile duct cannulation (P = 0.01) were the factors involved in residual stones. In multiple logistic regression analysis, performing P-GW was retained as the only independent factor of residual stones (adjusted odds ratio, 3.44; 95% CI, 1.19-9.88; P = 0.02). CONCLUSIONS: When removing bile duct stones with a pancreatic guidewire in place, paying attention to residual stones is necessary.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01428-3" class="uri">https://doi.org/10.1186/s12876-020-01428-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1442-1450</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32830034" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32830034</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. Gemcitabine and doxorubicin are commonly used as the chemotherapy agents, but most of PDAC tumors eventually acquired resistance to chemotherapy. Accumulating evidence indicates that Insulin-like growth factor binding protein 3 (IGFBP-3) plays a key role against tumor growth but its expression has commonly suppressed. The present study was designed to evaluate IGFBP-3 effects in chemotherapy sensitization of PDAC cells. Here, we report that the re-sensitization of chemoresistant PDAC cells was occurred by IGFBP-3 through recruitment of its death receptor (IGFBP-3R). Using gemcitabine, doxorubicin-resistant PDAC cell lines, we found that IGFBP-3 sensitized chemoresistant cells by activating apoptosis (as evaluated by Bax up-regulation, Bcl-2 down-regulation as well as Caspase-3 and Caspase 8 activation). IGFBP-3R was also found to have higher expression level in resistant AsPc-1 and MIA PaCa-2 cells in comparison to parental cells. IGFBP-3R was also highly expressed in PDAC tumor which exposed to chemotherapy in comparison to un-treated PDAC tumors. In addition, we confirmed our finding by using specific siRNA to knocking down of IGFBP-3R which prevents IGFBP-3 Chemosensitization. Taken together, the present study for the first time indicates the clinical relevance for combining IGFBP-3 with chemotherapy to reduce chemoresistance in PDAC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.406" class="uri">https://doi.org/10.1016/j.pan.2020.07.406</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The occurrence of prion protein in surgically resected pancreatic adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1218-1225</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32828686" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32828686</a></p>
<p>BACKGROUND: Among the several new targets for the comprehension of the biology of pancreatic ductal adenocarcinoma (PDAC), Prion proteins (PrPc) deserve particular mention, since they share a marked neurotropism. Actually, PrPc could have also a role in tumorigenesis, as recently demonstrated. However, only few in vitro studies in cell cultures showed the occurrence of PrPc in PDAC cells. We aim to evaluate the presence of PrPc in vivo in PDAC tissues as a potential new biomarker. METHODS: Samples from tumors of 23 patients undergone pancreatic resections from July 2018 to May 2020 at our institution were collected and analyzed. Immunohistochemistry and western blotting of PDAC tissues were compared with control tissues. Immunohistochemistry was used also to evaluate the localization of PrPc and of CD155, a tumoral stem-cell marker. RESULTS: All cases were moderately differentiated PDAC, with perineural invasion (PNI) in 19/23 cases (83%). According to western-blot analysis, PrPc was markedly expressed in PDAC tissues (273.5 ± 44.63 OD) respect to controls (100 ± 28.35 OD, p = 0.0018). Immunohistochemistry confirmed these findings, with higher linear staining of PrPc in PDAC ducts (127.145 ± 7.56 μm vs 75.21 ± 5.01 μm, p &lt; 0.0001). PrPc and CD155 exactly overlapped in ductal tumoral cells, highlighting the possible relationship of PrPc with cancer stemness. Finally, PrPc expression related with cancer stage and there was a potential correspondence with PNI. CONCLUSIONS: Our work provides evidence for increased levels of PrPc in PDAC. This might contribute to cancer aggressiveness and provides a potentially new biomarker. Work is in progress to decipher clinical implications.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.004" class="uri">https://doi.org/10.1016/j.pan.2020.08.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32826389" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32826389</a></p>
<p>OBJECTIVE: The primary objective of this study was to identify novel genes that predispose people in the Japanese population to FPC. SUMMARY OF BACKGROUND DATA: Familial history of pancreatic cancer is an important risk factor but, to date, few genes predisposing individuals to increased risk of developing FPC have been identified. METHODS: We performed whole-exome sequencing of germline DNA from 81 Japanese FPC patients. We also investigated somatic gene alterations in 21 matched tumor tissues through whole-exome sequencing and copy number analysis. RESULTS: Our germline variants identified previously known FPC susceptibility genes such as ATM and BRCA2, and several novel tumor suppressor genes with potentially deleterious variants for FPC. Interestingly, somatic whole-exome analysis demonstrated that most tumor samples with suspicious loss of heterozygosity of candidate genes were KRAS wild-types, implying that these cases may not have required KRAS activation as a driver event for carcinogenesis. CONCLUSIONS: Our findings indicate that FPC patients harbor potentially deleterious causative germline variants in tumor suppressor genes, which are known to acquire somatic mutations in pancreatic cancer, and that somatic loss of heterozygosity of some FPC susceptibility genes may contribute to the development of FPC in the absence of somatic KRAS-activating mutation. Genetic testing for a wider variety of FPC-predisposition genes could provide better screening approach for high-risk groups of pancreatic cancer.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004213" class="uri">https://doi.org/10.1097/SLA.0000000000004213</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4�� and SIX1/4</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32826305" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32826305</a></p>
<p>OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival of less than 5%. Transcriptomic analysis has identified two clinically relevant molecular subtypes of PDAC: classical and basal-like. The classical subtype is characterised by a more favourable prognosis and better response to chemotherapy than the basal-like subtype. The classical subtype also expresses higher levels of lineage specifiers that regulate endodermal differentiation, including the nuclear receptor hepatocyte nuclear factor 4 α (HNF4α). The objective of this study is to evaluate the role of HNF4α, SIX4 and SIX1 in regulating the growth and molecular subtype of PDAC. DESIGN: We manipulate the expression of HNF4α, SIX4 and SIX1 in multiple in vitro and in vivo PDAC models. We determine the consequences of manipulating these genes on PDAC growth, differentiation and molecular subtype using functional assays, gene expression analysis and cross-species comparisons with human datasets. RESULTS: We show that HNF4α restrains tumour growth and drives tumour cells toward an epithelial identity. Gene expression analysis of murine models and human tumours shows that HNF4α activates expression of genes associated with the classical subtype. HNF4α also directly represses SIX4 and SIX1, two mesodermal/neuronal lineage specifiers expressed in the basal-like subtype. Finally, SIX4 and SIX1 drive proliferation and regulate differentiation in HNF4α-negative PDAC. CONCLUSION: Our data show that HNF4α regulates the growth and molecular subtype of PDAC by multiple mechanisms, including activation of the classical gene expression programme and repression of SIX4 and SIX1, which may represent novel dependencies of the basal-like subtype.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2020-321316" class="uri">https://doi.org/10.1136/gutjnl-2020-321316</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prehabilitation prior to surgery for pancreatic cancer: A systematic review</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1243-1250</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32826168" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32826168</a></p>
<p>INTRODUCTION: Prehabilitation aims to improve fitness and outcomes of patients undergoing major surgery. This systematic review aimed to appraise current available evidence regarding the role of prehabilitation in patients undergoing oncological pancreatic resection. METHODS: A systematic literature search of PUBMED, MEDLINE, EMBASE databases identified articles describing prehabilitation programmes before pancreatic resection for malignancy. Data collected included timing of prehabilitation, programme type, duration, adherence and post-operative outcome reporting. RESULTS: Six studies, including 193 patients were included in the final analysis. Three studies included patients undergoing neoadjuvant therapy followed by resection and 3 studies included patients undergoing upfront resection. Time from diagnosis to surgery ranged between 2 and 22 weeks across all studies. Two studies reported a professionally supervised exercise programme, and four described unsupervised programmes. Exercise programmes varied from 5 days to 6 months in duration. Adherence to exercise programmes was better with supervised programmes (99% reaching weekly activity goal vs 85%) and patients not undergoing neoadjuvant therapy (90% reaching weekly activity goal vs 82%). All studies reported improvement in muscle mass or markers of muscle function following prehabilitation. Two studies reported the impact of Prehabilitation on postoperative outcomes and Prehabilitation was associated with lower delayed gastric emptying and a shorter hospital stay with no impact on other postoperative outcomes. CONCLUSION: Early evidence demonstrates that Prehabilitation programmes may improve postoperative outcomes following pancreatic surgery. However current Prehabilitaton programmes for patients undergoing pancreatic resection report diverse exercise regimens with no consensus regarding timing or length of Prehabilitation, warranting a need for standardisation of Prehabilitation programmes in pancreatic surgery.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.411" class="uri">https://doi.org/10.1016/j.pan.2020.07.411</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Gene of the month: TFE 3</strong></li>
</ul>
</summary>
<p><em>Journal of clinical pathology 2020 Nov;73(11):691-694</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32820043" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32820043</a></p>
<p>Transcription factor enhancer 3 (TFE3), on the short arm of chromosome Xp11.23 and its protein, belongs to the microphthalmia transcription family (MiTF) of transcription factors. It shares close homology with another member of the family, MiTF which is involved in melanocyte development. When a cell is stressed and/or starved, TFE3 protein translocates into the nucleus. TFE3 gene fusions with multiple different partner genes occur in several tumours with resultant nuclear expression of TFE3 protein. The main tumours associated with TFE3 gene fusions are: renal cell carcinoma, alveolar soft part sarcoma, a subset of epithelioid haemangioendotheliomas (EHE), some perivascular epithelioid cell tumours and rare examples of ossifying fibromyxoid tumour and malignant chondroid syringoma. TFE3 immunohistochemistry is of use in routine diagnostic practice with the aforementioned tumours harbouring TFE3 fusions leading to nuclear staining. In addition, there are tumours lacking TFE3 fusions but also display TFE3 nuclear immunolabeling, and these include: granular cell tumour, solid pseudopapillary neoplasm of the pancreas and ovarian sclerosing stromal tumour.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-206899" class="uri">https://doi.org/10.1136/jclinpath-2020-206899</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic volume does not correlate with histologic fibrosis in adult patients with recurrent acute and chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1078-1084</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32819846" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32819846</a></p>
<p>OBJECTIVES: Reduced pancreatic volume, often referred to as atrophy, is a commonly reported imaging feature of chronic pancreatitis (CP). This study evaluated whether there is an association between pancreatic volume and fibrosis, the criterion standard of CP, in patients undergoing total pancreatectomy with islet autotransplantation (TPIAT) for recurrent acute pancreatitis (RAP) and CP. METHODS: All adult patients who underwent TPIAT between 2010 and 2019 were categorized into 3 groups: RAP, definite CP and indeterminate CP. Pancreatic volume was calculated by summing up the areas from each thin section of the pancreas on 3D CT imaging. Excisional biopsies of the pancreatic head as well as body/tail region were obtained at the time of TPIAT. Two different fibrosis scores were used for histologic assessment. RESULTS: A total of 16, 29 and 15 patients underwent TPIAT for RAP, definite CP and indeterminate CP, respectively. The mean pancreatic volumes for patients with RAP, definite CP and indeterminate CP were 65.7 ± 28.5 cc, 54.9 ± 22.9 cc and 61.8 ± 23.6 cc, respectively (p = 0.3). The mean fibrosis scores were significantly higher in patients with definite CP compared to RAP (p &lt; 0.001) and indeterminate CP (p &lt; 0.001). Pancreatic volume was not associated with either fibrosis score after adjusting for age, gender, duration of disease, BMI and diabetes in the multivariable analysis. CONCLUSIONS: While the fibrosis scores were higher in definite CP compared to both RAP and indeterminate CP, there was no correlation between pancreatic volume and fibrosis. This suggests that atrophy alone cannot be used to diagnose CP.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.409" class="uri">https://doi.org/10.1016/j.pan.2020.07.409</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1205-1212</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32819845" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32819845</a></p>
<p>BACKGROUND: This study aimed to assess the prognostic values of preoperative maximum standardized uptake value (SUVmax) of primary pancreatic tumors and Glut-1 expression in patients with resectable pancreatic ductal adenocarcinoma (R-PDAC), and to investigate whether Glut-1 expression is more effective than SUVmax in predicting survival in patients with R-PDAC. METHODS: We investigated 101 R-PDAC patients who underwent pancreatectomy for pancreatic cancer treatment. SUVmax analyzed through 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT), and Glut-1 expression, were assessed for predicting the prognosis of patients with R-PDAC. RESULTS: In patients with R-PDAC, the high SUVmax group (≥4.25) had significantly shorter overall survival (OS) and disease-free survival (DFS) than the low SUVmax group (＜4.25). Surprisingly, Glut-1 expression was not significantly correlated with SUVmax. Moreover, the high Glut-1 expression group, which was related to higher levels of CA 19-9, had significantly shorter OS and DFS than the low Glut-1 expression group. Furthermore, among the high SUVmax group, OS and DFS were significantly shorter in the high Glut-1 expression group. Multivariate analyses revealed that Glut-1 overexpression was an independent prognostic factor in patients with R-PDAC. Glut-1 knockdown also induced cell cycle arrest in PDAC cells in vitro. CONCLUSIONS: The study determined that Glut-1 overexpression is a more powerful prognostic factor than SUVmax for predicting OS and higher risk of recurrence in R-PDAC patients. Glut-1 overexpression is also more likely to be associated with malignant activity in PDAC patients.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.407" class="uri">https://doi.org/10.1016/j.pan.2020.07.407</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Risk of malignancy in small pancreatic cysts decreases over time</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1213-1217</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32819844" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32819844</a></p>
<p>BACKGROUND: Pancreatic cysts &lt;15 mm without worrisome features have practically no risk of malignancy at the time of diagnosis but this can change over time. Optimal duration of follow-up is a matter of debate. We evaluated predictors of malignancy and attempted to identify a time to safely discontinue surveillance. METHODS: Bi-centric study utilizing prospectively collected databases of patients with pancreatic cysts measuring &lt;15 mm and without worrisome features who underwent surveillance at the Massachusetts General Hospital (1988-2017) and at the University of Verona Hospital Trust (2000-2016). The risk of malignant transformation was assessed using the Kaplan-Meier method and parametric survival models, and predictors of malignancy were evaluated using Cox regression. RESULTS: 806 patients were identified. Median follow-up was 58 months (6-347). Over time, 58 (7.2%) cysts were resected and of those, 11 had high grade dysplasia (HGD) or invasive cancer. Three additional patients had unresectable cancer for a total rate of malignancy of 1.7%. Predictors of development of malignancy included an increase in size ≥2.5 mm/year (HR = 29.54, 95% CI: 9.39-92.91, P &lt; 0.001) and the development of worrisome features (HR = 9.17, 95% CI: 2.99-28.10, P = 0.001). Comparison of parametric survival models suggested that the risk of malignancy decreased after three years of surveillance and was lower than 0.2% after five years. CONCLUSIONS: Pancreatic cysts &lt;15  mm at the time of diagnosis have a very low risk of malignant transformation. Our findings indicate the risk decreases over time. Size increase of ≥2.5 mm/year is the strongest predictor of malignancy.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.003" class="uri">https://doi.org/10.1016/j.pan.2020.08.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Comparison of surgical outcomes between isolated pancreaticojejunostomy, isolated gastrojejunostomy, and conventional pancreaticojejunostomy after pancreaticoduodenectomy: a systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):279</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32819274" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32819274</a></p>
<p>BACKGROUND: We aimed to compare the safety and effectiveness of the following procedures after pancreaticoduodenectomy: isolated pancreaticojejunostomy, isolated gastrojejunostomy, and conventional pancreaticojejunostomy. METHODS: We performed a systematic search of the following databases: PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov until 1 January 2020. Pooled odds ratios (OR) or weighted mean differences (WMD) with 95% confidence intervals (CIs) were calculated using STATA 12.0 statistical software. RESULTS: Thirteen studies involving 1942 patients were included in this study. Pooled analysis showed that reoperation rates following isolated pancreaticojejunostomy were lower reoperation than with conventional pancreaticojejunostomy (OR = 0.36, 95% CI: 0.15-0.86, p = 0.02, respectively), and that isolated pancreaticojejunostomy required longer operation time vs conventional pancreaticojejunostomy (WMD = 43.61, 95% CI: 21.64-65.58, P = 0.00). Regarding postoperative pancreatic fistula, clinically-relevant postoperative pancreatic fistula, delayed gastric emptying, clinically-relevant delayed gastric emptying, bile leakage, hemorrhage, reoperation, length of postoperative hospital stay, major complications, overall complications, and mortality, we found no significant differences for either isolated pancreaticojejunostomy versus conventional pancreaticojejunostomy or isolated gastrojejunostomy versus conventional pancreaticojejunostomy. CONCLUSIONS: This study showed that isolated pancreaticojejunostomy was associated with a lower reoperation rate, but required longer operation time vs conventional pancreaticojejunostomy. Considering the limitations, high-quality randomized controlled trials are required.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01415-8" class="uri">https://doi.org/10.1186/s12876-020-01415-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Oct;26(20):5462-5476</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32816949" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32816949</a></p>
<p>PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is associated with heterogeneous responses. EXPERIMENTAL DESIGN: We performed a seven-arm preclinical trial consisting of 471 mice, representing 12 unique PDAC patient-derived xenografts, of which nine were gBRCA mutated. From 179 patients whose PDAC was whole-genome and transcriptome sequenced, we identified 21 cases with homologous recombination deficiency (HRD), and investigated prognostic biomarkers. RESULTS: We found that biallelic inactivation of BRCA1/BRCA2 is associated with genomic hallmarks of HRD and required for cisplatin and talazoparib (PARPi) sensitivity. However, HRD genomic hallmarks persisted in xenografts despite the emergence of therapy resistance, indicating the presence of a genomic scar. We identified tumor polyploidy and a low Ki67 index as predictors of poor cisplatin and talazoparib response. In patients with HRD PDAC, tumor polyploidy and a basal-like transcriptomic subtype were independent predictors of shorter survival. To facilitate clinical assignment of transcriptomic subtype, we developed a novel pragmatic two-marker assay (GATA6:KRT17). CONCLUSIONS: In summary, we propose a predictive and prognostic model of gBRCA-mutated PDAC on the basis of HRD genomic hallmarks, Ki67 index, tumor ploidy, and transcriptomic subtype.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1439" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1439</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32816920" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32816920</a></p>
<p>OBJECTIVE: Adaptive immune resistance mediated by the cytokine interferon gamma (IFNG) still constitutes a major problem in cancer immunotherapy. We develop strategies for overcoming IFNG-mediated adaptive immune resistance in pancreatic ductal adenocarcinoma cancer (PDAC). DESIGN: We screened 429 kinase inhibitors for blocking IFNG-induced immune checkpoint (indoleamine 2,3-dioxygenase 1 (IDO1) and CD274) expression in a human PDAC cell line. We evaluated the ability of the cyclin-dependent kinase (CDK) inhibitor dinaciclib to block IFNG-induced IDO1 and CD274 expression in 24 human and mouse cancer cell lines as well as in primary cancer cells from patients with PDAC or ovarian carcinoma. We tested the effects of dinaciclib on IFNG-induced signal transducer and activator of transcription 1 activation and immunological cell death, and investigated the potential utility of dinaciclib in combination with IFNG for pancreatic cancer therapy in vivo, and compared gene expression levels between human cancer tissues with patient survival times using the Cancer Genome Atlas datasets. RESULTS: Pharmacological (using dinaciclib) or genetic (using shRNA or siRNA) inactivation of CDK1/2/5 not only blocks JUN-dependent immune checkpoint expression, but also triggers histone-dependent immunogenic cell death in immortalised or primary cancer cells in response to IFNG. This dual mechanism turns an immunologically ‘cold’ tumour microenvironment into a ‘hot’ one, dramatically improving overall survival rates in mouse pancreatic tumour models (subcutaneous, orthotopic and transgenic models). The abnormal expression of CDK1/2/5 and IDO1 was associated with poor patient survival in several cancer types, including PDAC. CONCLUSION: CDK1/2/5 kinase activity is essential for IFNG-mediated cancer immunoevasion. CDK1/2/5 inhibition by dinaciclib provides a novel strategy to overcome IFNG-triggered acquired resistance in pancreatic tumour immunity.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-320441" class="uri">https://doi.org/10.1136/gutjnl-2019-320441</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Diagnosis of pancreatic solid pseudopapillary neoplasms using cell-blocks and immunohistochemical evaluation of endoscopic ultrasound-guided fine needle aspiration biopsy specimens</strong></li>
</ul>
</summary>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32816310" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32816310</a></p>
<p>INTRODUCTION: Preoperative diagnostic imaging of pancreatic solid pseudopapillary neoplasms (SPNs) is challenging. A few studies have investigated the role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for the diagnosis of SPN. We investigated the diagnostic yield of cell-blocks and immunohistochemistry (IHC) for SPN using EUS-FNA specimens without cytological evaluation. PATIENTS AND METHODS: We retrospectively analysed the histopathology records of patients with suspected SPN, who underwent EUS-FNA biopsy between January 1997 and January 2020. Diagnosis based on cell-blocks (haematoxylin-eosin staining with complementary IHC) was compared with the definitive surgical diagnosis. RESULTS: This study included 25 patients (24 were women). Patients’ mean age was 33.7 years (range 12-78 years). The most common symptom was abdominal pain. SPN was an incidental finding in 52% of the patients. The mean lesion size was 4.3 cm (range 1.2-11.4 cm), and the most common endosonographic features included solid-cystic (56%) or solid (40%) tumours. Final diagnoses included SPNs (n = 23) and non-functioning neuroendocrine tumours (n = 2). The overall accuracy of EUS-FNA was 80%. Tumour cells showed immunopositivity for β-catenin, CD10, CD99 and progesterone receptor (PR) in 93.7%, 87.5%, 83.3% and 66.6% of patients, respectively. No SPN showed immunopositivity for chromogranin A. CONCLUSIONS: Intention-to-diagnose analysis showed that the diagnostic accuracy of EUS-FNA for SPNs using cell blocks and complementary IHC without cytological evaluation was fairly good. Evaluation of β-catenin, CD 10, CD99 and PR expression must be included in the IHC panel for diagnostic confirmation of SPNs using EUS-FNA biopsy specimens.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12905" class="uri">https://doi.org/10.1111/cyt.12905</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes</strong></li>
</ul>
</summary>
<p><em>The New England journal of medicine 2020 08;383(8):721-732</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32813948" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32813948</a></p>
<p>BACKGROUND: Some studies have suggested that in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on metabolic function that are independent of weight loss. METHODS: We evaluated metabolic regulators of glucose homeostasis before and after matched (approximately 18%) weight loss induced by gastric bypass (surgery group) or diet alone (diet group) in 22 patients with obesity and diabetes. The primary outcome was the change in hepatic insulin sensitivity, assessed by infusion of insulin at low rates (stages 1 and 2 of a 3-stage hyperinsulinemic euglycemic pancreatic clamp). Secondary outcomes were changes in muscle insulin sensitivity, beta-cell function, and 24-hour plasma glucose and insulin profiles. RESULTS: Weight loss was associated with increases in mean suppression of glucose production from baseline, by 7.04 μmol per kilogram of fat-free mass per minute (95% confidence interval [CI], 4.74 to 9.33) in the diet group and by 7.02 μmol per kilogram of fat-free mass per minute (95% CI, 3.21 to 10.84) in the surgery group during clamp stage 1, and by 5.39 (95% CI, 2.44 to 8.34) and 5.37 (95% CI, 2.41 to 8.33) μmol per kilogram of fat-free mass per minute in the two groups, respectively, during clamp stage 2; there were no significant differences between the groups. Weight loss was associated with increased insulin-stimulated glucose disposal, from 30.5±15.9 to 61.6±13.0 μmol per kilogram of fat-free mass per minute in the diet group and from 29.4±12.6 to 54.5±10.4 μmol per kilogram of fat-free mass per minute in the surgery group; there was no significant difference between the groups. Weight loss increased beta-cell function (insulin secretion relative to insulin sensitivity) by 1.83 units (95% CI, 1.22 to 2.44) in the diet group and by 1.11 units (95% CI, 0.08 to 2.15) in the surgery group, with no significant difference between the groups, and it decreased the areas under the curve for 24-hour plasma glucose and insulin levels in both groups, with no significant difference between the groups. No major complications occurred in either group. CONCLUSIONS: In this study involving patients with obesity and type 2 diabetes, the metabolic benefits of gastric bypass surgery and diet were similar and were apparently related to weight loss itself, with no evident clinically important effects independent of weight loss. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT02207777.).</p>
<p>doi: <a href="https://doi.org/10.1056/NEJMoa2003697" class="uri">https://doi.org/10.1056/NEJMoa2003697</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin</strong></li>
</ul>
</summary>
<p><em>Endocrine pathology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32813226" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32813226</a></p>
<p>Neuroendocrine neoplasms (NENs) have traditionally been identified via expression of proteins associated to the regulation of secretory vesicles and granules. We report the clinical usage of the “second-generation” proteins ISL LIM homeobox 1 (ISL1), INSM transcriptional repressor 1 (INSM1), and secretagogin (SECG) as immunohistochemical markers of neuroendocrine differentiation since their introduction in clinical routine and compare the results with the established proteins chromogranin A (CGA) and synaptophysin (SYP). In total, 161 tumors, including 139 NENs and 22 “non-NENs” (unrelated tumors with an initial suspicion of NEN), were informatively stained for ISL1, and subsets were also interrogated for INSM1 and/or SECG. Diffuse or focal positive immunoreactivity was noted for ISL1 in 91/139 NENs (65%) and in 6/22 (27%) non-NENs, for INSM1 in 76/85 NENs (89%) and in 2/5 (40%) non-NENs, and for SECG in 49 out of 64 NENs (77%) and in 0/5 non-NENs (0%). Generally, ISL1, INSM1, and SECG exhibited sensitivities in line with or slightly below that of CGA and SYP-largely attributable to tissue-specific patterns regarding tumoral origin. Moreover, for pancreatic and small intestinal NENs, the two largest subgroups, ISL1 staining results were consistent irrespectively of tumor source and WHO grade. We verify previously suggested immunohistochemical schemes of neuroendocrine markers of first- and second-generations to facilitate the diagnostic process for NENs and confirm that the second-generation neuroendocrine markers display tissue-specific patterns. We therefore recommend their implementation in tertiary endocrine pathology centers, not least to aid in the identification of primary tumors when analyzing metastases.</p>
<p>doi: <a href="https://doi.org/10.1007/s12022-020-09645-y" class="uri">https://doi.org/10.1007/s12022-020-09645-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Left-sided portal hypertension caused by peripancreatic lymph node tuberculosis misdiagnosed as pancreatic cancer: a case report and literature review</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):276</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32811429" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32811429</a></p>
<p>BACKGROUND: Left-sided portal hypertension (LSPH) is an extremely rare clinical syndrome, and it is the only form of curable portal hypertension. It is primarily caused by pancreatic disease, and is associated with complications that cause spleen vein compression. Specific symptoms are often lacking, rendering it difficult to diagnose. Splenectomy is the main treatment for cases complicated by variceal bleeding, and the effects of treatment primarily depend on the condition of the primary disease. CASE PRESENTATION: The patient was a 29-year-old woman who was admitted to the hospital for repeated hematemesis and black stool. She had been misdiagnosed with pancreatic cancer 7 years prior. Combined imaging and endoscopic examination indicated varicose gastric fundus veins, a pancreatic mass, and enlarged peripancreatic lymph nodes. Laboratory investigations revealed reduced erythrocyte, platelet, and leukocyte counts, the interferon gamma release assay was positive, and liver function was normal. Abdominal exploration, splenectomy, varicose vein dissection, and lesion resection were performed via laparotomy. Postoperative biopsy analysis confirmed the diagnosis of lymph node tuberculosis. Based on the above-described factors, LSPH caused by peripancreatic lymph node tuberculosis was a diagnosed. CONCLUSIONS: Herein we describe the first reported case of LSPH caused by peripancreatic lymph node tuberculosis. When left portal hypertension occurs simultaneously, peripancreatic lymph node tuberculosis is often misdiagnosed as pancreatic cancer. Further studies are necessary to develop a more favorable diagnostic method for pancreas masses and more advantageous therapy for LSPH, especially in cases caused by mechanical compression.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01420-x" class="uri">https://doi.org/10.1186/s12876-020-01420-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32804325" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32804325</a></p>
<p>BACKGROUND: The prediction of prognostic outcomes can provide the most suitable strategy for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate the clinical value of the preoperative tumor marker index (pre-TI) in predicting prognostic outcomes after resection for PDAC. METHODS: For 183 patients who underwent pancreatic resection of PDAC, adjusted carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), pancreatic cancer-associated antigen-2 (DUpan-2), and s-pancreas-1 antigen (SPan-1) were retrospectively evaluated, and the positive number of these markers was scored as the pre-TI. RESULTS: A high pre-TI (≥ 2) was significantly associated with a larger tumor and lymph node metastases, and the patients with a high pre-TI had worse prognostic outcomes in terms of both relapse-free survival (RFS) (P &lt; 0.0001, log-rank) and overall survival (OS) (P &lt; 0.0001, Λlog-rank) than the patients with a low pre-TI. The pre-TI was one of the independent factors of a poor prognosis for RFS (hazard ratio [HR], 2.36; P &lt; 0.0001) and OS (HR, 2.27; P &lt; 0.0001). In addition, even for the patients with normal adjusted CA19-9 values (n = 74, 40.4%), those with the high pre-TI had a significantly poorer prognosis than those with a low pre-TI (RFS: P = 0.002, log-rank; OS: P = 0.031, log-rank). CONCLUSIONS: The pre-TI could be a potent predictive marker of prognostic outcomes for patients with resections for PDAC. Patients with a high pre-TI may need additional strategies to improve their prognosis.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09022-3" class="uri">https://doi.org/10.1245/s10434-020-09022-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32803553" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32803553</a></p>
<p>BACKGROUND: Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection. This study aimed primarily to evaluate these hypotheses in a contemporary patient cohort treated with multimodality therapy. METHODS: The clinicopathologic and perioperative characteristics of consecutive resected PDAC patients (July 2011 to October 2018) were analyzed from a prospectively maintained database. Intraoperative administration of dexamethasone (4-10 mg) was retrospectively abstracted from the electronic medical record. RESULTS: The majority of 373 patients (59.8%) received intraoperative dexamethasone. Most of these patients underwent neoadjuvant therapy (75.3%), were potentially resectable at presentation (69.7%), and underwent pancreaticoduodenectomy (79.9%). Women were more likely to receive dexamethasone than men (69.9 vs 30.1%; p &lt; 0.001). The cohorts were otherwise clinically similar. Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39). Dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90). After adjustment for clinical factors including margin status, clinical classification, tumor size, and dexamethasone, the only factors independently associated with OS were pathologic node-positivity (hazard ratio [HR], 1.80, 95% confidence interval [CI], 1.32-2.47), perineural invasion (HR, 2.02; 95% CI, 1.23-3.31), multimodality therapy (HR, 0.30; 95% CI, 0.13-0.70), and PMCs (HR, 1.64; 95% CI, 1.17-2.29) (all p &lt; 0.006). CONCLUSIONS: Dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit. Tumor biology, multimodality therapy, and PMCs remain the main prognostic factors after PDAC resection.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09013-4" class="uri">https://doi.org/10.1245/s10434-020-09013-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1092-1102</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800653" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800653</a></p>
<p>INTRODUCTION: The Food and Drug Administration in 2006 required that all pancreatic enzyme products demonstrate bioavailability of lipase, amylase, and protease in the proximal small intestine. METHODS: In this phase I open-label, randomized, crossover trial, 17 adult chronic pancreatitis (CP) patients with severe exocrine pancreatic insufficiency (EPI) underwent two separate gastroduodenal perfusion procedures (Dreiling tube suctioning and [14C]-PEG instillation by an attached Dobhoff tube in the duodenal bulb). Patients received Ensure Plus® alone and Ensure Plus with Zenpep (75,000 USP lipase units) in random order. The bioavailability of Zenpep was estimated by comparing the recovery of lipase, amylase, chymotrypsin activity in two treatment conditions. 14C-PEG was used to correct duodenal aspirates volume. The primary efficacy endpoint was lipase delivery in the duodenum after Zenpep administration under fed conditions. Secondary efficacy endpoints included chymotrypsin and amylase delivery, serum CCK levels, and measuring duodenal and gastric pH. RESULTS: Zenpep administration with a test meal was associated with significant increase in duodenal aspiration of lipase (p = 0.046), chymotrypsin (p = 0.008), and amylase (p = 0.001), compared to the test meal alone, indicating release of enzymes to the duodenum. Lipase delivery was higher in the pH subpopulation (the efficacy population with acid hypersecretors excluded) (p = 0.01). Recovery of [14C]-PEG was 61%. Zenpep was generally well tolerated. All adverse events were mild and transient. CONCLUSIONS: In CP patients with severe EPI, lipase, chymotrypsin and amylase were released rapidly into the duodenum after ingestion of Zenpep plus meal compared to meals alone. Results also reflected the known pH threshold for enzyme release from enteric coated products.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.007" class="uri">https://doi.org/10.1016/j.pan.2020.07.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The role of asparagine synthetase on nutrient metabolism in pancreatic disease</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1029-1034</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800652" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800652</a></p>
<p>The pancreas avidly takes up and synthesizes the amino acid asparagine (Asn), in part, to maintain an active translational machinery that requires incorporation of the amino acid. The de novo synthesis of Asn in the pancreas occurs through the enzyme asparagine synthetase (ASNS). The pancreas has the highest expression of ASNS of any organ, and it can further upregulate ASNS expression in the setting of amino acid depletion. ASNS expression is driven by an intricate feedback network within the integrated stress response (ISR), which includes the amino acid response (AAR) and the unfolded protein response (UPR). Asparaginase is a cancer chemotherapeutic drug that depletes plasma Asn. However, asparaginase-associated pancreatitis (AAP) is a major medical problem and could be related to pancreatic Asn depletion. In this review, we will provide an overview of ASNS and then describe its role in pancreatic health and in the exocrine disorders of pancreatitis and pancreatic cancer. We will offer the overarching perspective that a high abundance of ASNS expression is hardwired in the exocrine pancreas to buffer the high demands of Asn for pancreatic digestive enzyme protein synthesis, that perturbations in the ability to express or upregulate ASNS could tip the balance towards pancreatitis, and that pancreatic cancers exploit ASNS to gain a metabolic survival advantage.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.08.002" class="uri">https://doi.org/10.1016/j.pan.2020.08.002</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Disconnected pancreatic duct syndrome: Updated review on clinical implications and management</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1035-1044</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800651" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800651</a></p>
<p>Disconnected Pancreatic Duct Syndrome (DPDS) is an important but often overlooked complication of acute necrotising pancreatitis (ANP) that occurs due to necrosis of the main pancreatic duct (PD). This segmental necrosis leads on to disconnection between the viable upstream pancreatic parenchyma and the duodenum. The disconnected and functional segment of pancreas continues to secrete pancreatic juice that is not drained into the gastrointestinal tract and lead on to recurrent pancreatic fluid collections (PFC), refractory external pancreatic flstulae and chronic abdominal pain/recurrent pancreatitis. Because of lack of awareness of this important complication of ANP, the diagnosis of DPDS is usually delayed. The delay in diagnosis increases the morbidity of the disease as well as increase the cost of treatment and duration of hospital stay. Surgery has remained the cornerstone for management of patients with DPDS. The conventional surgical approaches have been either resection or internal drainage procedures. Surgery for DPDS in the setting of ANP is often difficult due to presence of local inflammation and extensive venous collaterals in the operative field due to splenic vein thrombosis and therefore is associated with significant morbidity. Advancement in therapeutic endoscopy, especially advent of therapeutic endoscopic ultrasound has opened an exciting new field of minimally invasive therapeutic options for management of DPDS. The present review discusses the current understanding of the clinical manifestations, imaging features and management strategies in patients with DPDS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.402" class="uri">https://doi.org/10.1016/j.pan.2020.07.402</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Vascular complications of chronic pancreatitis: A tertiary center experience</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1085-1091</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800648" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800648</a></p>
<p>INTRODUCTION: Vascular complications such as venous thrombosis (VT) and pseudoaneurysm are not uncommon in patients with chronic pancreatitis (CP). The aim of this study to was to evaluate the prevalence and risk factors for vascular complications in patients with CP. METHODS: A retrospective analysis of a prospectively maintained database of patients with CP presenting from January 2002 to August 2019 was performed. Venous thrombosis and pseudoaneurysm were identified using radiological imaging, and their risk factors were identified using multivariate Cox-proportional hazards. RESULTS: Of 1363 patients with CP, 166 (12.2%) had vascular complications. Isolated VT was present in 132, pseudoaneurysm in 17, and both in 17 patients. They were more commonly seen in males and alcoholic CP (ACP), and less commonly in patients with pancreatic atrophy and calcification. It involved the vessels in the closest proximity to the pancreas, VT most commonly involving the splenic vein whereas pseudoaneurysm most commonly involved the splenic artery. Alcoholic CP [odds ratio (OR) 2.1, p = 0.002], pseudocyst (OR 4.6, p &lt; 0.001) and inflammatory head mass (OR 3.1, p = 0.006) were independent risk factors for VT, whereas ACP (OR 3.49, p = 0.006) and pseudocyst (OR 3.2, p = 0.002) were independent risk factors for pseudoaneurysm. Gastrointestinal bleed occurred in 3.5% patients, and more commonly in patients with pseudoaneurysm than VT (64.7% vs 15.9%), and in patients with ACP in comparison to other etiologies (p &lt; 0.001). CONCLUSION: Vascular complications are a common complication of CP, VT being more frequent than pseudoaneurysm. Pseudocyst and ACP are independent risk factors for the development of vascular complications.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.005" class="uri">https://doi.org/10.1016/j.pan.2020.07.005</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A machine learning approach identified a diagnostic model for pancreatic cancer through using circulating microRNA signatures</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1195-1204</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800647" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800647</a></p>
<p>Late diagnosis of pancreatic cancer (PC) due to the limited effectiveness of modern testing approaches, causes many patients to miss the chance of surgery and consequently leads to a high mortality rate. Pivotal improvements in circulating microRNA expression levels in PC patients make it possible to diagnose and treat patients at earlier stages. A list of circulating miRNAs was identified in this study using bioinformatics methods in association with pancreatic cancer through analyzing four GEO microarray datasets. The value of top miRNAs was then assessed via using a machine learning method. Taking the advantage of a combinatorial approach consisting of Particle Swarm Optimization (PSO) + Artificial Neural Network (ANN) and Neighborhood Component Analysis (NCA) iterations on a collection of top differentially expressed circulating miRNAs in PC patients, facilitated ranking them by significance. MiRNA’s functional analysis in the final index was performed by predicting target genes and constructing PPI networks. Remarkably, the final model consist of miR-663a, miR-1469, miR-92a-2-5p, miR-125b-1-3p and miR-532-5p showed great diagnostic results on investigated cases and the validation set (Accuracy: 0.93, Sensitivity: 0.93, and Specificity: 0.92). Kaplan-Meier survival assessments of the top-ranked miRNAs revealed that three miRNAs, hsa-miR-1469, hsa-miR-663a and hsa-miR-532-5p, had meaningful associations with the prognosis of patients with pancreatic cancer. This miRNA index may serve as a non-invasive and potential PC diagnostic model, although experimental testing is needed.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.399" class="uri">https://doi.org/10.1016/j.pan.2020.07.399</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Value of repeated cytology for intraductal papillary mucinous neoplasms of the pancreas with high risk potential of malignancy: Is it a promising method for monitoring a malignant transformation?</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1164-1174</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800646" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800646</a></p>
<p>OBJECTIVES: The efficacy of and indications for cytological reexamination to detect malignant changes in branch duct type intraductal papillary mucinous neoplasms (BD-IPMNs) have not been studied in detail. We conducted a retrospective study to evaluate the efficacy and indications of cytological reexamination by using pancreatic juice (repeated cytology) for BD-IPMNs. METHODS: Forty-five patients who underwent repeated cytology after a diagnosis of benignancy by using initial cytology were recruited for this study. RESULTS: Thirty-eight patients, excluding 7 patients with lack of surveillance period after the final cytology, were classified into Malignancy (n = 13) and Benignancy groups (n = 25) on the bases of the findings from resected specimens or changes in BD-IPMNs after repeated cytology. The sensitivity and specificity to detect malignant changes in BD-IPMNs by using repeated cytology were 62% and 100%, respectively. For the 12 patients with mural nodules (MNs) ≥ 5 mm (67% of them were malignant), the sensitivity was 50%, whereas, for the 26 patients without MNs ≥ 5 mm (19% of them were malignant), it was 80%. In addition, malignant changes in BD-IPMNs after initial cytology occurred in 62% of the patients with changes in the MNs and 27% of the patients with an increase in the cyst size. CONCLUSION: Repeated cytology can play a role in the determination for surgery even after a diagnosis of benignancy by using initial cytology, especially for BD-IPMNs without MNs ≥5 mm. In addition, changes in the MNs or cyst size may be appropriate indications for repeated cytology.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.05.021" class="uri">https://doi.org/10.1016/j.pan.2020.05.021</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1149-1154</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800645" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800645</a></p>
<p>BACKGROUND: /Objectives: Pancreatic ductal adenocarcinoma (PDAC) has a higher incidence in men compared to women, although the difference in known risk factors cannot explain this disparity completely. Reproductive and hormonal factors have been demonstrated in pre-clinical studies to influence pancreatic carcinogenesis, but the few published data on the topic are inconsistent. The aim was to investigate the role of reproductive and hormonal factors on PDAC occurrence in women. METHODS: We conducted a unicenter case-control study; PDAC cases were matched to controls by age with a 1:2 ratio. Risk factors were screened through questionnaires about gynecologic and medical history. Comparisons were made using Chi-square and Fisher’s exact tests where appropriate for categorical variables and Student’s t-test for continuous variables. Logistic regression was used to calculate Odds Ratios (ORs) and their 95% confidence intervals (CI). Multivariable logistic regression models were adjusted for potential confounders. RESULTS: 253 PDAC and 506 matched controls were enrolled. At logistic regression multivariable analysis adjusted for confounding factors, older age at menopause (OR:0.95 per year; 95% CI:0.91-0.98; p = 0.007), use of Oral Contraceptives (OR:0.52; 95% CI:0.30-0.89; p = 0.018), use of Hormonal Replacement Therapy (OR:0.31; 95% CI:0.15-0.64; p = 0.001), and having had two children (OR:0.57; 95% CI:0.38-0.84; p = 0.005) were significant, independent protective factors for the onset of PDAC. CONCLUSIONS: These data confirm some previous findings on menopause age and number of births while, to our knowledge, this is the first study to show a protective effect of HRT and OC use. The results collectively support the hypothesis that exposure to estrogens plays a protective role towards PDAC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.398" class="uri">https://doi.org/10.1016/j.pan.2020.07.398</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1062-1068</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800575" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800575</a></p>
<p>BACKGROUND/OBJECTIVES: Patients with autoimmune pancreatitis (AIP) sometimes progress to chronic pancreatitis (CP). We evaluated the ability of corticosteroids to prevent the progression to CP. METHODS: We defined patients with definitive findings of CP (stones in the main pancreatic duct [MPD] or multiple pancreatic calcifications) as having severe calcification (SC). A total of 145 AIP patients were enrolled. We measured the duration between AIP diagnosis and SC development and retrospectively compared the time to SC development between patients with and without steroids. Multivariate analysis for factors associated with SC were performed. RESULTS: Nineteen (13%) patients progressed to SC. Since 95 patients had pancreatic head swelling and SC was found in these patients only, our analysis focused mainly on these at-risk populations. In Kaplan-Meier analysis limited to patients with pancreatic head swelling, the incidence of SC was significantly lower in patients with steroids than in those without (hazard ratio [HR] 0.18, 95% confidence interval [CI] 0.07-0.52; p &lt; 0.001). Multivariate testing of patients with pancreatic head swelling confirmed that steroid therapy was significantly associated with a lower incidence of SC (HR 0.11, 95% CI 0.03-0.34; p &lt; 0.001), while MPD dilation at AIP diagnosis was related to a higher incidence of SC (HR 4.02, 95% CI 1.43-11.7; p = 0.009). CONCLUSIONS: Corticosteroids appeared to prevent progression to CP in AIP patients, especially in those with pancreatic head swelling. Patients with both pancreatic head swelling and MPD dilation at diagnosis have a higher incidence of progression to CP. Steroid therapy is suggested for these high-risk cases.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.408" class="uri">https://doi.org/10.1016/j.pan.2020.07.408</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1155-1163</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800574" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800574</a></p>
<p>BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has substantial heterogeneity in biophysical features and in outcomes of patients. Identifying reliable pretreatment imaging biomarkers for PDAC with distant metastases (stage IV) is a key imperative. Our objective was to determine whether visual tumor enhancement pattern on enhanced computed tomography (CT) can be used as a prognostic factor in stage IV PDAC treated with chemotherapy. METHODS: This is a retrospective cohort study of 133 patients with stage IV PDAC who underwent multiphasic enhanced CT before systemic chemotherapy. The enhancement pattern of PDAC was qualitatively categorized as hypoattenuation, isoattenuation, or hyperattenuation on each of the pancreatic, portal venous, and delayed phases. The effects of clinical prognostic factors and the visual tumor enhancement pattern on progression-free survival (PFS) and overall survival (OS) were assessed in univariate and multivariate analyses using Cox proportional hazards models. RESULTS: On univariate analysis, the number of metastatic organs and the visual tumor enhancement pattern during the delayed phase were significantly associated with PFS (p = 0.003 and &lt; 0.001, respectively) and OS (p = 0.005 and &lt; 0.001, respectively). Multivariate analysis identified the number of metastatic organs (PFS, p = 0.021; OS, p = 0.041) and visual tumor enhancement pattern during the delayed phase (PFS, p &lt; 0.001; OS, p &lt; 0.001) as independent predictors of PFS and OS. CONCLUSION: Visual enhancement pattern of PDAC on delayed phase enhanced CT appears to be associated with outcomes and could be a useful prognostic factor in stage IV PDAC, despite the need to add the delayed phase to CT protocol for pancreatic disease.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.009" class="uri">https://doi.org/10.1016/j.pan.2020.07.009</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pathological assessment of tumour regression following neoadjuvant therapy in pancreatic carcinoma</strong></li>
</ul>
</summary>
<p><em>Pathology 2020 Oct;52(6):621-626</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800331" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800331</a></p>
<p>Pancreatic carcinoma is a relatively common malignancy with an overall poor prognosis which is somewhat improved in those patients for whom resection and adjuvant therapy is feasible. In recent years there has been a trend to administering neoadjuvant therapy (combination chemotherapy and/or chemoradiotherapy), followed by resection in patients who remain surgical candidates at the completion of this treatment. Advantages of a neoadjuvant approach may include greater likelihood of achieving complete resection with negative surgical margins, reduced treatment toxicity and greater cost effectiveness, as well as potentially sparing patients with rapidly progressive disease from major surgery. To gauge the tumour’s response to preoperative therapy, and to compare the efficacy of different regimens, there is a need for a robust and reproducible system of assessing tumour regression in resection specimens. Several such systems have been proposed, but there is generally a lack of consensus as to which system is the ‘best’. This review describes the evolution of a number of tumour regression grading systems which have been proposed, and discusses the relative merits and shortfalls of several of the most frequently applied schemata. Some problems common to many of these include poorly defined criteria, low interobserver reproducibility and a reliance on fibrosis as a surrogate for tumour kill, which may not be valid. Despite that, recent evidence suggests that the Dworak grading system (first developed for rectal cancer) may be useful in terms of both interobserver concordance and correlation with survival.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pathol.2020.07.001" class="uri">https://doi.org/10.1016/j.pathol.2020.07.001</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Chronic pancreatitis</strong></li>
</ul>
</summary>
<p><em>Lancet (London, England) 2020 08;396(10249):499-512</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32798493" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32798493</a></p>
<p>Chronic pancreatitis is a multifactorial, fibroinflammatory syndrome in which repetitive episodes of pancreatic inflammation lead to extensive fibrotic tissue replacement, resulting in chronic pain, exocrine and endocrine pancreatic insufficiency, reduced quality of life, and a shorter life expectancy. The incidence and prevalence of chronic pancreatitis is rising and no curative treatment is available. Using novel diagnostic algorithms, definitive chronic pancreatitis can be diagnosed by imaging criteria alone, whereas probable chronic pancreatitis requires clinical features and imaging criteria. Criteria for the diagnosis of early chronic pancreatitis are still under discussion and need prospective validation in clinical trials. Cross-sectional imaging should be used first; endoscopic ultrasound is needed only when CT or MRI are inconclusive or to plan therapeutic interventions. Management of chronic pancreatitis requires an interdisciplinary approach including primary care practitioners, gastroenterologists, surgeons, radiologists, pain specialists, and nutritional therapists. Patients with chronic pancreatitis should be seen at least once a year and re-evaluated for causal risk factors, symptom control, and complications such as malnutrition, pancreatic exocrine insufficiency, and diabetes; refer to a specialised centre if symptoms are poorly controlled or there is risk of deterioration. Scoring systems to monitor disease progression have been developed and validated internationally. Interventional treatments for pain or cholestasis should be done by specialists only, and early discussion of treatment approaches should include all medical disciplines involved in care. Throughout this Seminar, we address research needs such as staging of pancreatitis, aspects of malnutrition and pain, and cancer surveillance, to help improve the care of patients.</p>
<p>doi: <a href="https://doi.org/10.1016/S0140-6736(20)31318-0" class="uri">https://doi.org/10.1016/S0140-6736(20)31318-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32792597" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32792597</a></p>
<p>Diagnostic testing of pancreatic cyst fluid obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has traditionally utilized elevated carcinoembryonic antigen (CEA) (≥192 ng/ml) and cytomorphologic examination to differentiate premalignant mucinous from benign pancreatic cystic lesions (PCLs). Molecular testing for KRAS/GNAS mutations has been shown to improve accuracy of detecting mucinous PCLs. Using a targeted next-generation sequencing (NGS) panel, we assess the status of PCL-associated mutations to improve understanding of the key diagnostic variables. Molecular analysis of cyst fluid was performed on 108 PCLs that had concurrent CEA and/or cytological analysis. A 48-gene NGS assay was utilized, which included genes commonly mutated in mucinous PCLs such as GNAS, KRAS, CDKN2A, and TP53. KRAS and/or GNAS mutations were seen in 59 of 68 (86.8%) cases with multimodality diagnosis of a mucinous PCL. Among 31 patients where surgical histopathology was available, the sensitivity, specificity, and diagnostic accuracy of NGS for the diagnosis of mucinous PCL was 88.5%, 100%, and 90.3%, respectively. Cytology with mucinous/atypical findings were found in only 29 of 62 cases (46.8%), with fluid CEA elevated in 33 of 58 cases (56.9%). Multiple KRAS mutations at different variant allele frequencies were seen in seven cases favoring multiclonal patterns, with six of them showing at least two separate PCLs by imaging. Among the 6 of 10 cases with GNAS + /KRAS- results, uncommon, non-V600E exon 11/15 hotspot BRAF mutations were identified. The expected high degree of accuracy of NGS detection of KRAS and/or GNAS mutations for mucinous-PCLs, as compared with CEA and cytological examination, was demonstrated. Multiple KRAS mutations correlated with multifocal cysts demonstrated by radiology. In IPMNs that lacked KRAS mutations, the concurring BRAF mutations with GNAS mutations supports an alternate mechanism of activation in the Ras pathway.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-00647-z" class="uri">https://doi.org/10.1038/s41379-020-00647-z</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1045-1055</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32792253" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32792253</a></p>
<p>BACKGROUND/OBJECTIVES: This paper is part of the international consensus guidelines on chronic pancreatitis, presenting for interventional endoscopy. METHODS: An international working group with experts on interventional endoscopy evaluated 26 statements generated from evidence on 9 clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to evaluate the level of evidence. To determine the level of agreement, a nine-point Likert scale was used for voting on the statements. RESULTS: Strong consensus was obtained for 15 statements relating to nine questions including the recommendation that endoscopic intervention should be offered to patients with persistent severe pain but not to those without pain. Endoscopic decompression of the pancreatic duct could be used for immediate pain relief, and then offered surgery if this fails or needs repeated endoscopy. Endoscopic drainage is preferred for portal-splenic vein thrombosis and pancreatic fistula. A plastic stent should be placed and replaced 2-3 months later after insertion. Endoscopic extraction is indicated for stone fragments remaining after ESWL. Interventional treatment should be performed for symptomatic/complicated pancreatic pseudocysts. Endoscopic treatment is recommended for bile duct obstruction and afterwards surgery if this fails or needs repeated endoscopy. Surgery may be offered if there is significant calcification and/or mass of the pancreatic head. Percutaneous endovascular treatment is preferred for hemosuccus pancreaticus. Surgical treatment is recommended for duodenal stenosis due to chronic pancreatitis. CONCLUSIONS: This international expert consensus guideline provides evidenced-based statements concerning indications and key aspects for interventional endoscopy in the management of patients with chronic pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.05.022" class="uri">https://doi.org/10.1016/j.pan.2020.05.022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The role of older age and obesity in minimally invasive and open pancreatic surgery: A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1234-1242</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32782197" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32782197</a></p>
<p>BACKGROUND/OBJECTIVES: The aim of this study was to assess the impact of older age (≥70 years) and obesity (BMI ≥30) on surgical outcomes of minimally invasive pancreatic resections (MIPR). Subsequently, open pancreatic resections or MIPR were compared for elderly and/or obese patients. METHODS: A systematic review was conducted as part of the 2019 Miami International Evidence-Based Guidelines on MIPR (IG-MIPR). Study quality assessment was according to The Scottish Intercollegiate Guidelines Network (SIGN). A meta-analysis was performed to assess the impact of MIPR or open pancreatic resections in elderly patients. RESULTS: After screening 682 studies, 13 observational studies with 4629 patients were included. Elderly patients undergoing laparoscopic distal pancreatectomy (LDP) had less blood loss (117 mL, p &lt; 0.001) and a shorter hospital stay (3.5 days p &lt; 0.001) than elderly patients undergoing open distal pancreatectomy (ODP). Postoperative pancreatic fistula (POPF) B/C, major complication and reoperation rate were not significantly different in elderly patients undergoing either laparoscopic or open pancreatoduodenectomy (OPD). One study compared robot PD with OPD in obese patients, indicating that patients with robotic surgery had less blood loss (mean 250 ml vs 500 ml, p = 0.001), shorter operative time (mean 381 min vs 428 min, p = 0.003), and lower rate of POPF B/C (13% vs 28%, p = 0.039). CONCLUSION: The current available limited evidence does not suggest that MIPR is contraindicated in elderly or obese patients. Additionally, outcomes in MIPR are equal or more beneficial compared to the open approach when applied in these patient groups.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.06.013" class="uri">https://doi.org/10.1016/j.pan.2020.06.013</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Immunohistochemical staining as supportive diagnostic tool for pseudomyxoma peritonei arising from intraductal papillary mucinous neoplasm: A report of two cases and literature review</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1226-1233</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32768178" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32768178</a></p>
<p>BACKGROUND/OBJECTIVES: Pseudomyxoma peritonei (PMP) arising from an intraductal papillary mucinous neoplasm of the pancreas (IPMN) is a rare condition. The diagnosis of IPMN as the origin of PMP is mainly inferred from the clinical course and the exclusion of PMP from other organs. The pathological diagnosis has not yet been established. To evaluate the usefulness of immunohistochemical staining for the diagnosis of the primary lesion of PMP as IPMN. METHODS: There are 2 cases of PMP arising from IPMN between March 2010 and December 2019 at National Center for Global Health and Medicine. A PubMed search that reported PMP arising from IPMN identified 16 additional cases. Diagnostic methods and clinicopathological features of 18 cases were compared. RESULTS: Four cases including our two cases used immunohistochemical staining for the diagnosis of PMP arising from IPMN. The correspondence of the immunohistochemical staining between PMP and IPMN was shown in the three cases including previously reported two cases and one of our two cases to identify the primary lesion of PMP as IPMN. In addition, we revealed that the comparison of the immunostaining pattern of PMP with the representative immunostaining pattern of the candidate primary lesions is helpful for the diagnosis of the primary lesion of PMP. CONCLUSIONS: Immunohistochemical staining is helpful to identify the primary lesion of PMP as IPMN.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.06.008" class="uri">https://doi.org/10.1016/j.pan.2020.06.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Liver regeneration: biological and pathological mechanisms and implications</strong></li>
</ul>
</summary>
<p><em>Nature reviews. Gastroenterology &amp; hepatology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32764740" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32764740</a></p>
<p>The liver is the only solid organ that uses regenerative mechanisms to ensure that the liver-to-bodyweight ratio is always at 100% of what is required for body homeostasis. Other solid organs (such as the lungs, kidneys and pancreas) adjust to tissue loss but do not return to 100% of normal. The current state of knowledge of the regenerative pathways that underlie this ‘hepatostat’ will be presented in this Review. Liver regeneration from acute injury is always beneficial and has been extensively studied. Experimental models that involve partial hepatectomy or chemical injury have revealed extracellular and intracellular signalling pathways that are used to return the liver to equivalent size and weight to those prior to injury. On the other hand, chronic loss of hepatocytes, which can occur in chronic liver disease of any aetiology, often has adverse consequences, including fibrosis, cirrhosis and liver neoplasia. The regenerative activities of hepatocytes and cholangiocytes are typically characterized by phenotypic fidelity. However, when regeneration of one of the two cell types fails, hepatocytes and cholangiocytes function as facultative stem cells and transdifferentiate into each other to restore normal liver structure. Liver recolonization models have demonstrated that hepatocytes have an unlimited regenerative capacity. However, in normal liver, cell turnover is very slow. All zones of the resting liver lobules have been equally implicated in the maintenance of hepatocyte and cholangiocyte populations in normal liver.</p>
<p>doi: <a href="https://doi.org/10.1038/s41575-020-0342-4" class="uri">https://doi.org/10.1038/s41575-020-0342-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>LncRNA CYTOR promotes pancreatic cancer cell proliferation and migration by sponging miR-205-5p</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1139-1148</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32732173" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32732173</a></p>
<p>BACKGROUND/AIMS: Studies have found that LncRNA CYTOR is an important regulator of cancer. However, the function of lncRNA CYTOR in pancreatic cancer (PC) is unclear. This study amid to explore the regulation of lncRNA CYTOR in PC. METHODS: The expression of CYTOR and miR-205-5p in PC was detected by RT-qPCR. CCK-8 assay, colony formation assay and scratch test were conducted to detect the effects of CYTOR and miR-205-5p on proliferation and migration of PC cells. Target gene prediction and screening and luciferase reporter assays were used to verify downstream target genes of CYTOR and miR-205-5p. The expression of Cyclin-dependent protein kinase 6 (CDK6) was detected by Western blotting. The tumor growth in mice was detected by in vivo experiments in nude mice. RESULTS: The expression of LncRNA CYTOR was significantly elevated in PC. Knockdown of CYTOR significantly inhibited cell proliferation and migration of PC cells. In vivo animal studies showed that CYTOR promoted tumor growth. MiR-205-5p was a direct target of CYTOR, and the expression levels of miR-205-5p were significantly reduced in PC cell lines. Furthermore, co-transfection of shCYTOR with miR-205-5p inhibitor partially abolished the effect of shCYTOR on cell proliferation and migration. In addition, CYTOR was negatively correlated with the expression of miR-205-5p. CDK6 was a direct target of miR-205-5p, and miR-205-5p mimic and sh CYTOR significantly reduced the expression levels of CDK6. CONCLUSION: CYTOR can promote PC progression by modulating the miR-205-5p/CDK6 axis, which may be a potential therapeutic target for PC.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.05.004" class="uri">https://doi.org/10.1016/j.pan.2020.05.004</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Interventional cytopathology in the COVID-19 era</strong></li>
</ul>
</summary>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 11;31(6):509-513</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32654199" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32654199</a></p>
<p>INTRODUCTION: The dramatic spread of COVID-19 has raised many questions about cytological procedures performed in and out of the laboratories all over the world. METHODS: We report a heterogeneous series of fine needle aspirations performed during the period of phase 1 of the lockdown for the COVID-19 pandemic to describe our experience and measures taken during this period. RESULTS: A total of 48 fine needle aspirations (ultrasound, computed tomography and endoscopic ultrasound guided) were processed and reported. CONCLUSIONS: Pre-existing procedures have been modified to allow healthcare professionals to work safely ensuring patients the necessary assistance with samples suitable for cellularity, fixation and staining for an accurate cytological diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12886" class="uri">https://doi.org/10.1111/cyt.12886</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice</strong></li>
</ul>
</summary>
<p><em>Laboratory investigation; a journal of technical methods and pathology 2020 09;100(9):1169-1183</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32472097" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32472097</a></p>
<p>Type 1 diabetes is a T-cell mediated autoimmune disease characterized by pancreatic beta cells destruction. Angiotensin-converting enzyme 2 (ACE2), a component of renin-angiotensin system (RAS) has been identified in pancreas from type 2 diabetic mice and its overexpression prevents beta cell dysfunction. We studied the effect of ACE2 deletion on pancreatic and renal function in the nonobese diabetic mice, a model that mimics type 1 diabetes. ACE2-deficient NOD mice and the respective controls were generated. Pancreas function and immunohistochemistry studies were performed. Renal function and RAS gene expression were also analyzed. Renal proximal tubular cells were obtained from these animals to dissect the effect of ACE2 deficiency in these cells. In NOD mice, ACE2 deletion significantly worsened glucose homeostasis, decreased islet insulin content, increased beta cell oxidative stress, and RIPK1-positive islets as compared with control mice. Angiotensin-converting enzyme and angiotensin II type 1 receptor (AT1R) were also increased in ACE2-deficient mice. In kidneys of 30-day diabetic mice, ACE2 deletion decreased podocyte number within the glomeruli, and altered renal RAS gene expression in tubules. ACE2 deletion influenced the expression of fibrosis-related genes in isolated primary renal proximal tubular cells before diabetes onset in NOD mice. Our findings suggest that ACE2 deletion may have a deleterious impact on beta cell and renal function, by promoting oxidative stress and increasing necroptosis mediators. In addition, this effect is accompanied by RAS alterations in both pancreas and renal proximal tubular cells, indicating that ACE2 may exert a renopancreatic protective effect on type 1 diabetes, which is activated before diabetes starts.</p>
<p>doi: <a href="https://doi.org/10.1038/s41374-020-0440-5" class="uri">https://doi.org/10.1038/s41374-020-0440-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 10;33(10):2026-2034</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32457408" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32457408</a></p>
<p>Neoadjuvant chemotherapy (NAC) is often the treatment of choice for borderline resectable and locally advanced invasive pancreatic ductal adenocarcinoma (PDAC); however, most cancers only partially respond to therapy. We hypothesized that the location of residual neoplastic cells in resected specimens following NAC could provide a clue as to the mechanisms of resistance. PDAC cells invade the stroma but can also invade back into and spread via the pancreatic ducts, which has been referred to as “cancerization of ducts” (COD). We compared the responsiveness to chemotherapy between PDAC cells in the stroma and PDAC cells in the duct. Pancreatic resections from a total of 174 PDAC patients (NAC, n = 97; immediate surgery, n = 77) were reviewed. On hematoxylin and eosin sections, COD was identified at the same prevalence in both groups (NAC: 50/97 cases, 52%; immediate surgery: 39/77 cases, 51%; p = 0.879, Fisher’s exact test). However, using quantitative image analysis of CK19 immunohistochemistry, we found that the proportion of cancer cells that were intraductal was significantly different between the NAC and immediate surgery groups (median; 12.7% vs. 1.99%, p &lt; 0.0001, Mann-Whitney U test). This proportion was highest in patients with marked therapy responses (36.2%) compared with patients with moderate or poor responses (7.21 &amp; 7.91%). In summary, our data suggest that intraductal components in PDAC are less responsive to chemotherapy than the remainder of the tumor, which could have important implications for therapeutic resistance.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0572-6" class="uri">https://doi.org/10.1038/s41379-020-0572-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Nov;477(5):687-696</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32424767" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32424767</a></p>
<p>Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02830-8" class="uri">https://doi.org/10.1007/s00428-020-02830-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic cancer stroma: an update on therapeutic targeting strategies</strong></li>
</ul>
</summary>
<p><em>Nature reviews. Gastroenterology &amp; hepatology 2020 08;17(8):487-505</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32393771" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32393771</a></p>
<p>Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the Western world with limited therapeutic options and dismal long-term survival. The neoplastic epithelium exists within a dense stroma, which is recognized as a critical mediator of disease progression through direct effects on cancer cells and indirect effects on the tumour immune microenvironment. The three dominant entities in the PDAC stroma are extracellular matrix (ECM), vasculature and cancer-associated fibroblasts (CAFs). The ECM can function as a barrier to effective drug delivery to PDAC cancer cells, and a multitude of strategies to target the ECM have been attempted in the past decade. The tumour vasculature is a complex system and, although multiple anti-angiogenesis agents have already failed late-stage clinical trials in PDAC, other vasculature-targeting approaches aimed at vessel normalization and tumour immunosensitization have shown promise in preclinical models. Lastly, PDAC CAFs participate in active cross-talk with cancer cells within the tumour microenvironment. The existence of intratumoural CAF heterogeneity represents a paradigm shift in PDAC CAF biology, with myofibroblastic and inflammatory CAF subtypes that likely make distinct contributions to PDAC progression. In this Review, we discuss our current understanding of the three principal constituents of PDAC stroma, their effect on the prevalent immune landscape and promising therapeutic targets within this compartment.</p>
<p>doi: <a href="https://doi.org/10.1038/s41575-020-0300-1" class="uri">https://doi.org/10.1038/s41575-020-0300-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;27(11):4553-4560</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32367502" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32367502</a></p>
<p>BACKGROUND: The prognostic factors for duodenal carcinoma (DC) remain unclear because of its rarity. This study aimed to investigate the prognostic impact of pancreatic invasion (PI) on postoperative survival for patients with DC. METHODS: This study retrospectively analyzed 86 patients with DC, including 18 patients with PI, who underwent surgical resection between October 2002 and March 2018. The clinicopathologic features and survival outcomes of these patients were investigated to identify the prognostic factors in DC. The long-term survival for the DC patients with PI was compared with that for the patients who underwent resection for resectable pancreatic head carcinoma (RPHC) during the same period. RESULTS: The median survival time (MST) for the DC patients with PI was 25.7 months, which was significantly worse than for the patients with T2 or deeper DC without PI (p = 0.010). The multivariate analysis showed that the independent prognostic factors were PI (hazard ratio [HR] 7.59; p = 0.019) and lymph node metastasis (LNM) (HR 5.01; p = 0.026). The MST for the DC patients with PI did not differ significantly from that for the RPHC patients treated without adjuvant chemotherapy (p = 0.135). Comparable rates of microscopic venous invasion and hematogenous metastasis were observed for the DC patients with PI and the RPHC patients. CONCLUSIONS: Pancreatic invasion was an independent prognostic factor in DC. The survival outcomes for the DC patients with PI did not differ from those for the patients with RPHC, which was associated with a high rate of hematogenous recurrence.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08512-8" class="uri">https://doi.org/10.1245/s10434-020-08512-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>RAF1 rearrangements are common in pancreatic acinar cell carcinomas</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 09;33(9):1811-1821</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32358589" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32358589</a></p>
<p>There is now evidence that gene fusions activating the MAPK pathway are relatively common in pancreatic acinar cell carcinoma with potentially actionable BRAF or RET fusions being found in ~30%. We sought to investigate the incidence of RAF1 fusions in pancreatic malignancies with acinar cell differentiation. FISH testing for RAF1 was undertaken on 30 tumors comprising 25 ‘pure’ acinar cell carcinomas, 2 mixed pancreatic acinar-neuroendocrine carcinomas, 1 mixed acinar cell-low grade neuroendocrine tumor and 2 pancreatoblastomas. RAF1 rearrangements were identified in 5 cases and confirmed by DNA and RNA sequencing to represent oncogenic fusions (GATM-RAF1, GOLGA4-RAF1, PDZRN3-RAF1, HERPUD1-RAF1 and TRIM33-RAF1) and to be mutually exclusive with BRAF and RET fusions, as well as KRAS mutations. Large genome-wide copy number changes were common and included 1q gain and/or 1p loss in all five RAF1 FISH-positive acinar cell carcinomas. RAF1 expression by immunohistochemistry was found in 3 of 5 (60%) of fusion-positive cases and no FISH-negative cases. Phospho-ERK1/2 expression was found in 4 of 5 RAF1-fusion-positive cases. Expression of both RAF1 and phospho-ERK1/2 was heterogeneous and often only detected at the tumor-stroma interface, thus limiting their clinical utility. We conclude that RAF1 gene rearrangements are relatively common in pancreatic acinar cell carcinomas (14.3% to 18.5% of cases) and can be effectively identified by FISH with follow up molecular testing. The combined results of several studies now indicate that BRAF, RET or RAF1 fusions occur in between one third and one-half of these tumors but are extremely rare in other pancreatic malignancies. As these fusions are potentially actionable with currently available therapies, a strong argument can be made to perform FISH or molecular testing on all pancreatic acinar cell carcinomas.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0545-9" class="uri">https://doi.org/10.1038/s41379-020-0545-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 09;33(9):1822-1831</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32350415" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32350415</a></p>
<p>Entosis is a type of regulated cell death that promotes cancer cell competition. Though several studies have revealed the molecular mechanisms that govern entosis, the clinical and genetic correlates of entosis in human tumors is less well understood. Here we reviewed entotic cell-in-cell (CIC) patterns in a large single institution sequencing cohort (MSK IMPACT clinical sequencing cohort) of more than 1600 human pancreatic ductal adenocarcinoma (PDAC) samples to identify the genetic and clinical correlates of this cellular feature. After case selection, 516 conventional PDACs and 21 ASCs entered this study and ~45,000 HPFs (median 80 HPFs per sample) were reviewed; 549 entotic-CICs were detected through our cohort. We observed that entotic-CIC occurred more frequently in liver metastasis compared with primary in PDAC. Moreover, poorly differentiated adenocarcinoma or adenosquamous carcinoma had more entotic-CIC than well or moderately differentiated adenocarcinoma. With respect to genetic features TP53 mutations, KRAS amplification, and MYC amplification were significantly associated with entosis in PDAC tissues. From a clinical standpoint entotic CICs were independently associated with a poor prognosis by multivariate Cox regression analysis when considering all cases or primary PDACs specifically. These results provide a contextual basis for understanding entosis in PDAC, a highly aggressive cancer for which molecular insights are needed to improve survival.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0549-5" class="uri">https://doi.org/10.1038/s41379-020-0549-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;27(10):3898-3912</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32307617" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32307617</a></p>
<p>BACKGROUND: The authors hypothesized that in resected pancreatic adenocarcinoma (PDAC), pathologic characteristics, oncologic outcomes, prognostic factors, and the accuracy of the American Joint Committee on Cancer (AJCC) staging system might differ based on tumor location. METHODS: Patients undergoing pancreatectomy for PDAC at two academic institutions from 2000 to 2015 were retrieved. A comparative analysis between head (H-PDAC) and body-tail (BT-PDAC) tumors was performed using uni- and multivariable models. The accuracy of the eighth AJCC staging system was analyzed using C-statistics. RESULTS: Among 1466 patients, 264 (18%) had BT-PDAC, which displayed greater tumor size but significantly lower rates of perineural invasion and G3/4 grading. Furthermore, BT-PDAC was associated with a lower frequency of nodal involvement and a greater representation of earlier stages. The recurrence-free survival and disease-specific survival times were longer for BT-PDAC (16 vs 14 months [p = 0.020] and 33 vs 26 months [p = 0.026], respectively), but tumor location was not an independent predictor of recurrence or survival in the multivariable analyses. The recurrence patterns did not differ. Certain prognostic factors (i.e., CA 19.9, grading, R-status, and adjuvant treatment) were common, whereas others were site-specific (i.e., preoperative pain, diabetes, and multivisceral resection). The performances of the AJCC staging system were similar (C-statistics of 0.573 for H-PDAC and 0.597 for BT-PDAC, respectively). CONCLUSIONS: Despite differences in pathologic profile found to be in favor of BT-PDAC, tumor location was not an independent predictor of recurrence or survival after pancreatectomy. An array of site-specific prognostic factors was identified, but the AJCC staging system displayed similar prognostic power regardless of primary tumor location.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-08354-4" class="uri">https://doi.org/10.1245/s10434-020-08354-4</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="gallbladder" class="section level2">
<h2>Gallbladder</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>PIPAC-OX: A Phase I study of Oxaliplatin-based Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Peritoneal Metastases</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33148667" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33148667</a></p>
<p>BACKGROUND: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel, laparoscopic intraperitoneal chemotherapy delivery technique aiming to improve drug distribution and tissue penetration to treat peritoneal metastases. Thus far, PIPAC oxaliplatin is conducted at an arbitrary dose of 92mg/m2. We conducted a phase 1 study to establish safety and tolerability. EXPERIMENTAL DESIGN: We used a 3+3 dose escalation design of PIPAC oxaliplatin for patients with peritoneal metastases from gastrointestinal tumors, after failure of at least first-line chemotherapy. Dose levels were planned at 45, 60, 90 and 120mg/m2. FINDINGS: This study included 16 patients with 24 PIPAC procedures (8 gastric, 5 colorectal and 1 gallbladder, pancreas and appendix cancer each). Median age and Peritoneal Cancer Index (PCI) score were 62 years and 17, respectively. Two patients developed pancreatitis (grade 2 and 3) at 45mg/m2, necessitating cohort expansion. Another patient developed grade 2 pancreatitis at 90mg/m2. There were no other dose limiting toxicities and the highest dose cohort (120 mg/m2) tolerated PIPAC well. Pharmacokinetic analyses demonstrated good linearity between dose and maximum concentration (r2=0.95) and area under the curve (AUC) (r2=0.99). Based on response evaluation criteria in solid tumors, 62.5% and 50% had stable disease after one and two PIPAC procedures, respectively. 8 patients underwent 2 PIPAC procedures, with improvement of median PCI and Peritoneal Regression Grade Score from 15 to 12 and 2.5 to 2.0, respectively. CONCLUSIONS: The recommended phase 2 dose is 120 mg/m2. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-2152" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-2152</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Correction to: Defining and Predicting Early Recurrence After Resection for Gallbladder Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33135147" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33135147</a></p>
<p>In the original version of this abstract, the visual abstract is missing. The original abstract has been updated.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09315-7" class="uri">https://doi.org/10.1245/s10434-020-09315-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Changes in plasma bile acids are associated with gallbladder stones and polyps</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):363</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33129276" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33129276</a></p>
<p>BACKGROUND: The development of gallbladder disease (GBD) is related to bile acid (BA) metabolism, and the rate of BA circulation increases the risk of biliary cancer. However, it is unclear whether patterns of circulating bile acids (BAs) change in patients with benign GBDs such as gallbladder stones and polyps. Herein, we compared and characterised plasma BA profiles in patients with cholecystolithiasis and non-neoplastic polyps with healthy controls, and explored relationships between plasma BA profiles, demographics, and laboratory test indices. METHODS: A total of 330 subjects (13 healthy controls, 292 cholecystolithiasis and 25 non-neoplastic polyps) were recruited and plasma BA profiles including 14 metabolites from patients with pathologically confirmed cholecystolithiasis and non-neoplastic polyps were compared with controls. BAs were quantitated by liquid chromatography and mass spectrometry, and statistical and regression analyses of demographics and laboratory test indices were performed. RESULTS: Females displayed a higher burden of GBD than males (63.36% cholecystolithiasis, 60% non-neoplastic polyps). Cholecystolithiasis and non-neoplastic polyps were associated with increased plasma total secondary BAs, while levels of primary BAs were lower than in healthy controls. Plasma ursodeoxycholic acid (UDCA), tauroursodeoxycholic acid (TUDCA), glycyurdeoxycholic acid (GUDCA), taurochenodeoxycholic acid (TCDCA) and glycochenodeoxycholic acid (GCDCA) were decreased significantly in GBDs, and ursodeoxycholic acid (UDCA) was negatively correlated with white blood cell count and neutrophil percentage. CONCLUSIONS: Secondary BA levels were higher in patients with cholecystolithiasis and non-neoplastic polyps. White blood cell count and percentage of neutrophil in peripheral blood were negatively correlated with UDCA, indicating an anti-inflammation effect of UDCA.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01512-8" class="uri">https://doi.org/10.1186/s12876-020-01512-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Mural Intracholecystic Neoplasms Arising in Adenomyomatous Nodules of the Gallbladder: An Analysis of 19 Examples of a Clinicopathologically Distinct Entity</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33060404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33060404</a></p>
<p>Intracholecystic neoplasms (ICNs) (pyloric gland adenomas and intracholecystic papillary neoplasms, collectively also called intracholecystic papillary/tubular neoplasms) form multifocal, extensive proliferations on the gallbladder mucosa and have a high propensity for invasion (&gt;50%). In this study, 19 examples of a poorly characterized phenomenon, mural papillary mucinous lesions that arise in adenomyomatous nodules and form localized ICNs, were analyzed. Two of these were identified in 1750 consecutive cholecystectomies reviewed specifically for this purpose, placing its incidence at 0.1%. Median age was 68 years. Unlike other gallbladder lesions, these were slightly more common in men (female/male=0.8), and 55% had documented cholelithiasis. All were characterized by a compact multilocular, demarcated, cystic lesion with papillary proliferations and mucinous epithelial lining. The lesions’ architecture, distribution, location, and typical size were suggestive of evolution from an underlying adenomyomatous nodule. All had gastric/endocervical-like mucinous epithelium, but 5 also had a focal intestinal-like epithelium. Cytologic atypia was graded as 1 to 3 and defined as 1A: mucinous, without cytoarchitectural atypia (n=3), 1B: mild (n=7), 2: moderate (n=2), and 3: severe atypia (n=7, 3 of which also had invasive carcinoma, 16%). Background gallbladder mucosal involvement was absent in all but 2 cases, both of which had multifocal papillary mucosal nodules. In conclusion, these cases highlight a distinct clinicopathologic entity, that is, mural ICNs arising in adenomyomatous nodules, which, by essentially sparing the “main” mucosa, not displaying “field-effect/defect” phenomenon, and only rarely (16%) showing carcinomatous transformation, are analogous to pancreatic branch duct intraductal papillary mucinous neoplasms.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001603" class="uri">https://doi.org/10.1097/PAS.0000000000001603</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pitfalls in Morphologic Diagnosis of Pathogens: Lessons Learned From the Pseudo-Cystoisospora Epidemic</strong></li>
</ul>
</summary>
<p><em>International journal of surgical pathology 2020 Oct;():1066896920960813</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33016162" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33016162</a></p>
<p>Multiple groups have recently reported involvement of the gallbladder mucosa of immunocompetent patients by cystoisospora organisms. However, this has recently been disproved with the support of molecular and ultrastructural studies. Here we present a summary of these events, recounting how this pseudo-Cystoisospora epidemic began and ended. This review also highlights the important role played by ancillary techniques in supplementing the morphologic diagnosis of pathogens.</p>
<p>doi: <a href="https://doi.org/10.1177/1066896920960813" class="uri">https://doi.org/10.1177/1066896920960813</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Incidence and significance of GATA3 positivity in gallbladder adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>Human pathology 2020 Sep;106():39-44</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32991930" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32991930</a></p>
<p>GATA3 immunostaining is a sensitive marker for mammary and urothelial carcinomas. It is routinely used in surgical pathology during workup of carcinomas of unknown origin. To the best of our knowledge, this is the first focused study of GATA3 expression in gallbladder adenocarcinomas. In this study, we evaluated GATA3 expression in 38 gallbladder adenocarcinomas. Eight of 38 (21%) gallbladder adenocarcinomas were positive for GATA3. The expression of GATA3 tended to be moderate to strong when present. It was patchy (&lt;50% positivity) in 4 cases, characterized by discrete clusters or groups of malignant cells with areas of intervening negative tumor cells, whereas it was diffuse (&gt;50% positivity) in the other 4 cases. GATA3 expression did not show any significant correlation with clinicopathologic features such as sex, histologic grade, perineural invasion, vascular invasion, pathologic stage, or distance metastasis. The results of our study show that a subset of gallbladder adenocarcinomas (21%) can be GATA3 positive. Awareness of this phenomenon is important while working up GATA3-positive carcinomas immunohistochemically.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.09.012" class="uri">https://doi.org/10.1016/j.humpath.2020.09.012</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32925194" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32925194</a></p>
<p>Identification of the primary site of cancer is essential for the treatment of patients with cancer. Numerous immunohistochemical markers have been developed to determine the differentiation of tumor cells and suggest possible primary sites, but markers of gastric and pancreatic adenocarcinomas are still lacking. Claudin-18 is a tight-junction protein uniquely expressed in gastric epithelial cells and has been shown to be expressed in gastric and pancreatic adenocarcinoma. Whether claudin-18 can be used as a marker for identifying the primary site of cancer is still unclear. In this study, we used the immunohistochemical method to stain claudin-18 in tissue arrays containing 575 carcinomas from different anatomic sites and representative sections of 157 metastatic adenocarcinomas. In the group of primary tumors, claudin-18 was frequently expressed in gastric, pancreatic, and pulmonary mucinous adenocarcinomas. Half of cholangiocarcinomas and ovarian mucinous carcinomas and some colorectal and pulmonary adenocarcinomas were also positive for claudin-18. In the metastatic cohort, 15 of 17 (88%) gastric adenocarcinomas, 18 of 23 (78%) pancreatic adenocarcinomas, and 4 of 7 (57%) cholangiocarcinomas and gallbladder adenocarcinomas were positive for claudin-18. Only 4 tumors that originated outside the stomach and pancreatobiliary tract were positive for claudin-18. After normalization to the tumor frequency, the sensitivity of claudin-18 for identifying the stomach and pancreatobiliary tract as primary tumor sites was 79%, and the specificity was 93%. The positive and negative predictive values were 76% and 94%, respectively. In conclusion, claudin-18 represents a sensitive and specific marker for stomach and pancreatobiliary adenocarcinoma that may be a useful diagnostic tool in routine surgical pathology.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001583" class="uri">https://doi.org/10.1097/PAS.0000000000001583</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Secondary Involvement of the Uterine Cervix by Nongynecologic Neoplasms: A Detailed Clinicopathologic Analysis</strong></li>
</ul>
</summary>
<p><em>The American journal of surgical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32910021" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32910021</a></p>
<p>Secondary involvement of the uterine cervix by nongynecologic neoplasms is rare accounting for &lt;2% of metastases to the gynecologic tract. This study aimed to analyze the clinicopathologic features of cervical involvement by nongynecologic malignancies. A total of 47 cases were identified including 39 (83%) carcinomas, 6 lymphomas (12.8%), and 2 (4.2%) cutaneous malignant melanomas. The most common primary site of origin among carcinomas was the gastrointestinal tract (27, 69.2%), followed by breast and urothelium (5 each, 12.8%), gallbladder, and lung (1 each, 2.6%). The gynecologic tract was involved at the presentation in 16 patients (34%), including 5 (10.6%) with the cervix being the first site, 7 (14.9%) with synchronous involvement of the cervix and other gynecologic sites, and 4 (8.5%) with the involvement of other gynecologic sites before the cervical presentation. Patients with lymphoma were younger compared with those with carcinoma (43.7 vs. &gt;50.5) (P=0.01). Mean time to identification of cervical metastases was &lt;1 year for gallbladder carcinoma, melanomas, and gastrointestinal signet ring cell carcinomas (P=0.03). Features that varied with different types of metastatic tumor included lymphovascular space invasion, depth of stromal invasion, growth pattern (glands lacking architectural complexity, cribriforming, solid), presence of goblet cells, and signet ring cells, degree of cytologic atypia, and overall findings mimicking a benign/noninvasive process (P≤0.027). Six tumors (12.8%) were initially misdiagnosed as cervical primary. Metastatic nongynecologic tumors can mimic primary in situ or invasive neoplasms in both ectocervix and endocervix. In patients with a known prior malignancy, the clinical history with ancillary studies and a high level of suspicion are crucial to ensure accurate diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1097/PAS.0000000000001578" class="uri">https://doi.org/10.1097/PAS.0000000000001578</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32895766" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32895766</a></p>
<p>The diagnosis of invasive adenocarcinoma of the gallbladder can sometimes be challenging. The presence of true desmoplastic reaction facilitates the diagnosis of invasion. However, desmoplasia-like changes can be observed in benign gallbladder conditions, and recognition of desmoplasia may be challenging based on morphology. In this study, we tested the expression pattern of microfibril-associated protein 5 (MFAP5), a promising immunohistochemical marker for desmoplasia, in benign gallbladders with desmoplasia-like reaction and gallbladders with invasive adenocarcinoma. We also evaluated the diagnostic utility of MFAP5 in challenging cases with an interobserver agreement study. The results showed that all benign cases retained intact/positive MFAP5 staining pattern in periglandular connective tissue, whereas 79.3% (23 out of 29) of cases of adenocarcinomas demonstrated diffuse and complete loss of MFAP5 staining in the tumor stroma. Interobserver agreement was improved by 2.66 times when images of MFAP5 immunohistochemistry were provided. In conclusion, MFAP5 expression is downregulated in the desmoplastic stroma of gallbladder adenocarcinoma and may provide a useful diagnostic marker in difficult cases.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02925-2" class="uri">https://doi.org/10.1007/s00428-020-02925-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32892270" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32892270</a></p>
<p>BACKGROUND: The optimal time interval to define early recurrence (ER) among patients who underwent resection of gallbladder cancer (GBC) is not well defined. We sought to develop and validate a novel GBC recurrence risk (GBRR) score to predict ER among patients undergoing resection for GBC. PATIENTS AND METHODS: Patients who underwent curative-intent resection for GBC between 2000 and 2018 were identified from the US Extrahepatic Biliary Malignancy Consortium database. A minimum p value approach in the log-rank test was used to define the optimal cutoff for ER. A risk stratification model was developed to predict ER based on relevant clinicopathological factors and was externally validated. RESULTS: Among 309 patients, 103 patients (33.3%) had a recurrence at a median follow-up period of 15.1 months. The optimal cutoff for ER was defined at 12 months (p = 3.04 × 10-18). On multivariable analysis, T3/T4 disease (HR: 2.80; 95% CI 1.58-5.11) and poor tumor differentiation (HR: 1.91; 95% CI 1.11-3.25) were associated with greater hazards of ER. The GBRR score was developed using β-coefficients of variables in the final model, and patients were classified into three distinct groups relative to the risk for ER (12-month RFS; low risk: 88.4%, intermediate risk: 77.9%, high risk: 37.0%, p &lt; 0.001). The external validation demonstrated good model generalizability with good calibration (n = 102: 12-month RFS; low risk: 94.2%, intermediate risk: 59.8%, high risk: 42.0%, p &lt; 0.001). The GBRR score is available online at <a href="https://ktsahara.shinyapps.io/GBC_earlyrec/" class="uri">https://ktsahara.shinyapps.io/GBC_earlyrec/</a> . CONCLUSIONS: A novel online calculator was developed to help clinicians predict the probability of ER after curative-intent resection for GBC. The proposed web-based tool may help in the optimization of surveillance intervals and the counselling of patients about their prognosis.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09108-y" class="uri">https://doi.org/10.1245/s10434-020-09108-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer</strong></li>
</ul>
</summary>
<p><em>Human pathology 2020 Sep;105():9-19</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32891647" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32891647</a></p>
<p>Human epidermal growth factor receptor 2 (HER2)-targeted therapy has improved clinical outcomes in patients with HER2-positive breast and gastric cancers, although ineffective or recurrent cases are present. One reason for this is the heterogeneity of HER2 expression in cancer cells. The aim of this study was to investigate the clinicopathological characteristics and HER2 status of patients with biliary tract cancers (BTCs). We examined HER2 protein expression by immunohistochemistry, HER2 gene amplification by fluorescence in situ hybridization, and both HER2 protein and gene levels simultaneously by gene-protein assay. Samples were collected from 454 patients who underwent surgical resection for BTCs (110 intrahepatic cholangiocarcinomas [ICC], 67 perihilar extrahepatic cholangiocarcinomas [ECC-Bp], 119 distal extrahepatic cholangiocarcinomas [ECC-Bd], 80 gallbladder carcinomas [GBC], and 79 ampullary carcinomas [AVC]). HER2 status was assessed according to the guidelines for HER2 testing in gastroesophageal adenocarcinoma. HER2-positive status was detected in 14.5% of BTCs (3.7% of ICC, 3.0% of ECC-Bp, 18.5% of ECC-Bd, 31.3% of GBC, and 16.4% of AVC). Furthermore, HER2-positivity tended to correlate with low histological grade, tumor histology, and macroscopic features in certain tumors. HER2 heterogeneity was common and highly frequent (83%) in BTC cases. Reduced HER2 protein expression in the deeper invasive areas with simultaneous dedifferentiation was frequently observed in HER2-positive cancer cells. The findings of this study suggest that a large subgroup of HER2-positive BTC cases can be considered for HER2-targeted therapy. Moreover, the HER2 status in BTCs should be determined carefully using a sensitive approach toward larger cancer tissues.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.08.006" class="uri">https://doi.org/10.1016/j.humpath.2020.08.006</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer</strong></li>
</ul>
</summary>
<p><em>Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32878766" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32878766</a></p>
<p>PURPOSE: Dickkopf-1 (DKK1) modulates Wnt signaling, promoting tumor growth, metastasis, and immunosuppression. High DKK1 expression has been detected in various tumor types-including biliary tract cancer (BTC)-and is associated with poor prognosis. DKN-01-a humanized mAb targeting DKK1-was evaluated in a phase I multicenter study in combination with gemcitabine and cisplatin in patients with unresectable or metastatic BTC with no prior systemic therapy for advanced disease. PATIENTS AND METHODS: This study included a dose-escalation phase assessing DKN-01 at two dose levels (150 mg and 300 mg) combined with gemcitabine (1,000 mg/m2) and cisplatin (25 mg/m2) followed by dose expansion. Primary endpoints evaluated safety and tolerability; secondary endpoints evaluated efficacy, pharmacokinetics, and circulating biomarkers. RESULTS: Fifty-one patients with intrahepatic cholangiocarcinoma (63%), extrahepatic cholangiocarcinoma (8%), and gallbladder cancer (29%) were enrolled. No dose-limiting toxicities were seen, and the expansion phase proceeded with DKN-01 300 mg (N = 47). The most frequent grade 3/4 treatment-emergent adverse events included neutropenia (60%), thrombocytopenia (34%), and anemia (23%). The objective response rate was 21.3% and median progression-free survival was 8.7 months (95% confidence interval, 5.4-10.3 months). Better outcomes were associated with biomarkers of angiogenesis inhibition (increased sVEGFR1 and lower VEGF-C) and reduced inflammation (lower IL6 and decreased TNFα). CONCLUSIONS: DKN-01 300 mg was well tolerated in this combination but did not appear to have additional activity beyond historically reported efficacy with gemcitabine/cisplatin alone. Exploratory pharmacokinetic and biomarker data indicate potential antiangiogenic and immunomodulatory activity of DKN-01/chemotherapy and the need for increased dose/intensity. A study with DKN-01 600 mg in combination with a PD-1 inhibitor in BTC is ongoing.</p>
<p>doi: <a href="https://doi.org/10.1158/1078-0432.CCR-20-1310" class="uri">https://doi.org/10.1158/1078-0432.CCR-20-1310</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A predictive nomogram for lymph node metastasis of incidental gallbladder cancer: a SEER population-based study</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Aug;20(1):828</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32867722" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32867722</a></p>
<p>BACKGROUND: Existing imaging techniques have a low ability to detect lymph node metastasis (LNM) of gallbladder cancer (GBC). Gallbladder removal by laparoscopic cholecystectomy can provide pathological information regarding the tumor itself for incidental gallbladder cancer (IGBC). The purpose of this study was to identify the risk factors associated with LNM of IGBC and to establish a nomogram to improve the ability to predict the risk of LNM for IGBC. METHODS: A total of 796 patients diagnosed with stage T1/2 GBC between 2004 and 2015 who underwent surgery and lymph node evaluation were enrolled in this study. We randomly divided the dataset into a training set (70%) and a validation set (30%). A logistic regression model was used to construct the nomogram in the training set and then was verified in the validation set. Nomogram performance was quantified with respect to discrimination and calibration. RESULTS: The rates of LNM in T1a, T1b and T2 patients were 7, 11.1 and 44.3%, respectively. Tumor diameter, T stage, and tumor differentiation were independent factors affecting LNM. The C-index and AUC of the training set were 0.718 (95% CI, 0.676-0.760) and 0.702 (95% CI, 0.659-0.702), respectively, demonstrating good prediction performance. The calibration curves showed perfect agreement between the nomogram predictions and actual observations. Decision curve analysis showed that the LNM nomogram was clinically useful when the risk was decided at a possibility threshold of 2-63%. The C-index and AUC of the validation set were 0.73 (95% CI: 0.665-0.795) and 0.692 (95% CI: 0.625-0.759), respectively. CONCLUSION: The nomogram established in this study has good prediction ability. For patients with IGBC requiring re-resection, the model can effectively predict the risk of LNM and make up for the inaccuracy of imaging.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07341-y" class="uri">https://doi.org/10.1186/s12885-020-07341-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma</strong></li>
</ul>
</summary>
<p><em>BMC cancer 2020 Aug;20(1):826</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32867709" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32867709</a></p>
<p>BACKGROUND: Role of tumor markers in gall bladder carcinoma (GBC) is not well established. We evaluated the prognostic value of carbohydrate antigen 19-9 (CA19-9) and carcinoma embryonic antigen (CEA) in patients with GBC. METHODS: Of the 225 patients of GBC enrolled,176 patients were included in the study (excluded 49 patients with jaundice). Patients were divided into 3 groups; resectable n = 92, unresectable n = 17, metastatic n = 67. The clinico-pathological characteristics, tumor markers and survival data were analysed. The cutoff values of CA19-9 &amp; CEA for predicting metastases were computed using receiver operating characteristic curve. Kaplan Meir survival and Cox regression analysis were done for factors predicting survival and recurrence. RESULTS: The median value of Ca19-9 was significantly higher in metastatic group [resectable: 21.3, unresectable: 53.9 and metastatic: 79; p &lt; 0.001] but not for CEA [3.5, 7.8 and 5 ng/ml (p = 0.20)]. A cutoff value of 72 IU/ml for CA19-9, 5 ng/ml for CEA had a sensitivity and specificity of 52 and 80%, 51 and 72% respectively for detection of metastatic disease. Median, 3-year &amp; 5-year survival were significantly lower in patients with CEA &gt; 4 (p = 0.041), Ca19.9 &gt; 37 (p = 0.019), T3/T4 (p = 0.001), node positive (p = 0.001) and presence of perineural invasion (p = 0.001). However, on multivariate analysis, only Ca19.9 &gt; 37 predicted recurrence (p = 0.002, HR 5.8). CONCLUSIONS: Raised CA19.9 and CEA predict metastatic disease in patients with GBC without jaundice with a high specificity and may help in prognostication of the patient. CA19-9 was better than CEA in prediction of tumor burden and in predicting recurrence.</p>
<p>doi: <a href="https://doi.org/10.1186/s12885-020-07334-x" class="uri">https://doi.org/10.1186/s12885-020-07334-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A case of inflammatory pseudotumour of the gallbladder presenting as a big mass of uncertain behavior</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):282</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747</a></p>
<p>BACKGROUND: Inflammatory pseudotumour has been used to describe an inflammatory or fibrosing tumoral process of an undetermined cause that may involve a variety of organ systems, including the lungs, spleen, liver, lymph nodes, pancreas and extrahepatic bile duct with potential for recurrence and persistent local growth. In this article, we report a patient with a big mass of uncertain nature and behavior. CASE PRESENTATION: A 60-year-old woman presented with a 1-week history of abdominal pain, fever and jaundice. Six months before she had had right upper quadrant pain that was interpreted as biliary colic. A contrast-enhanced CT scan showed a big mass of soft tissue with diffuse infiltration of the gallbladder, displacement of the transverse colon, hepatic flexure and duodenum. For diagnostic distinction between a chronic inflammatory disease or a neoplasm, exploratory laparotomy was required. Intraoperative exploration disclosed a big mass of hard texture involving the gallbladder, with multiple concrements, hepatoduodenal ligament, right and transverse mesocolon, stomach and duodenum. Cholecystectomy was performed, preserving adjacent organs with macroscopic desmoplastic reaction. Histopathologic examination of the gallbladder showed a spindle cell proliferation with diffuse chronic inflammatory infiltrate of lymphocytes, plasma cells and hyalinized fibrous stroma. No vascular invasion or cellular atypia were evident. CONCLUSION: Inflammatory pseudotumour is a rare condition and diagnostic distinction from a chronic inflammatory disease or other neoplasm is only possible by histopathologic examination. There is a limited number of case reports in the literature indicating tumor location in the gallbladder.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01408-7" class="uri">https://doi.org/10.1186/s12876-020-01408-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32815036" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32815036</a></p>
<p>The persistence of SARS-CoV-2 after death of infected individuals is unclear. The aim of this study was to investigate the presence of SARS-CoV-2 RNA in different organs in correlation with tissue damage and post-mortem viral dynamics in COVID-19 deceased. Twenty-eight patients (17 males, 11 females; age 66-96 years; mean 82.9, median 82.5 years) diagnosed with COVID-19 were studied. Swabs were taken post-mortem during autopsy (N = 19) from the throat, both lungs, intestine, gallbladder, and brain or without autopsy (N = 9) only from the throat. Selective amplification of target nucleic acid from the samples was achieved by using primers for ORF1a/b non-structural region and the structural protein envelope E-gene of the virus. The results of 125 post-mortem and 47 ante-mortem swabs were presented as cycle threshold (Ct) values and categorized as strong, moderate, and weak. Viral RNA was detected more frequently in the lungs and throat than in the intestine. Blood, bile, and the brain were negative. Consecutive throat swabs were positive up to 128 h after death without significant increase of Ct values. All lungs showed diffuse alveolar damage, thrombosis, and infarction and less frequently bronchopneumonia irrespective of Ct values. In 30% the intestine revealed focal ischemic changes. Nucleocapsid protein of SARS-CoV-2 was detected by immunohistochemistry in bronchial and intestinal epithelium, bronchial glands, and pneumocytes. In conclusion, viral RNA is still present several days after death, most frequently in the respiratory tract and associated with severe and fatal organ damage. Potential infectivity cannot be ruled out post-mortem.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02903-8" class="uri">https://doi.org/10.1007/s00428-020-02903-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Bile cholesterol and viscosity, the keys to discriminating adenomatous polyps from cholesterol polyps by a novel predictive scoring model</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):268</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32799793" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32799793</a></p>
<p>BACKGROUND: Adenomatous gallbladder polyps, premalignant lesions of the gallbladder, have fatal outcomes, whereas cholesterol polyps have benign features. Herein, we proposed a novel, predictive scoring model of adenomatous polyps to distinguish them from cholesterol polyps, by analyzing bile components and bile viscosity. METHODS: Patients with gallbladder polyp pathologically confirmed after cholecystectomies were analyzed. After dividing patients into two groups (adenomatous or cholesterol polyps), the clinicopathologic profiles and bile nature, including components and viscosity were compared and a predictive scoring model for adenomatous polyps was assessed. RESULTS: Eleven adenomatous polyps and 96 cholesterol polyps were analyzed. The variables significantly associated with adenomatous polyps were age &gt; 55 years (OR = 23.550, p = 0.020), bile viscosity&lt; 7.5 s- 1 (OR = 22.539, p = 0.012), and bile cholesterol&lt; 414.5 mg/dl (OR = 10.004, p = 0.023) and the points for each variable in the predictive scoring model were allocated as 3, 3, and 2, respectively. Final scores ranged from 0 to 8 points and the best performance of model at a cutoff of ≥6 points had 90.9% of sensitivity and 80.2% of specificity. CONCLUSIONS: Bile viscosity and bile cholesterol accompanied by age were revealed as significant predictors of adenomatous polyps, distinguishing them from cholesterol polyps of gallbladder. It can be the cornerstone for creating accurate guidelines for preoperatively determining treatment strategies of gallbladder polyps.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01414-9" class="uri">https://doi.org/10.1186/s12876-020-01414-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Jul;477(1):33-45</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32447492</a></p>
<p>Biliary tract carcinomas are divided into intrahepatic, perihilar, distal extrahepatic cholangiocarcinomas, and gallbladder adenocarcinomas. Therapies targeting ROS1, ALK, MET, and HER2 alterations are currently evaluated in clinical trials. We assessed ROS1 and ALK translocations/amplifications as well as MET and HER2 amplifications for each tumor subtype by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) in 73 intrahepatic, 40 perihilar bile duct, 36 distal extrahepatic cholangiocarcinomas, and 45 gallbladder adenocarcinomas (n = 194). By FISH, we detected targetable alterations in 5.2% of cases (n = 10): HER2 and MET amplifications were found in 4.1% (n = 8) and 1.0% (n = 2), respectively. The HER2-amplified cases were mostly gallbladder adenocarcinomas (n = 5). The MET- and HER2-amplified cases were all positive by IHC. Fourteen cases without MET amplification were positive by IHC, whereas HER2 over-expression was detected by IHC only in HER2-amplified cases. We detected no ALK or ROS1 translocation or amplification. Several alterations were consistent with aneuploidy: 24 cases showed only one copy of ROS1 gene, 4 cases displayed a profile of chromosomal instability, and an over-representation of centromeric alpha-satellite sequences was found in five cases. We confirm a relatively high rate of HER2 amplifications in gallbladder adenocarcinomas and the efficacy of IHC to screen these cases. Our results also suggest the value of IHC to screen MET amplification. Contrary to initial publications, ROS1 rearrangements seem to be very rare in biliary tract adenocarcinomas. We confirm a relatively high frequency of aneuploidy and chromosomal instability and reveal the over-representation of centromeric alpha-satellite sequences in intrahepatic cholangiocarcinomas.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02822-8" class="uri">https://doi.org/10.1007/s00428-020-02822-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Innervation of the proximal human biliary tree</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Sep;477(3):385-392</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31993770" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=31993770</a></p>
<p>The autonomic nervous system plays a role in a variety of liver regenerative and metabolic functions, including modulating bile secretion and cholangiocyte and hepatobiliary progenitors of the canals of Hering. However, the nature and location of nerves which link to the proximal biliary tree have remained uncertain. We investigate the anatomic relationship of nerves to the proximal biliary tree including the putative stem/progenitor cell niche of the canal of Hering. Using double immunostaining (fluorescence, histochemistry) to highlight markers of cholangiocytes (biliary-type keratins), nerves (S100, neurofilament protein, PGP9.5, tyrosine hydroxylase), and stellate cells (CRBP-1), we examined sections from normal adult livers from autopsy or surgical resections. There is extensive contact between nerves and interlobular bile ducts, bile ductules, and canals of Hering (CoH). In multiple serial sections from 4 normal livers, biliary-nerve contacts were seen in all of these structures and were more common in the interlobular bile ducts (78/137; 57%) than in the ductules and CoH (95/294; 33%) (p &lt; 0.001). Contacts appear to consist of nerves in juxtaposition to the biliary basement membrane, though crossing through basement membrane to interface directly with cholangiocytes is also present. These nerves are positive for tyrosine hydroxylase and are, thus, predominately adrenergic. Electron microscopy confirms nerves closely approximating ductules. Nerve fiber-hepatic stellate cell juxtaposition is observed but without stellate cell approximation to cholangiocytes. We present novel findings of biliary innervation, perhaps mediated in part, by direct cholangiocyte-nerve interactions. The implications of these findings are protean for studies of neuromodulation of biliary physiology and hepatic stem/progenitor cells.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02761-4" class="uri">https://doi.org/10.1007/s00428-020-02761-4</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="bileducts" class="section level2">
<h2>Bile Ducts</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Adding ursodeoxycholic acid to the endoscopic treatment and common bile duct stenting for large and multiple biliary stones: Will it improve the outcomes?</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Nov;20(1):374</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33172395" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33172395</a></p>
<p>BACKGROUND: The role of common bile duct (CBD) stenting in the establishment of bile stream in the elderly patients and the ones who are not good candidates for surgery due to not responding to treatments was well documented in previous studies. The current study aimed at investigating the effect of adding Ursodeoxycholic acid (UDCA) to CBD stenting alone in order to reduce the size of large and multiple CBD stones. METHODS: Clinical outcomes including success rates in CBD stones clearance, incidence of pancreatitis, perforation, bleeding, as well as, decrease in size of stones and liver enzymes after a two-month period were assessed in the UDCA + CBD stenting group. RESULTS: A total of 64 patients referring to Shahid Beheshti Hospital in Qom, Iran with multiple or large CBD stones (above three or larger than 15 mm) received standard endoscopic therapies and UDCA + CBD stenting (group B) and controls only received standard endoscopic therapies with only CBD stenting (group A). The mean reduction in the size of stones in group B was significantly higher than that of group A (3.22 ± 1.31 vs 4.09 ± 1.87 mm) (p = 0.034). There was no difference in the incidence rate of complications including pancreatitis, cholangitis, bleeding, and perforation between the two groups (P &gt; 0.05). CONCLUSION: Adding UDCA to CBD stenting, due to decrease in the stone size and subsequently facilitation of the stones outlet, can be considered as the first-line treatment for patients with large and multiple CBD stones. Also, in the cases with large or multi stones may be effective in reducing size and subsequently stone retrieval. Trial registry The study protocol was approved by the Ethics Committee of Qom University of Medical Sciences (ethical code: IR.MUQ.REC.1397.075); the study was also registered in the Iranian Registry of Clinical Trials (No. IRCT20161205031252N8). This study adheres to CONSORT guidelines.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01523-5" class="uri">https://doi.org/10.1186/s12876-020-01523-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Liver Transection-First Approach in Hepatopancreatoduodenectomy for Hilar Cholangiocarcinoma: A Safe and Secure Technique for the Early Assessment of Curable Resection and Vascular Reconstruction</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33169301" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33169301</a></p>
<p>BACKGROUND: Hepatopancreatoduodenectomy (HPD) is often indicated in the resection of cholangiocarcinoma but is associated with high mortality.1-3 From a risk-benefit perspective, HPD can be justified only when curative resection is achievable.4-6 METHODS: A liver transection-first approach is a surgical technique in which liver transection precedes pancreatoduodenectomy (PD) and skeletonization of the hepatoduodenal ligament in HPD. This approach enables an early assessment of resectability and curability. RESULTS: A 64-year-old with jaundice had a tumor located mainly in the proximal bile duct, spreading from the confluence of hepatic ducts (dominant in the left hepatic duct) to the intrapancreatic bile duct. The right hepatic artery and portal vein existed in close proximity to the tumor. HPD (left hemi-hepatectomy and subtotal stomach-preserving PD) with vascular resection was performed. After liver transection along the Cantlie line, the right Glissonean pedicle was collectively secured inside the liver. The right hepatic artery, right portal vein, and right hepatic duct (RHD) were isolated, and the feasibility of vascular reconstruction was confirmed. After the RHD was divided and the negative margin was confirmed, we proceeded to perform PD. The portal vein was reconstructed between the right portal vein and the portal vein trunk. The right hepatic artery was anastomosed to the second jejunal artery of the jejunal loop with the right gastroepiploic artery as an interposition graft. CONCLUSION: The liver transection-first technique in HPD facilitates early assessment of curability and resectability as well as a safe and secure manipulation and reconstruction of the hepatic artery and portal vein.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09303-x" class="uri">https://doi.org/10.1245/s10434-020-09303-x</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Granulomatous cholangitis mimicking hilar cholangiocarcinoma: a case report</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Nov;20(1):369</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33148196" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33148196</a></p>
<p>BACKGROUND: Hilar biliary stricture caused by isolated fungal infections in immunocompetent patients are considered to be extremely rare and difficult to the diagnose from the outset. CASE PRESENTATION: We report a unique case of granulomatous cholangitis based on isolated biliary fungal infection manifesting as obstructive jaundice and mimicking hilar cholangiocarcinoma in an immunocompetent woman. A 67-year-old Japanese woman was referred to our hospital for obstructive jaundice. She had been followed up for hypochondroplasia by the referring physician. Her total bilirubin level was 5.4 mg/dL. Viral hepatitis screening was found to be negative, and serum IgG4 was within normal limits; however, her CA19-9 level was high. Abdominal computed tomography revealed dilatation of the intrahepatic bile ducts. Abdominal echogram detected a solid mass in the hilar bile duct. Her magnetic resonance cholangiopancreatography has also revealed an abrupt stenosis of the primary biliary confluence with upstream dilatation of the intrahepatic bile ducts. Endoscopic nasobiliary drainage was then performed to improve the obstructive jaundice. Although biliary cytology did not reveal malignant findings, the bile duct in the hilum showed severe stenosis, and hilar cholangiocarcinoma could not be completely excluded. The patient had a developmental disorder based on chondrodystrophy. To avoid excessive surgical stress, such as hepatic lobectomy, we performed resection of the extrahepatic bile duct and Roux-en-Y hepaticojejunostomy reconstruction. Intraoperative frozen sections of the resection margins were determined to be negative for tumor. The resected specimen showed multiple strictures inside the common bile duct, numerous calculi in the lumen, and little free space. The final pathological diagnosis was granulomatous cholangitis due to fungal infection. The patient’s postoperative course was deemed uneventful. She was discharged from our hospital 23 days after surgery without antifungal treatment. CONCLUSIONS: For a unique case of granulomatous cholangitis based on isolated biliary fungal infection mimicking hilar cholangiocarcinoma, we were able to avoid excessive invasion and performed appropriate surgical management.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01519-1" class="uri">https://doi.org/10.1186/s12876-020-01519-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Interobserver Agreement in Pathologic Evaluation of Bile Duct Biopsies</strong></li>
</ul>
</summary>
<p><em>Human pathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33129823" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33129823</a></p>
<p>Intraductal biopsy is commonly used for preoperative evaluation of the etiology of biliary strictures. Interpretation of intraductal biopsies is frequently challenging. The diagnosis often suffers from interobserver disagreement, which has not been studied in the literature. We sought to assess interobserver concordance in the interpretation of intraductal biopsies. Eighty-five biopsies were retrieved, falling into five diagnostic categories: negative for dysplasia (NED), indefinite for dysplasia (IND), low grade dysplasia (LGD), high grade dysplasia (HGD), and carcinoma (CA). Eight gastrointestinal pathologists blindly reviewed all the slides. Agreement among pathologists was analyzed using Fleiss κ and weighted concordance coefficient S<em>. A face-to-face consensus/training session was held to discuss the classification criteria, followed by a second round review. The overall interobserver agreement was fair in the first round review (κ=0.39; S</em>=0.56), and improved to moderate in the second round review (κ=0.48; S<em>=0.69). The agreement before and after consensus meeting was substantial to nearly perfect for CA (κ= 0.65, S</em>=0.83; and κ= 0.80, S<em>=0.91), fair for HGD (κ=0.28, S</em>=0. 69; and κ=0.40, S<em>=0.63), and moderate for NED (κ=0.47, S</em>=0.50; and κ=0.47, S<em>=0.53). Agreement improved from fair to moderate for LGD (κ=0.36, S</em>=0.61; and κ=0.49, S<em>=0.71), and slight to fair for IND (κ=0.16, S</em>=0.51; and κ=0.33, S*=0.50). Compared to Hollande’s fixed specimens, the agreement was higher in almost all diagnostic categories in formalin fixed biopsies. Overall, interobserver concordance was improved after a consensus/training session. Interobserver reproducibility was high at the end of the diagnostic spectrum (CA) but fair to moderate for other diagnostic categories.</p>
<p>doi: <a href="https://doi.org/10.1016/j.humpath.2020.10.003" class="uri">https://doi.org/10.1016/j.humpath.2020.10.003</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Regeneration Defects in Yap and Taz Mutant Mouse Livers are Caused by Bile Duct Disruption and Cholestasis</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33127392" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33127392</a></p>
<p>BACKGROUND AND AIMS: The Hippo pathway and its downstream effectors YAP and TAZ (YAP/TAZ) are heralded as important regulators of organ growth and regeneration. However, different studies provided contradictory conclusions about their role during regeneration of different organs ranging from promoting proliferation to inhibiting it. Here, we resolve the function of YAP/TAZ during regeneration of the liver, where Hippo’s role in growth control has been studied most intensely. METHODS: We evaluated liver regeneration after CCl4 toxic liver injury in mice with conditional deletion of Yap/Taz in hepatocytes and/or biliary epithelial cells and measured the behavior of different cell types during regeneration by histology, RNA-sequencing and flow cytometry. RESULTS: We found that YAP/TAZ were activated in hepatocytes in response to CCl4 toxic injury. However, their targeted deletion in adult hepatocytes did not noticeably impair liver regeneration. In contrast, Yap/Taz deletion in adult bile ducts caused severe defects and delay in liver regeneration. Mechanistically, we show that Yap/Taz mutant bile ducts degenerated, causing cholestasis which stalled the recruitment of phagocytic macrophages and the removal of cellular corpses from injury sites. Elevated bile acids activated PXR, which was sufficient to recapitulate the phenotype observed in mutant mice. CONCLUSIONS: Our data show that YAP/TAZ are practically dispensable in hepatocytes for liver development and regeneration. Rather, YAP/TAZ play an indirect role in liver regeneration by preserving bile duct integrity and securing immune cell recruitment and function.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.10.035" class="uri">https://doi.org/10.1053/j.gastro.2020.10.035</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>How to Perform Total Laparoscopic Duodenum-Preserving Pancreatic Head Resection Safely and Efficiently with Innovative Techniques</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857</a></p>
<p>BACKGROUND: Although rapid progress has been achieved in laparoscopic pancreaticoduodenectomy (PD) over the last decade, laparoscopic duodenum-preserving pancreatic head resection (LDPPHR) remains a challenging surgery that has been rarely reported due to not only requiring complicated pancreaticojejunostomy (PJ) but also ensuring sufficient blood supplies to duodenum and common bile duct (CBD). We completed LDPPHR for 22 patients safely and efficiently with innovative techniques. PATIENTS AND METHODS: Clinical outcomes, including rate of conversion to laparotomy, time of residual pancreatic duct reconstruction, incidence of postoperative complications, and time of hospital stay, were collected for 22 consecutive patients who underwent LDPPHR with innovative techniques as follows: application of indocyanine green (ICG) to visualize and preserve CBD and the vessels supplying the duodenum and CBD, Hong’s PJ, and pancreatic duct end-to-end anastomosis (ETEA) for the residual pancreas. RESULTS: All surgeries were performed successfully under laparoscopy except for one case. The duration of ETEA was significantly shorter than PJ (18.2 ± 5.1 min versus 27.5 ± 8.3 min, p &lt; 0.05). There was no significant difference in incidence of postoperative complications between the Hong’s PJ and ETEA group. The overall incidence of postoperative pancreatic fistula (POPF) in the Hong’s PJ and ETEA group was 23.5% and 20%, respectively, without grade C fistula. All complications were resolved after conservative treatment. CONCLUSIONS: By utilizing intraoperative ICG navigation, LDPPHR is a minimally invasive, safe, and efficient approach for chronic pancreatitis with pancreatic head stones by using pancreatic duct ETEA and benign or low-grade malignant tumors of the pancreatic head by using Hong’s PJ.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09233-8" class="uri">https://doi.org/10.1245/s10434-020-09233-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Biliary Stricture after Necrotizing Pancreatitis: An Underappreciated Challenge</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33086318" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33086318</a></p>
<p>OBJECTIVE: Biliary stricture in necrotizing pancreatitis (NP) has not been systematically categorized; therefore, we sought to define the incidence and natural history of biliary stricture caused by NP. SUMMARY/BACKGROUND DATA: Benign biliary stricture occurs secondary to bile duct injury, anastomotic narrowing, or chronic inflammation and fibrosis. The profound loco-regional inflammatory response of NP creates challenging biliary strictures. METHODS: NP patients treated between 2005-2019 were reviewed. Biliary stricture was identified on cholangiography as narrowing of the extrahepatic biliary tree to &lt; 75% of the diameter of the unaffected duct. Biliary stricture risk factors and outcomes were evaluated. RESULTS: Among 743 NP patients, 64 died, 13 were lost to follow up; therefore, a total of 666 patients were included in the final cohort. Biliary stricture developed in 108 (16%) patients. Mean follow up was 3.5 ± 3.3 years. Median time from NP onset to biliary stricture diagnosis was 4.2 months (IQR, 1.8-10.9). Presentation was commonly clinical or biochemical jaundice, n = 30 (28%) each. Risk factors for stricture development were splanchnic vein thrombosis and pancreatic head parenchymal necrosis. Median time to stricture resolution was 6.0 months after onset (2.8-9.8). A mean of 3.3 ± 2.3 procedures were performed. Surgical intervention was required in 22 (20%) patients. Endoscopic treatment failed in 17% (17/99) of patients and was not associated with stricture length. Operative treatment of biliary stricture was more likely in patients with infected necrosis or NP disease duration ≥6 months. CONCLUSION: Biliary stricture occurs frequently after necrotizing pancreatitis and is associated with splanchnic vein thrombosis and pancreatic head necrosis. Surgical correction was performed in 20%.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004470" class="uri">https://doi.org/10.1097/SLA.0000000000004470</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Subtotal (segment II-VIII) hepatectomy for bilateral diffuse hepatolithiasis with compensatory caudate lobe hypertrophy: a report of two cases</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):350</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33081716" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33081716</a></p>
<p>BACKGROUND: Hepatolithiasis often leads to atrophy-hypertrophy complex due to bile duct obstruction, inflammation or infection in the affected liver segments and compensatory response in the normal segments. In severe bilateral diffuse cases, main liver can all be atrophic, leaving the caudate lobe to be extremely hypertrophic. Subtotal (segment II-VIII) hepatectomy can be an option in selected patients under such circumstances. Since rare cases have been reported, our study aims to highlight the preoperative evaluation and key points of this procedure. CASE PRESENTATION: Two patients with primary and secondary bilateral diffuse hepatolithiasis, respectively, were enrolled in this case series. The atrophy of the left and right liver with an exceeding hypertrophy of the caudate lobe were observed. Since the liver anatomy had completely been changed, contrast computed tomography, magnetic resonance imaging combined with 3D liver reconstruction were employed for comprehensive evaluation and pre-operational planning. The patients underwent standard subtotal (segment II-VIII) hepatectomy. During operation, the hepatoduodenal ligament around porta hepatis was dissected firstly to expose the hepatic artery, portal vein, bile duct and their branches successively. And then the vessels and bile duct to caudate lobe were preserved safely through cutting off the left and right hepatic artery, portal vein and bile duct at a safe point distal to the origin of the branches to caudate lobe. Operation time was 300 min and 360 min, respectively. Blood loss was 200 ml and 300 ml. No evidence of liver dysfunction, hepatolithiasis relapse or cholangitis was observed during the follow-up of 12 and 26 months. CONCLUSIONS: Subtotal (segment II-VIII) hepatectomy may be one of several treatments possible in selected patients with compensatory caudate lobe hypertrophy caused by bilateral diffuse hepatolithiasis.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01503-9" class="uri">https://doi.org/10.1186/s12876-020-01503-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Mantle cell lymphoma with EBV-positive Hodgkin and Reed-Sternberg-like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors</strong></li>
</ul>
</summary>
<p><em>Pathology international 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33079423" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33079423</a></p>
<p>The case of 70-year-old man with mantle cell lymphoma (MCL) carrying t(11;14) translocation that relapsed as nodal lymphoma combining MCL and classic Hodgkin lymphoma (cHL) 9 years after autologous peripheral blood stem cell transplant (auto-PBSCT) is reported. Lymph nodes contained two separate areas of MCL and cHL-like components. Hodgkin and Reed-Sternberg (HRS)-like cells were accompanied by a prominent histiocyte background. HRS-like cells were CD5- , CD15+ , CD20- , CD30+ , PAX5+ , Bob.1- , Oct2- and EBER+ . The MCL component expressed cyclin D1 and SOX11, whereas cyclin D1 and SOX11 expressions were reduced and lost, respectively, in HRS-like cells. Polymerase chain reaction results showed a single clonal rearrangement of the IGH gene in MCL and cHL-like components. CCND1 break apart fluorescence in situ hybridization showed split signals in both MCL and HRS-like cells, suggesting that MCL and cHL-like components were clonally related. Acquisition of p53 expression and Epstein-Barr virus (EBV)-positivity was seen in HRS-like cells. The patient died of disease progression with elevated hepatobiliary enzymes. The autopsy showed both MCL and cHL-like components around the bile ducts, splenic white pulp and bone marrow. The two components were phenotypically distinct, but genetically related, suggesting that transformation of MCL to HRS-like cells during the course of MCL in association with EBV infection.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.13038" class="uri">https://doi.org/10.1111/pin.13038</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The use of immunohistochemistry for IgG4 in the diagnosis of autoimmune pancreatitis: A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017</a></p>
<p>BACKGROUND: The diagnosis of autoimmune pancreatitis (AIP) remains challenging, especially when serum IgG4 is normal or imaging features are indeterminate. We performed a systematic review and meta-analysis to evaluate the performance of IgG4 immunostaining of pancreatic, biliary, and ampullary tissues as a diagnostic aid for AIP. METHODS: A comprehensive literature search of the PubMed, EMBASE, and Ovid MEDLINE databases was conducted until February 2020. The methodological quality of each study was assessed according to the Quality Assessment of Diagnostic Accuracy Studies checklist. A random-effects model was used to summarize the diagnostic odds ratio and other measures of accuracy. RESULTS: The meta-analysis included 20 studies comprising 346 patients with AIP and 590 patients with other pancreatobiliary diseases, including 371 pancreatobiliary malignancies. The summary estimates for tissue IgG4 in discriminating AIP and controls were as follows: diagnostic odds ratio 38.86 (95% confidence interval (CI), 18.70-80.75); sensitivity 0.64 (95% CI, 0.59-0.69); specificity 0.93 (95% CI, 0.91-0.95). The area under the curve was 0.939 for tissue IgG4 in discriminating AIP and controls. Subgroup analysis revealed no significant difference in diagnostic accuracy according to control groups (pancreatobiliary cancer versus other chronic pancreatitis) and sampling site (pancreas versus bile duct/ampulla). CONCLUSIONS: Current data demonstrate that IgG4 immunostaining of pancreatic, biliary, and ampullary tissue has a high specificity but moderate sensitivity for diagnosing AIP. IgG4 immunostaining may be useful in supporting a diagnosis of AIP when AIP is clinically suspected, but a combination of imaging and serology does not provide a conclusive diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.028" class="uri">https://doi.org/10.1016/j.pan.2020.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Stratification of Postoperative Prognosis by Invasive Tumor Thickness in Perihilar Cholangiocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33040247" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33040247</a></p>
<p>BACKGROUND: The pathological tumor classification of distal cholangiocarcinoma in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition is based on invasive depth, whereas that of perihilar cholangiocarcinoma (PHCC) continues to be layer-based. We aimed to clarify whether invasive depth measurement based on invasive tumor thickness (ITT) could help determine postoperative prognosis in patients with PHCC. METHODS: We enrolled 184 patients with PHCC who underwent hepatectomy plus extrahepatic bile duct resection or hepatopancreatoduodenectomy with curative intent. ITT was measured using simple definitions according to the sectioning direction or gross tumor pattern. RESULTS: The median ITT was 5.8 mm (range 0.7-15.5). Using the recursive partitioning technique, ITT was classified into grades A (ITT &lt; 2 mm, n = 9), B (2 mm ≤ ITT &lt; 5 mm, n = 68), C (5 mm ≤ ITT &lt; 11 mm, n = 81), and D (11 mm &lt; ITT, n = 26). The median survival times (MSTs) in patients with grade B, C, or D were 90.8, 44.6, and 21.1 months, respectively (patients with grade A did not reach the MST). There were significant differences in postoperative prognosis between ITT grades (A vs. B, p = 0.027; B vs. C, p &lt; 0.001; C vs. D, p = 0.004). Through multivariate analysis, regional node metastasis, invasive carcinoma at the resected margin, and ITT grade were determined as independent prognostic factors. CONCLUSION: ITT could be measured using simple methods and may be used to stratify postoperative prognosis in patients with PHCC.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09135-9" class="uri">https://doi.org/10.1245/s10434-020-09135-9</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Peritumoral ductular reaction can be a prognostic factor for intrahepatic cholangiocarcinoma</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):322</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008300" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008300</a></p>
<p>BACKGROUND: Peritumoral ductular reaction (DR) was reported to be related to the prognosis of combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma. Non-mucin-producing intrahepatic cholangiocarcinoma (ICC) which may be derived from small bile duct cells or liver progenitor cells (LPCs) was known to us. However, whether peritumoral DR is also related to non-mucin-producing ICCs remains to be investigated. METHODS: Forty-seven patients with non-mucin-producing ICC were eventually included in the study and clinicopathological variables were collected. Immunohistochemical analysis and immunofluorescence staining for cytokeratin 19, proliferating cell nuclear antigen, and α-smooth muscle actin were performed in tumor and peritumor liver tissues. RESULTS: A significant correlation existed between peritumoral DR and local inflammation and fibrosis. (r = 0.357, 95% CI, 0.037-0.557; P = 0.008 and r = 0.742, 95% CI, 0.580-0.849; P &lt; 0.001, respectively). Patients with obvious peritumoral DR had high recurrence rate (81.8% vs 56.0%, P = 0.058) and poor overall and disease-free survival time (P = 0.01 and P = 0.03, respectively) comparing with mild peritumoral DR. Compared with the mild peritumoral DR group, the proliferation activity of LPCs/ cholangiocytes was higher in obvious peritumoral DR, which, however, was not statistically significant. (0.43 ± 0.29 vs 0.28 ± 0.31, P = 0.172). Furthermore, the correlation analysis showed that the DR grade was positively related to the portal/septalα-SMA level (r = 0.359, P = 0.001). CONCLUSIONS: Peritumoral DR was associated with local inflammation and fibrosis. Patients with non-mucin-producing ICC having obvious peritumoral DR had a poor prognosis. Peritumoral DR could be a prognostic factor for ICC. However, the mechanism should be further investigated.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01471-0" class="uri">https://doi.org/10.1186/s12876-020-01471-0</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Fishbone foreign body ingestion in duodenal papilla: a cause of abdominal pain resembling gastric ulcer</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):323</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33008291" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33008291</a></p>
<p>BACKGROUND: Foreign body ingestion is a common clinical problem. The upper esophagus is the most common site of foreign body, accounting for more than 75% of all cases, but cases with a foreign body in the duodenal papilla or common bile duct are rarely reported. CASE PRESENTATION: Herein, we report a rare case that a patient’s abdominal pain resembling gastric ulcer was caused by a 3 cm long fishbone inserted into the duodenal papilla. CONCLUSION: Fishbone inserted into the duodenal papilla can cause an abdominal pain resembling gastric ulcer. Endoscopy is useful for the diagnosis and treatment of fishbone ingestion in clinical.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01475-w" class="uri">https://doi.org/10.1186/s12876-020-01475-w</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32989224" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32989224</a></p>
<p>Nivolumab is an immune checkpoint inhibitor (ICI) approved for treatment of many cancers, including hepatocellular carcinoma (HCC). Liver injury is a known complication in patients treated with nivolumab for nonliver tumors. To date, the morphologic changes to tumor and nontumor liver have not been well-characterized in HCC patients. We identified 20 patients who underwent partial hepatectomy or liver transplantation after receiving nivolumab for HCC. Demographics, laboratory values, and imaging results were obtained from medical records. All available slides from resection specimens were evaluated for tumor necrosis, tumor-infiltrating lymphocytes (TILs), and features of liver injury. Patients in the study included 16 males and 4 females with median age of 56 years. The underlying liver disease was HBV in 10, HCV in 6, and unknown/other in 4. Twelve patients were treated with nivolumab in the neoadjuvant setting, whereas eight were treated with nivolumab, usually along with other therapies, before undergoing liver transplantation. On review of resection specimens, three patients (all from the neoadjuvant group) demonstrated marked treatment response attributable to nivolumab. TILs were present in 17/20 cases. One case that showed treatment response in the neoadjuvant group demonstrated non-necrotizing granulomas and prominent bile duct intraepithelial lymphocytes (IELs) in the nontumor liver. One case from the transplant group showed bile duct damage and prominent ductular reaction after long-term nivolumab therapy (32 doses). Our findings indicate that nivolumab is effective in a subset of patients, including in the neoadjuvant setting. Granulomas and bile duct IELs are rare findings in cases treated with nivolumab but, when seen, may indicate potential response to therapy. Bile duct damage and ductular reaction may be manifestations of long-term nivolumab therapy. Future prospective and longitudinal studies with pretreatment tumor biopsies may help identify patients apt to respond to ICI therapy and further characterize patterns of ICI-related liver injury.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-00679-5" class="uri">https://doi.org/10.1038/s41379-020-00679-5</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Oncologic Reappraisal of Bile Duct Resection for Middle-Third Cholangiocarcinoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32960392" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32960392</a></p>
<p>BACKGROUND: Although bile duct resection (BDR) in addition to pancreaticoduodenectomy (PD) is considered a surgical approach in patients with middle-third cholangiocarcinoma (MCC), available prognostic information after BDR remains very limited. The aim of this study was to reappraise BDR from the viewpoint of surgical oncology. METHODS: Patients who underwent BDR or PD for MCC between 2001 and 2010 at 32 Japanese hospitals were included. Clinicopathological factors were retrospectively compared according to surgical procedure to identify a subset cohort who benefited most from BDR. RESULTS: During the study, 92 patients underwent BDR (n = 38) or PD (n = 54). BDR was characterized by a shorter operation time, less blood loss, less frequent complications, and lower mortality, than PD. The incidence of positive surgical margins was 26.3% versus 5.6% (P = 0.007). The survival rate after BDR was significantly worse than that after PD: 38.8% versus 54.8% at 5 years (P = 0.035), and BDR was independently associated with deteriorated survival [hazard ratio (HR), 1.76; P = 0.023] by multivariable analysis. In the BDR group, tumor length &lt; 15 mm (HR, 3.38; P = 0.017) and ductal margin length ≥ 10 mm (HR, 2.54; P = 0.018) were independent positive prognostic factors. Stratified by these two favorable factors, the 5-year survival rate was 63.0% in patients with 1/2 factors and 6.7% in those with 0 factors (P &lt; 0.001). CONCLUSION: In patients with MCC, BDR provided a better short-term and a worse long-term outcome than PD. However, patient selection using tumor length and ductal margin length may allow a favorable survival probability even after BDR.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09157-3" class="uri">https://doi.org/10.1245/s10434-020-09157-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Intraductal papillary mucinous neoplasm complicated with intraductal bleeding in a young woman mimicked a cystic solid pseudo-papillary tumor: a case report</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):304</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938404" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938404</a></p>
<p>BACKGROUND: There are only 6 cases of intraductal papillary mucinous neoplasm (IPMN) complicated with intraductal hemorrhage have been reported in English literatures. All these 6 cases of IPMN occurred in the old people. The present rare case of IPMN complicated with intraductal hemorrhage occurred in a young woman, and mimicked a cystic solid pseudo-papillary neoplasm (SPN) on preoperative imaging findings. CASE PRESENTATION: A 29-year-old young woman complained of a sustained mild right upper quadrant abdominal pain. CT and MRI showed a lobulated, partly ill-defined cystic lesion located in the pancreatic head. Spotted calcification within cystic wall was seen on CT. The lesion was demonstrated as predominantly homogeneous hyperattenuation on CT and homogeneous high signal without decreased signal on fat suppression sequence on T1WI. After contrast administration, the cystic wall and septa of lesion was showed gradually mild to moderate degree of enhancement over time both on CT and MRI. No communication between lesion and the main duct was found on MRCP and the main pancreatic duct and common bile duct were not dilated. Considering patient’s age, gender and manifestations of lesion on CT and MRI (calcification, bleeding and gradually enhanced pattern), the present case mimicked as a cystic SPN. The lesion was pathologically confirmed a branch type IPMN after surgical resection. CONCLUSION: We propose that IPMN may need to be taken into account in the differential diagnosis when pancreatic cystic lesions occur in young women with bleeding, calcification, progressive enhancement of cystic wall and no communication with the main pancreatic duct.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01436-3" class="uri">https://doi.org/10.1186/s12876-020-01436-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Gastric submucosal abscess caused by Edwardsiella tarda infection: a case report</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):299</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32928124" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32928124</a></p>
<p>BACKGROUND: Edwardsiella tarda is a motile, facultatively anaerobic gram-negative bacillus that is isolated from a wide spectrum of animals in aquatic environments but rarely causes infection in humans. Here, we describe the case of a gastric submucosal abscess caused by E. tarda infection. CASE PRESENTATION: The patient was a 74-year-old man with a history of hypertension and chronic alcohol consumption who was admitted to our hospital for abdominal pain, appetite loss and vomiting. Contrast-enhanced computed tomography (CT) revealed choledocholithiasis in the common bile duct, a gastric wall abscess and an intra-abdominal abscess. Endoscopic ultrasound (EUS)-guided drainage with antibiotics successfully cured the patient. CONCLUSION: The combination of CT, endoscopy and EUS-guided drainage with antibiotic therapy might be effective for diagnosis and treatment of a gastric submucosal abscess caused by E. tarda infection.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01446-1" class="uri">https://doi.org/10.1186/s12876-020-01446-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Histological evaluation of tumor differentiation score and prognosis of extrahepatic bile duct cancer: A proposal for a new histological grading system</strong></li>
</ul>
</summary>
<p><em>Pathology international 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32909295" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32909295</a></p>
<p>Extrahepatic bile duct (EHBD) cancer is a devastating cancer, and more common in Asian countries than in Western countries. Histological grading continues to be a highly relevant factor in prognosis and management of many kinds of cancer, however no uniform histological grading system exists for EHBD cancer. Histological heterogeneity within tumors is a problem in the evaluation of EHBD cancer. We developed an EHBD histological grading scheme to evaluate tumor differentiation pattern, and statistically analyzed its relationship with prognosis. In the present study, 257 surgically resected EHBD cancers were reviewed and their histological glandular differentiation (HGD) pattern was scored, and then we summed up the most and second most predominant scores. These scores were statistically analyzed for their relationship with patient prognosis. Patients showed a trend of shortening recurrence-free survival (RFS) and overall survival (OS) in association with higher HGD scores. In multivariate analyses, HGD score was determined to be an influential factor in RFS (P = 0.00041) and OS (P &lt; 0.0001). In addition, combining HGD score and lymph node status correctly stratified patient prognosis in RFS. In conclusion, this new HGD scoring system is highly practical and has powerful prognostic value for EHBD cancer.</p>
<p>doi: <a href="https://doi.org/10.1111/pin.13014" class="uri">https://doi.org/10.1111/pin.13014</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Right Hepatectomy with Vascular and Biliary Reconstruction for a Portal Vein Leiomyosarcoma</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32909126" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32909126</a></p>
<p>BACKGROUND: Vascular leiomyosarcomas (LMS) are rare malignant mesenchymal tumors arising from vessel smooth muscle cells. They represent only 2% of soft tissue sarcomas and most commonly (50%) originate from the inferior vena cava.1-3 Portal vein LMS are very rare, and their resection combines en bloc negative margin sarcoma surgery principles and complex liver surgery procedures with vascular reconstructions.3-5 METHODS: This is the case of a 42-year-old female presenting with a moderate cholestasis. Imaging revealed a 3-cm tumor originating from the main portal vein and its right branch while being in contact with both the right hepatic artery and biliary confluence. No metastases were identified. Core needle biopsy confirmed the diagnosis and tumor board decision was surgical resection. RESULTS: The procedure included anatomic right hepatectomy with en bloc resection of the portal vein bifurcation, common bile duct, and biliary confluence. Portal venous reconstruction was performed using an autogenous external iliac vein interposition graft, while biliary reconstruction was performed via a Roux-en-Y end-to-side hepatico-jejunostomy. Duration of surgery was 300 min, and blood loss was 300 ml. Postoperative outcomes were uneventful and patient was discharged on postoperative day 8 with a transient right limb edema. Pathology confirmed R0 resection of a T1N0M0 leiomyosarcoma, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade 2 tumor. Patient was free of disease at 20 months post-surgery. CONCLUSIONS: Portal vein leiomyosarcomas are extremely rare. En bloc extensive surgical resection should be proposed to obtain R0 resection, and achieve prolonged survival.4,6,7.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09021-4" class="uri">https://doi.org/10.1245/s10434-020-09021-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Endoscopic ultrasound-guided fine needle aspiration of pancreatic mass</strong></li>
</ul>
</summary>
<p><em>Cytopathology : official journal of the British Society for Clinical Cytology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32894783" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32894783</a></p>
<p>doi: <a href="https://doi.org/10.1111/cyt.12912" class="uri">https://doi.org/10.1111/cyt.12912</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Liver biopsy findings in patients on immune checkpoint inhibitors</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32884128" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32884128</a></p>
<p>Immune checkpoint inhibitors (ICI) can induce a durable response against a wide range of malignancies but cause immune related adverse events. The purpose of this study was to evaluate whether the pattern of inflammation in a liver biopsy in patients on ICIs is likely to be related to ICIs or other causes, and whether the pattern correlates with LFT abnormalities, imaging findings, and responsiveness to steroids. Cancer patients on ICIs who underwent liver biopsy were identified. Clinical data were obtained from electronic records. Liver biopsies were recorded as hepatitic, cholangitic, mixed, steatotic, or as mild nonspecific changes. In total, 28 liver biopsies had a predominantly hepatitic pattern of inflammation, including 11 biopsies with granulomas and 10 with endothelialitis. Eight biopsies had a mixed hepatocytic and cholangitic pattern of injury, including 6 with granulomas and 4 with endothelialitis. Sixteen patients had a predominantly cholangitic pattern, with portal-based inflammation. Three patients had a pattern resembling fatty liver, and five had mild nonspecific changes. The three most common histologic patterns correlated with the pattern of LFT abnormalities. The majority of patients with a cholangitic pattern had competing causes for elevated LFTs, including disease progression or concomitant chemotherapy. The cholangitic pattern was more likely to have bile duct dilatation or narrowing on liver imaging. The pattern of inflammation, degree of lobular injury, or presence of granulomas or endothelialitis did not predict response to steroids or the need for secondary immunosuppression. In this retrospective study, the pattern of inflammation did not predict the need for steroids, the length of time that steroids is required, or the need for secondary immunosuppression. A cholangitic pattern was seen when the pattern of LFTs was cholestatic, and was associated with imaging abnormalities of the bile duct, but a similar pattern was seen in bile duct obstruction and other drug reactions.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-00653-1" class="uri">https://doi.org/10.1038/s41379-020-00653-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A case of inflammatory pseudotumour of the gallbladder presenting as a big mass of uncertain behavior</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):282</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747</a></p>
<p>BACKGROUND: Inflammatory pseudotumour has been used to describe an inflammatory or fibrosing tumoral process of an undetermined cause that may involve a variety of organ systems, including the lungs, spleen, liver, lymph nodes, pancreas and extrahepatic bile duct with potential for recurrence and persistent local growth. In this article, we report a patient with a big mass of uncertain nature and behavior. CASE PRESENTATION: A 60-year-old woman presented with a 1-week history of abdominal pain, fever and jaundice. Six months before she had had right upper quadrant pain that was interpreted as biliary colic. A contrast-enhanced CT scan showed a big mass of soft tissue with diffuse infiltration of the gallbladder, displacement of the transverse colon, hepatic flexure and duodenum. For diagnostic distinction between a chronic inflammatory disease or a neoplasm, exploratory laparotomy was required. Intraoperative exploration disclosed a big mass of hard texture involving the gallbladder, with multiple concrements, hepatoduodenal ligament, right and transverse mesocolon, stomach and duodenum. Cholecystectomy was performed, preserving adjacent organs with macroscopic desmoplastic reaction. Histopathologic examination of the gallbladder showed a spindle cell proliferation with diffuse chronic inflammatory infiltrate of lymphocytes, plasma cells and hyalinized fibrous stroma. No vascular invasion or cellular atypia were evident. CONCLUSION: Inflammatory pseudotumour is a rare condition and diagnostic distinction from a chronic inflammatory disease or other neoplasm is only possible by histopathologic examination. There is a limited number of case reports in the literature indicating tumor location in the gallbladder.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01408-7" class="uri">https://doi.org/10.1186/s12876-020-01408-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pancreatic duct guidewire placement for biliary cannulation as a risk factor for stone residue after endoscopic transpapillary stone removal</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):285</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32831030" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32831030</a></p>
<p>BACKGROUND: Recent improvements in stone extraction implements and apparatus have lessened the complexity of the endoscopic bile duct stone treatment. However, despite confirmation of complete removal, cases of residual stones have been reported, which can result in recurrent biliary symptoms, cholangitis, and pancreatitis and considerably increase cost given the need for repeat imaging and/or procedures. To date, risk factors for residual bile duct stones following endoscopic retrograde cholangiopancreatography (ERCP) extraction have not been thoroughly evaluated. This study retrospectively investigated the incidence and risk factors of residual bile duct stones following extraction via ERCP. METHODS: We retrospectively reviewed all ERCP cases that underwent endoscopic bile duct stone extraction between April 2014 and March 2019. A total of 505 patients were enrolled and evaluated for the incidence and risk factors of residual bile duct stones after ERCP. RESULTS: The rate of residual stones was 4.8% (24/505). Residual stones were detected by computed tomography (12/24) or magnetic resonance cholangiopancreatography (12/24). In univariate analyses, a large number of stones (P = 0.01), long procedure time (P = 0.005), and performance of the pancreatic duct guidewire placement method (P-GW) for selective bile duct cannulation (P = 0.01) were the factors involved in residual stones. In multiple logistic regression analysis, performing P-GW was retained as the only independent factor of residual stones (adjusted odds ratio, 3.44; 95% CI, 1.19-9.88; P = 0.02). CONCLUSIONS: When removing bile duct stones with a pancreatic guidewire in place, paying attention to residual stones is necessary.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01428-3" class="uri">https://doi.org/10.1186/s12876-020-01428-3</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Usefulness of peroral cholangioscopy in the differential diagnosis of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma: a single-center retrospective study</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):287</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32831026" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32831026</a></p>
<p>BACKGROUND: In the diagnosis of IgG4-related sclerosing cholangitis (IgG4-SC), differentiation from extrahepatic cholangiocarcinoma (ECC) is extremely important but is still a clinical challenge. This study aimed to elucidate the usefulness of peroral cholangioscopy (POCS) for the differential diagnosis between IgG4-SC and ECC. METHODS: POCS findings for bile duct stricture were retrospectively evaluated in 17 patients with IgG4-SC diagnosed at the Hiroshima University Hospital and 53 patients with surgically resected infiltrating ECC. Mucosal surface, dilated vessels (tortuosity, caliber alteration, and disruption), and easily bleeding were compared between the groups. RESULTS: The stricture sites of IgG4-SC evaluated by POCS were 10 extrapancreatic bile ducts and 9 intrapancreatic bile ducts. In patients with IgG4-SC, smooth mucosal surface was observed in 89% (17/19), dilated vessels in 58% (11/19) [tortuosity 82% (9/11), caliber alteration 18% (2/11), and disruption 9% (1/11)], and easily bleeding in 0%. Irregular mucosal surface and easily bleeding were observed significantly more frequently in ECC (both P &lt;  0.001). The frequency of caliber alteration and disruption of dilated vessels was significantly less in IgG4-SC (P &lt;  0.001 and 0.005, respectively). The sensitivity and specificity of POCS in the diagnosis of ECC were 96 and 89%, respectively. Dilated vessels in IgG4-SC were observed significantly more frequently in the extrapancreatic bile duct, especially the hilar bile duct (P = 0.006). Concerning image evaluation, the interobserver agreement was κ = 0.719, and the intraobserver agreement was κ = 0.768 and 0.754. CONCLUSIONS: Characteristic POCS findings of the stricture sites in IgG4-SC were smooth mucosal surface, dilated vessels without caliber alteration and disruption, and lack of easily bleeding. These POCS findings are extremely useful for distinguishing between IgG4-SC and ECC.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01429-2" class="uri">https://doi.org/10.1186/s12876-020-01429-2</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial</strong></li>
</ul>
</summary>
<p><em>The Lancet. Oncology 2020 09;21(9):1234-1243</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32818466" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32818466</a></p>
<p>BACKGROUND: Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabrafenib and trametinib has shown activity in several BRAFV600E-mutated cancers. We aimed to assess the activity and safety of dabrafenib and trametinib combination therapy in patients with BRAFV600E-mutated biliary tract cancer. METHODS: This study is part of an ongoing, phase 2, open-label, single-arm, multicentre, Rare Oncology Agnostic Research (ROAR) basket trial in patients with BRAFV600E-mutated rare cancers. Patients were eligible for the biliary tract cancer cohort if they were aged 18 years or older, had BRAFV600E-mutated, unresectable, metastatic, locally advanced, or recurrent biliary tract cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received previous systemic treatment. All patients were treated with oral dabrafenib 150 mg twice daily and oral trametinib 2 mg once daily until disease progression or intolerance of treatment. The primary endpoint was the overall response rate, which was determined by Response Evaluation Criteria in Solid Tumors version 1.1 in the intention-to-treat evaluable population, which comprised all enrolled patients regardless of receiving treatment who were evaluable (ie, had progression, began a new anticancer treatment, withdrew consent, died, had stable disease for 6 weeks or longer, or had two or more post-baseline assessments). The ROAR trial is registered with ClinicalTrials.gov, NCT02034110. These results are based on an interim analysis; the study is active but not recruiting. FINDINGS: Between March 12, 2014, and July 18, 2018, 43 patients with BRAFV600E-mutated biliary tract cancer were enrolled to the study and were evaluable. Median follow-up was 10 months (IQR 6-15). An investigator-assessed overall response was achieved by 22 (51%, 95% CI 36-67) of 43 patients. An independent reviewer-assessed overall response was achieved by 20 (47%, 95% CI 31-62) of 43 patients. The most common grade 3 or worse adverse event was increased γ-glutamyltransferase in five (12%) patients. 17 (40%) patients had serious adverse events and nine (21%) had treatment-related serious adverse events, the most frequent of which was pyrexia (eight [19%]). No treatment-related deaths were reported. INTERPRETATION: Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine testing for BRAFV600E mutations should be considered in patients with biliary tract cancer. FUNDING: GlaxoSmithKline and Novartis.</p>
<p>doi: <a href="https://doi.org/10.1016/S1470-2045(20)30321-1" class="uri">https://doi.org/10.1016/S1470-2045(20)30321-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Drug-induced liver injury in older people</strong></li>
</ul>
</summary>
<p><em>The lancet. Gastroenterology &amp; hepatology 2020 09;5(9):862-874</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32818465" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32818465</a></p>
<p>Drug-induced liver injury (DILI) is a rare, unpredictable, and potentially serious adverse reaction. It is induced by many drugs, herbs, and dietary supplements and represents a diagnostic challenge to clinicians. Older people (aged 65 years and older) are often polymedicated, and their declining physiological function affects drug pharmacokinetics. There is no consistent evidence that age is a general risk factor for DILI; however, age might be a risk factor with specific medications, with antimicrobials and cardiovascular drugs being the most likely medications to cause DILI in older people. Ageing influences DILI phenotypes, making cholestatic damage and chronic DILI more likely. In older people with DILI, comorbidities act as confounding causes and account for higher mortality unrelated to the liver. There are no specific therapies for DILI and supportive measures are still the mainstay of management. This Review highlights current advances and gaps in DILI epidemiology, mechanisms, and diagnosis that are pertinent to older individuals.</p>
<p>doi: <a href="https://doi.org/10.1016/S2468-1253(20)30006-6" class="uri">https://doi.org/10.1016/S2468-1253(20)30006-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Pure Laparoscopic Right Hepatectomy for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus (with Video)</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Aug;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32803552" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32803552</a></p>
<p>BACKGROUND: Laparoscopic liver resection has been increasingly utilized due to its less invasiveness approach compared with open surgery,1-3 but often creates challenges. Hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) portends a poorer prognosis and often precludes patients from potential liver resection.4-6 We herein report a case of laparoscopic hepatectomy and thrombectomy in a patient with HCC and BDTT. METHODS: CT, ERCP, and POCS showed a 40-mm tumor located in the right lobe with BDTT. A five 12-mm trocar was inserted at the umbilicus for laparoscope, the epigastrium, both sides of the hypochondrium, and right lateral region. Moreover, a 5-mm trocar was inserted at left hypochondrium. After cholecystectomy, hepatoduodenal ligament was encircled using the tourniquet through 5-mm trocar site. The right portal vein was transected by stapler following transection of the right hepatic artery. After ICG staining (0.5 mg/body i.v.),7 hepatic parenchymal transection was performed using clamp-crashing technique. Moreover, CUSA also was used near Glissonian sheath. BDTT was removed from the right BD. Moreover, the cholangioscopy confirmed no BDTT remnants. The resection stump was then sutured. Finally, the right hepatic vein was divided with a stapler. A drainage tube was placed in the right subphrenic space. Operation time was 496 min, and blood loss was 91 ml. The patient was discharged without complications on postoperative day 11. Pathological diagnosis showed moderately differentiated HCC, tumor size 40 × 45 mm with negative surgical margins. CONCLUSIONS: Pure laparoscopic resection for HCC with BDTT is a radical, yet feasible procedure.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09019-y" class="uri">https://doi.org/10.1245/s10434-020-09019-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1045-1055</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32792253" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32792253</a></p>
<p>BACKGROUND/OBJECTIVES: This paper is part of the international consensus guidelines on chronic pancreatitis, presenting for interventional endoscopy. METHODS: An international working group with experts on interventional endoscopy evaluated 26 statements generated from evidence on 9 clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to evaluate the level of evidence. To determine the level of agreement, a nine-point Likert scale was used for voting on the statements. RESULTS: Strong consensus was obtained for 15 statements relating to nine questions including the recommendation that endoscopic intervention should be offered to patients with persistent severe pain but not to those without pain. Endoscopic decompression of the pancreatic duct could be used for immediate pain relief, and then offered surgery if this fails or needs repeated endoscopy. Endoscopic drainage is preferred for portal-splenic vein thrombosis and pancreatic fistula. A plastic stent should be placed and replaced 2-3 months later after insertion. Endoscopic extraction is indicated for stone fragments remaining after ESWL. Interventional treatment should be performed for symptomatic/complicated pancreatic pseudocysts. Endoscopic treatment is recommended for bile duct obstruction and afterwards surgery if this fails or needs repeated endoscopy. Surgery may be offered if there is significant calcification and/or mass of the pancreatic head. Percutaneous endovascular treatment is preferred for hemosuccus pancreaticus. Surgical treatment is recommended for duodenal stenosis due to chronic pancreatitis. CONCLUSIONS: This international expert consensus guideline provides evidenced-based statements concerning indications and key aspects for interventional endoscopy in the management of patients with chronic pancreatitis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.05.022" class="uri">https://doi.org/10.1016/j.pan.2020.05.022</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer</strong></li>
</ul>
</summary>
<p><em>Histopathology 2020 Sep;77(3):402-412</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32473032" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32473032</a></p>
<p>AIMS: Histology-based tumour microenvironment (TME) scores are useful in predicting the prognosis of gastrointestinal cancer. However, their prognostic roles in distal bile duct cancer (DBDC) have not been previously studied. This study aimed to evaluate the prognostic significance of the TME scores using the Klintrup-Mäkinen (KM) grade, tumour stroma percentage (TSP) and the Glasgow microenvironment score (GMS) in resected DBDC. METHODS AND RESULTS: Eighty-one patients with DBDC who underwent curative resection were enrolled. DBDC was graded according to KM grade, TSP and GMS. A high KM grade was found in 19 patients (24%) and a high TSP was found in 47 patients (58%). A high TSP was significantly correlated with a low KM grade (P &lt; 0.001). The distribution of the GMS, which was developed by combining the KM grade and TSP, was as follows: 0 (n = 19, 24%), 1 (n = 19, 24%) and 2 (n = 43, 52%). A low KM grade, high TSP and high GMS were significantly associated with short overall survival (OS) (P &lt; 0.001) and relapse-free survival (RFS) (P &lt; 0.001). Furthermore, multivariate analysis showed that a low KM grade [hazard ratio (HR) = 3.826; confidence interval (CI) = 1.650-8.869; P = 0.014], high TSP (HR = 2.193; CI = 1.173-4.100, P = 0.002) and high GMS (HR = 7.148; CI = 2.811-18.173) were independent prognostic factors for short RFS; a low KM grade (HR = 4.324; CI = 1.594-11.733) and high GMS (HR = 6.332; CI = 2.743-14.594) were independent prognostic factors for short OS. CONCLUSION: Histology-based TME scores, including the KM grade, TSP and GMS, are useful for predicting the survival of patients with resected DBDC.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14163" class="uri">https://doi.org/10.1111/his.14163</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Tiny but mighty: use of next generation sequencing on discarded cytocentrifuged bile duct brushing specimens to increase sensitivity of cytological diagnosis</strong></li>
</ul>
</summary>
<p><em>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 10;33(10):2019-2025</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32457409" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32457409</a></p>
<p>Bile duct brushing (BDB) is used to evaluate pancreatobiliary lesions as it widely samples lesions with a low complication rate. Cytological evaluation of BDB is a specific but insensitive test. There is limited literature on the use of post-cytocentrifuged (PCC) samples, which are usually discarded, for next-generation sequencing (NGS) as an adjunct to cytological diagnosis of BDB. In this study we investigate whether molecular analysis by NGS of PCC specimens improves the sensitivity of diagnosis. PCC samples from 100 consecutive BDB specimens spanning 93 unique patients were retained. DNA was extracted and mutational analysis was performed agnostic of morphologic or clinical findings. Each BDB specimen was characterized as negative, atypical or positive based on morphological analysis by trained cytopathologists. Performance characteristics for mutational profiling and morphological analysis were calculated on the basis of clinicopathologic follow-up. There was sufficient clinicopathologic follow-up to classify 94 of 100 cases as either malignant (n = 43) or benign (n = 51). Based on morphologic analysis of cytology, these 94 cases were classified as either benign (n = 55), atypical (n = 18), or as at least suspicious or positive for malignancy (n = 21). Morphologic analysis of cytology showed a sensitivity of 49% and a specificity of 100% if atypical cases were considered negative. NGS revealed oncogenic alterations in 40/43 (93%) of malignant cases based on clinicopathologic follow-up. The most common alterations were in KRAS and TP53, observed in 77% and 49% of malignant cases respectively. No alterations were observed in the 51 benign cases classified based on clinicopathologic follow-up. Supplementing cytomorphologic analysis with molecular profiling of PCC by targeted NGS analysis increased the sensitivity to 93% and maintained specificity at 100%. This study provides evidence for the utility of NGS molecular profiling of PCC specimens to increase the sensitivity of BDB cytology samples, although studies with larger cohorts are needed to verify these findings.</p>
<p>doi: <a href="https://doi.org/10.1038/s41379-020-0577-1" class="uri">https://doi.org/10.1038/s41379-020-0577-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions</strong></li>
</ul>
</summary>
<p><em>Virchows Archiv : an international journal of pathology 2020 Oct;477(4):527-534</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32296928" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32296928</a></p>
<p>The distinction between well-differentiated intrahepatic cholangiocarcinoma (iCCA) from its morphological mimics such as bile duct adenoma (BDA) and hamartoma (BDH) can be challenging, particularly in small biopsies. Although a few cases of BDA and BDH have been reported to undergo malignant transformation into iCCA, their neoplastic versus benign nature remains debated. DNA flow cytometry was performed on 47 formalin-fixed paraffin-embedded samples of iCCA, 14 BDA, and 18 BDH. Aneuploidy was detected in 22 iCCA (47%) but in none of the 32 BDA and BDH samples. Among the 34 iCCA patients who underwent complete resection and were followed up to tumor recurrence, tumor-related death, or at least for 1 year, the overall recurrence or death rates (regardless of flow cytometric results) were 18, 56, and 71% within 1, 3, and 5 years, respectively. The 1-, 3-, and 5-year recurrence or death rates in 18 iCCA patients with aneuploidy were 28, 66, and 66%, respectively, whereas 16 iCCA patients in the setting of normal DNA content had 1-, 3-, and 5-year rates of 6, 44, and 72%, respectively. Although aneuploid tumors were associated with worse outcomes during the first 3 years, this difference was not statistically significant (hazard ratio = 1.4, p = 0.473) in the present sample size. In conclusion, the frequency of aneuploidy was significantly higher in iCCA (47%) than in its benign morphological mimics (0%), suggesting that it may potentially serve as a diagnostic marker of malignancy in challenging situations. Our findings also suggest that most BDAs and BDHs, if not all, are benign entities and may not represent precursor lesions to iCCAs that often harbor aneuploidy. Although a larger cohort will be necessary to further determine the prognostic significance of aneuploidy in iCCA patients after resection, the patients with aneuploid tumors may have a higher risk for tumor progression, especially during the first 3 years.</p>
<p>doi: <a href="https://doi.org/10.1007/s00428-020-02812-w" class="uri">https://doi.org/10.1007/s00428-020-02812-w</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
<div id="ampulla" class="section level2">
<h2>Ampulla</h2>
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A New Medial-to-Lateral Approach for Laparoscopic D3 Lymphadenectomy plus Complete Mesocolic Excision (D3���+���CME) for Right-Sided Colon Cancer</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Nov;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33135146" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33135146</a></p>
<p>BACKGROUND: D3 lymphadenectomy is important for accurate staging and provides long-term benefits, especially for T3-4/N + tumors.1,2 Both D3 lymphadenectomy as well as complete mesocolic excision (CME) require central ligation of vessels at their origins to ensure radical resection.3 Currently, superior mesentery vein (SMV) is navigated by ileocolic vessels while its sheath is dissected stepwise from caudal to cranial.4-6 This report describes a new medial-to-lateral approach for laparoscopic right hemicolectomy with D3 + CME. METHODS: The patient was a 47-year-old man with diagnosis of hepatic flexure cancer (cT4N1M0). First, the pedicle of the middle colic vessels and ileocolic vessels were both grasped, then the sheath of SMV was dissected at its left side as there are fewer blood vessels entering here compared with its right side. Second, after identification of middle colic artery (MCA), SMV was skeletonized from medial to lateral and no. 213 and no. 203 lymph nodes were dissected. Third, MCA and ileocolic vein and artery (ICV and ICA) were ligated at their roots. After separating the transverse mesocolon from the duodenum, the branches of the Henle trunk were exposed and no. 223 lymph nodes were dissected. Accessory right colic vein, right colic vein, and middle colic vein were ligated respectively. Fourth, the ascending mesocolon was separated from the retroperitoneal tissues through the front side of Toldt’s fascia, the mesocolon was mobilized completely, and the tumor was removed en bloc. RESULTS: The operation time was 175 min, with estimated blood loss of 50 ml. The patient recovered well without bleeding complications and was discharged on postoperative day 7. Histology revealed moderately differentiated adenocarcinoma with 5 of 24 lymph nodes involved (pT3N2M0). CONCLUSIONS: The medial-to-lateral approach presented in the video might be helpful for standardization of laparoscopic D3 + CME for right-sided colon cancer.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09264-1" class="uri">https://doi.org/10.1245/s10434-020-09264-1</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Non-Conventional Dysplasia of The Tubular Gut: A Review and Illustration of Their Histomorphologic Spectrum</strong></li>
</ul>
</summary>
<p><em>Histopathology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33124049" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33124049</a></p>
<p>The increasing use of gastrointestinal endoscopic procedures has led to the recognition by histopathologists of non-conventional (or special-type) dysplasias of the gastrointestinal tract. These lesions can be recognized in association with prevalent gastrointestinal underlying conditions, such as Barrett oesophagus, chronic atrophic gastritis, and inflammatory bowel disease. The diagnosis of these special types can be challenging, and their biologic behaviours are not fully characterized. The aim of this review is to provide a global view of non-conventional dysplastic lesions observed in the various segments of the tubular gastrointestinal tract and describe their salient features. Furthermore, as the clinical implications of these various subtypes have not been broadly tested in practice and are not represented in most management guidelines, we offer guidance on the best management practices for these lesions.</p>
<p>doi: <a href="https://doi.org/10.1111/his.14294" class="uri">https://doi.org/10.1111/his.14294</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>How to Perform Total Laparoscopic Duodenum-Preserving Pancreatic Head Resection Safely and Efficiently with Innovative Techniques</strong></li>
</ul>
</summary>
<p><em>Annals of surgical oncology 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33123857</a></p>
<p>BACKGROUND: Although rapid progress has been achieved in laparoscopic pancreaticoduodenectomy (PD) over the last decade, laparoscopic duodenum-preserving pancreatic head resection (LDPPHR) remains a challenging surgery that has been rarely reported due to not only requiring complicated pancreaticojejunostomy (PJ) but also ensuring sufficient blood supplies to duodenum and common bile duct (CBD). We completed LDPPHR for 22 patients safely and efficiently with innovative techniques. PATIENTS AND METHODS: Clinical outcomes, including rate of conversion to laparotomy, time of residual pancreatic duct reconstruction, incidence of postoperative complications, and time of hospital stay, were collected for 22 consecutive patients who underwent LDPPHR with innovative techniques as follows: application of indocyanine green (ICG) to visualize and preserve CBD and the vessels supplying the duodenum and CBD, Hong’s PJ, and pancreatic duct end-to-end anastomosis (ETEA) for the residual pancreas. RESULTS: All surgeries were performed successfully under laparoscopy except for one case. The duration of ETEA was significantly shorter than PJ (18.2 ± 5.1 min versus 27.5 ± 8.3 min, p &lt; 0.05). There was no significant difference in incidence of postoperative complications between the Hong’s PJ and ETEA group. The overall incidence of postoperative pancreatic fistula (POPF) in the Hong’s PJ and ETEA group was 23.5% and 20%, respectively, without grade C fistula. All complications were resolved after conservative treatment. CONCLUSIONS: By utilizing intraoperative ICG navigation, LDPPHR is a minimally invasive, safe, and efficient approach for chronic pancreatitis with pancreatic head stones by using pancreatic duct ETEA and benign or low-grade malignant tumors of the pancreatic head by using Hong’s PJ.</p>
<p>doi: <a href="https://doi.org/10.1245/s10434-020-09233-8" class="uri">https://doi.org/10.1245/s10434-020-09233-8</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Patterns of Mycobacterium avium-intracellulare complex infection in duodenal endoscopic biopsies in HIV/AIDS patients</strong></li>
</ul>
</summary>
<p><em>Annals of diagnostic pathology 2020 Oct;49():151638</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33069083" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33069083</a></p>
<p>Mycobacterium avium-intracellulare complex (MAIC) is a nontuberculous opportunistic infection in immunocompromised patients. Involvement of the gastrointestinal tract (GIT) is usually part of a disseminated disease in AIDS patients with a low CD4 count, however with standard antiretroviral therapy (ART), a localized presentation is more likely. It can affect any part of the GIT, mostly the duodenum and typically as patches. Incomplete or refractory ART for HIV-strains, therapy-related side effects, noncompliant or incomplete treatment to previous MAIC infections, superimposed complications and comorbid opportunistic infections may result in atypical clinical, endoscopic and histopathologic manifestations. We performed a retrospective review study retrieving cases of MAIC in duodenal endoscopic biopsy. We found five cases of MAIC in HIV/AIDS patients. They were males with an average age of 40-years. They showed different histopathologic features, variable patterns of MAIC-histiocytic infiltrates, and varying intensity of intracellular acid-fast positive bacilli. Enterocytes vacuolization and transepithelial elimination were also observed. Three cases were associated with cytomegalovirus and cryptococcal infections. A case was complicated by lymphangiectasia-associated protein-losing enteropathy. Initially, three cases were morphologically missed. Ziehl-Neelsen stain helped reach the correct diagnosis. Pathologists have an important role in patients’ management by guiding clinicians to the correct diagnosis. Pathologists should be aware of these different histopathologic manifestations, their potential pitfalls, look for certain helpful clues complemented with multiple levels and special stains. In particular, AFB stains are mandatory in all mucosal biopsy specimens from HIV/AIDS patients regardless of their appearances.</p>
<p>doi: <a href="https://doi.org/10.1016/j.anndiagpath.2020.151638" class="uri">https://doi.org/10.1016/j.anndiagpath.2020.151638</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>The use of immunohistochemistry for IgG4 in the diagnosis of autoimmune pancreatitis: A systematic review and meta-analysis</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33060017</a></p>
<p>BACKGROUND: The diagnosis of autoimmune pancreatitis (AIP) remains challenging, especially when serum IgG4 is normal or imaging features are indeterminate. We performed a systematic review and meta-analysis to evaluate the performance of IgG4 immunostaining of pancreatic, biliary, and ampullary tissues as a diagnostic aid for AIP. METHODS: A comprehensive literature search of the PubMed, EMBASE, and Ovid MEDLINE databases was conducted until February 2020. The methodological quality of each study was assessed according to the Quality Assessment of Diagnostic Accuracy Studies checklist. A random-effects model was used to summarize the diagnostic odds ratio and other measures of accuracy. RESULTS: The meta-analysis included 20 studies comprising 346 patients with AIP and 590 patients with other pancreatobiliary diseases, including 371 pancreatobiliary malignancies. The summary estimates for tissue IgG4 in discriminating AIP and controls were as follows: diagnostic odds ratio 38.86 (95% confidence interval (CI), 18.70-80.75); sensitivity 0.64 (95% CI, 0.59-0.69); specificity 0.93 (95% CI, 0.91-0.95). The area under the curve was 0.939 for tissue IgG4 in discriminating AIP and controls. Subgroup analysis revealed no significant difference in diagnostic accuracy according to control groups (pancreatobiliary cancer versus other chronic pancreatitis) and sampling site (pancreas versus bile duct/ampulla). CONCLUSIONS: Current data demonstrate that IgG4 immunostaining of pancreatic, biliary, and ampullary tissue has a high specificity but moderate sensitivity for diagnosing AIP. IgG4 immunostaining may be useful in supporting a diagnosis of AIP when AIP is clinically suspected, but a combination of imaging and serology does not provide a conclusive diagnosis.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.10.028" class="uri">https://doi.org/10.1016/j.pan.2020.10.028</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A retrospective study on the association of gastrointestinal symptoms in children with low lactase activity and low activity of other disaccharidases</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):331</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33036568" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33036568</a></p>
<p>BACKGROUND: Disaccharides such as lactose and sucrose are sugars commonly found in human diet. They are broken down by mucosal disaccharidases in the duodenum. Previous small studies found no associations between gastrointestinal (GI) symptoms and combined low disaccharidase activity. We aim to explore the associations of low activity of disaccharidase and combinations of low activity of different disaccharidases with general GI symptom presentations in a large cohort of pediatric patients. METHODS: We examined a cohort (0-21 yrs.) who have undergone esophagogastroduodenoscopy and received disaccharidase activity assay from duodenal biopsy in the time period 2010 to 2012. Disaccharidase assays tested for activity of lactase, sucrase, maltase, and palatinase. GI symptoms were grouped into four categories, abdominal pain, diarrhea, weight loss, and gastroesophageal reflux. RESULTS: Of the 347 subjects, we found an association between low lactase activity and abdominal pain (OR = 1.78; 95% CI = 1.07-2.97; p &lt; 0.05). Subjects with a lactase/sucrase ratio &lt; 0.2 were found to be associated with abdominal pain (OR = 2.25; 95% CI = 1.25-4.04; p &lt; 0.05), Subjects with low pandisaccharidase may be correlated with abdominal pain and have a unique frequency of GI symptoms due to low frequency of diarrhea and weight loss, but they were not statistically significant. CONCLUSIONS: Low activities of certain disaccharidase combinations may be associated with GI symptoms in subjects; a prospective study may be needed to investigate further.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01443-4" class="uri">https://doi.org/10.1186/s12876-020-01443-4</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A unique type of fully covered metal stent for the management of post liver transplant biliary anastomotic strictures</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Oct;20(1):329</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33028218" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33028218</a></p>
<p>BACKGROUND: We report our experience of treating anastomotic strictures using a novel type of fully covered metal stent (FCSEMS). This stent, known as the Kaffes Stent, is short-length with an antimigration waist and is easily removable due to long retrieval wires deployed within the duodenum. METHODS: Sixty-two patients underwent ERCP and Kaffes stent insertion for post-transplant anastomotic strictures following confirmation of a stricture on MRCP. These patients were retrospectively analysed for immediate and long-term stricture resolution, improvement in symptoms and liver function tests (LFTs), stricture recurrence and complication rates. RESULTS: Of the 56 patients who had their stent removed at the time of analysis, 54 (96%) had immediate stricture resolution and 42 continued to have long-term resolution (mean follow-up period was 548 days). Of the 16 patients with symptoms of biliary obstruction, 13 had resolution of their symptoms. Overall, there was a significant improvement in LFTs after stent removal compared to before stent insertion. Complication rates were 15% with only one patient requiring biliary reconstruction. CONCLUSIONS: The Kaffes stent is effective and safe at resolving post liver transplant biliary anastomotic strictures.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01479-6" class="uri">https://doi.org/10.1186/s12876-020-01479-6</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Identification of new enterosynes using prebiotics: roles of bioactive lipids and mu-opioid receptor signalling in humans and mice</strong></li>
</ul>
</summary>
<p><em>Gut 2020 Oct;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33020209" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33020209</a></p>
<p>OBJECTIVE: The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia is still developed. We studied whether the modulation of gut microbiota by prebiotics could permit the identification of novel enterosynes. DESIGN: We measured the effects of prebiotics on the production of bioactive lipids in the intestine and tested the identified lipid on ENS-induced contraction and glucose metabolism. Then, we studied the signalling pathways involved and compared the results obtained in mice to human. RESULTS: We found that modulating the gut microbiota with prebiotics modifies the actions of enteric neurons, thereby controlling duodenal contraction and subsequently attenuating hyperglycaemia in diabetic mice. We discovered that the signalling pathway involved in these effects depends on the synthesis of a bioactive lipid 12-hydroxyeicosatetraenoic acid (12-HETE) and the presence of mu-opioid receptors (MOR) on enteric neurons. Using pharmacological approaches, we demonstrated the key role of the MOR receptors and proliferator-activated receptor γ for the effects of 12-HETE. These findings are supported by human data showing a decreased expression of the proenkephalin and MOR messanger RNAs in the duodenum of patients with diabetic. CONCLUSIONS: Using a prebiotic approach, we identified enkephalin and 12-HETE as new enterosynes with potential real beneficial and safety impact in diabetic human.</p>
<p>doi: <a href="https://doi.org/10.1136/gutjnl-2019-320230" class="uri">https://doi.org/10.1136/gutjnl-2019-320230</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Combinatorial transcriptional profiling of mouse and human enteric neurons identifies shared and disparate subtypes in situ</strong></li>
</ul>
</summary>
<p><em>Gastroenterology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=33010250" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=33010250</a></p>
<p>BACKGROUND &amp; AIMS: The enteric nervous system (ENS) coordinates essential intestinal functions through the concerted action of diverse enteric neurons (EN). However, integrated molecular knowledge of EN subtypes is lacking. To compare human and mouse ENs, we transcriptionally profiled healthy ENS from adult humans and mice. We aimed to identify transcripts marking discrete neuron subtypes and visualize conserved EN subtypes for humans and mice in multiple bowel regions. METHODS: Human myenteric ganglia and adjacent smooth muscle were isolated by laser-capture microdissection for RNA-Seq. Ganglia-specific transcriptional profiles were identified by computationally subtracting muscle gene signatures. Nuclei from mouse myenteric neurons were isolated and subjected to single-nucleus RNA-Seq (snRNA-Seq), totaling over four billion reads and 25,208 neurons. Neuronal subtypes were defined using mouse snRNA-Seq data. Comparative informatics between human and mouse datasets identified shared EN subtype markers, which were visualized in situ using hybridization chain reaction (HCR). RESULTS: Several EN subtypes in the duodenum, ileum, and colon are conserved between humans and mice based on orthologous gene expression. However, some EN subtype-specific genes from mice are expressed in completely distinct morphologically defined subtypes in humans. In mice, we identified several neuronal subtypes that stably express gene modules across all intestinal segments, with graded, regional expression of one or more marker genes. CONCLUSIONS: Our combined transcriptional profiling of human myenteric ganglia and mouse EN provides a rich foundation for developing novel intestinal therapeutics. There is congruency among some EN subtypes, but we note multiple species differences that should be carefully considered when relating findings from mouse ENS research to human GI studies.</p>
<p>doi: <a href="https://doi.org/10.1053/j.gastro.2020.09.032" class="uri">https://doi.org/10.1053/j.gastro.2020.09.032</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Outcomes of limited resection for patients with intraductal papillary mucinous neoplasm of the pancreas: A single-center experience</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Oct;20(7):1399-1405</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32972836" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32972836</a></p>
<p>BACKGROUND: /ObjectivesThe aim of this study was to clarify the oncological outcomes of patients with intraductal papillary mucinous neoplasm (IPMN) who underwent limited resection (LR). METHODS: This retrospective study analyzed the data of 110 patients with IPMN. Patients with IPMN without a history of pancreatitis who had neither tumor infiltration nor regional lymph node swelling on imaging findings underwent LR. We assessed the oncological outcomes of LR for patients with IPMN by comparing the surgical outcomes of LR and standard resection. RESULTS: LR was performed in 50 patients (45.5%), including duodenum-preserving pancreatic head resection (n = 31), middle-pancreatectomy (n = 12), spleen-preserving distal pancreatectomy (n = 3), total parenchymal pancreatectomy (n = 3), and partial resection (n = 1). In the LR group, 18 patients had postoperative complications of Clavien-Dindo classification ≥ IIIa. After histopathological examination, the presence of high-grade dysplasia (HGD) and invasive carcinoma (IC) were observed in nine and three patients, respectively, in the LR group, and eight and 22 patients, respectively, in the standard resection group. There was a significant difference in the histopathological diagnosis of IC between the two groups (p &lt; 0.001). Finally, in the LR group, postoperative recurrences occurred in three patients, and the 5-, 10-, and 15-year disease-specific survival rates were all 97.0%. CONCLUSIONS: For patients with IPMN judged to have no infiltrating lesions based on the detailed imaging examination, LR is acceptable and may be considered as an alternative to standard resection.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.09.008" class="uri">https://doi.org/10.1016/j.pan.2020.09.008</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Protruded duodenal tumor arising from Santorini’s duct of the pancreas: a rare case of intraductal papillary mucinous neoplasm mimicking a duodenal polypoid tumor</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Sep;20(1):303</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32938427" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32938427</a></p>
<p>BACKGROUND: We experienced a rare case of intraductal papillary mucinous neoplasm arising from Santorini’s duct (SD) forming a tumor protruding into the duodenum . CASE PRESENTATION: A 71-year-old woman was incidentally diagnosed with a 3 cm type Isp polypoid tumor in the second portion of the duodenum at another hospital. Enhanced CT and endoscopic ultrasound revealed that the origin of this protruding tumor was arising from SD and that the tumor mimicked a pedunculated duodenal tumor. Our preoperative diagnosis was a malignant pancreatic tumor arising from SD with invasion into the duodenum. She underwent a subtotal stomach-preserving pancreaticoduodenectomy, and the resected specimen showed a 25 mm tumor protruding into the duodenum with a villous surface. The pathological findings revealed that the tumor was intraductal papillary mucinous adenoma (IPMA) arising from SD. CONCLUSIONS: To the best of our knowledge, this is the first case of IPMA protruding into the duodenal lumen from SD, although most of the tumors arising from SD have been reported to be malignant.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01449-y" class="uri">https://doi.org/10.1186/s12876-020-01449-y</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours</strong></li>
</ul>
</summary>
<p><em>Journal of clinical pathology 2020 Sep;():</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32934105" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32934105</a></p>
<p>AIMS: Determining the site of origin of a metastatic neuroendocrine tumour (NET) can be challenging and has important prognostic and therapeutic implications. An immunohistochemical (IHC) panel consisting of TTF1, CDX2, PAX8/PAX6 and Islet1 is often employed. However, there can be a significant IHC overlap among different primary sites. Herein, we sought to determine the utility of including Special AT-rich sequence binding protein-2 (SATB2) in the IHC panel that is used for determining the site of origin of a metastatic NET. METHODS: Paraffin tissue microarrays consisting of 137 primary NETs (26 lung, 22 jejunoileal, 8 appendix, 5 stomach, 4 duodenum, 17 rectum and 55 pancreas) were stained for SATB2, in addition to the well-described lineage-associated markers, such as TTF1, CDX2, PAX6 and Islet1. Additionally, a tissue microarray consisting of 21 metastatic NETs (1 lung, 1 stomach, 8 jejunoileal and 11 pancreas) was stained for TTF1, CDX2, SATB2 and Islet1. The results were recorded as no staining, weak staining and moderate to strong staining. RESULTS: All appendiceal NETs and majority (88%) of the rectal NETs were positive for SATB2. All primary foregut NETs (stomach, pancreas, duodenum and lung) were negative for SATB2, except for one pulmonary NET with weak staining. However, among the metastatic tumours, 5 of 11 pancreatic NETs, 1 stomach NET, 1 lung NET and 2 of 8 jejunoileal NETs showed weak staining. Receiver operating characteristic analysis incorporating sensitivity and specificity data of IHC panel, considering moderate to strong staining as truly positive cases, showed that inclusion of SATB2 to the previously described NET IHC panel outperformed the panel without SATB2, raising the specificity for pancreaticoduodenal NETs from 81.2% to 100%, with a positive predictive value (PPV) of 100% and negative predictive value (NPV) of 82.22% (p&lt;0.0001); for appendiceal NETs the specificity changed from 99.1% to 98.5% and sensitivity increased from 11.8% to 80%, with a PPV and NPV of 66.67% and 99.26%, respectively (p&lt;0.0001); and for rectal NETs the specificity increased from 97.6% to 99.3% and sensitivity raised from 7.1% to 66.7%, with a PPV and NPV of 80% and 98.53%, respectively (p&lt;0.0001). CONCLUSIONS: SATB2 stain is useful in differentiatingIslet1/PAX6 positive pancreatic and rectal NETs, as rectal NETs are typically moderately to strongly positive for SATB2 and pancreatic NETs are usually negative or weakly positive for SATB2. Moderate to strong staining for SATB2 is suggestive of an appendiceal or a rectal primary. SATB2 may complement the panel of CDX2, TTF1 and Islet1 in determining the site of origin of an NET in a metastatic setting.</p>
<p>doi: <a href="https://doi.org/10.1136/jclinpath-2020-206645" class="uri">https://doi.org/10.1136/jclinpath-2020-206645</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Efficacy and Safety of the Duodeno-Jejunal Bypass Liner in Patients With Metabolic Syndrome: A Multicenter Randomized Controlled Trial (ENDOMETAB)</strong></li>
</ul>
</summary>
<p><em>Annals of surgery 2020 11;272(5):696-702</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32889869" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32889869</a></p>
<p>OBJECTIVE: The aim of this study was to compare the efficacy and safety of 12-month implantation of a duodeno-jejunal bypass liner (DJBL) with conventional medical care in patients with metabolic syndrome (MS). SUMMARY BACKGROUND DATA: DJBL is an endoscopic device for treating obesity and related disorders. The persistence of favorable results after 6 months has not been tested in a controlled study. METHODS: We conducted a multicenter randomized controlled trial, stratified by center and diabetes status. The primary endpoint was the remission of MS at 12 months. The secondary endpoints included body mass index (BMI), glucose control, blood pressure, and lipids, assessed at 12 months after implantation, and again, at 12 months after the removal of the DJBL. Up to 174 subjects were planned to be randomized into either the DJBL or the control arm at a 2:1 ratio, respectively. Study enrollment was discontinued by the Scientific Monitoring Committee due to the early termination of the ENDO trial (NCT01728116) by the US Food and Drug Administration. The study was terminated after withdrawal of the device’s European Conformity marking by the European Medicines Agency, and an interim analysis was performed. RESULTS: A total of 82 patients were enrolled (67.5% female, 48.8% with diabetes). At 12 months after randomization, the primary endpoint was met in 6 (12%) DJBL patients and 3 (10%) controls (P = 0.72). Patients in the DJBL group experienced greater BMI loss [mean adjusted difference (95% confidence interval, CI) -3.1 kg/m (-4.4 to -1.9) kg/m, P &lt; 0.001] and HbA1c change [mean adjusted difference -0.5% (95% CI -0.9 to -0.2); P &lt; 0.001] than those in the control group. No difference remained statistically significant at 12 months after the removal of the DJBL. In the DJBL group, 39% of patients experienced at least one device-related serious adverse event, which was classified as Grade III Dindo-Clavien in 22%, and required premature device explantation in 16%. CONCLUSIONS: The present study showed a transient clinical benefit of DJBL, which was only apparent at 1 year, when the device was still in situ, and was obtained at the risk of serious device-related adverse events in 39% of patients. These results do not support the routine use of DJBL for weight loss and glucose control in patients with MS.</p>
<p>doi: <a href="https://doi.org/10.1097/SLA.0000000000004339" class="uri">https://doi.org/10.1097/SLA.0000000000004339</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>A case of inflammatory pseudotumour of the gallbladder presenting as a big mass of uncertain behavior</strong></li>
</ul>
</summary>
<p><em>BMC gastroenterology 2020 Aug;20(1):282</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32838747</a></p>
<p>BACKGROUND: Inflammatory pseudotumour has been used to describe an inflammatory or fibrosing tumoral process of an undetermined cause that may involve a variety of organ systems, including the lungs, spleen, liver, lymph nodes, pancreas and extrahepatic bile duct with potential for recurrence and persistent local growth. In this article, we report a patient with a big mass of uncertain nature and behavior. CASE PRESENTATION: A 60-year-old woman presented with a 1-week history of abdominal pain, fever and jaundice. Six months before she had had right upper quadrant pain that was interpreted as biliary colic. A contrast-enhanced CT scan showed a big mass of soft tissue with diffuse infiltration of the gallbladder, displacement of the transverse colon, hepatic flexure and duodenum. For diagnostic distinction between a chronic inflammatory disease or a neoplasm, exploratory laparotomy was required. Intraoperative exploration disclosed a big mass of hard texture involving the gallbladder, with multiple concrements, hepatoduodenal ligament, right and transverse mesocolon, stomach and duodenum. Cholecystectomy was performed, preserving adjacent organs with macroscopic desmoplastic reaction. Histopathologic examination of the gallbladder showed a spindle cell proliferation with diffuse chronic inflammatory infiltrate of lymphocytes, plasma cells and hyalinized fibrous stroma. No vascular invasion or cellular atypia were evident. CONCLUSION: Inflammatory pseudotumour is a rare condition and diagnostic distinction from a chronic inflammatory disease or other neoplasm is only possible by histopathologic examination. There is a limited number of case reports in the literature indicating tumor location in the gallbladder.</p>
<p>doi: <a href="https://doi.org/10.1186/s12876-020-01408-7" class="uri">https://doi.org/10.1186/s12876-020-01408-7</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1092-1102</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800653" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800653</a></p>
<p>INTRODUCTION: The Food and Drug Administration in 2006 required that all pancreatic enzyme products demonstrate bioavailability of lipase, amylase, and protease in the proximal small intestine. METHODS: In this phase I open-label, randomized, crossover trial, 17 adult chronic pancreatitis (CP) patients with severe exocrine pancreatic insufficiency (EPI) underwent two separate gastroduodenal perfusion procedures (Dreiling tube suctioning and [14C]-PEG instillation by an attached Dobhoff tube in the duodenal bulb). Patients received Ensure Plus® alone and Ensure Plus with Zenpep (75,000 USP lipase units) in random order. The bioavailability of Zenpep was estimated by comparing the recovery of lipase, amylase, chymotrypsin activity in two treatment conditions. 14C-PEG was used to correct duodenal aspirates volume. The primary efficacy endpoint was lipase delivery in the duodenum after Zenpep administration under fed conditions. Secondary efficacy endpoints included chymotrypsin and amylase delivery, serum CCK levels, and measuring duodenal and gastric pH. RESULTS: Zenpep administration with a test meal was associated with significant increase in duodenal aspiration of lipase (p = 0.046), chymotrypsin (p = 0.008), and amylase (p = 0.001), compared to the test meal alone, indicating release of enzymes to the duodenum. Lipase delivery was higher in the pH subpopulation (the efficacy population with acid hypersecretors excluded) (p = 0.01). Recovery of [14C]-PEG was 61%. Zenpep was generally well tolerated. All adverse events were mild and transient. CONCLUSIONS: In CP patients with severe EPI, lipase, chymotrypsin and amylase were released rapidly into the duodenum after ingestion of Zenpep plus meal compared to meals alone. Results also reflected the known pH threshold for enzyme release from enteric coated products.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.007" class="uri">https://doi.org/10.1016/j.pan.2020.07.007</a></p>
</details>
<hr />
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<details open>
<summary>
<ul>
<li><strong>Disconnected pancreatic duct syndrome: Updated review on clinical implications and management</strong></li>
</ul>
</summary>
<p><em>Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2020 Sep;20(6):1035-1044</em></p>
<p>PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=32800651" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/?term=32800651</a></p>
<p>Disconnected Pancreatic Duct Syndrome (DPDS) is an important but often overlooked complication of acute necrotising pancreatitis (ANP) that occurs due to necrosis of the main pancreatic duct (PD). This segmental necrosis leads on to disconnection between the viable upstream pancreatic parenchyma and the duodenum. The disconnected and functional segment of pancreas continues to secrete pancreatic juice that is not drained into the gastrointestinal tract and lead on to recurrent pancreatic fluid collections (PFC), refractory external pancreatic flstulae and chronic abdominal pain/recurrent pancreatitis. Because of lack of awareness of this important complication of ANP, the diagnosis of DPDS is usually delayed. The delay in diagnosis increases the morbidity of the disease as well as increase the cost of treatment and duration of hospital stay. Surgery has remained the cornerstone for management of patients with DPDS. The conventional surgical approaches have been either resection or internal drainage procedures. Surgery for DPDS in the setting of ANP is often difficult due to presence of local inflammation and extensive venous collaterals in the operative field due to splenic vein thrombosis and therefore is associated with significant morbidity. Advancement in therapeutic endoscopy, especially advent of therapeutic endoscopic ultrasound has opened an exciting new field of minimally invasive therapeutic options for management of DPDS. The present review discusses the current understanding of the clinical manifestations, imaging features and management strategies in patients with DPDS.</p>
<p>doi: <a href="https://doi.org/10.1016/j.pan.2020.07.402" class="uri">https://doi.org/10.1016/j.pan.2020.07.402</a></p>
</details>
<hr />
<!-- rnb-text-end -->
<!-- rnb-text-begin -->
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
</div>
</div>
<div id="feedback" class="section level1">
<h1>Feedback</h1>
<p><a href="https://docs.google.com/forms/d/e/1FAIpQLSeD3Z9J6Y7eMmiyM12f_SfAmHUlykb1zxZcwO6lg7cebGYQIQ/viewform">Google Feedback Form</a></p>
<script>var DISQUSWIDGETS,disqus_domain,disqus_shortname;
typeof DISQUSWIDGETS==="undefined"&&(DISQUSWIDGETS=function(){var f=document,a=f.getElementById("dsq-count-scr"),a=a&&a.src.match(/(https?:)?\/\/(?:www\.)?([\w_\-]+)\.((?:dev\.)?disqus\.(?:com|org)(?::\d+)?)/i),e={},s=f.head||f.body,j={},q={identifier:1,url:2};e.domain=a&&a[3]||disqus_domain||"disqus.com";e.forum=a&&a[2]||disqus_shortname;e.proto=a&&a[1]||"";e.getCount=function(b){var c;c=encodeURIComponent;var a=e.proto+"//"+e.forum+"."+e.domain+"/count-data.js?",d=[],k=0,l=10,r="",b=b||{};b.reset&&
(j={},r="&_="+ +new Date);for(var b=[f.getElementsByTagName("A"),f.getElementsByClassName&&f.getElementsByClassName("disqus-comment-count")||[]],m,i,g,h,n=0;n<b.length;n++){m=b[n];for(var o=0;o<m.length;o++){i=m[o];g=i.getAttribute("data-disqus-identifier");h=i.hash==="#disqus_thread"&&i.href.replace("#disqus_thread","")||i.getAttribute("data-disqus-url");if(g)h=q.identifier;else if(h)g=h,h=q.url;else continue;var p;j.hasOwnProperty(g)?p=j[g]:(p=j[g]={elements:[],type:h},d.push(c(h)+"="+c(g)));p.elements.push(i)}}d.sort();
for(c=d.slice(k,l);c.length;)b=f.createElement("script"),b.src=a+c.join("&")+r,s.appendChild(b),k+=10,l+=10,c=d.slice(k,l)};e.displayCount=function(b){for(var c,a,d,e=b.counts,b=b.text.comments;c=e.shift();)if(a=j[c.id]){switch(c.comments){case 0:d=b.zero;break;case 1:d=b.one;break;default:d=b.multiple}c=d.replace("{num}",c.comments);a=a.elements;for(d=a.length-1;d>=0;d--)a[d].innerHTML=c}};return e}());DISQUSWIDGETS.getCount();</script>
<div id="disqus_thread">

</div>
<script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://pbpath-org.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>
Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a>
</noscript>
<hr />
<p><a href="#top" target="_self">Back to top</a></p>
<hr />
<div style="page-break-after: always;"></div>
<!-- rnb-text-end -->
</div>

<div id="rmd-source-code">---
title: "Pancreatobiliary Pathology Society Journal Watch"
output:
  html_notebook: 
    code_folding: none
    fig_caption: yes
    highlight: null
    theme: paper
  pdf_document: 
    toc: yes
    number_sections: yes
    latex_engine: xelatex
    keep_tex: yes
  html_document:
    df_print: paged
date: "Last Update on `r format(Sys.Date())`"
subtitle: Recent Articles that will be Selected
header-includes:
- \renewcommand{\linethickness}{0.05em}
- \usepackage{booktabs}
- \usepackage{sectsty} \allsectionsfont{\nohang\centering \emph}
---

```{r global_options, include=FALSE}
knitr::opts_chunk$set(cache = TRUE)
```


```{r library, include=FALSE}
suppressPackageStartupMessages(library("tidyverse"))
suppressPackageStartupMessages(library("readxl"))
suppressPackageStartupMessages(library("RefManageR"))

```


```{r data load, include=FALSE}
articles <- readRDS("~/JournalWatchPBPath/articles.rds")
```


<style type="text/css">

h1{
  text-align: center;
}
h2{
  text-align: center;
}
h3{
  text-align: center;
}
h4{
  text-align: center;
}
h4.date{
  text-align: center;
}

</style>



<!-- Open all links in new tab-->  
<base target="_blank"/>  



---

# PBPath Journal Watch Articles {.tabset .tabset-fade .tabset-pills #pbpath_jw}


```{r strings , include=FALSE}
PubMedString <- "PubMed: https://www.ncbi.nlm.nih.gov/pubmed/?term="

doiString <- "doi: https://doi.org/"

```



```{r read PMID csv, include=FALSE, cache=FALSE}
pancreas_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_pancreas.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

gallbladder_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_gallbladder.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

bileducts_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_bileducts.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))

ampulla_recent_PMID <-
    readr::read_csv(file      = "~/AutoJournalWatch/data/PMIDList_ampulla.csv",
                    col_names = c("PMID"),
                    readr::cols(PMID = readr::col_character()))
```





```{r read PMID from previous JW, include=FALSE, cache=FALSE}
previousJW <- list.files(path = here::here("archive-of-published"),
                          pattern = ".Rmd",
                          full.names = TRUE)


text_previousJW <- unname(sapply(previousJW, readLines))
text_previousJW <- unlist(text_previousJW, use.names=FALSE)

# text_previousJW <- purrr::map(
#     .x = previousJW,
#     .f = readLines
# )



PMID_List_previousJW <-
    stringr::str_extract(
        string = text_previousJW,
        pattern =
            "PubMed_(\\d{8})"
    )


PMID_List_previousJW <- PMID_List_previousJW[!is.na(PMID_List_previousJW)]


PMID_List_previousJW <- PMID_List_previousJW %>%
  unique() %>%
  gsub(pattern = "PubMed_", replacement = "", x = .)

previousJW_PMID <- NULL
previousJW_PMID$PMID <- PMID_List_previousJW
previousJW_PMID <- as.data.frame(previousJW_PMID)

```




---

**Welcome to the PBPath Journal Watch!** 



This bi-monthly journal watch features exciting recently published pancreas and biliary pathology articles that will provide up to date medical knowledge in our field. These articles will be showcased in several convenient categories, including surgical pathology, cytopathology, molecular pathology, pancreas, gallbladder, bile ducts, and ampulla among others. The articles in each category are in no particular order. See the list of journals we search regularly [here](http://pbpath.org/pbpath-journal-watch/). Previous months’ issues may be found in our *[archive](http://pbpath.org/journal-watch-archive/)* and you may see [drafts of the upcoming issue here](http://pbpath.org/journal-watch-upcoming-issue/).  

We encourage members to actively participate by recommending new articles and providing feedback using the [forms provided below.](#feedback){target="_self"}  

**We hope that you will enjoy the new PBPath Journal Watch!**


```{r headerRecent,  child='~/JournalWatchPBPath/_headerRecent.Rmd'}
```



\pagebreak



## Pancreas {#pancreas}



```{r pancreasRecent,  child='~/JournalWatchPBPath/_pancreasRecent.Rmd'}
```

---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak



## Gallbladder {#gallbladder}




```{r gallbladderRecent,  child='~/JournalWatchPBPath/_gallbladderRecent.Rmd'}
```


---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


## Bile Ducts {#bileducts}




```{r bileductsRecent,  child='~/JournalWatchPBPath/_bileductsRecent.Rmd'}
```



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak

## Ampulla {#ampulla}




```{r ampullaRecent,  child='~/JournalWatchPBPath/_ampullaRecent.Rmd'}
```



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak



---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


# Feedback {#feedback}


[Google Feedback Form](https://docs.google.com/forms/d/e/1FAIpQLSeD3Z9J6Y7eMmiyM12f_SfAmHUlykb1zxZcwO6lg7cebGYQIQ/viewform)  


<script id="dsq-count-scr" src="//pbpath-org.disqus.com/count.js" async></script>
<div id="disqus_thread"></div>
<script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://pbpath-org.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
                            


---

<a href="#top" target="_self">Back to top</a>

---

\pagebreak


</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("RecentPBPathJW.Rmd");
});
</script>


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
